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Summary
Background
There is a need for a robust, non-invasive clinical test to assess fat digestion, especially in 
children with cystic fibrosis. Labelling of substrates with enables investigation of their 
digestion, absorption and subsequent metabolism. The mixed triacylglcerol (MTG) *^C- 
breath test is an indirect measure of fat digestion, and therefore exocrine pancreatic 
function. Cystic fibrosis is the commonest cause of pancreatic insufficiency in children. 
^^C-breath tests are particularly attractive for use in children because they are non-invasive, 
and pose no radiation hazard.
MTG is a synthetic triacylglycerol (1,3 distearyl 2-[l-*^C] octanoyl-glycerol). Pancreatic 
lipases preferentially hydrolyse triacylglycerol at the sn-l and -3 positions, releasing ^Re­
labelled octanoate which is rapidly absorbed and oxidised with the generation of ^^COz. 
Quantitation of tracer excretion requires knowledge of the volume of distribution of the 
^RC-labelled tracer as well as quantity of ingested dose and ^^ C abundance in breath CO2 
In ^^C-breath tests, labelled CO2 originating from oxidation of the tracer is diluted by 
endogenously produced CO2 from metabolic processes. Therefore knowledge of CO2 
production rate (FCO2) is required. A resting value based on basal metabolic rate is often 
assumed, but if subjects are not at rest and in the postprandial state thi'oughout the test, this 
will be an underestimate o f the true CO2 production rate and therefore underestimate the 
quantity of tracer excreted.
The MTG breath test has not been widely adopted because it lacks discrimination due to its 
poor specificity. The hypothesis tested in this study is that the poor specificity o f the 
[^RC]MTG breath test is due to lack of knowledge of the true carbon dioxide production 
rate during the test.
Subjects and Methods
A series of interrelated studies were undertaken to test this hypothesis.
Eight healthy adults, ten healthy children and seven children with cystic fibrosis were the 
subjects of these interrelated studies. Use of calibrated heart rate monitors to estimate 
FCO2 fi'om heart rate continuously during ^RC-breath tests was investigated. Use of a
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generic calibration, applied to subjects of all ages and size was explored by normalising 
measured VCO2 to various body parameters including surface area, weight" and height".
[^^CjMTG breath tests were performed on all subjects. The percentage dose recovered in 
each breath sample was calculated using predicted or measured values of resting FCO2 and 
non-resting FCO2 estimated from heart rate. Cumulative excretion of in breath CO2 
(cPDR) was calculated using the trapezoidal rule. The physical activity level (PAL) during 
the test was determined by dividing cPDR calculated using non-resting FCO2 by cPDR 
calculated using resting VCO2 .
[l-^RC]acetate breath tests were performed on all of the adults and twelve of the children 
(nine healthy controls and three children with cystic fibrosis). Use of an acetate correction 
to account for retained in the body during the [^^CjMTG test was also explored.
Two healthy adults took part in studies using [^^CjMTG and its labelled metabolites, to 
assess the effect of factors including rest, exercise, fasting and feeding on the recovery o f 
^ ^ 0 0 2  in breath, and simultaneous use of a tracers, which do not enter the body’s CO2 pool, 
deuterium (^H) labelled MTG, octanoate and acetate.
Results and Discussion
Calibration o f heart rate monitors to estimate VCO2 during ^^C breath tests 
The most accurate and precise method of estimating FCO2 from heart rate was use of a 
sigmoid model on smoothed heart rate data. Use of a generic calibration, to avoid the need 
for individual calibration, introduced unacceptably large errors.
The [^^CJMTG test: VCO2 estimated from heart rate
The reference range (mean ± 2SD) of cPDR in the breath of pancreatic sufficient subjects 
(« = 19) in 6  h following ingestion of [^^CjMTG was 24 to 58 %, when FCO2 was 
estimated continuously from heart rate. The cut-off point determined using Two Graph- 
Receiver Operator Characteristics on data from 25 subjects was 25 %, with sensitivity, 
specificity, positive and negative predictive values all = 1.0. For comparison, the reference 
range calculated using a constant value of FCO2 of 5 mmol.min"\m'R was 18 to 43 % and 
using a constant value of measured resting FCO2 was 17 to 40 %. In both cases the cut-off 
point was 2 0  % with sensitivity and specificity = 0 .8 6 , giving an equivocal range of 17 to 
20 %. The positive predictive value was 0.71 and the negative predictive value was 0.94, 
which is similar to previous studies. Use of individually calibrated heart rate monitors to
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estimate FCO2 during the test improved the positive predictive value of the test
from 0.71 using resting FCO2 to 1.0 using non-resting FCO2 estimated from heart rate.
The mean PAL in tests that were performed under clinical conditions was 1.3. This factor 
was applied to the cumulative recovery in six hours (PDReh) during the [^^CjMTG breath 
test data from children with cystic fibrosis (n = 45), who took part in a previous study. The 
results were compared with the reference range established in this study with no loss of 
specificity. This approach could be adopted in future [^^CjMTG tests undertaken under 
clinical conditions, thus avoiding the need for individual heart rate calibration.
The [^^CJMTG test with an acetate correction
Use o f acetate correction factors is not recommended as it requires two breath tests on 
separate occasions, and the assumptions that any deviations from basal FCO2 are the same 
on each occasion and both tracers are metabolised in an identical manner may not be valid. 
Use o f labelled substrates revealed that acetate and MTG are not metabolised in the 
same manner by the body. Less was recovered in body water following ingestion of 
[^Hs]acetate (87 & 91 %) than pH]MTG (93 & 98 %) or [^Hisjoctanoate (94 & 101 %), 
suggesting that a greater proportion of acetate may be sequestered, most probably 
during lipogenesis.
The [^HjMTG test
The [RfiJMTG test may provide a simpler, more robust non-invasive test of fat digestion. 
Conclusions
Use of non-resting FCO2 improved the discrimination of the [^^CjMTG breath test by 
increasing the positive predictive value o f the test. Calculation of recovery of during 
the [^^CJMTG breath test, using resting FCO2 with a PAL of 1.3, together with the 
reference range from pancreatic sufficient subjects measured in this study, could provide a 
useful clinical test of fat digestion in children with cystic fibrosis. Problems associated 
with lack of knowledge of the tme CO2 production rate during the ['^CjMTG could be 
avoided by using [^HJMTG, if supplies of this novel stable isotope labelled tracer were 
available.
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Chapter 1 Introduction 
1.1 Background
There is a well-recognised need for a non-invasive method of measuring fat digestion 
especially in children with cystic fibrosis, who have impaired exocrine pancreatic function. 
Cystic fibrosis is the most common inherited disease in the UK, affecting over 7500 
babies, children and young adults (data from the Cystic Fibrosis Trust). The incidence of 
the disease is 1 in 2000 live births and 135 children attend the cystic fibrosis clinic at the 
Royal Hospital for Sick Children, Yorkhill NHS Trust, Glasgow. Clinically, cystic fibrosis 
is characterized by recurrent pulmonary infections, pancreatic insufficiency with 
maldigestion and malabsorption and excessive losses of electrolytes in sweat caused by 
abnormal function o f an epithelial chloride channel called the cystic fibrosis 
transmembrane conductance regulator (CFTR).
This inherent defect in anion transport by epithelial cells of exocrine glands results in 
reduction of Cl", Na% K^  and HCO3' levels in secretions. Fluid secretion is also reduced, 
but is normal when adjusted for Cl" and HCO3" levels, suggesting that this is secondary to 
the reduction in these ions. Since the CI /HCO3 ratio is unchanged in cystic fibrosis, it is 
likely that the secretion of both these ions is abnormal. The finding that HCO3" passes 
readily through the ORDIC (outwardly rectifying, depolarisation-induced Cl") channel (and 
other Cl" channels) suggests that the same defect may be responsible for both abnormalities 
(Alton & Smith, 2000). In the pancreas, the consequence of this is viscous secretions, 
which result in blockage of the pancreatic ducts reducing the amount of pancreatic 
enzymes reaching the small intestine (Shepherd et a l 1991; Couper et a l 2002). Only 1-2 
% of residual pancreatic capacity for secreting enzyme is required to prevent maldigestion 
(Gaskin et a l  1984). This allows patients to be classified as either pancreatic insufficient 
(PI) with less than 2  % of normal activity, or pancreatic sufficient (PS) with 2-100 % of 
normal activity (Couper et a l 2002). Patients with PI secrete insufficient pancreatic 
lipolytic enzymes (e.g. lipase, colipase) or proteolytic enzymes (e.g. trypsin, chymotrypsin) 
and bicarbonate for normal fat and protein digestion and absorption. In patients with PS, 
the pancreas is affected, but they have sufficient exocrine pancreatic fonction to permit 
normal nutrient digestion and absorption.
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In children, cystic fibrosis is the commonest cause of exocrine pancreatic insufficiency. 
Between 10 and 15 % of children with cystic fibrosis are PS. They have milder disease 
expression, slower progression of lung disease, better nutritional status and a higher 
survival rate than PI patients (Wilson & Pencharz, 1998). When diagnosis of cystic 
fibrosis has been established, PI is often inferred by clinical signs and symptoms such as, 
frequent, malodorous, greasy stools, the presence of meconium ileus, or distal intestinal 
obstruction syndrome (Borowitz, Baker & Stallings, 2002). In about 85 % of children with 
cystic fibrosis, PI is present from neonatal life. Some patients, whose tests initially 
indicate that they are PS become PI. The Consensus Report on Nutrition for Pediatric 
Patients with Cystic Fibrosis advises that PS patients should be re-evaluated annually for 
conversion to PI (Borowitz et a l 2002).
Treatment of PI in children with cystic fibrosis is based on oral replacement with 
pancreatic enzymes, usually porcine enzyme extracts. Adults with PI due to chronic 
pancreatitis or pancreatic cancer may also require pancreatic enzyme replacement therapy 
(PERT). Pancreatic enzymes are rapidly degraded by stomach acid and pepsin and 
function best in an alkaline environment. Enteric-coated microspheres have been shown to 
increase delivery of enzymes to the duodenum and distal small bowel. This results in 
improved utility, but there have been problems with miscibility of the microspheres with 
food and sub-optimal dissolution of the spheres in the relatively acid environment caused 
by inefficient alkalinisation of the duodenal contents in children with cystic fibrosis due to 
deficient bicarbonate production (Couper et a l 2002). Proton pump inhibitors, H2 
antagonists and misoprostil have all been used to either reduce stomach acid or to render 
the duodenum contents more alkaline and hence improve enzyme utility. Lipase doses 
above 25,000 units o f lipase/kg/d have been associated with fibrosing colonopathy (Smyth 
et a l 1994, 1995), which may result in intestinal obstruction secondary to colonic stricture, 
failure to thrive and abdominal pain (Schwarzenberg et a l  1995, Smyth, 1996). For this 
reason, it is recommended that lipase dose does not exceed 1 0 , 0 0 0  units/kg/d.
The aim of PERT is to achieve normal or near-normal fat and protein digestion. From this 
should follow normal nutrition, growth and development, and a normal or near-normal 
stooling pattern (Davidson, 2000). Despite prescription of adequate enzyme dosage, 10 % 
or more of children with cystic fibrosis may continue to have significant fat malabsorption, 
abdominal complaints or poor growth (Littlewood, 1996). A pancreatic function test is 
required for conversion to PI and also to optimise PERT to ensure adequate nutrition, 
while avoiding the complications associated high doses of PERT. There are three specific
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times when special attention should be focussed on growth and nutritional status. These 
are in the first twelve months after diagnosis of cystic fibrosis, birth to twelve months of 
age for infants diagnosed prenatally or at birth, and the peripubertal growth period, which 
occurs between about nine and sixteen years in girls and about twelve to eighteen years of 
age in boys (Borowitz et a l 2002).
The ideal pancreatic function test should be inexpensive, easily performed, repeatable and 
reliable (Couper et a l  2002). It should be specific for pancreatic disease and able to define 
the exact level of pancreatic function in subjects with PI in whom partial impairment of 
exocrine function is present, but nutrient assimilation is unaffected. There should be no 
interference from pancreatic enzyme supplements. None of the currently available tests 
meets all these criteria.
The classical 72-hour fat balance technique is widely used and is a measure of the 
difference between dietary fat intake and stool output (Van de Kamer, Huinick & Weyers, 
1949), but does not discriminate between PI and other causes of steatorrhea (foul smelling, 
fatty stools), e.g. untreated coeliac disease, Crohn’s disease and small intestinal bacterial 
overgrowth. It does not take endogenous lipids into account, nor does it discriminate 
between fat maldigestion and malabsorption.
The definitive test for exocrine pancreatic function is duodenal intubation with secretin- 
pancreozymin stimulation (Wong, Turtle & Davidson, 1982), but the test is invasive, 
uncomfortable, expensive and difficult to perform. However, it remains the only test 
capable of measuring functional reserve. Non-specific evidence of pancreatic 
insufficiency is provided by demonstration of unsplit fat globules on stool smear (by 
microscopy), by increased 3-day faecal fat excretion, or by evidence of fat-soluble vitamin 
deficiency (Davidson, 2000). Other currently available tests of exocrine pancreatic 
function include: serum immunoreactive trypsinogen, the pancreolauryl test, BT-PABA 
(N-benzoyl-L-tyrosyl-/?-aminobenzoic acid) or PABA test, faecal elastase-1 and faecal 
chymotrypsin (Borowitz et a l 2002, Boeck et a l 2001). The last two have the advantage 
of requiring a single stool sample and are relatively inexpensive to assay, but do not 
establish the adequacy of enzyme replacement. The faecal elastase test has been shown to 
be more sensitive and specific than the faecal chymotiypsin test, is not affected by 
concurrent administration of PERT (Loser et a l  1998, Brydon et a l  2004). Both tests 
could be used simultaneously to verify therapeutic fulfilment (Martinez-Costa, 2 0 0 2 ).
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The ^^C-mixed triacylglycerol (MTG) breath test is non-invasive, safe and avoids the need 
for stool sampling, which is greatly appreciated by patients, their parents and laboratory 
staff. It has been used to assess the need for (PERT) in children with cystic fibrosis and to 
assess the ideal dose (Amarri et a/. 1997; de Boeck et al. 1998). It has not been widely 
adopted because it lacks discrimination due to its poor specificity, resulting in too many 
false positive results caused by low recovery of in the breath of healthy subjects, and 
requires breath sampling for five to six hours in order to discriminate between PI and 
disorders of motility e.g. delayed gastric emptying. Disorders of motility have been shown 
to be present in children with cystic fibrosis (Davidson, 2000) and could result in the late 
appearance of labelled CO2 in the breath of a child with PS, although the amount of tracer 
recovered in breath (area under the cuiwe of rate of appearance versus time) might be the 
same as a healthy child.
MTG is a synthetic triacylglycerol (1,3 distearyl 2-[l-^^C] octanoyl-glycerol). Pancreatic 
lipases preferentially hydrolyse triacylglycerol at the sn-l and -3 positions, releasing ^Re­
labelled octanoate which is rapidly absorbed and oxidised with the generation of ^^ 0 0 2 . 
Quantitation of tracer excretion requires knowledge of the volume of distribution of the 
^RC-labelled tracer as well as quantity of ingested dose and abundance in breath CO2 . 
In ^^C-breath tests, labelled CO2 originating from oxidation of the tracer is diluted by 
endogenously produced CO2 from metabolic processes. Therefore knowledge of CO2 
production rate (ECO2) is required. A resting value based on basal metabolic rate is often 
assumed, but if subjects are not at rest and in the postprandial state throughout the test, this 
will be an underestimate of the tme CO2 production rate and therefore underestimate the 
quantity of tracer excreted.
The [^^CJMTG breath test is an indirect measure of fat digestion, as medium-chain fatty 
acids are absorbed without the aid of bile salts once the long-chain fatty acids have been 
hydrolysed by pancreatic lipase. Hence, it is a test of maldigestion (defective enzymatic 
degradation to absorbable products) independently from malabsorption (insufficient 
product solubilization caused by bile salt deficiency or diminished absorption resulting 
from damaged intestinal mucosa), and therefore an indication of exocrine pancreatic 
function.
Christine Slater 2004 Chapter 1, 5
Cost issues
The full economic cost of tests is difficult to calculate. Labour costs are often excluded and 
are highly variable. The full economic cost of MTG test for a 50 kg child (10 mg/kg 
MTG) is approximately £100, including tracer, salary, laboratory consumables, mass 
spectrometer maintenance and depreciation, PC consumables and indirect costs at 100% of 
salary. The cost of the [^^CjMTG amounts to half the total (£50), but if market demand 
were bigger, the price would fall. Analysis by spectroscopic methods may be cheaper, but 
the current instmments are not as sensitive as isotope ratio mass spectrometry and 
therefore a larger dose would be required. The price quoted above does not include the 
time of the clinical staff taking the breath samples, which will vary depending on whether 
an auxiliary nurse, trained nurse or research fellow is involved. The latter is relatively 
expensive because they would need to devote the whole six-hour sampling time to this 
activity, whereas a member of the nursing staff could perform other activities between 
breath samples.
The Yorkhill NHS Tmst has not calculated the full economic cost of the tests it performs, 
but an internet search revealed two hospital laboratories with price lists for their assays. 
The cost of a human pancreatic faecal elastase-1 assay at the City Hospital Birmingham is 
£25. The same test costs NZ$112 (approx £41) at the Canterbury Health Laboratories in 
Christchurch, New Zealand. The New Zealand Laboratory also quoted prices for faecal fat 
analysis (NZ$150, approx £55), faecal chymotiypsin (NZ$50, approx £20) and analysis of 
pancreatic enzymes in duodenal juice (NZ$100, approx £36). The latter does not include 
the time of the gastroenterologist and support staff necessary to obtain the sample of 
duodenal juice.
The MTG breath test is currently more expensive than its main competitor, the faecal 
elastase-1 test, as a test of exocrine pancreatic function. Neither test directly measures 
residual pancreatic function. Both tests are non-invasive and can be used to assess the 
conversion from PS to PI, but in addition, the MTG test can be used to assess the adequacy 
ofPERT.
The MTG breath test avoids the need for stool sampling, but the discrimination of the test 
must be improved if it is to be adopted into clinical practice and before any economy of 
scale can be realised.
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1.2 Dietary lipids
1.2.1 Introduction
Lipids are present in the diet in many forms. They can be overtly present as in salad oils, 
butter and margarines, or they can be concealed in cooked and processed foods such as 
biscuits, cakes and confectionery. They comprise about 40% of the energy value o f the 
average UK diet (British Nutrition Foundation, 1992). Children with cystic fibrosis are 
advised to consume a high fat diet (35-40 % energy as fat), contrary to the 
recommendation for the general population (<35 % energy as fat. Department o f Health,
1991), as fat is more energy dense than protein and carbohydrate (Borowitz et a l 2002).
To a chemist, the term lipid (from the Greek lipos, meaning ‘fat’) refers to any naturally 
occurring, nonpolar substance that is nearly or totally insoluble in water, but is soluble in 
nonpolar solvents (Bohinski, 1983). To a nutritionist, lipids are the component of the diet 
composed mainly of storage fats of mammals and fish, and the seed oils of plants (British 
Nutrition Foundation, 1992). The lipid in most foods is a mixture of triacylglycerols 
(previously referred to as triglycerides), phospholipids, sterols and related compounds. 
Triacylglycerols are the major component (92-96 %) in Western diets (Carey & Hernell,
1992). Figures quoted in nutritional tables refer to total fat and not just to the 
triacylglycerols (Holland et a l  1991).
1.2.2 Structure and nomenclature of fatty acids
A fatty acid is an aliphatic carboxylic acid with from 2 to 24 carbon atoms. The 
hydrocarbon chain terminates with a carboxyl (-COOH) group at one end and a methyl 
(-CH3) group at the other. Short chain fatty acids, or volatile fatty acids, have between two 
and six carbon atoms. Medium chain fatty acids have between 6 and 12 carbon atoms, and 
long chain fatty acids have between 14 and 24 carbon atoms. Most animal and plant 
derived fatty acids have an even number of carbon atoms in the hydrocarbon chain, 
although odd-numbered fatty acids can be synthesised by bacteria in the colon of 
monogastric animals or in the rumen o f ruminants. Fatty acids are ionised at physiological 
pH and are often referred to according to their carboxyiate form e.g. acetate, octanoate, 
palmitate (Stryer, 1988).
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When each of the carbon atoms, except the two terminal ones, is bonded to two hydrogen 
atoms, the acid is said to be saturated, since all of the bonding capacity o f the carbon is 
saturated with hydrogen. When each of two adjacent carbon atoms is bonded to only one 
hydrogen, there is a double bond between the pair of carbons and the fatty acid is said to be 
unsaturated. If the chain contains only one double bond, it is a monounsaturated fatty acid 
(MUFA) and if the chain contains more than one double bond, it is a polyunsaturated fatty 
acid (PUFA), Saturated fatty acids are given systematic names, according to the rules of 
International Union of Pure and Applied Chemistry (lUPAC), that denote the number of 
carbon atoms (Table 1.1) e.g. the 18-carbon, straight chain saturated fatty acid is 
octadecanoic acid. The presence of a double bond is indicated by the change of the suffix 
from -anoic to -enoic. An 18-carbon acid with one double bond is octadecenoic acid, and 
with two double bonds is octadecadienoic acid.
A system of common names, widely used by nutritionists, has grown up beside that of the 
official chemical nomenclature. Octadecanoic acid is also known as stearic acid. The most 
widespread form of octadecenoic acid is known as oleic acid and the most common form 
of octadecadienoic acid is known as linoleic acid. Some very long chain fatty acids (e.g. 
eicosapentenoic acid, EPA and docosahexenoic acid, DHA) do not have trivial names, but 
are usually referred to by the abbreviated form of the systemic name. A useful shorthand 
nomenclature consists of two numbers separated by a colon. The number before the colon 
signifies the carbon chain length, and the number after the colon signifies the number of 
double bonds. Thus, stearic acid is 18:0, oleic acid is 18:1 and linoleic acid is 18:2.
The position of double bonds in the hydrocarbon chain of a fatty acid is denoted by a 
prefix indicating the number o f the first of the pair of carbon atoms, which form the double 
bond. Carbon 1 is the carboxyl carbon atom. Thus, the systematic name for oleic acid is 
cA-9-octadecanoic acid and linoleic acid is C75'-9,12-octadecanoic acid.
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Table 1.1 Nomenclature of medium and long chain fatty acids
Common name/ 
abbreviation
Systematic Name-
numbers are position of double bonds from
8:0 caprylic octanoic
10:0 capric decanoic
12:0 lauric dodecanoic
14:0 myristic tetradecanoic
16:0 palmitic hexadecanoic
16:1 n-7 palmitoleic cis-9-hexadecenoic
18:0 stearic octadecanoic
18:1 n-9 oleic cis-9-octadecenoic
18:1 n-9 elaidic trans-9-octadecanoic
18:2 n-6 linoleic cis, cis-9,12-octadecadienoic
18:3 n-3 alpha-linolenic all-cis-9,12,15-octadecatrienoic
18:3 n-6 gamma-linolenic all-cis-6,9,12-octadecatrienoic
20:0 arachidic eicosanoic
20:1 n-9 gadoleic cis-11-eicosaenoic
20:4 n-6 arachidonic all-cis-5,8,11,14-eicosatetraenoic
20:5 n-3 EPA all-cis-5,8,11,14,17-eicosapentenoic
22:0 behenic docosanoic
22:1 n-9 erucic cis-13 -docosaenoic
22:6 n-3 DHA all-cis-4,7,10,13,16,19-docosahexenoic
When a fatty acid is elongated, two carbon atoms are added at the carboxyl end of the 
chain, and therefore the numbering of the double bonds in the systematic name changes 
each time the chain is lengthened.
An alternative notation, often used in metabolic studies, numbers the carbon atoms from 
the methyl terminal carbon atom rather than from the carboxyl end. Under this system, the 
shorthand notation for oleic acid is 18; 1 n-9 and that for linoleic acid is 18:2 n-6. 
Arachidonic acid is 20:4 n-6 and gamma linolenic acid is 18:3 n-6, and it is easier to see 
that the former has been formed from the latter by the addition of two carbon atoms and 
one double bond.
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Some older publications use a system of notation based on the Greek alphabet (Stryer, 
1988).
3 2  1
HsC - (CH2)n - CH2 - CH2 - COOH 
ro P a
Carbon atoms 2 and 3 are often referred to as a  (alpha) and P (beta), respectively. The 
terminal methyl carbon is the œ (omega) carbon. The position of a double bond is 
represented by the symbol A (Delta) followed by a superscript number e.g. Under
this system Cx:y A^  is the general formula for an unsaturated fatty acid (Bohinski, 1983), 
and linoleic acid is (C i8:2)A^’^  ^or cis, cw-A^’^ ^-octadecadienoic acid. If  the position of the 
double bond is denoted by counting from the terminal methyl group, the m notation is used 
e.g. arachidonic acid is an œ-6 fatty acid and alpha linolenic acid is an co-3 fatty acid 
(Marinetti, 1990).
1.2,3 Triacylglycerols
Triacylglycerol (TAG) molecules are composed of three fatty acids esterified to a glycerol 
moiety. In most natural oils and fats, the three constituent fatty acids are not randomly 
distributed (Table 1.2).
Table 1.2 Characteristic positioning of fatty acids in triacylglycerol and 
phosphoglyceride molecules
Cows’ milk fat Human milk fat Animal depot fat Phosphoglycerides
sn-\ Random 
sn-2 Random 
5W-3 Short chain
Unsaturated
Saturated
Saturated
Unsaturated and 
short chain 
Random
Saturated 
Unsaturated 
Phosphate group
British Nutrition Foundation (1992)
There is a tendency for specific fatty acids to be located at particular positions on the three 
glycerol carbons. These are given stereospecific numbers, sn~\, sn~2 and sn-3. In nature, 
the more unsaturated fatty acids tend to be found at the sn~2 position. In human milk, the 
sn-2 position tends to be occupied by palmitic acid (16:0), and unsaturated fatty acids are 
found in the sn-\ position. These specific distributions are important both in terms of the 
physico-chemical properties o f lipids and their metabolic activities.
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L2.4 Phosphoglycerides
In mammals, the lipids involved in membrane structures are mainly phosphoglycerides and 
unesterified cholesterol. Phosphoglycerides belong to the more general class of 
phosphorous containing lipids, the phospholipids, which also includes sphingomyelins and 
cerebrosides, found mainly in nervous tissue.
Phospholipids have important properties in membranes and foods because of their 
amphipathic properties i.e. they possess both hydrophilic and hydrophobic moieties. In 
contrast, hydrophobic fats, without polar groups, such as triacylglycerols are often called 
neutral, apolar or non-polar lipids.
1.2.5 Food fats
Fat makes an important contribution to the texture and palatability of foods and plays an 
important role in providing energy, especially in the diets of young children. Food fats 
usually contain small amounts o f other fat-soluble substances, including flavour 
components and vitamins. The amount of energy obtained from common fats is about the 
same, despite the different functions o f the fatty acid constituents. It is estimated that at 
least 15% of dietary energy should be provided by fat to facilitate the absorption o f the fat- 
soluble vitamins A, D, E and K. However, the indispensable role of fat in the diet is to 
provide the essential fatty acids, linoleic and a-linolenic acid and their derivatives, because 
the body cannot synthesise these from other constituents in the diet (Sanders, 1994).
Lipid in human diets is derived mainly from the storage fats of mammals, birds, fish, and 
the seed oils of plants (British Nutrition Foundation, 1992). The fatty acid profile depends 
on the source of the oil; animal fats have a higher percentage of saturated fatty acids (16:0 
and 18:0), than plants sources, such as soyabean, sunflower and maize, which contain 
higher concentrations of polyunsaturated fatty acids (18:2 and 18:3) than animal sources. 
Oleic acid (18:1) is a common fatty acid from both plant and animal sources. Fish oils are 
distinguished from mammalian and avian sources by the relatively high concentration of 
fatty acids with 20 or more carbon atoms and are normally rich in polyunsaturated fatty 
acids of the n-3 family.
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1.3 Lipid digestion, absorption and metabolism
1.3.1 Background
Approximately 92-96 % of the fat in a typical Western diet is long chain triacylglycerol 
and the rest is composed of phospholipids, free and esterified cholesterol, fat-soluble 
vitamins and other lipid-soluble components. These lipids are mixed with endogenous 
lipids originating from bile, desquamated cells and dead bacteria. Faecal fat is therefore a 
mixture of dietary, biliary, cellular and bacterial sources. In healthy subjects fat uptake is 
very efficient and faecal fat is only -2.5 % of the intake (Hernell, 2001).
1.3.2 Introduction to digestion and absorption
Digestion is the chemical breakdown of food by enzymes secreted in the mouth, stomach 
and the exocrine cells of the pancreas (Johnson, 1997). Although some digestion of dietary 
macronutrients takes place in the stomach, the final breakdown occurs in the small 
intestine (Figure 1.1). Luminal digestion is due to enzymes secreted by the salivary 
glands, stomach and pancreas. Absorption is the movement of the products of digestion 
from the intestinal lumen into the blood. Only digestion and absorption of lipids will be 
discussed here. Dietary fat must be made accessible to the enzymes, which break it down. 
This achieved by émulsification -  the formation of microscopic droplets in which the ratio 
of surface area (where enzymes can act) to volume is very large. Thus, both physico­
chemical changes and enzymatic processes must be considered in the digestion and 
absorption of lipids.
The process of digestion and preparation for absorption begins before food enters the 
mouth. The cephalic phase represents the brain’s anticipation of food through the sight, 
smell or thought of food. This is reinforced by the taste of food in the mouth. Cephalic 
stimulation of the flow of saliva occurs through activation of the parasympathetic nervous 
supply to the salivary glands (Frayn, 1996). Stimulation of gastric juice secretion also 
occurs. Lingual lipase is also secreted into the mouth from glands behind the tongue and 
soft palate. It is not thought to produce much hydrolysis o f lipids in adults, but may have 
an important role in neonates, as a large proportion of the energy in milk is in the form of 
triacylglycerol. Its pH optimum is low (-5), and it may produce some lipid hydrolysis in 
the stomach. The most important processes that occur in the mouth are the mechanical 
breakdown of food and its hydration with saliva.
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Figure 1.1 Diagram of the gastrointestinal tract
After swaUowing, the chewed food is propelled rapidly through the oesophagus into the 
stomach, where it is physically broken up further and mixed with the stomach’s digestive 
juices. Food is pounded into a creamy mixture known as chyme by the rhythmical 
contractions of the lower part of the stomach. Entry to the duodenum is regulated by the 
pyloric sphincter, which opens at regular intervals - about twice each minute. The pyloric 
sphincter only opens partially, so large particles are retained for further pummelling. 
Except for short-chain fatty acids, there is no absorption of fat from the stomach (Johnson, 
1997).
1,3.3 Small intestinal digestion
The first part o f the small intestine is the duodenum. Two important organs discharge into 
it. The gall bladder, the storage reservoir for bile salts produced in the liver, discharges its 
contents via the common bile duct. The exocrine part of the pancreas releases its 
secretions through the pancreatic duct. The common bile duct joins the pancreatic duct
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and both discharge into the duodenum (Frayn, 1996). Thus bile salts and pancreatic 
enzymes are liberated together into the small intestine.
1.3.3.1 The pancreas
The pancreas contains both exocrine and endocrine tissues. The exocrine function of the 
pancreas is to discharge digestive juices into the small intestine. The endocrine function 
consists of the production and secretion of hormones (most importantly insulin and 
glucagon) into the bloodstream. The vast majority of cells in the pancreas are exocrine.
Pancreatic exocrine secretion is an alkaline digestive juice composed of bicarbonate, water 
and enzymes such as amylase, trypsinogen and lipase. Three phases of pancreatic exocrine 
stimulation can be identified. The cephalic stage is initiated by the sight, smell or thought 
of food, and increases bicarbonate and enzyme output by a neural mechanism via the vagus 
nerve. The gastric phase starts when food distends the stomach and the hormone, gastrin is 
secreted. The most significant phase is the intestinal phase. This is mediated by the 
secretion of the hormones, secretin and cholecystokinin (CCK). Both of these hormones 
are secreted by specific endocrine cells in the intestinal epithelium of the duodenum and 
jejunum, with low concentrations found elsewhere in the gut. Secretin stimulates the 
output of fluid and bicarbonate by the pancreas and is released in response to gastric acid 
entering the duodenum. CCK secretion is initiated by the presence of fatty acids and 
amino acids in the proximal small intestine and stimulates pancreatic enzyme production 
(Woodward & Colagiovanni, 1998), but also slows gastric motility and emptying when fat 
is in the small intestine (Johnson, 1997).
1.3.3.2 Micelle formation and triacylglycerol digestion
Lipid digestion and absorption depend upon émulsification of triacylglycerol and 
formation of micelles. The main emulsifying agents are the bile salts. Bile salts are 
derivatives of cholesterol, which are synthesised in the liver and secreted in bile in the 
form of covalent conjugates. The major bile salts are sodium glycocholate -  a conjugate of 
cholic acid and glycine, and sodium taurocholate -  a conjugate of cholic acid and taurine. 
Bile salts are amphipathic molecules with a predominantly non-polar ring structure and a 
highly polar acidic group. As lipid digestion proceeds, further amphipathic molecules are 
formed, which may help émulsification. These include monoacylglycerols and 
phospholipids. Micelles form an oil-in-water emulsion by the non-polar tails of the
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amphipathic molecules stabilising small groups of non-polar molecules, predominantly 
triacylglycerol. The polar end faces outwards to the aqueous environment of the intestinal 
contents. A net repulsive action of the outward facing polar groups also tends to split the 
lipid droplets further, resulting in a finer and finer emulsion. These emulsified particles are 
typically 1 pm in diameter. It is in this form that most of the hydrolysis of triacylglycerols 
proceeds (Frayn, 1996).
Pancreatic lipase (EC 3.1.1.3) is a family o f lipases that act on the ester links in the 1 and 3 
positions in an acylglycerol, but not the 2-position. Thus fatty acids are liberated and 
2-monoacylglycerol remains. Pancreatic lipase has optimum activity at pH 8 and remains 
active down to pH 3. Although bile salts inhibit its activity, this is prevented under 
physiological circumstances by the combination of lipase with colipase, which is secreted 
by the pancreas as procolipase in a 1:1 ratio with lipase. Procolipase is activated by 
trypsin. Lipase-colipase complexes are scarce within the duodenum during fasting, but the 
presence of fat stimulates their secretion in large quantities. Colipase can replace bile salts 
at the oil-water interface. Once colipase is attached to the fat droplet, lipase binds to a 
specific site on the colipase molecule in a 1:1 ratio and consequently carries out its 
catalytic function, hydrolysing fatty acids from the 1 and 3 positions of a triacylglycerol. 
There is very little hydrolysis of the ester bond at position 2 and very little isomerization 
to 1 (3)-monoacylgIycerol, presumably because of rapid uptake of the monoacylglycerol 
into epithelial cells (Gurr, Harwood & Frayn, 2002).
Both fatty acids and monoacylglycerols have amphipathic properties. The 
monoacylglycerol is an effective emulsifying agent and aids in the action o f bile salts. 
Gradually, much smaller groups of molecules are formed -  the mixed micelles. Mixed 
micelles contain bile salts and other molecules, particularly fatty acids and 
raonoacyglycerols and are typically 4-6 nm in diameter. They are so small that they can 
diffuse easily through the unstirred aqueous layer overlying the enterocytes (Figure 1.2) 
and thus bring the products of triacylglycerol hydrolysis, i.e. non-esterified fatty acids and 
monoacyglycerols, to the surface of the absorptive cells.
1.3.4 Lipid absorption
The bmsh border membrane is separated from the bulk solution of the intestinal lumen by 
the unstirred aqueous layer. Non-esterified fatty acids and monoacylglycerols are poorly 
soluble in water and therefore move slowly across this barrier. Since uptake depends on
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the number of molecules in contact with the enterocyte membrane, their absorption is 
diffusion limited. In contrast, mixed micelles are water soluble, diffuse readily through the 
unstirred layer and increase the concentration of fatty acids and monoacylglycerols at the 
membrane by 100- to 1000-fold. Short- and medium-chain fatty acids are not dependent 
on micelles for uptake because of their higher solubility in and diffusion through the 
unstirred aqueous layer (Johnson, 1997).
Solutes moving across the enterocyte from the intestinal lumen to the blood must traverse 
an unstirred layer of fluid, a glycocalyx covering the microvilli, the apical cell membrane, 
the cytoplasm of the cell, the basal or lateral cell membrane, the basement membrane, and 
finally the wall of the capillary or lymph vessel (Figure 1.2). Microvilli are morphological 
modifications of the cell membrane and comprise the brush border.
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Figure 1.2 Schematic diagram of the mucosal barrier
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Figure 1.3 Schematic diagram of a typical animal cell
1.3.4.1 Absorption of long-chain fatty acids
It was thought that uptake of monoacylglycerols and fatty acids by the intestinal epithelial 
cells (enterocytes) occurred by simple diffusion, but there is evidence of protein-mediated 
transport processes (Frayn, 1996). It is possible that both protein-mediated and diffusional 
mechanisms contribute to the in vivo movement of fatty acids (Frohnert & Bernlohr, 2000). 
Several candidate proteins have been identified: the first was plasma membrane fatty acid 
binding protein (PABPpm), which was isolated from rat liver plasma (or cell) membranes. 
PABPpm is expressed on the plasma membrane of liver, adipose tissue, cardiac muscle 
intestinal and vascular epithelium as well as internal membranes (Frohnert & Bernlohr, 
2000). PABPpm is not related structurally to the family of intracellular fatty acid binding 
proteins (Gurr et al. 2002). Fatty acid transport protein (FATP) is also found in the liver. 
It is an integral membrane protein found in the plasma membrane and internal membranes. 
It is highly expressed in adipose tissue, skeletal muscle and heart, but is also expressed at 
lower levels in liver, brain, kidney and lung (Frohnert & Bernlohr, 2000).
Once inside the cell, fatty acids must be ‘activated’ before taking part in metabolic 
reactions. The active form is usually the thiolester of the fatty acid with the complex 
nucleotide, coenzyme A (CoA) or the small protein known as acyl carrier protein (ACP).
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Both these molecules contain a thiolester, which renders the acyl chains water soluble 
(Gurr et a i 2002). The formation of acyl-CoAs is catalysed by acyl-CoA synthetases. The 
acyl-CoA synthetases differ from each other with respect to their subcellular location and 
their specificity for fatty acids of different chain lengths. Their overlapping chain length 
specificities and tissue distributions mean that most fatty acids in the range 2-22C can be 
activated, although at different rates. Originally, it was thought that short-, medium- and 
long-chain isoforms were often present, but molecular biology techniques have revealed 
many more.
Within the enterocyte, long-chain fatty acids and monoacylglycerols are re-esterified to 
form new triacylglycerol molecules. This occurs mainly by the monoacylglycerol 
estérification pathway, which begins with monoacylglycerol, unlike most other tissues in 
which the formation of triacylglycerols occurs by the phosphatidic acid pathway, which 
begins with glycerol-3-phosphate. The monoacylglycerol estérification pathway involves 
the synthesis of triacylglycerols from 2-monoacylglycerols and coenzyme A (CoA)- 
activated fatty acids. The enzymes involved in this pathway are associated with the 
smooth endoplasmic reticulum (Figure 1.3 and Section 1.3.5.2). Certain fatty acids are 
used in preference to others, and this occurs despite similar rates of absorption by 
enterocytes and similar rates of enzymatic Co-A activation and acylglycerol estérification. 
These observations have been explained by the presence of intracellular FABP’s, which 
have affinities for fatty acids of different chain lengths and varying degrees of saturation, 
and which may play a role as carriers and for intracellular storage.
Absorbed fatty acids bind strongly to the apical membrane of enterocytes. Solubilization is 
brought about when the fatty acids bind specifically with receptors on FABP’s. This 
facilitates the transfer of the non-esterified fatty acids from the apical membrane, through 
the cytosol to the smooth endoplasmic reticulum, where estérification to diacylglycerols 
and triacylglycerols takes place (Johnson, 1997).
Triacylglycerols form lipoprotein particles, chylomicrons, with phospholipids and proteins, 
particularly apolipoprotein B. Chylomicrons are typically 100 nm -  1 pm in diameter and 
are the largest of the lipoprotein particles present in blood. Synthesis of both 
triacylglycerol and apolipoprotein B occurs in the endoplasmic reticulum, where they form 
complexes with phospholipids. This complex is transported to the Golgi apparatus (or 
Golgi body), where the protein is glycosylated. Newly formed chylomicrons are secreted 
by exocytosis into the interstitial space, traverse the basement membrane, and enter the
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gaps between the endothelial cells, which comprise the lacteal s. From there they flow 
slowly into more major branches of the lymphatic system, up the thoracic duct and thence 
into the circulation. Chylomicrons are too large to enter the pores of capillary blood 
vessels.
The process described above is summarised in Figure 1.4, but only applies to long-chain 
(Ci6 or more) fatty acids. Short- and medium-chain fatty acids are present in the diet in 
dairy products, but most dietary fatty acids are long-chain and enter the bloodstream as 
chylomicron-triacylglycerol. This route of absorption means that dietary triacylglycerols, 
unlike other nutrients, bypass the liver on their entry into the circulation. Most of the 
triacylglycerol is removed from chylomicrons in tissues outside the liver, particularly 
adipose tissue and to a lesser extent skeletal muscle and heart (Frayn, 1996).
Non-esterified fatty acids are liberated from adipose tissue in the post-absorptive state i.e. 
when all of the last meal has been absorbed from the intestinal tract, but not much 
thereafter. In humans, this is usually represented by the state after an overnight fast before 
breakfast is consumed. After an overnight fast, the concentration of non-esterified fatty 
acids in plasma is around 0.5 mM, and the total triacylglycerol concentration is around 
1 mM. The chylomicron triacylglycerol concentration will be very low, usually less than 
0.05 mM. Lipid fuels are an important energy source at this time. The turnover of non- 
esterified fatty acids involves their liberation fi-om adipose tissue and uptake by a number 
of tissues, predominantly skeletal muscle and liver.
1.3.4.2 Absorption of short- and medium-chain fatty acids
Short- and medium-chain fatty acids show less affinity for the enterocyte cell membrane, 
are water-soluble and are not bound to specific proteins. They are not esterified within 
enterocytes because the specific medium-chain acyl-CoA synthetase (EC 6.2.1.2) required 
for their activation is not present (Frayn, 1996). Therefore, they enter the capillary plasma 
directly in the form of non-esterified fatty acids and are transported into portal blood 
without involvement of chylomicrons. Short- and medium-chain fatty acids are carried 
jfrom the small intestine to the liver via the portal vein, weakly bound to albumin. Their 
uptake by the liver reaches from 80 to 100 % of the portal flux. The remaining fraction is 
discharged into the bloodstream and is available to peripheral tissues (Guillot ei al. 1993).
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Figure 1.4 Digestion and absorption of dietary triacylglycerol in the small intestine
Lipid droplets entering the small intestine from the stomach are subjected to the action of 
pancreatic lipase, which hydrolyses triacylglycerol (TAG) to produce monoacylglycerols 
(MAG) and fatty acids (FA). These are emulsified with bile salts (from the gall bladder) to 
produce a micellar suspension (the mixed micelles) from which components are absorbed 
across the epithelial cell (enterocyte) membranes. Short- and medium-chain fatty acids 
pass through into the portal vein, and are carried to the liver. Bile salts are reabsorbed in 
the lower part of the small intestine. Within the enterocyte TAG is reformed from MAG 
and FA, and packaged into chylomicrons (the largest of the lipoprotein particles). 
Chylomicrons are secreted into small branches of the lymphatic system, the lacteals and 
eventually enter the circulation via the thoracic duct.
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1.3.5 Lipid metabolism in the liver
1.3.5.1 Structure and function of the liver
The portal vein is short (7-8 cm in length) and is formed by the union of veins from 
different parts of the intestinal tract, including the stomach. These veins carry water- 
soluble substances absorbed from the intestinal tract to the liver, and thereafter via the 
hepatic veins to the heart.
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Figure 1,5 Arrangement of hepatocytes
The major part of the liver (80 % by volume) is composed of hepatocytes. These are 
arranged as hexagonal units or lobules (Figure 1.5). At the corner of the hexagon is a triad 
of three blood vessels, which are tiny branches of the portal vein, hepatic artery and bile 
duct. In the centre of the lobule is branch of the hepatic vein, which carries blood away. 
The hepatocytes radiate outwards from the central vein. Blood flows from the triads 
towards the central vein in small passages between the hepatocytes, the sinusoids. 
Sinusoids are the equivalent of the capillaries found in other tissues and are lined with flat 
endothelial cells, as are all capillaries. The blood in the sinusoids is in intimate contact 
with the hepatocytes.
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The precise arrangement of hepatocytes within the liver is closely related to the function of 
the cells. This is known as the metabolic zonation of hepatic metabolism. The periportal 
hepatocytes on the outside of each lobule are exposed to blood that has recently arrived at 
the liver in the hepatic portal vein and hepatic artery. Thus these cells are well oxygenated 
and supplied with substrates, and oxidative metabolism predominates. The synthesis of 
glucose (gluconeogenesis) occurs mainly in these cells, whereas the cells nearer the centre 
of each lobule (perivenous hepatocytes) are more involved in glycolysis and ketone body 
production. This arrangement is very flexible, and each individual cell can perform either 
function depending upon its location in the lobule and the prevailing physiological 
circumstances (Frayn, 1996).
1.3.5.2 Hepatocyte structure and function
The internal structure of a typical hepatocyte is comparable to that shown in Figure 1.3. 
The cell membrane or plasma membrane serves as the interface between the interior of the 
cell and its external environment. Cell membranes are composed of a phospholipid 
bilayer, which is differentially permeable i.e. permits water molecules to pass through, but 
is a barrier to the easy passage of ions such as Na^, K'*', CF. The phospholipid bilayer has 
associated proteins, some of which are much more intimately associated with the lipids 
than others. The proteins that are less closely allied to lipids tend to be quite hydrophilic 
glycoproteins and are known as extrinsic proteins. They occur on both the outer and inner 
surface o f the membrane. The extrinsic proteins probably do not penetrate into the 
phospholipid bilayer of the membrane. Other proteins penetrate into and, in some cases, 
all the way through the lipid bilayer. These are intrinsic proteins such as transport 
proteins. The cell membrane is not symmetrical. The extrinsic proteins associated with 
the outer surface of the membrane are usually different from those associated with the 
inner surface (Kimball, 1978).
The nucleus is responsible for replication. Several kinds of RNA molecules are 
synthesised in the nucleolus. Some of this RNA is used in the assembly of ribosomes. 
Ribosomes are essential for protein synthesis in the cell. The term cytoplasm is 
traditionally used to describe everything within the cell except the nucleus. Electron 
microscopy reveals the extraordinary complexity of structures within the cytoplasm. These 
clearly defined structures are called organelles. Cytosol is the fluid in which the organelles 
are suspended. It is an aqueous solution of small molecules, ions and proteins. A number 
of important enzymes are found in the cytosol, including some of those involved in de
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novo lipogenesis (Section 1.3.5.3), but most of the functions of the cytoplasm are the 
functions of the organelles located in it.
Mitochondria are spherical or rod shaped bodies that range in size from 0.2 jum to 5 |Lim. 
Muscle mitochondria are typically sausage-shaped and several micrometers long, whereas 
liver mitochondria are more nearly spherical, 1-2 p.m diameter. Hepatocytes, as 
metabolically very active cells, may have over a thousand mitochondria.
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Figure 1.6 Schematic drawing of a mitochondrion
Each mitochondrion is bounded by a double membrane (Figure 1.6). The outer membrane 
provides a smooth, uninterrupted boundary to the mitochondrion. The inner membrane is 
repeatedly extended into folds that project into the inner space of the mitochondrion. 
These inner folds are called cristae. The membranes of the mitochondria are similar to 
those of the cell membrane. They contain phospholipid and protein. Some of the protein 
is extrinsic, but much of it is intrinsic i.e. embedded in the lipid bilayer. Mitochondria 
contain the enzymes that carry out the oxidation of sugars, amino acids and fatty acids 
from the diet, and are the site of cellular respiration via the TCA (tricarboxylic acid) cycle.
Ribosomes are amongst the smallest structures suspended in the cytoplasm (-20 nm). They 
are the site at which protein synthesis takes place. Some of the proteins are simply added 
to the cytosol and perform their function there; others are packaged in some type of
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membrane-bound organelle and are ultimately secreted from the cell. The ribosomes that 
secrete these proteins are attached to the membranes of the endoplasmic reticulum.
The endoplasmic reticulum is an elaborate system of membranes within the cell, which are 
probably interconnected with each other. The membranes have a lipid-protein structure 
similar to that of other membranes in the cell. Each membrane of the endoplasmic 
reticulum has one surface that faces the cytosol and one that faces the interior of the cavity. 
Evenly spaced ribosomes adhere to the cytosol-facing surface of the reticulum membranes. 
Ribosome-studded endoplasmic reticulum is known as rough endoplasmic reticulum. 
Proteins and polypeptides synthesised by the ribosomes are deposited in the interior space 
of the reticulum. As this happens further processing of the polypeptide takes place, such as 
the formation of disulphide bonds between cysteine residues or glycosylation. The 
proteins synthesised by the rough endoplasmic reticulum are thus packed within a 
membrane. They may remain to be used within the cell or they may be secreted from the 
cell. Endoplasmic reticulum is also found without adhering ribosomes. This is called 
smooth endoplasmic reticulum and is involved in the synthesis of fats, phospholipids and 
steroids. It may be the source of the membranes that make up the Golgi apparatus.
The Golgi apparatus (or Golgi body) consists of a stack of flat membrane-bounded sacs. 
Proteins synthesised by the rough endoplasmic reticulum are transferred to the Golgi 
apparatus, Here additional carbohydrate may be added. Proteins accumulate within the 
sacs o f the Golgi apparatus until they are stuffed with protein. These protein-filled sacs 
may migrate to the surface of the cell and discharge their contents to the outside. Others 
may be retained within the cell as lysosomes.
Lysosomes are roughly spherical structures bounded by a single membrane and filled with 
hydrolytic enzymes that digest polysaccharides, lipids, phospholipids, nucleic acids and 
proteins. They are prevented from digesting the other components of the cell by 
confinement within the lysosome. Lysosomes play an important role in the death of cells. 
When a cell is injured or dies, its lysosomes aid in its disintegration. This clears it away so 
that a healthy cell can replace the damaged one.
Peroxisomes are about the size of lysosomes and are bounded by a single membrane. They 
are filled with catalase, which catalyses the breakdown of hydrogen peroxide (H2O2), a 
potentially dangerous product of cell metabolism produced during peroxisomal P-oxidation 
of fatty acids.
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1.3.5.3 Fatty acid metabolism in the liver
Summary
The main pathways of fatty acid metabolism in the liver, and their hormonal regulation are 
shown in Figure 1.7. The liver, like many other tissues, may take up non-esterified fatty 
acids from the plasma. These occur due to leakage from the peripheral tissues after 
lipoprotein lipase action, or after hydrolysis of adipose tissue triacylglycerol, or within 
remnant lipoproteins as triacylglycerol or cholesteryl esters. Short- and medium-chain 
fatty acids are carried directly to the liver via the hepatic portal vein. Fatty acids have two 
major fates within the liver: oxidation or acylglycerol formation (triacylglycerol and 
phospholipids).
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Figure 1.7 Fatty acid metabolism in the liver
The liver may oxidise fatty acids by the mitochondrial p-oxidation pathway to produce 
energy for its metabolic activities. Gluconeogenesis, an energy requiring process, appears 
to be fuelled by oxidation of fatty acids (Frayn, 1996). During the oxidation of fatty acids 
in the liver, the ketone bodies acetoacetate and 3-hydroxybutyrate are produced and 
exported into the circulation to provide energy rich substrates to the periphery. Ketones 
can substitute for glucose in muscle and brain at times of reduced dietary intake. The rate 
of ketogenesis in the liver is determined by the rate of fatty acid oxidation, which in turn is
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determined by the availability of fatty acids and the balance between their two fates in the 
liver. The alternative fate of fatty acids taken up by the liver is estérification to form 
triacylglycerol, which is stored within hepatocytes. Hepatic triacylglycerol can be 
mobilised to be incorporated into very-low-density lipoprotein (VLDL) and secreted from 
the liver into the bloodstream. Accumulation of triacylglycerol can occur when the supply 
of fatty acids to the liver exceeds the rate of oxidation and VLDL-triacylglycerol secretion 
in certain pathological conditions. Insulin and glucagon control the balance between fatty 
acid oxidation and estérification in the liver.
Long-chain fatty acid metabolism in the liver
Long chain fatty acids cross the hepatocyte membrane by a carrier mediated process 
(Frayn, 1996). Inside the hepatocyte they are transported through the cytosol by binding to 
specific fatty acid-binding proteins. Further metabolism of long-chain fatty acids is 
dependent upon their activation by forming thioesters with coenzyme-A (CoASFI). Acyl- 
CoA synthetase (EC 6.2.1.3) activates fatty acids containing from six to 20 carbon atoms 
and occurs on the outer mitochondrial membrane, in endoplasmic reticulum and 
peroxisomes (Gurr et a l 2002). In animals, it is thought that mitochondrial and 
peroxisomal acyl-CoA synthetases are used for fatty acid oxidation, whilst the endoplasmic 
reticulum enzyme is used for lipid biosynthesis.
CoASH + R-COOH R-CO.SCoA + H2O (1.1)
Coenzyme A + fatty acid thioester (acyl-SCoA) + water
The enzymes participating in the degradation of the acyl group (by (I-oxidation) are located 
in mitochondria and peroxisomes. This compartmentalisation requires the passage of acyl- 
SCoA from the cytoplasm into the organelle. However, the inner mitochondrial membrane 
is impermeable to CoA, therefore fatty acyl-CoAs formed in the cytosol cannot enter the 
mitochondria directly for oxidation. This barrier is overcome by the participation of 
carnitine, which serves as an acyl-group carrier. Estérification of the fatty acid with 
carnitine is catalysed by carnitine O-palmitoyltransferase-1 (CPT-1, CPT-I or CPTo, EC 
2.3.1.21), that is found on the outer mitochondrial membrane. This enzyme is able to 
transfer a variety of fatty acyl groups from coenzyme A to carnitine. There is a specific 
carrier to transport fatty acyl-carnitine across the outer membrane. In order to achieve 
effective transport of acyl-SCoA, carnitine palmitoyltransferase activity is also present on 
the inner surface of inner mitochondrial membrane (Figure 1.8).
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The properties of the enzymes in the two locations are different and the ‘outer’ enzyme is 
known as carnitine palmitoyltransferase-1 (CPT-1) and the ‘inner’ enzyme is known as 
carnitine palmitoyltransferase-2 (CPT-2, CPT-II or CPTi). These two proteins are the 
products of different genes (Zammit, 1999a). CPT-1 generates acyl-carnitine (from acyl- 
SCoA), which is transported across the inner membrane, after which CPT-2 regenerates 
acyl-SCoA and free carnitine. The latter is transported out of the mitochondrion by the 
same carrier that transports acyl carnitine in. In fact, the entry of acyl-carnitine is 
obligatorily linked to the exit of carnitine.
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Figure 1,8 Movement of acyl residues Into mitochondria via carnitine 
ACS = acyl-CoA synthetase; T = translocase; CPT = carnitine palmitoyltransferase
CPT-1 is inhibited by malonyl-CoA (McGarry & Foster, 1980), an intermediate in the 
pathway of hepatic de novo lipogenesis (Figure 1.13). Glucagon increases fatty acid 
oxidation, by lowering malonyl-CoA concentrations. By contrast, in ‘fed’ conditions, 
when insulin is elevated, malonyl-CoA levels will be high and fatty acid oxidation will be 
inhibited. Fatty acids will tend to be esterified to form triacylglycerol. This process also 
appears to be stimulated by insulin, although the exact locus of control is not clear (Frayn, 
1996). Hence in the fed state, the liver tends to divert a higher proportion of fatty acid 
metabolism towards acylglycerol synthesis, rather than oxidation.
Peroxisomes and the endoplasmic reticulum also have CPTs, which are identical to CPT-1 
and are also severely inhibited by malonyl-CoA. The collective term for all of these
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transferases is CPTo, so termed because of the overt or cytosol-facing active site (Zammit, 
1999a,b).
Medium- and short-chain fatty acid metabolism in the liver
Medium- and short-chain fatty acids are highly ionised at physiological pH and therefore 
soluble in aqueous biological fluids. Their small size and water solubility enables them to 
cross the cell membrane by facilitated diffusion, which is also know as passive diffusion or 
passive transport. This is made possible by membrane proteins that provide a pathway for 
specific solutes through the lipid bilayer. These membrane proteins are known as 
transporters or permeases (Nelson & Cox, 2000). Transporters are not enzymes in the usual 
sense; their ‘substrates’ are moved from one compartment to another, but are not 
chemically altered. Transporters span the lipid bilayer at least one and usually several 
times, forming a transmembrane channel lined with hydrophilic amino acid side chains. 
The channel provides an alternative route for a specific substrate to move across the lipid 
bilayer without having to dissolve in the bilayer. The result is an increase in the rate of 
transmembrane passage of the substrate, of orders of magnitude. The rate of uptake is 
proportional to the difference in the concentrations inside and outside the cell.
In all tissues, mitochondria are the main oxidative site of medium-chain fatty acids. 
Although activation of medium-chain fatty acids can occur in the cytoplasm (Zammit, 
1984), it takes place mostly in the mitochondrial matrix, where a medium-chain acyl-CoA 
synthetase has been found. Medium-chain acyl-CoA synthetase (EC 6.2.1.2*) activates 
fatty acids containing from four to twelve carbon atoms. Although carnitine
0-octanoyltransferase (EC 2.3.1.137) is found in liver mitochondria, octanoate oxidation is 
not limited by mitochondrial transport (Groot & Hulsmann, 1973) and carnitine 
0-octanoyltransferase is not inhibited by malonyl-CoA to the same extent as carnitine 
O-palmitoyltransferase-1 under either fasting or fed conditions (Saggerson & Carpenter, 
1981). The oxidation rate of medium-chain fatty acids is faster than that of long-chain 
fatty acids. Medium-chain fatty acids are extensively oxidised by the liver regardless of 
the physiological state of the subject (Bach, Ingenbleek & Frey, 1996).
*Enzyme classification number according to the recommendations of the International 
Union of Biochemistry and Molecular Biology (lUBMB) - a system introduced to avoid 
confusion caused by some enzymes having several common names. The database can be 
searched at http://www.chem.qmul.ac.uk/iubmb/enzyme.
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1.3.5.4 Beta-oxidatioii
The mitochondrial |3-oxidation pathway is quantitatively the most important route of fatty 
acid oxidation. The mechanism was originally proposed by Knoop in 1904 (Stenesh, 1999, 
Gurr et al. 2002). The process consists of four steps (Figure 1.9); dehydrogenation, 
addition of water to the resulting double bond, oxidation of the (3-hydroxyacy 1-CoA to a 
ketone, and thiolytic cleavage by coenzyme A, which results in the cleavage of two 
carbons at a time from the acyl chain. The 2C product, acetyl-CoA, may then enter the 
TCA cycle (Section 1.3.5.5) and the acyl-CoA (two carbons shorter) is recycled. The 
enzymatic stages of mammalian mitochondrial P-oxidation were elucidated 30-40 years 
ago, but molecular biology techniques have revealed many more isoforms than was 
previously assumed. Eaton, Bartlett & Pourfarzam (1996) reviewed the enzymological and 
organisational aspects of mitochondrial p-oxidation together with its intrinsic control.
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Figure 1.9 M itochondrial p-oxidation pathway
Each of the four enzymes involved (acyl-CoA dehydrogenase, EC 1.3.2.2; enoyl hydratase, 
EC 4.2.1.17; L-3-hydroxyacyl-CoA dehydrogenase, EC 1.1.1.35; acyl-CoA:acetyl-CoAS 
acyltransferase, EC 2.3.1.16, a thiolase) are present as isoforms that have varying chain- 
length specificities. Three of the enzymes (enoyl hydratase, 3-hydroxyacyl-CoA 
dehydrogenase (EC 1.1.1.211) and thiolase) have their long-chain isoforms present on the 
inner mitochondrial membrane. All the other isoforms of the enzymes are soluble in the 
mitochondrial matrix. There is evidence of metabolite channelling between individual
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enzymes. This improves the efficiency of p-oxidation and prevents intermediates building 
up, which could be inhibitory or lead to a greater requirement for scarce CoA (Eaton et a l 
1996). As a generalisation, it is thought that long-chain acids are oxidised by the 
membrane located enzymes while medium-chain substrates use the matrix enzymes (Liang 
et a i 2001).
Acetyl-CoA from mitochondrial p-oxidation of fatty acids is the substrate for two 
competing reactions: with oxaloacetate to form citrate in the TCA cycle (Figure 1.10) and 
with acetoacetyl-CoA to form ketone bodies (ketogenesis). Which reaction predominates 
depends partly on the rate of p-oxidation and partly on the availability of oxaloacetate. 
The proportion of acetyl groups entering the TCA cycle relative to ketogenesis is 
sometimes referred to as the ‘acetyl ratio’. Availability of fatty acids and the rate of 
utilisation of P-oxidation products control the overall rate of p-oxidation.
An active p-oxidation pathway is present in peroxisomes as well as mitochondria. This 
pathway is particularly important in the liver and kidneys. In fact, in the liver it seems that 
mitochondria and peroxisomes collaborate in overall fatty acid oxidation (Gurr et al. 
2002). Very long-chain fatty acyl-CoA is oxidised to medium-chain products in 
peroxisomes. The medium-chain fatty acids are then transported to mitochondria for 
complete P-oxidation or to the endoplasmic reticulum, where they may form glycerolipids. 
The final fate depends on the identity of the acyl chain (Sprecher et al. 1995).
Peroxisomal p-oxidation has been estimated to contribute up to 30 % (Frayn, 1996) or 
50 % (Gurr et al. 2002) of the total rate of hepatic fatty acid oxidation. A high fat diet, 
such as that recommended to children with cystic fibrosis, increases the rate of 
peroxisomal P-oxidation. Thus, although medium-chain fatty acids comprise only a small 
portion of dietary fatty acids, they are not unusual substrates for mitochondrial P-oxidation 
in the liver as they are produced during intermediary metabolism in this tissue.
1,3,6 Acetate metabolism in the liver
1.3.6.1 The tricarboxylic acid (TCA) cycle
The tricarboxylic acid (TCA) cycle is also known as the citric acid cycle or the Krebs 
cycle, after the metabolic studies of Hans Krebs, who won the Nobel Prize in 1953 for 
elucidating the reaction sequence (Figure 1.10). The TCA cycle is a hub in metabolism
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integrating the m etabolic flow o f  carbon am ong the main classes o f  biom olecules, w ith 
degradative pathways leading in and anabolic pathways leading out. It is closely regulated 
in coordination with other pathways.
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Figure 1.10 Reactions of the TCA Cycle
The carbon atoms shaded in pink are those derived from the acetate o f  acetyl-CoA in the 
first turn o f  the cycle; these are not the carbons released as CO 2 in the first turn. In 
fumarate, the tw o-carbon group derived from acetate can no longer be identified, because 
succinate and fum arate are symmetrical m olecules, C -I and C-2 are indistinguishable from 
C-4 and C-3. Steps (I) , (3) and (4) are irreversible in the cell; all o ther steps are reversible.
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Acetyl-CoA from mitochondrial P-oxidation of fatty acids (or oxidation of glucose and 
some amino acids) donates its acetyl group to the four-carbon compound oxaloacetate 
(OAA) to form the six-carbon citrate. Citrate is then transformed into isocitrate, also a six- 
carbon molecule, which is dehydrogenated with loss of CO2 to yield the five-carbon 
a-ketoglutarate (a~KG). Alpha-KG undergoes loss of CO2 and ultimately yields the four- 
carbon compound succinate. Succinate is then enzymatically converted in three steps into 
the four-carbon oxaloacetate, with which the cycle began. OAA is then ready to react with 
another molecule of acetyl-CoA. In each turn of the cycle, one acetyl group (2 carbons) 
enters as acetyl-CoA and two molecules of CO2 leave. One molecule of OAA is used to 
form citrate, but after a series of reactions, the OAA is regenerated. No net removal of 
OAA occurs and OAA is present in cells at very low concentrations.
The TCA cycle is an amphibolic pathway, i.e. one that serves in both catabolic and 
anabolic processes. Besides its role in the oxidative catabolism of carbohydrates, fatty 
acids and amino acids, the cycle provides precursors for many biosynthetic pathways 
(Figure 1.11). For example, a-KG and OAA can serve as precursors of the amino acids, 
glutamate and aspartate by transamination. Through aspartate and glutamate, the carbons 
of OAA and a-KG are then used to build other amino acids as well as purine and 
pyrimidine nucleotides. OAA is converted to glucose in gluconeogenesis. Succinyl-CoA 
is a central intermediate in the synthesis of the poiphyrin ring of haem groups, which serve 
as oxygen carriers in haemoglobin and myoglobin (Nelson & Cox, 2000). Quantitatively, 
synthesis of aspartate and glutamate from OAA and a-KG are the most important. The 
mitochondrial membrane is impermeable to OAA and a-KG, therefore these intermediates 
are removed in the form of their precursors-malate and isocitrate, respectively (Figure 
1.10), which can be transported across the membrane. The action o f dehydrogenase 
enzymes produces OAA and a-KG in the cytosol.
As intermediates of the TCA cycle are removed to serve as biosynthetic precursors, they 
are replenished by anaplerotic reactions (Figure 1.11). Under normal circumstances, the 
reactions by which cycle intermediates are siphoned off into other pathways and those by 
which they are replenished are in dynamic equilibrium. Thus, concentrations of the TCA 
cycle intermediates remain almost constant. The most important anaplerotic reaction in 
mammalian liver is the reversible carboxylation of pyruvate by CO2 to form OAA. When 
the TCA cycle is deficient in OAA or any other intermediates, pyruvate is carboxylated to 
produce more OAA.
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Figure 1.11 Role of the TCA cycle in anabolism
Intermediates o f  the TCA cycle are drawn o ff in many biosynthetic pathways. Shown in 
red are anaplerotic reactions that replenish depleted cycle intermediates.
The flow o f  carbon atom s into and through the TCA cycle is under strict regulation at two 
levels: the conversion o f  pyruvate to acetyl-CoA and the entry o f  acetyl-CoA into the 
cycle. Follow ing a mixed meal, glucose is transported into the liver and phosphorylated to 
form glucose-6-phosphate, which can be metabolised to  pyruvate via glycolysis in 
hepatocytes. Pyruvate is converted to  acetyl-CoA, but acetyl-CoA is produced by the 
oxidation o f  fatty acids and certain am ino acids, as well as from pyruvate, therefore 
availability o f  interm ediates from  these pathw ays is also im portant in the regulation o f  
pyruvate oxidation and o f  the TCA  cycle.
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1.3.6.2 Fatty acid biosynthesis
Chapter 1, 33
In humans, fatty acid biosynthesis consists of de novo synthesis, where a small precursor 
molecule (usually acetyl-CoA) is gradually lengthened by 2C units to give rise to 16C and 
18C products. This can be followed by various modifications of which elongation and 
desaturation are the most important.
The starting point of de novo lipogenesis may be glucose or amino acids, which can form 
pyruvate or acetyl-CoA, or acetyl-CoA from P-oxidation of fatty acids. The pathway 
occurs in the cytosol of both hepatocytes and adipocytes, but acetyl-CoA is mainly 
generated in mitochondria. Under conditions favouring fatty acid biosynthesis, pyruvate is 
transported into mitochondria, where pyruvate dehydrogenase is activated (Figure 1.13) 
and acetyl-CoA is produced. Acetyl-CoA is also produced during P-oxidation o f fatty 
acids (Figure 1.9). Acetyl-CoA is combined with oxaloacetate to produce citrate, which 
leaves the mitochondria via a tricarboxylate anion carrier. In the cytosol, acetyl-CoA is 
produced by ATP:citrate lyase (Gurr et a l 2002).
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Figure 1.12 Acetyl-CoA generation for de novo fatty acid biosynthesis
1: pyruvate dehydrogenase; 2: pymvate carboxylase; 3: tricarboxylate anion carrier; 
4: ATP:citrate lyase; 5: malic enzyme; 6 : PEP carboxykinase
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The process of de novo synthesis to produce long-chain fatty acids involves two enzymes, 
acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). Both of these are complex 
and catalyse multiple reactions (Figure 1.13). The intermediates at all steps of the reaction 
are attached to a protein known as acyl carrier protein (ACP).
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Figure 1.13 Pathway of de novo lipogenesis
The repeat cycle of reactions for the addition of two carbons by fatty acid synthase. 
Reactions o f the cycle: (1) condensation (3-ketoacyl-ACP synthase); (2 ) reduction 
(3-ketoacyl-ACP reductase); (3) dehydration (3-hydroxy acyl-ACP dehydrase;
(4) reduction (enoyl-ACP reductase).
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1,3,7 Transport of CO2 to the lungs
CO2 released fiom respiring tissues, such as the liver and skeletal muscle, into blood 
plasma enters erythrocytes via the chloride-bicarbonate exchanger. Within the erythrocyte, 
it is converted into bicarbonate (HCO3 ) by carbonic anhydrase (EC 4.2.1 .1 ). The HCO3 
re-enters the plasma for transport to the lungs. HCO3' is much more soluble in blood 
plasma than CO2, and thus the capacity of the blood to carry CO2 from the tissues to the 
lungs is increased. In the lungs, HCO3' re-enters the erythrocyte and is converted to CO2, 
which is eventually released into the lung space and exhaled. This shuttle requires very 
rapid movement of HCO3' across the erythrocyte membrane (Nelson & Cox, 2 0 0 0 ).
The chloride-bicarbonate exchanger, also called the anion exchange protein, increases the 
permeability of the erythrocyte membrane to HCO3 by a factor of more than a million. It 
is an intrinsic protein that mediates the simultaneous movement o f two anions; for each 
HCO3 ion that moves in one direction, one Cl" ion moves in the opposite direction (Figure 
1.14). The coupling o f Cl" and HCO3" is obligatory; in the absence of chloride, bicarbonate 
transport stops.
Carbon dioxide produced 
by catabolism enters 
eiythrocyte
Bicarbonate 
dissolves in 
blood plasma
CO2 Chloride-bicarbonate V HCOm Cl"
exchange protein
In respiring tissues
carbonic anhydrase
'CO3 + H2O ----------------- >HGo; + H" c r
HCOi + I-I+ c r
carbonic anJrydrase
In lungs
CO2
Carbon dioxide leaves 
erythrocyte and is 
exhaled
Hco; c r
Bicarbonate enters 
erythrocyte from 
blood plasma
after Nelson & Cox (2000)
Figure 1.14 Chloride-bicarbonate exchanger of the erythroctye membrane
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1.4 breath tests
1.4.1 Introduction to C breath tests à
Breath tests are based on the idea that the sampling of exhaled breath can provide 
information about biochemical, physiological or pathological processes within the body. 
^^C-breath tests have become useful non-invasive tools to measure gastrointestinal 
functions and to monitor pharmacological and nutritional interventions (Young & Ajami,
1999). Labelling of nutritional substrates with enables investigation of their digestion, 
absorption and subsequent metabolism. The labelled compound is taken by mouth, usually 
as part of a test meal. Thereafter it is digested, absorbed, it or its products oxidised and the 
label appears in breath carbon dioxide (CO2). Typically, a substrate is chosen such that the 
rate-limiting step in its metabolism to CO2 is the process to be measured. CO2 is the end 
product of the oxidation of carbohydrate, fat and protein. The CO2 in breath reflects 
alveolar CO2, which is in equilibrium with circulating bicarbonate (Section 1.3.7). *^ C- 
breath tests are particularly attractive for use in children and pregnant women, in whom the 
use of radioactive tracers is prohibited.
Breath is composed of a mixture of exhaled air and a mixture of the products of 
metabolism. Air is composed nitrogen (79 %), oxygen (21 %), argon (1 %), carbon dioxide 
(0.035 %) and water vapour. The products of metabolism are mainly water vapour, carbon 
dioxide (~5 % of breath), traces of hydrogen, hydrocarbons including methane, nitric 
oxide, ketones, ammonia and other gases at concentrations o f parts per million (ppm). 
Hydrogen and methane are not generated by mammalian biochemical pathways and their 
presence in the breath is an indication of bacterial metabolic activity, most often in the 
large bowel, but sometimes in the small bowel or elsewhere. Hydrogen breath tests have 
been used to measure oro-caecal transit rate and small intestinal bacterial overgrowth 
(Bond & Levitt, 1975; Barr et al. 1978; King & Toskes, 1979; Jorge, Wexner & 
Ehrenpreis, 1994).
When a ^^C-labelled substrate is ingested, it is subject to a number of physiological 
processes, each of which can be considered potentially rate limiting. Taken by mouth the 
substrate is exposed to salivary enzymes, gastric acid and enzymes, is emptied from the 
stomach, and may be digested in the small intestine under the influence of pancreatic 
enzymes. Substrate that escapes digestion in the small intestine may reach the colon where 
it may be metabolised by bacterial enzymes. It, or its products of digestion, is absorbed
' 1
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and may or may not be incorporated in the synthesis of a new substrate, transported 
directly or by a carrier molecule to the liver via the portal circulation, where all or a 
proportion may undergo metabolism, culminating in oxidation with the generation of CO2
Decline in cost of isotopically labelled compounds, the development of more user-friendly 
analytical instrumentation, and the avoidance of radioactive hazards, have made ^^C-breath 
tests increasingly attractive tools in biomedical research and clinical diagnosis. The urea 
breath test to detect the presence of Helicobacter pylori in the stomach is now a well 
established test for both diagnostic and research purposes (e.g. Graham et al, 1987; 
Graham & Klein, 1991; Weaver et al. 1993; Thomas, 1998; Weaver, 1998; Savarino, 
Vigneri & Celle, 1999; Slater, Preston & Weaver, 2004). It can be viewed as an example 
of an ideal breath test: a single rate-limiting step (the presence or absence of urea-secreting 
bacteria in the stomach) determines the rate of recovery of in the breath after
ingestion of ^^C-labelled urea. Many other breath tests have been developed to study organ 
function including gastric emptying rate, liver function, pancreas exocrine function, 
intestinal integrity; to study digestion, absorption or metabolism of carbohydrates, fat or 
protein; and to detect bacterial colonisation in the stomach or small intestine (Stellaard & 
Geypens, 1998).
The labelled CO2 is diluted many-fold by the much larger volume of CO2 produced in the 
body by other metabolic processes, leading to very small enrichments over the background 
level. There have been several reviews of the use of breath tests e.g. Schoeller et a l 
(1977); Barr et al. (1978); Klein & Klein (1985); Klein (1991); Amarri & Weaver (1995) 
Rating & Langhans (1997); Weaver, Manson & Amarri (1997); Klein & Helge (1998) 
Perri & Andriulli (1998).
1.4.2 Determining the value of a diagnostic test
1.4.2.1 Sensitivity and specificity
Diagnostic tests are designed to aid the clinician in determining whether or not a patient 
has a particular condition or disordered organ function, i.e. whether they are disease 
positive or disease negative. The effectiveness of a test can be determined by how well it 
identifies those with the condition (disease positives) and excludes those without the 
condition (disease negatives). The indices usually used to do this are sensitivity and 
specificity (Bland, 1995).
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Sensitivity = Number who are both disease positive and test positive (1.2)
Number who are disease positive
Specificity = Number who are both disease negative and test negative (1.3)
Number who are disease negative
The sensitivity is the proportion of people with the disease, who test positive, and 
specificity is the proportion of people without the disease who test negative.
1.4.2.2 Positive and negative predictive values
The positive predictive value and negative predictive value of a test can also be estimated. 
The positive predictive value is the probability that a subject who is test positive will also 
be a true positive i.e. has the disease and has been correctly classified. The negative 
predictive value is the probability that a person who is test negative will be a true negative 
i.e. does not have the disease and is correctly classified (Bland, 1995). These depend on 
the prevalence of the condition {pp, e^ ) as well as the sensitivity ipsen^ and specificity {pspe^. 
The probability of being disease positive and test positive is (pprev x psem), and the 
probability of being disease negative and test positive is (1 - PpreT) x {l-pspec), so the 
probability of being test positive is {pprev x psens) + ((1- Pprev) x {l-pspec)). The positive 
predictive value is:
P P Y  —  __________________ prev -P sens  )    ( 1 4 )
Similarly, the negative predictive value is:
NPV = -[r f  P ftJ p ^ J   (1.5)
W -  P p r . ,  )P s ,.c  I + -  P ..„ .  ) )
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1.4.2.3 Normal range or reference interval
Diagnostic tests for a particular condition require knowledge of the normal range of 
whatever is measured in healthy individuals from the same local population for 
comparison. To avoid confusion between the “normal distribution” as used in statistics 
and “normal range” as used in medicine, the term “reference interval” is finding increasing 
favour. If the variable is normally distributed, the reference interval is the mean ±1.96  
standard deviations. This will include 95 % of the observations, with 2.5 % lying outside 
the reference range at each extreme.
If the reference data are not normally distributed, it is possible to estimate percentiles 
without any assumptions about the distribution (Bland, 1997). The data must be sorted in 
rank order, and the 2.5 and 97.5 centiles calculated. If there are n observations, then the 
point below which 2.5 % of the observations lie, the z-th observation, is 0.025 x («+1), and 
the point above which 97.5 % of the observations lie is 0.975 x (w+1). The interval 
between is the 95 % reference interval.
1.4.2.4 Determining the cut-off point
When the results of a test are based on a continuous variable, the sensitivity and specificity 
can be altered by changing the cut-off point. If high values indicate the disease positive 
state then raising the cut-off point will mean fewer cases, so the sensitivity will be 
decreased. However, there will be fewer false positives, so the specificity will be 
increased. Two graph-receiver operator characteristics (TG-ROC) is a mathematical 
method of determining the appropriate cut-off, where both the sensitivity and specificity 
are maximised (Greiner, 1995). TG-ROC is a plot of the test sensitivity (Se) and 
specificity (Sp) against the threshold (cut-off) value assuming the latter to be an 
independent variable. A cut-off (dO) that realises equal test parameters (Se = Sp = 6  ^o, 
theta-zero) can be obtained at the intersection point of the two graphs at the chosen level of 
accuracy (95 % or 90 %). Since the value for is below the chosen accuracy level, two 
cut-off values are selected that represent the bounds of an intermediate range (IR) that can 
be considered as the equivocal range for the clinical interpretation of test results (Greiner, 
Sohr & Gobel, 1995). The proportion of the measurement range (MR) that gives 
unambiguous test results is the valid range proportion (VRP). VRP == (MR - IR) / MR 
VRP and 6 o can be used to compare tests since they do not depend upon the selection of a 
single cut-off point. In the ideal test both equal unity.
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1.4.3 Basic principles of stable isotope methodology
is the minor stable isotope of carbon. Isotopes of an element have the same atomic 
number (the number of protons in the nucleus) but different atomic mass (the sum of the 
number of protons and the number o f neutrons). For instance, has 6  protons and 6  
neutrons in the nucleus; has 6  protons and 7 neutrons; has 6  protons and 8  
neutrons. The 6  protons in the nucleus are balanced electrostatically by 6  electrons, and all 
isotopes of carbon take part in the same chemical reactions within the body. is the 
radioisotope of carbon and decays to (7 protons and 7 neutrons) with the loss of a beta 
particle. The use of in clinical studies has diminished in recent years because of 
concerns about safety and disposal.
and are stable isotopes and are present in all organic materials. forms 1 .1% of 
all the carbon atoms naturally present in the environment. This is the natural abundance of 
Enrichment is the term used to describe abundance of a sample above a baseline level. 
In metabolic tracer studies the term “stable isotope” is often synonymous with a non­
radioactive isotope that is less abundant than the most abundant naturally occurring 
isotope, for example The isotope of greatest abundance (^^C) is sometimes referred to 
as the major isotope, and that of lower abundance as the minor isotope. In fact both 
and are stable isotopes of carbon.
Stable isotope labelled tracers are compounds in which one or more of the naturally 
occurring, major isotopes of its atoms have been replaced by the minor (heavy) stable 
isotope of the atom. The compound is said to be labelled with the minor stable isotope. 
The unlabelled endogenous compound is known as the tracee. It is incorrect to refer to a 
labelled compound as a stable isotope, because this term refers to atoms rather than 
molecules.
It is possible to synthesise “highly enriched” compounds in which 99 % of the atoms in a 
particular position on the molecule are in the form of the heavy isotope of that atom, 
e.g. 99 atom % [^^C]-urea, where 99 % of the carbons are rather than Such highly 
enriched tracers can be “diluted” with unlabelled material to achieve enrichments of any 
percentage above natural abundance.
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1.4.4 Measuring stable isotope abundance
1,4.4.1 Measuring abundance in breath, stool and labelled substrates
The abundance in breath CO2 is most commonly measured using gas isotope ratio mass 
spectrometry (IRMS). There are two kinds if IRMS commonly available: dual inlet IRMS 
and continuous-flow IRMS. Dual inlet IRMS is a very accurate method, but many fewer 
samples can be prepared and analysed in a day compared to continuous flow techniques 
(Preston and McMillan, 1988). Samples for analysis by IRMS must be in the form of a 
pure gas and hence breath CO2 must be separated from N2 and O2 IRMS are low 
resolution mass spectrometers for analysis of simple gases. They measure up to three ions 
simultaneously e.g. 44/45/46 for CO2 analysis, but can measure very small differences in 
isotope ratios (of the order of 0.0001 atom % or 1 ppm). Spectroscopic methods including 
those based on laser diode arrays are coming onto the market. They potentially provide 
instant results at the bedside, but the current instruments are not as sensitive as IRMS.
The simplest CF-IRMS instruments are those dedicated to the analysis of ^^C0 2  in breath 
samples. They are composed of an autosampler for gas sampling vials (e.g. 1 0  ml 
Exetainer Breath Sampling Vials, Labco, Welwyn Garden City, UK), water trap, 
isothermal GC oven (to separate CO2 from N2 and O2) and capillary for introduction of the 
sample into the IRMS. Analysis of the abundance of in solid samples e.g. labelled 
substrates (Harding et al. 1994; Boirie et al. 1995; Evenepoel et al. 1997; Morrison et al. 
2 0 0 1 ; Edwards et al. 2 0 0 2 ) requires combustion of the solid to produce CO2, N2 and water. 
Combu stion-IRMS differs from the breath test instrument in having oxidation and 
reduction furnaces prior to the water trap and an autosampler for solid samples. This 
technique can also be used to measure tracer excreted in stool in studies of lipid 
metabolism (Murphy et al. 1998; Slater et al. 1998; Slater et al. 2002), and tracer excreted 
in urine in gastrointestinal motility studies (Morrison, Dodson & Preston, 1999).
The IRMS should be calibrated against internationally agreed standards to take into 
account day-to-day fluctuations and to standardise measurements between laboratories. In 
practice each laboratory will have a secondary standard (reference gas), which should be 
traceable to the international standard. For analysis of breath abundance, a suitable 
reference gas contains 3-5 % CO2, with the balance being nitrogen.
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Compound specific analysis of highly enriched ^^C-labelled tracer excreted in stool can be 
made by gas chromatography-mass spectrometry (GC/MS) (Slater et a l  1998; Slater et al. 
2 0 0 2 ), and low enrichments in plasma, urine or tissue samples can be measured using GC- 
combustion-IRMS (Preston & Slater, 1994). There are few internationally traceable 
standards for compound specific isotope analysis therefore each laboratory must make its 
own gravimetric standards using carefully weighed mixtures of labelled and unlabelled 
material (Slater et a l 1998).
1.4.4.2 Measuring and H abundance in body fluids
e.g. ô^ ^CpDB -
I  I? I?  ^ f  I  T? \  ^
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where is the ratio in the sample and Rpdb is the ratio in the standard.
The supply of PDB was exhausted in the mid 1990’s and Standard Mean Ocean Water 
(SMOW), the international standard for stable hydrogen and oxygen isotopes, but did not 
have a unique definition. Therefore, the Commission on Atomic Weights and Isotopic
The abundance of and in body fluids such as plasma, saliva and urine can be j
measured by continuous flow IRMS techniques by sampling the head-space after 
equilibration of the sample with a reference gas in an Exetainer (McMillan, Preston &
Taggart, 1989; Posser et al. 1991; Scrimgeour et al. 1993). The abundance o f is 
usually measured as CO^^O, and can be therefore be measured on the same instrument as 
breath ^^C0 2  abundance. It is technically more challenging to measure deuterium 
enrichment by continuous flow methods, but several instruments are now commercially
■
available for this purpose. The first was described by Prosser & Scrimgeour (1995).
1.4.5 Units of stable isotope abundance and enrichment
h
Most IRMS software calculates isotopic abundance in terms of delta notation (5; in units of 
7oo, per mil), which is a convention used in geochemistry, since most of the original IRMS 
instruments were developed in isotope geochemistry laboratories, to measure natural 
abundance variations. Delta is defined as the relative difference in parts per thousand 
between the sample isotope ratio and the isotope ratio of the international standard. The 
international standard for was Pee Dee Belemnite (PDB), a limestone standard. The 
isotope ratio of PDB is 0.0112372.
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Abundances of the International Union of Pure and Applied Chemistry recommended that 
the use o f PDB and SMOW be discontinued and that isotope abundances of hydrogen-, 
carbon-, and oxygen-bearing materials be reported relative to the reference water VSMOW 
(Vienna standard mean ocean water) and to VPDB (Vienna Pee Dee Belemnite), defined 
by adopting a 5’^C value o f +1.95 per mil (7oo) for NBS 19 carbonate relative to VPDB 
(Coplen 1995). Relative ^H/^H values (ô^H) and ^^O/^O (ô^^O) should be expressed per 
mil (7oo) relative to VSMOW water ( 0  7oo) on a scale normalized such that SLAP 
(standard light Antarctic precipitation) has a ô^H value of -428 7oo and a 5^^0 value of 
-55.5 7oo (Coplen, 1996).
Units of atom per cent (atom %) are preferred for tracer studies. Atom % is a measure of 
absolute isotope concentration, rather than the relative ratio delta (5) notation and has its 
basis in SI units (Slater, Preston & Weaver, 2001a). Atom % (AP) is the atom fraction 
expressed as a percentage.
atom % "C  = - | , ^  U  X 100 (1.7)
Small abundances can be expressed in units o f parts per million (ppm) (Klein & Klein, 
1982).
ppm = atom % X 1 0 "^ ( 1 .8 )
In practice, IRMS measures ratios of molecular species, rather than isotopes and the ^^ C 
abundance of CO2 is usually determined by measuring the ion intensities at m/z 44 and 45. 
The ion beam at m/z 45 contains a small contribution from [^^0]C0. In practice, this is 
removed using the ‘Craig correction’ (Craig, 1957) when calculating ^^ C units using the 
IRMS software.
To convert Ô C pdb to atom % ^^ C,
= ~ --------—  (1.9)
where 5 = measured ô^^Cpdb and Rpdb is the isotope ratio of PDB = 0.0112372.
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Similar equations can be used to convert ô^Hvsmow to atom % and ô^^Ovsmow to atom 
% using the isotope ratios shown in Table 1.3.
Enrichment is the abundance o f a sample above a baseline level and is expressed in units o f 
atom % excess (APE).
APE = (atom % ) e  - (atom % ) b  
where, (atom % ) e  is the measured abundance of the enriched sample 
and (atom % ) b  is the measured abundance of the baseline sample.
( 1.10)
Low enrichments can be quoted in parts per million excess (ppm excess = APE x 10"^ ).
Sometimes enrichment is expressed as delta over baseline (DOB or A^^Cpdb). This is 
defined as the difference between the basal abundance of breath CO2 (ô^^Cpdb) before
administration o f labelled substrate and the abundance of breath CO2 at a certain time
point after administration.
D O B  dpost-dose “ dbaseline ( 1.11)
Table 1.3 Isotope ratios of international standards
Standard Isotope ratio
Vienna Standard Mean Ocean Water (VSMOW) 0.00015576
Vienna Standard Mean Ocean Water (VSMOW) 1 8 0 /I6 0 0.00200520
Standard Light Antarctic Precipitation (SLAP) 0.00008909
Standard Light Antarctic Precipitation (SLAP) 1 8 0 /I6 0 0.00189391
Vienna Pee Dee Belemnite (VPDB) 13c/12c 0.0112372
Vienna Pee Dee Belemnite (VPDB) I8 0 /I6 0 0.0020671
Atmospheric Nitrogen 0.0036765
Canyon Diablo Troilite meteorite 34s/32s 0.0450045
after De Bievre & Barnes (1985)
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1,4.6 Procedure for a typical breath test
1.4.6.1 Breath sampling methods
The labelled compound is taken by mouth, often as part of a test meal. Breath samples are 
collected before ingestion of the labelled compound and at intervals thereafter. A simple 
way to collect breath samples is by blowing through a straw into a glass vial 
(e.g. Exetainer, 10 ml gas sampling vial, Labco, High Wycombe, UK). The cap, 
containing a septum, is replaced immediately thereafter. For younger children and babies a 
“bag and mask” can be used (Weaver et al. 1993), constructed from an anaesthetic mask 
attached to a gas tight bag via a one-way valve. These are commercially available from 
QuinTron (Milwaukee, Wisconsin, USA), or can be made in-house using an Ambu 
Transparent Face Mask attached to an Ambu Paedi Valve (Ambu, Brondby, Denmark; 
www.ambu.com) and a 600 ml gas sampling bag (Laerdal Medical, Orpington, UK; 
www.laerdal.com), which has been fitted with a 3-way Luer tap to facilitate gas transfer. 
The child breathes into the mask and exhaled breath is collected in the bag, the breath 
sample is transferred to an evacuated vial using a syringe, and the abundance of is 
measured by IRMS.
1.4.6.2 Control of background abundance
The amount of in breath CO2 is expressed as enrichment above the background 
abundance of ^^C0 2 . It is important to have low and constant background abundance, 
especially if the end point of interest is quantitation of cumulative excretion of label from 
the tracer. It is therefore important that the test meal is composed of ingredients of low 
abundance. The abundance of the test meal can be calculated from food composition 
tables, and the natural abundance of each individual component (Monison et al. 2000). 
Foods eaten before and during breath tests should be of low abundance so that they 
and the test meal will have minimal effect on basal breath ^^C0 2  enrichment. It is possible 
to achieve baseline variations of approximately ±7 ppm (0.6 per mil) on a 
controlled diet, compared with variations of ±30 ppm (2.7 per mil) on an uncontrolled 
diet (Jones et al. 1985; Garlick et al. 1987; Morrison, 2000).
In terms of their abundance, there are two major classes of plants, which are consumed 
as part of the diet of humans. They can be distinguished on the basis of isotope 
fractionation during photosynthesis. C3 plants incorporate CO2 from the atmosphere by
' "  ?
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carboxylation o f ribulose bisphosphate (RuBP) via the enzyme RuBP carboxylase, 
producing a 3-carbon product, phosphoglycerate (O’Leary, 1981; Boutton, 1991). The 
average VPDB value of C3 plants is -27 7oo C4 plants reduce CO2 to aspartic or malic 
acid, both 4-carbon compounds, via the enzyme phosphoenolpyruvate (PEP) carboxylase.
This enzyme does not discriminate against as much as RuBP carboxylase, so that C4 
plants have relatively high content (average -13 ô^^Cvpdb)- C3 and C4 plant species 
thus have distinct ô^^Cvpdb values and differ from each other by approximately 14 7oo 
(-160 ppm ^^C). Most terrestrial plant species are C3, including the staple food plants, 
wheat, rice, potatoes and sugar beet, but tropical and subtropical grasslands consist almost 
exclusively o f C4 species, including important food crops such as maize and sugar cane.
Photosynthesis in the marine environment occurs mainly via the C3 pathway. However, 
ô^ ^CvpDB values of phytoplankton are substantially higher than terrestrial plants, averaging 
-22 7oo- This is related to the use of bicarbonate as a carbon source for photosynthesis, 
which has substantially higher content than atmospheric CO2 (Boutton, 1991). Fish, 
which consume the plankton have an even higher ô^^Cvpdb value closer to -17 7oo. For 
this reason, fish should also be excluded from the diet in the days preceding breath 
tests.
The European diet is composed mainly of foods derived from C3 plants, but it is necessary 
to avoid foods containing maize, maize products, sugar cane, pineapple and seafood for 
several days before the test day, in order to minimise the background enrichment.
The natural abundance of food is not the only factor that can affect basal ^^ C0 2  variation.
Physical activity is another factor that should be considered when planning breath tests.
Increased energy expenditure may generate unwanted changes in the abundance o f
breath CO2, owing to changes in the relative proportion of fat and carbohydrate oxidised, 
which can cause breath ^^C0 2  enrichment to fluctuate (Jacobson et al. 1970). Fat stores 
are more depleted in than the body’s carbohydrate stores due to fractionation occurring 
during biosynthesis in both plant and animal tissues. Hence changes in the ratio of fat to 
carbohydrate oxidised will influence the isotopic ratio of in breath CO2 (Schoeller
et al. 1977; Schoeller et al. 1984). For these reasons, it is recommended that food intake 
should be controlled for three days prior to test, the diet should be strictly controlled during 
the test, and physical activity should be restricted.
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1.4.6.3 Factors concerning the dose of labelled material
Many ^^C-breath tests are performed using synthesised tracers with 99 atom % at a 
particular position on the tracer molecule. This will be diluted by several orders of 
magnitude in the test meal and in the body. It is, therefore, important to give sufficient 
labelled material to allow detection of significant elevation above the background 
abundance of 1.1 atom % or 11,000 ppm Ideally the maximum enrichment of breath 
CO2 should be -100 ppm excess Labelled tracers are expensive and not always 
available in large quantities, and economic considerations therefore often determine the 
dose given and the number of subjects studied. In any case, the amount of material 
ingested should be weighed accurately and account taken of losses during preparation, or 
incomplete consumption, of the test meal.
L4.7 Expression of breath test results
The results of breath tests can be expressed in one of four ways. In the simplest 
diagnostic test, the urea breath test (UBT), they are reported to the clinician as being 
positive or negative, based simply on the analysis of enrichment in breath CO2, usually 
at 30 min post dose (e.g. Rowland et al. 1997; Thomas et al. 1999; Kato et al. 2002; Slater 
et a l 2004). The next category of test, such as in GI motility studies, reports results in 
units of time. In the case of gastric emptying, gastric emptying half time and lag time may 
be expressed (e.g. Ghoos et al. 1993; Maes et al. 1994; Wyse et al. 2001a,b; Bluck et al. 
2002). Although rarely used for diagnosis, it is easy to imagine that the result from an 
individual subject’s test could be reported as being ‘fast, normal or slow’ when compared 
with the range of results o f a standard test from a healthy population. The third type of 
test, such as liver function or exocrine pancreatic function, express results as the quantity 
of dose recovered in breath (commonly, percentage dose recovered or PDR) (e.g. Parker et 
al. 1994, 1997a,b; Amarri et al. 1997; Manson et al 1999; Ling et al. 2000; Slater et al. 
2002). A diagnostic form of such a test could report a standardised test on an individual as 
being ‘high, normal or low’ when compared with the reference range of results from a 
healthy population. Finally, in substrate oxidation studies results are expressed as the 
absolute quantity of substrate oxidised in a given time (e.g. Sidossis et al. 1995a; 
Mittendorfer et al. 1998; Bowtell et a l  2000).
PDR is calculated from CO2 production rate (FCO2) and breath CO2 enrichment.
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PDR h"‘ = PCO2 (mmol.h'^) x Breath CO2 enrichment (ppm excess) x 100 (1.12)
Tracer amount (mmol) x Tracer enrichment (atom % excess x 10^)
The sum of the PDR from each sample in a test is the cumulative per cent dose recovered 
(cPDR).
When PDR is the desired outcome, it is necessary to have a measurement of FCO2 or to 
use a predicted value (Shreeve, Cerasi & Lull, 1970; Schofield 1985). This will be 
discussed further in Section 1.5.
1.4.S The mixed triacylglycerol breath test
The mixed triacylglycerol breath test, commonly known as the mixed triglyceride (MTG) 
breath test, was developed by Ghoos et al. (Ghoos et al. 1981; Vantrappen et al. 1989) as 
an indirect measure of intraluminal fat digestion in adults with impaired pancreatic 
function. The substrate is a synthetic triacylglycerol (1,3 distearyl 2-[l-^^C]octanoyl- 
glycerol) composed of two long-chain saturated fatty acids (18:0, stearic acid) at the sn-\ 
and -3 positions, and a ^^C-labelled medium-chain fatty acid (8:0, octanoic acid) at the sn-2 
position (Figure 1.16).
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Figure 1.16 Structure of [’^C]mixed triacylglycerol (MTG)
Pancreatic lipases preferentially hydrolyse mixed triacylglycerol at the sn-\ and -3 
positions, leaving 2 -[l-^‘^ C]octanoyl-glycerol. Hydrolysis of medium-chain 2-monoacyl 
glycerol is rapid and complete (Desnuelle & Savery, 1963), releasing [l-^'^C]octanoate. 
The enhanced water solubility of octanoate, its diminished affinity for acyl-CoA synthetase 
compared to long-chain fatty acids, and lack o f medium-chain acyl-CoA synthetase for its 
activation in enterocytes, results in rapid absorption via the portal vein. The increased 
blood flow relative to lymph also contributes to more rapid entry of medium-chain fatty
Cliristine Slater 2004 Chapter 1, 49
acids into the circulatory system (Odle, 1997). As a consequence, the liver is the first 
organ reached by octanoic acid, whereas long-chain fatty acids enter systemic circulation 
via chylomicrons in the thoracic duct and may perfuse other tissues prior to the liver 
(Figure 1.4).
In the liver, octanoate may be incorporated into long-chain fatty acids (Carnielli et al. 
1994; Pakula et al. 1997), but the major metabolic fate is oxidation. The ^^C-label is 
removed by (3-oxidation in the mitochondria resulting in [l-^^C]acetyl-CoA, which reacts 
with oxaloacetate and enters the TCA cycle (Sectionl.3.6.1). Some leaves the TCA 
cycle as ^^COz, which equilibrates with the bicarbonate pool before being excreted in 
breath as labelled CO2 or urine as labelled bicarbonate, or it can enter the urea cycle and be 
excreted in urine as labelled urea. Some ^^ C enters anaplerotic reactions (Figure 1 .1 1 ) and 
products so formed re-enter the TCA cycle and these carbons may become sequestered in 
shared carbon skeletons (e.g. oxaloacetate => aspartate, a-ketoglutarate => glutamate). 
The rate-limiting step in the digestion, absorption and oxidation of MTG in children with 
cystic fibrosis is hydrolysis of the long-chain fatty acids by pancreatic lipase, and the 
[^^CjMTG breath test is an indirect measure of intraluminal fat digestion and hence 
exocrine pancreatic function.
Digestion and absorption of lipids by children with cystic fibrosis has been studied using 
[^^CJtripalmitin (Murphy et al. 1998) and [^^CJtriolein (Wutzke et al. 1999). The MTG 
test is a test of lipid digestion, and indirectly of exocrine pancreatic function, whereas the 
[^^Cjtripalmitin/triolein tests are tests of both digestion and absorption.
In adults, the [^^CjMTG breath test gives an excellent correlation between lipase output in 
the duodenum and 6 -h cumulative excretion in breath (Ghoos et al. 1981;
Vantrappen et al. 1989), where low lipase output and low recovery of in breath 
indicate poor exocrine pancreatic function. As a test of exocrine pancreatic function, the 
MTG test was found to have a sensitivity of 0.89, specificity of 0.81, positive predictive 
value of 0.63 and negative predictive value of 0.95 (Perri & Andriulli, 1998), compared to 
duodenal lipase output. It has been shown to be a specific test of intraluminal digestion 
and to be independent of factors affecting absorption, such as small bowel disease 
(Vantrappen et al. 1989; Amarri et al. 1997) and coeliac disease (Amarri et al. 1997; Perri 
et al. 1998). In children with cystic fibrosis, the presence of concurrent liver disease has 
been shown not to affect the amount of excreted in breath (Ling et al. 2000).
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The [^^C]MTG test has been largely confined to research projects (e.g. Kalivianakis et al. 
1997, 2000; Swart et al. 1997; Loser et al. 1998; Perri et al. 1998; Wutzke et al. 1999) due 
to its poor positive predictive value and the need to collect breath samples for six hours. 
However, it has been used to assess the adequacy of pancreatic enzyme replacement 
therapy in children with cystic fibrosis (Amarri et al. 1997; de Boeck et al. 1998), to study 
the development of fat digestion in infancy (Manson et al. 1999) and the effect of liver 
disease on intraluminal fat digestion in children with cystic fibrosis (Ling et al. 2000). In 
pancreatic sufficient subjects 15-44 % of the label is excreted in breath CO2 (Amarri et 
al. 1997; van Dijk-van Aalst et al. 2001). In healthy children and children with cystic 
fibrosis, who were taking their normal pancreatic enzyme replacement therapy, only about 
1 % of the tracer was recovered in stool (Slater et al. 2002). The remainder must be 
retained in the body. It can therefore be concluded that variability in breath cPDR, other 
than due to MTG digestion, is due to postabsorptive rather than predigestive factors.
The final oxidation product of [^^CjMTG is ^^C0 2 . Most of the labelled CO2 is excreted in 
breath, but some is excreted in urine either as [^^Cjbicarbonate or [^^CJurea, fixed via the 
urea cycle, and in faeces. The remainder is retained within the body. Labelled CO2 
originating from oxidation of [^^C]MTG is greatly diluted by endogenously produced CO2 
from metabolic processes. Therefore, to estimate PDR, knowledge of CO2 production rate 
(FCO2) is required. A resting value based on basal metabolic rate is often assumed, but if 
subjects are not lying quietly on a bed and in the postabsorptive state throughout the test, 
this will be an underestimate of the true CO2 production rate. Factors affecting CO2 
production rate are discussed further in Section 1.5.
There are two methods of approaching the problem of lack of knowledge of CO2 
production rate. FCO2 can either be measured continuously during the test or an 
empirically derived conection can be used, which eliminates the need for its measurement 
by compensating for tracer sequestered in the body.
1.4,9 Sequestration of^^C within the body
Bicarbonate and acetate coiTection factors are used in studies o f substrate oxidation, where 
a tracer is infused into a vein and blood and breath samples are taken at intervals to 
determine the rate of oxidation of the tracer. There is a need to correct the calculated 
oxidation rate, to take account of the proportion of labelled CO2 that does not appear as 
breath CO2, but is temporarily sequestered into other metabolites, usually via the TCA
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cycle. The bicarbonate correction factor accounts for label entering the bicarbonate pool 
(mainly bone and intracellular reserves e.g. skeletal muscle) and therefore not excreted in 
breath during the test (e.g. Irving et al. 1983, 1984, 1985; Kien, 1989; Armon et al. 1990). 
Alternatively an acetate correction factor can be used when this is more appropriate i.e. in 
studies of lipid and carbohydrate metabolism (Sidossis et al. 1995a,b). The acetate 
correction factor accounts for label fixation that might occur at any step between the 
entrance of acetyl-CoA into the TCA cycle (Section 1.3.6.1) until recovery of label in 
breath CO2 .
Changes in metabolic rate induced by feeding, physical activity or hormonal changes affect 
both correction factors (Van Hall, 1999). It may be necessary to use bicarbonate or acetate 
correction factors with the calculated PDR from ^^ C breath tests, if the aim is to account 
for all of the ingested tracer (Slater, Preston & Weaver, 2001b), in which case it will be 
necessary to perform two breath tests on separate days.
1.5 Measurement of CO2 production rate
1.5.1 Background
As shown by Equation 1 .1 2 , any error in the FCO2 term results in a proportional error in 
the calculated PDR. The enrichment of breath CO2 and of the tracer can be analysed 
accurately and precisely (CV 0.5%) by continuous-flow isotope ratio mass spectrometry 
(Prosser et al. 1991). The amount of tracer taken can be determined accurately by 
weighing on a 5-figure balance, and by rinsing vessels and consuming the contents to 
ensure that all the tracer is consumed. FCO2 can be measured at rest with less, but 
acceptable precision (CV 2 .6 %) using a ventilated hood indirect calorimeter (Ventham & 
Reilly, 1999). However, resting EC02 is not the appropriate value to use unless subjects 
are sitting still and fasting during the entire breath test procedure. This is particularly 
unlikely with children, and in tests lasting for up to 24 hours (Morrison et al. 1998; 
Edwards, Zavoshy & Preston, 1998; Monison et al. 2003b). Many researchers have not 
measured VCO2 , but have simply used a predicted value o f 5 mmol.min"\m'^ (Shreeve et 
al, 1970). Body surface area (m^) can be predicted from height (cm) and weight (kg) using 
the Haycock equation in both adults and children (Haycock, Schwartz & Wisotsky, 1978). 
Basal metabolic rate can also be predicted from the subject’s height and weight using the 
Schofield equations (Schofield, 1985).
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Physical activity is not the only factor that can affect FCO2 during a breath test. Amarri ei 
al. (1998) have shown that resting ECO2 is higher in children with cystic fibrosis than in 
healthy children. CO2 production rate is also increased following food intake, including 
consumption of the test meal as well as subsequent meals. This is due to the thermic effect 
of the food eaten or “diet-induced thermogenesis”, and is approximately 1 0  % of total daily 
energy expenditure.
The factors discussed so far all lead to an increase in FCO2 and therefore an 
underestimation of PDR. However, if subjects fall asleep during the study, their metabolic 
rate will fall below their resting metabolic rate, and for this period use of resting FCO2 will 
result in an overestimation of PDR. There is, therefore, a need to find a way of 
continuously monitoring CO2 production rate during the entire breath test, in order that the 
con ect FCO2 value for the particular circumstances of the test can be used to calculate the 
percent dose recovered in each breath sample.
1.5,2 Components of daily energy expenditure
Total daily energy expenditure (TEE) is composed of three major components: basal 
metabolic rate (BMR), the thermic effect of food or diet-induced thermogenesis (DIT), and 
the energy required for physical activity (PA). The latter is highly variable between 
individuals.
TEE -  BMR + DIT + PA (1.13)
Basal metabolism is the energy required to sustain the basic essential metabolic processes 
involved in keeping the body alive and healthy and, where appropriate, growing at an 
appropriate rate (van Raaij, 2002). The energy required to sustain basal metabolism is 
usually expressed as basal metabolic rate (BMR). BMR is defined as the energy 
expenditure of a healthy subject lying at rest, in a thermally neutral environment, at least 
12 h postprandially (Harris & Benedict, 1919). In most individuals BMR is the largest 
component of TEE, amounting to 50-70 % TEE (FAO/WHO/UNU, 1985).
BMR is measured under precisely defined conditions. It is measured while the subjects are 
lying in bed or on a couch, immediately after awakening, in a state of physical and 
emotional relaxation, and in a thermo neutral environment. They should have fasted for the 
12-14 h immediately before the measurement, and heavy physical exercise should be
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avoided on the day before the measurement (van Raaij, 2002). Subjects should also be free 
from disease and not suffer from fever. If any of the conditions for BMR are not met, the 
energy expenditure of the subject should be termed resting metabolic rate (RMR).
The BMR of a subject is influenced by many factors including body size, body 
composition, age, gender, and nutritional and physiological state. Body size and 
composition are major determinants of BMR, since adipose tissue has a lower metabolic 
rate than the tissues, with core tissues such as viscera having a higher oxygen demand at 
rest than peripheral tissues, such as skeletal muscle. These tissues compromise the lean 
body mass, (LBM). In lean male adult subjects, LBM accounts for approximately 75 % 
body weight and fat mass accounts for approximately 18 % body weight (ICRP 23, 1975). 
In obese adults and children, fat mass can rise to -40 % body weight (Slater & Preston, 
2002). Therefore BMR is usually expressed per kg body weight or preferably per kg lean 
body mass. This eliminates the effect of body size and therefore differences between 
males and females. The lower resting energy expenditure observed in women than in men 
is partly explained by the fact that women are usually smaller than men, and partly by the 
fact that a woman of the same weight as a man has more body fat and less muscle. As 
muscle is more metabolically active than adipose tissue, men have a relatively high BMR. 
Nevertheless, BMR per kg body weight declines with increasing age, so that small children 
have a relatively high BMR, compared to adults.
1. 5 .3 Resting energy expenditure
BMR and RMR can either be predicted or measured.
1.5.3.1 Predicting basal metabolic rate and resting energy expenditure
There have been several proposals of equations to predict BMR including Harris & 
Benedict (1919), FAO/WHO/UNU (1985), Schofield (1985), Maffeis et a l (1993). The 
Schofield (1985) equations are the most widely used and are recommended by the UK 
Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy 
(Department of Health, 1991). Schofield (1985) proposes two sets of equations to estimate 
basal metabolic rate from weight alone or from weight and height. The latter are superior 
in children (Kaplan et a l  1995; Rodriguez et a l  2000) and probably in patients with 
wasting diseases. FCO2 can be estimated from BMR by assuming a respiratory quotient 
(FCO2/EO2) of 0.85 (IDECG, 1990). Resting FCO2 is elevated in certain diseases
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compared with healthy control subjects e.g. children with cystic fibrosis (Amarri et al. 
1998; Castro et al. 2002) and patients with pancreatic cancer (Wigmore et al. 1995; Barber 
et al. 1999). In such cases it is important to measure ECO2, rather than use the prediction 
equations.
1.5.3.2 Measuring basal metabolic rate and resting energy expenditure
RMR is usually measured using a ventilated hood indirect calorimeter, although portable 
respirometers and whole body calorimeters are sometimes used. Indirect calorimetry is 
based on measuring respiratory gas exchange i.e. whole body consumption o f oxygen 
(EO2) and production of carbon dioxide (FCO2) during the oxidation of various fuels. In a 
ventilated hood system, the subject lies under a perspex hood, which is made air-tight 
around the neck or shoulders using a canopy. A stream of air is drawn through the hood 
using a pump. This mixes with expired air and the concentration of O2 and CO2 is 
measured using on-stream analysers. The rate of energy expenditure is calculated from the 
volume of air flowing through the hood and the difference in concentration of O2 and CO2 
between the out-flowing and in-flowing air. This is described in more detail in Section 
2 .2 .2 .2 .
Principles o f indirect calorimetry
Humans consume macronutrients (carbohydrate, fat and protein) in the food they eat. 
These are absorbed, oxidised and eventually leave the body as CO2, H2O and urea. The 
macronutrients are almost completely oxidised, except for the formation of urea from 
protein. The body produces heat and energy for external work from the oxidation of 
macronutrients. It is irrelevant that the process of oxidation within the body may not be 
direct e.g. glucose may form glycogen, then lactate, then be recycled as glucose before 
being oxidised, or it may be converted to fat before oxidation. The net heat production will 
be the same as if the oxidation had occurred directly (Frayn, 1996).
Glucose from starch, sugars and glucogenic amino acids is the most commonly 
metabolised fuel in the body. A glucogenic amino acid is any amino acid, which is 
catabolised to pyruvate or a TCA cycle intermediate. Alanine is quantitatively the most 
important (Newsholme & Leech, 1985). The equation for complete oxidation of glucose is;
C6H 12O6 + 6 O2 6 CO2 + 6 H2O + heat (1.14)
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The ratio of CO2 production to O2 consumption, the respiratory quotient (RQ) for this 
reaction is 6/6 = 1.00.
1 mol glucose (180 g) + (6 x 22.4) L O2 ^  (6 x 22.4) L CO2 + (6 x 18 g) water + 2780 kJ
1 L oxygen = 2780 -  (6 x 22.4) kJ = 20.7 kJ (1.15)
If a subject is metabolising only carbohydrate, then for every litre of oxygen used in 
respiration, 20.7 kJ of heat (energy) is produced and therefore energy expenditure can be 
measured from the oxygen utilisation (Raaij, 2002).
If the body is using fat as an energy source, whether from the diet or stored adipose tissue, 
the equation is more complex because triacylglycerol molecules are larger and can be 
composed of a range of fatty acids. A typical fatty acid molecule e.g. palmitic acid 
(C16H34O2) contains a lower proportion of oxygen than glucose. Therefore, fat metabolism 
requires more oxygen than the metabolism of glucose because oxygen is used for the 
oxidation of hydrogen to water as well as carbon to CO2
A typical triacylglycerol is palmitoyl, stearoyl, oleoly-glycerol, CssHioeOe.
2 C55H 106O6 + 15702 IIOCO2 + IO6 H2O + heat (1.16)
The RQ for this reaction is 110/157 or 0.70.
The RQ for oxidation of one mole of a standard protein is 0.83 from,
C100H 159N32O32S0.7 + IO4 O2 —5“ 8 6 .6 CO2 + 5 O.6 H2O + other products + heat (1.17)
The other products are assumed to be urea (11.7 mol), ammonia (1.3 mol), creatinine (0.43 
mol) and sulphuric acid (0.7 mol). The RQ for this reaction is 86.6/104 or 0.83 (Frayn, 
1996).
Elia (1990) gives a detailed discussion of the energy equivalence of different fuels in terms 
of the heat liberated for each litre of oxygen consumed and carbon dioxide produced. The 
heat produced per litre of oxygen consumed is almost constant, but energy equivalence of 
CO2 varies to a much greater extent (Table 1.4), and therefore the RQ depends on the 
mixture of fuels being oxidised.
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Table 1.4 Energy equivalent of O2 & CO2 and RQ of macronutrients & alcohol
Energy equivalent 
RQ O2 CO2
Protein* 0.835 19.48 23.33
Carbohydrate** 1.000 21.12 21.12
Alcohol 0.677 20.33 30.49
From Livesey & Elia (1988). *End products assumed to be urea, ammonia and creatinine 
in the nitrogenous ration 90:5:5. **Glucose polysaccharide
î i
Fat 0.710 19.60 27.46
The measurement of oxygen consumption alone allows the calculation of energy 
expenditure to a reasonable accuracy, but the estimate can be improved by also measuring 
CO2 production and urinary nitrogen excretion. Most ventilated hood indirect calorimeters 
measure both oxygen consumption and CO2 production and energy expenditure (EE) is 
related to oxygen consumption (KO2) and carbon dioxide production (FCO2) by the 
modified Weir equation (Weir, 1949) without directly measuring urinary nitrogen 
excretion.
EE (kcal) = 1 .4 4 (3 .9 F0 2  + I.IFCO 2) (1.18)
where,
EE = Energy Expenditure (kcah24h, 1 kcal = 4.18 kJ)
VO2 = O2 consumption (ml.min"^ at STPD)
FCO2 = CO2 production (ml.min'^ at STPD)
In the context o f breath tests, the measurement of CO2 production is the required 
output, but factors that lead to an increase in energy expenditure, such as postprandial 
thermogenesis and physical activity also lead to an increase in CO2 production.
RQ and FQ
The energy content of a person’s diet can be calculated from macronutrient content of the 
diet. The food quotient (FQ) is the calculated CO2 produced divided by the O2 consumed 
during oxidation o f foods (Black et a l  1986). Under conditions of perfect nutrient balance 
the FQ must equal the RQ. The equation for calculating the FQ of a diet or meal is shown 
in full in section 2.4.2. The FQ of the average British or ‘western’ type diet composed of
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11 % energy from protein, 38 % energy from fat, 6  % energy from alcohol and the 
remaining 45 % energy from carbohydrate is 0.85 (Elia, 1990).
1.5.4 Postprandial or diet-induced thermogenesis
Diet-induced thermogenesis (DIT) is the stimulation of metabolism that occurs for 3-6 h 
after a meal and represents the energy cost of digestive activity including gastric emptying, 
intestinal motility, digestion, absorption, metabolism and storage of nutrients within the 
body. Weststrate (1993) showed that DIT could be measured in 3 h following a mixed 
meal of 1.3-2.6 MJ. Approximately 85 % of the total observed thermic effect (over 3.5 h) 
was observed in the first 2 h o f the postprandial period. The magnitude of DIT over 24 h is 
about 10 % of the total daily energy expenditure. DIT was originally called ‘the specific 
dynamic effect of food’ because the stimulation of energy expenditure depends upon the 
composition of the meal. DIT is also called postprandial thermogenesis (PPT) and the 
thermic effect of food (TEF).
1.5.5 Physical activity level (PAL)
The 1985 FAO/WHO/UNU expert committee on energy and protein requirements 
expressed the energy needs of adults as multiples of BMR (FAO/WHO/UNU, 1985). The 
ratio of TEE to BMR later became known as physical activity level or PAL (James, Ferro- 
Luzzi & Waterlow, 1988).
PAL = TEE/BM R (1.19)
The PAL ratio is a convenient way to control for age, gender, weight and body 
composition, and to express the energy needs of a wide range of people in shorthand form 
(Black et al. 1996). Annex 5 of the 1985 FAO/WHO/UNU report, gives the gross energy 
expenditure of specified activities, expressed in terms of BMR multiplied by a “metabolic 
constant”. Examples for adult males are; sleeping 1.0, sitting quietly 1.2, standing quietly 
1.4, walking slowly 2.8, playing cards 1.4. The term physical activity ratio (PAR) is now 
used for this metabolic constant (Department of Health, 1991). PAR can be used to 
estimate the contribution of a particular activity to TEE by multiplying the time spent on a 
particular activity by the energy cost of that activity. The weighted sum of PAR over a 24 
hour period equates to PAL. The PAL of sedentary adults undertaking non-active pursuits 
in their leisure time and light occupational activity is 1.4 (Department of Health, 1991).
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Recently, the term MET for the “metabolic constant” has found increasing favour. One 
MET is the ratio of the metabolic rate associated with a particular activity to resting 
metabolic rate (Ainsworth et a l  1992, 2000). MET’s are not exactly equivalent to PAR 
e.g. the MET associated with sleeping is 0.9, sitting quietly 1.0, standing quietly 1.2 and 
sitting playing cards, playing board games 1.5, but MET’s are finding increasing use as 
data are available for more activities.
BMR is rarely measured prior to ^^C-breath tests, although resting metabolic rate (RMR) is 
sometimes measured 3-4 h following the test meal (Amarri et a l  1997, 1998). Most 
studies use a predicted value of BMR. In any case energy expenditure during a breath test 
is above BMR, even in compliant subjects, because they are usually sitting, not lasting and 
are mentally alert, because they are concentrating on the protocol. During the course o f a 
6 - 1 0  h breath test, metabolic rate will vary depending on nutritional status as well as 
activity. The appropriate value of FCO2 should be used to calculate PDR in each breath 
sample, rather than assuming a constant rate throughout.
1.5.6 Use of heart-rate monitors to measure total energy expenditure
1.5.6.1 Introduction
Heart rate monitors have been used to measure TEE in individuals of all ages and offer 
potential to estimate of FCO2 over periods of several hours. The doubly labelled water 
method can accurately measure TEE over a period of several days (IDECG, 1990), but is 
not suitable for the time course o f a typical breath test, which lasts for several hours 
rather than several days. The doubly labelled water method averages EE during the 
measurement period and cannot detect patterns of activity. Accelerometers and other 
motion sensors have been widely used to monitor physical activity (e.g. Meijer et a l  1989; 
Pambianco, Wing & Robertson, 1990; Sallis et a l  1990; Freedson, 1991; Bouten et a l  
1994; Janz, 1994; Melanson & Freedson, 1995; Welk & Corbin, 1995; Eston, Rowlands & 
Ingldew, 1998; Johnson, Russ & Goran, 1998; Trost et a l  1998; Ekelund et a l  2002; 
Jackson et a l  2003 ; Reilly et a l  2004), but do not take account of infection, inflammation, 
diet-induced thermogenesis and other factors which might increase FCO2 independently of 
increased physical activity. Activity questionnaires (Harro, 1997; Bernstein et a l  1998; 
Kriemler et a l 1999) do not give detailed enough information to detect changes in ECO2 
over short time periods. Heart rate monitors provide minute-by-minute data, which 
potentially enables estimation of FCO2 at the time of each breath sample.
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1.5.6.2 Heart rate monitors
Booyens & Hervey (1960) explored the possibility of using pulse rate as a means o f 
measuring metabolic rate in man over 40 years ago. They noted that observations of the 
correlation between changes in heat production and changes in pulse rate had been 
reported by Benedict as early as 1907, and a relationship between changes in pulse rate and 
oxygen consumption was observed by Lindhard (1913) and Murlin & Greer (1914). 
Henderson & Prince (1914) were the first to show that in any one individual, one 
relationship between pulse rate and oxygen consumption existed during rest and very light 
activity, while there was an abrupt transition to a second relationship when activity was 
increased during exercise. The relationship during exercise was found to be consistent and 
linear, though it broke down at high levels of exertion. Booyens & Hervey themselves 
measured metabolic rate in two female and four male subjects (Booyens & Hervey, 1960). 
The relationship between pulse rate and metabolic rate was established lying, sitting and 
standing and at three rates of work on a bicycle ergometer.
By 1969, it was possible to measure heart rate and oxygen consumption simultaneously, 
and Bradfield, Huntzicker & Fmehan (1969) compared this technique with the 
respirometer-diary technique of Durnin and co-workers (Garry et al. 1955; Durnin, Blake 
& Brockway, 1957; Durnin & Brockway, 1959; Durnin el al. 1961a, 1961b) in a group of 
24 young men. Christensen et a l (1983) used Bradfield’s method (Bradfield et al. 1969) 
to estimate EE from heart rate and oxygen consumption data in patients with metabolic 
disorders (obesity, untreated thyrotoxicosis and anorexia nervosa). He found considerable 
intrasubject variability when measurements were made on the same subject under identical 
conditions on consecutive days. Generally the coirelation coefficients of the regression 
lines were high, but fairly large differences between the slopes and intercepts of the 
duplicate lines resulted in large discrepancies between duplicate estimates. Christensen, 
therefore concluded that the method had limited applicability in subjects with low levels of 
activity, because heart rate is influenced by factors which do not affect VO2 .
Uncalibrated heart-rate monitors have been used to study the pattern of physical activity in 
6-7 y old children (Gilliam et al. 1981). Treiber et al. (1989) showed that heart rate 
monitors give an accurate record of heart rate in children (aged 4-10 y), when compared to 
electrocardiographic (ECG) telemetry in the laboratory. Activities, such a throwing a 
tennis ball, batting a tennis ball and playing on a climbing frame were included in the 
study. These are activities which are commonly performed by children, but which might
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result in poor reception by the receiver or disconnection of the transmitter. They concluded 
that heart rate monitors are a practical and inexpensive means of accurately assessing heart 
rate in children under field conditions. This was confirmed by Durant ei al. (1993).
Calibrated heart rate monitors have been used in studies o f TEE in free-living populations 
of adults including Livingstone et al. (1990), Davidson et al. (1997), Morio ei a l  (1997), 
Wareham et al. (1997). Heart rate monitoring has also been used in studies of activity in 
pre-school children (Bar-Or et al. 1996; Pate et al. 1996), primary school children and 
adolescents (Emons et al. 1992; Janz et al. 1992; Livingstone et al. 1992; Treuth, Adolph 
& Butte, 1998; Ribeyre et al. 2000a, Vermorel et al. 2002), and pregnant women (Heini et 
al. 1991). These studies have relied on individual calibration o f the heart rate monitor 
either using indirect calorimetry or analysis o f oxygen in exhaled breath.
1.5,6.3 Calibration methods
All published studies have relied on individual calibration to establish a relationship 
between heart rate and oxygen consumption or EE. Methods of calibrating heart rate 
against EE, VO2 or VCO2 need to take into account the fact that there is a different linear 
relationship at resting levels than at levels of activity above resting (Figure 1.15). 
Calibration procedures therefore must include measurements where the subjects are lying 
quietly, sitting quietly and standing still as well as at levels of increasing activity, usually 
either on a bicycle ergometer or a treadmill.
The most widely used calibration method in studies of energy expenditure is that of Spurr 
et al. (1988), which used a two-component linear model. Measurements were made after 
several minutes equilibration time in each position (lying, sitting on a chair, standing and 
sitting on a bicycle ergometer). The mean of all the inactive measurements was used as the 
resting metabolic rate, RMR, which is -5  MJ d‘^  in the example shown in Figure 1.15. The 
subjects then began cycling on the ergometer at 50 cycles min'^ with no resistance. Every 
3 min the resistance was elevated until the subject’s heart rate increased to approximately 
150 beats min"\ Measurements of VO2 were made during the last minute of each 3 min 
cycling period.
Spurr et al. (1988) defined a critical heart rate, above which the slope and intercept of the 
linear calibration curve obtained on the exercise bicycle was used to determine VO2 , and 
below which the resting rate was used. The critical value was calculated by adding 10 to
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the flex heart rate, which was determined empirically by taking the average of the highest 
resting heart rate and the lowest during exercise on the bicycle. The flex point in the 
example shown in Figure 1.15 is approximately 90 beats per min. Therefore, the critical 
value is 100 beats per min. Below a heart rate of 100 beats per min a constant relationship 
(RMR) is assumed, and above 100 beats per min the linear calibration curve is used. EE 
calculated from heart rate data was - 2 0  to +15 % of that determined in the whole body 
calorimeter (mean -2.4 %). The inter-individual coefficient of variation (CV) was 9.6 %. 
Ceesay et al. (1989) used a modification o f SpuiT’s method to validate the heart rate 
method against whole-body indirect calorimetry in 20 healthy adult subjects. They found 
that on average the heart rate method underestimated TEE by only 1.2 %. The difference 
between the two methods was not significant.
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Figure 1.15 Relationship between heart rate and energy expenditure
A variation of the linear-flex method was used by Livingstone (1992) who used a treadmill 
to calibrate heart rate and VO2 in children aged 7 to 15 y. TEE calculated from heart rate 
data was compared to that determined by the doubly labelled water method (Coward, 1988; 
IDECG, 1990), During the calibration procedure, heart rate and VO2 were measured 
simultaneously at three resting levels (supine, sitting quietly, standing quietly) and two 
levels of work on a treadmill. A preliminary equilibration period of 3 min was allowed for 
each activity, followed by a 3 min sampling period. The calibration point for each activity 
was computed as the mean for the 3 min sampling period of heart rate and FO2 . As before,
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RMR was determined as the mean VO2 o f the resting activities, and the flex point was 
defined as mean of the highest heart rate for the resting activities and the lowest heart rate 
from the treadmill. Unlike Spurr ei a l (1988), Livingstone did not add 10 to the flex heart 
rate to determine the critical point. In this case the critical point was equal to the flex 
point.
Determination of a flex point can be avoided by the use o f non-linear models. Schulz, 
Westerterp & Breuck (1989) and Davidson et al. (1997) used a 2”  ^order polynomial with 
reasonable success, and order polynomials have been used by Bitar et al. (1996); Mario 
ei al. (1997); Ribeyre et al. (2000a); Beghin et al. (2002); Rodriguez et al. (2002) and 
Vermorel et al. (2002). A disadvantage o f 2"^ and 3“^* order polynomials is that at low 
heart rates, such as when sleeping, they tend to overestimate energy expenditure, unless a 
flex point is introduced at the minimum of the model. This problem is avoided by the use 
of an appropriate exponential model. As long ago as 1979, Dauncey and James (1979) 
assessed the heart-rate method for determining energy expenditure over 24 h periods on 
subjects carrying out near-normal activities in a whole-body calorimeter. In this study, 
simultaneous measurements of heart rate and heat production were made with the subjects 
lying, sitting, standing quietly and while cycling at four levels of work on a bicycle 
ergometer. Dauncey and James compared several linear regression methods of their non­
resting data with a logistic fit o f all their calibration data, including both resting and non­
resting data in a single model. The percentage difference between the measured and 
predicted heat production for every subject was calculated using each method. This was 
taken as a measure of the accuracy of the method. The use of coixelation coefficients was 
found to be misleading, since a perfect correlation could be associated with a large mean 
difference and standard deviation i.e. the method was neither accurate nor precise. The 
logistic model, was also used by Li, Deurenberg & Huatvast (1993) and has the advantage 
of fitting the data, without assuming a flex point.
An alternative non-linear model is the Sigmoid model. Like the logistic model, it makes 
no assumptions about resting heart rate and avoids the use of a flex point. Moon and Butte 
(1996) compared linear, 2"  ^ order, 3"^  order, logistic and sigmoid models of calibrating 
heart rate monitors. They found that the Sigmoid model had the highest coefficient of 
determination (R  ^ ^  0.91), but used a two-component model based on RMR and HR^ to 
estimate 24-h FO2 and FCO2 using a combination of heart rate and activity monitors.
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1.5.6.4 Generic calibration
It would not be necessary to perform individual heart rate calibrations for each subject, if a 
generic calibration could be found, scaling VCO2 to some allometric parameter. In many 
studies, scaling to body surface area is used to compare the results from different subjects.
This removes the effect of the increase in CO2 production rate with body size.
The consensus in studies o f energy expenditure using heart rate monitors seems to be that 1
individual calibration is necessary to obtain estimates o f energy expenditure that are 
sufficiently accurate to detect small differences in population studies. Spurr et al. (1988) 
obtained estimates from heart rate data that were within 15-20 % of those measured by 
whole body indirect calorimetry, a method which is clearly unsuitable for studies in free- 
living individuals. Li et al. (1993) obtained inter-individual CV’s of 11-20 % and intra­
individual CV’s of 14-18 %. This level o f precision may, however be adequate for I
breath tests, where the error introduced by using resting LCO2, when individuals are not at 
rest, can be up to 1 0 0  %.
as the heart rate of a working animal divided by the heart rate at rest. Energy expenditure 
was normalised to kg body weight* '^^ .^ A similar relationship was found by Sneddon et al. 
(1985) in young calves.
1.6 Use of deuterium labelled tracers
1,6,1 Introduction
Use of deuterium (^H) labelled tracers could avoid the problems associated with lack of 
knowledge of FCO2 , incomplete recovery of tracer and changes in background 
abundance. Furthermore, the proportion of label that may be sequestered into organic 
molecules is small, approximately 4 % (Haggerty, 1990). The volume of distribution o f  ^ H 
is total body water, which is not affected by food intake, physical activity or nutritional 
status over the required time course of 6 - 8  h, which is similar to the sampling time during
Animal studies have attempted to predict energy expenditure from heart rate measurements i 
using a generic calibration (Richards & Lawrence, 1984; Sneddon, Mathers & Thomson,
1985). Richards and Lawrence (1984) found that the rate of energy expenditure of adult
cattle pulling loads whilst walking on a treadmill, was related to relative heart rate, defined
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the [^^CjMTG breath test. Body water can be sampled in the form of saliva, urine or 
plasma.
1,6.2 The fHJMTGtest
It is possible to synthesise MTG using [^Hisjoctanoic acid, rather than [l-^^C]octanoic 
acid. [^HjMTG is not available commercially, but [^^C]MTG and [^HJMTG will be 
digested and absorbed in the same manner. However, the fate of the label is different after 
p-oxidation. The label on [1-^^CJoctanoic acid is removed at the first pass through the 
mitochondrial p-oxidation pathway as [l-^^C]acetyl Co A, which enters the TCA cycle for 
oxidation to ^^COz, but the label may be sequestered into other carbon pools during 
anabolic and anaplerotic processes (Figure 1.11), and thus only approximately 30 % of 
ingested tracer is recovered in breath CO2 within 6  h (Amarri et al. 1998). By contrast, 
most of the deuterium exchanges with body water during P-oxidation and sequestration of 
^H into body glycogen, protein and lipid stores is small (Haggerty, 1990; Haggerty et al. 
2000) compared to sequestration of carbon. The ^H non-aqueous exchange factor 
accepted in the calculation of total body water from deuterium dilution is 1.04 (Schoeller 
& Jones, 1987) i.e. -4  % of ingested deuterium is sequestered. Therefore approximately 
96 % ingested ^H should be recovered in body water in healthy subjects. There will be 
small losses in insensible water in faeces, perspiration etc.
To calculate percentage dose recovered in body water from deuterium labelled tracers, a 
measure or estimate of the tracer distribution volume (total body water) is required. Total 
body water can be measured independently by -dilution (Schoeller et al. 1980), but this 
would be prohibitively expensive for routine use and supplies of 1 0  % enriched water 
are unreliable. In adults, total body water can be estimated using equations based on 
height and weight (Hume & Weyers, 1971). Estimation of total body water from 
bioimpedence measurements is possible if suitable equations are available for population 
being studied (Houtkooper et al. 1992; Hannan et al. 1994; Berger et al. 2000; Sun et al. 
2003), but these may not be accurate in children (Reilly et al. 1996; Parker et al. 2003). 
The simple formula devised by Slater and Preston (2002) to predict total body water from 
height, based on measurements in subjects aged from 3 to 83, may be sufficiently accurate 
in this context.
The cost of deuterium analysis has improved considerably since the advent of continuous- 
flow methods of deuterium analysis (Section 1.4.4). These are much less labour-intensive
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than traditional methods, which require off-line preparation of pure hydrogen samples 
followed by deuterium analysis by dual-inlet IRMS. It is now possible to prepare and 
analyse many more samples in a day than previously and therefore analytical costs are 
considerably reduced. However, the body water pool is much larger than the bicarbonate 
pool, so larger doses of ^ H-labelled substrates (10-15 times more than for breath tests) 
are required to achieve sufficient enrichment for accurate analysis.
Use of [^H]MTG as a test o f exocrine pancreatic insufficiency that is not affected by diet or 
physical activity could prove to be feasible in the near future, if supplies of [^H]MTG can 
be secured.
L 6.3 Validation of^^C breath tests using ^ H4abelled substrates
Bluck et al. (2002) used simultaneous doses of [^Hisjoctanoic acid and [l-^^C]octanoic 
acid in their validation study of the octanoic acid test of gastric emptying. The hypothesis 
was that the majority o f the label will be removed during P-oxidation, passing directly into 
body water and therefore the kinetics observed should be more closely related to the 
reference method, radioscintigraphy.
Deuterium labelled substrates can also be used to test the assumptions related to recovery 
of in breath and sequestration within the body. The acetate correction factor accounts 
for fixation that might occur at any step between the entrance of acetyl-CoA into the 
TCA cycle until recovery o f label in breath CO2 (Section 1.4.9). Assumptions in its use are 
that CO2 production rate is the same on each occasion, that there are no other major routes 
of sequestration of label, and that oxidation of both tracers take place at the same rate. If 
these assumptions are true, then recovery in breath corrected for label sequestered in the 
body should be 95 to 100 % and should be similar to the recovery of in body water 
following ingestion of pHjMTG. If recovery is not within 5 % of 95 %, then the 
assumptions are not valid.
Comparison of recovery o f deuterium in body water following ingestion of [^HjMTG and 
[^Hjoctanoate would confirm that hydrolysis of the long-chain fatty acids from the sn-\ 
and position of MTG is the rate-limiting step in its metabolism. Comparison of 
recovery of deuterium in body water following ingestion of [^Hnjoctanoate and 
[^Hsjacetate would confirm that acetate and octanoate are metabolised in the same manner 
following absorption.
Cliristine Slater 2004 Chapter 1, 66
1.7 Summary of the problem
The MTG breath test provides an indirect measure of exocrine pancreatic insufficiency in 
children with cystic fibrosis and could be used to optimise pancreatic enzyme replacement 
therapy (PERT) in these children (Amarri et al. 1997). However, in validation studies, the 
test had a sensitivity of 0.89 and specificity o f 0.81 resulting in a positive predictive value 
of 0.63 and negative predictive value of 0.95 (Vantrappen, 1989; Perri & Andriulli, 1998). 
This implies that there were few false positive results and that the majority of patients with 
exocrine pancreatic insufficiency were correctly identified, but there were too many false 
negative results shown by low recovery of in breath CO2 of healthy subjects. The 
same pattern was observed by Amarri et a l  (1997) in children. Large intra-individual 
variation of ^^C0 2  excretion has also been reported in healthy adult subjects (Kalivianakis 
et al. 1997), with a coefficient of repeatability of cPDR 9h of 22.7 %. Reasons for low 
recovery in the breath of healthy subjects, and children with cystic fibrosis taking their 
normal PERT, could be due to one or more of the following:
1 . errors in dosage
2 . inaccurate measurement
3. loss in stool
4. inaccurate CO2 production rate measurement
5. sequestration within the body.
Errors in dosage can be controlled by careful weighing to sufficient accuracy, ensuring 
homogeneous distribution within the test meal, taking account of losses during preparation 
and adjusting for incomplete consumption of the test meal. The natural abundance of 
the test meal should also be controlled by using low ingredients.
Inaccurate isotope abundance measurement can be avoided by careful calibration of the 
IRMS, and frequent checks of linearity and precision. Accuracy of measured enrichment 
also depends on taking steps to maintain constant background abundance.
Losses in stool and urine have been shown to be small, amounting to less than 5 % of the 
ingested dose in healthy children and children with cystic fibrosis taking their normal dose 
of PERT (Slater et al. 2002). The vast majority of tracer must thus be exhaled in breath 
CO2 or sequestered in metabolic products within the body. Accurate accounting for the 
sequestered tracer should result in a test with improved discrimination.
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Quantitation o f tracer excretion requires knowledge of the volume o f distribution of the 
tracer as well as ingested dose and breath abundance. In the case of breath the
volume of distribution is endogenously produced CO2 from metabolic processes, which is 
usually expressed as CO2 production rate (FCO2). A resting value based on BMR is 
usually assumed, but if subjects are not resting and in the postabsorptive state throughout 
the test, this will be an underestimate of the true CO2 production rate.
1.8 Hypothesis and Aims
1.8.1 Global hypothesis
The global hypothesis is that the poor positive predictive value of the ^^C-mixed 
triacylglycerol (MTG) breath test used to assess exocrine pancreatic insufficiency is due to 
lack of knowledge of the true carbon dioxide production rate (FCO2) during the test.
Use of a constant value o f resting VCO2, whether predicted from body surface area (300 
mmol.h'\m"^), calculated from BMR predicted using the Schofield (1985) equations, or 
measured, underestimates the true CO2 production rate and does not take account of 
variations during the test.
This results in an underestimate of the percentage dose recovered, especially in 
children, who are unable to maintain resting conditions for the six-hour duration of the test.
The solution to this problem is either to measure CO2 production rate for the duration of 
the test, or to use an empirically derived correction to eliminate the need for its 
measurement.
L8.2 Aim
To improve the positive predictive value of the MTG breath test, either by continuously 
measuring FCO2 during the test, or by using a correction for tracer loss in the products of 
intermediary metabolism. A series of interrelated experiments and human studies were 
designed to achieve this aim and to test the hypothesis above.
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1.8.3 Objectives
1 Validation of laboratory methods. To optimise laboratory procedures and thus 
ensure that mass spectrometric methods provide accurate and precise results.
2 Measuring CO2 production rate. To assess the potential o f using heart rate 
monitors to estimate CO2 production rate and sources o f  its variation during
breath tests, and to determine the most suitable calibration procedure in 
healthy adults.
3 Generic calibration of heart rate monitors. To assess potential generic 
calibration methods to predict CO2 production rate from heart rate during ^^C- 
breath tests.
4 Development of a test meal. 7b design a test meal to cany both hydrophilic 
([12 ^ C] acetate, [^Hs]acetate) and. lipophilic ([J-^CJoctanoic acid, 
fHisJoctanoic acid, [^^CJMTG and [^HJMTG) substrates to study intermediary 
metabolism within the context o f the [^^C]M7G test.
5 Investigation of [^^CJMTG metabolism. To investigate aspects o f  [^^CjMTG 
metabolism by comparing the cumulative percentage dose recovered (cPDR) 
from the [^^CJMTG breath test with that from  [l^^C]octanoic acid, 
[l-^C]acetate and [^^C]bicarbonate breath tests in subjects wearing calibrated 
heart rate monitors.
6 Intra-individual variation in the MTG test. 7b measure the intra-individual 
variation o f the cPDR in the [^^C]M7G and [ 7 - ^C]acetate breath tests in 
subjects wearing calibrated heart rate monitors.
1 Deuterium-labelled MTG test. 7b investigate the use o f deuterium labelled.
M7G as a simpler alternative to the ^^C-breath test and to validate 
improvements to the ^^C-MTG breath test.
8 [^^CJMTG breath test in healthy adults and children. To investigate the effect o f 
different levels and. patterns o f activity by performing [^^C]J\4TG and 
[7-^CJacetate breath tests in healthy adult volunteers, healthy child volunteers 
and children with cystic fibrosis, all wearing individually calibrated heart rate 
monitors.
9 [^^CJMTG breath test using generic heart rate calibration. 7b investigate 
potential generic calibration methods to predict CO2 production rate from 
heart rate during breath tests in subjects with a wide range o f age and body 
habitus and to demonstrate their use in the f ‘^C]M7G and [l~^C]acetate 
breath tests.
Cliristine Slater 2004 Chapter 1, 69
10 Empirical compensation for individual FCO2 . To investigate the use o f  an 
acetate correction as an empirically derived means o f compensating fo r  lack o f  
knowledge o f CO2 production rate during the [^^CjMTG breath test.
11 Determination of the cut-off point of the [^^C]MTG test. To determine the 
appropriate cut-off o f the modified MTG breath test using two graph-receiver 
operator characteristics (TG-ROC), and to calculate the positive and negative 
predictive values o f the new test.
1.9 Ethical considerations
Ethical approval was obtained from the Yorkhill Research Ethics Committee for the 
studies involving children and from the University of Glasgow Ethics Committee for Non 
Clinical Research Involving Human Subjects for the studies involving adults. The purpose 
of the study was carefully explained and written informed consent was obtained from all 
subjects (adults and children) taking part in the study, and where appropriate their parents. 
The study posed no danger to those taking part and subjects were free to drop out at any 
time.
Appendix 1 contains copies of the letters of approval from the University o f Glasgow 
Ethics Committee for Non Clinical Research Involving Human Subjects and Yorkhill 
Research Ethics Committee, plus the information sheets for volunteers and a blank consent 
form.
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Chapter 2 Methods 
Summary of Chapter 2
In this chapter, the methods used to test the hypothesis and address the aims described at 
the end of Chapter 1, are described. Each group of experiments or studies was designed to 
address each of the objectives listed in Section 1.8.3. The results o f each set of 
experiments or studies are reported in Chapter 3.
The experiments described in Sections 2.1 to 2.4 were designed to establish accurate 
methods of quantifying tracer excretion in breath. Quantitation of tracer excretion requires 
knowledge of the volume o f distribution of the tracer as well as ingested dose and breath 
^^ C abundance. In the case of ^^ C breath tests, ^^COz originating from oxidation of the 
tracer is diluted by endogenously produced CO2 from metabolic processes. Therefore 
knowledge of CO2 production rate (VCO2) is required. A resting value based on basal 
metabolic rate is usually assumed, but if subjects are not resting and in the postprandial 
state throughout the test, this will be an underestimate of the true CO2 production rate.
There are three alternative approaches to solving this problem:
i. Measure CO2 production rate throughout the breath-sampling period
ii. Use an empirically derived correction to compensate for the effect of “unknown” CO2 
production
iii. Use a tracer which does not enter the body’s CO2 pool.
Each of these approaches was explored during this study:
i. CO2 production rate was measured throughout the breath-sampling period using 
calibrated heart rate monitors. Alternative calibration procedures were investigated 
and the possibility o f using a generic calibration was explored (Sections 2.2, 2.3, 2.8 
and 2.9).
ii. Use of an acetate correction to account for retained in the body was explored. 
This approach requires two breath tests to be performed, as simultaneous use of 
with the radioisotope is precluded. CO2 production rate is assumed to be the 
same on both occasions, but knowledge of the actual value is not required (Sections 
2 . 6  and 2 .1 0 ).
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iii. Use of deuterium (^H) labelled MTG, rather than ^^C-labelled MTG, avoids the need 
to know CO2 production rate. is distributed through the body water pool and 
therefore requires sampling of urine or saliva, rather than breath, and also a 
measurement or estimate of total body water (Section 2.7).
Once accurate methods to quantify tracer excretion in breath and other minor losses have 
been established, mass balance can be used to estimate the quantity of tracer retained 
within the body using [^^C]MTG and its metabolites, [l-^^C]octanoate, [l-^^C]acetate and 
[^^Cjbicarbonate (Sections 2.5 and 2.6). Section 2.7 describes experiments using I^T- 
labelled MTG, octanoate and acetate in the same subjects.
Use of heart rate monitors to estimate FCO2 during the [^^CjMTG test was investigated in 
eight healthy adults, ten healthy children and seven children with cystic fibrosis (Section 
2.8). Cumulative breath ^^C0 2  excretion was calculated using resting and non-resting 
values of VCO2 . Physical activity level during the test was defined as non-resting PDR 
divided by resting PDR. Use o f generic heart rate calibration methods, which avoid the 
need for individual calibration, was also investigated (Section 2.9).
[l-^^C]acetate breath tests were performed on eight healthy adults, nine healthy children 
and three children with cystic fibrosis, who had also performed the [^^C]MTG breath test. 
The cumulative excretion of ^ ^C0 2  during the [^^CjMTG breath test was corrected for label 
sequestered in the body using the cumulative excretion of ^^C0 2  during the [l-^^C]acetate 
breath test (Section 2 .1 0 ).
Two graph-receiver operator characteristics (TG-ROC) were used to determine the 
appropriate cut-off for the [^^C]MTG test with a 6  h sampling time. PDR was calculated 
using both resting and non-resting values o f VCO2 . The positive and negative predictive 
values of the tests were calculated (Section 2 .1 1 ).
Cluistine Slater 2004 Chapter 2 , 72
2.1 Validation of laboratory methods
-42.1.1 Introduction
The laboratory methods used to measure isotopic abundance were validated, to ensure that 
all measurements were accurate (traceable to international standards or gravimetrically 
prepared standard curves), precise (standard deviation o f three replicate analyses < 1 ppm) 
and linear (the isotope ratio was constant over the expected concentration range). This
' .i
ensured that measurement of isotopic abundance was not a major source of error in the
■■'Icalculation of cumulative excretion.
The isotopic abundance o f in breath CO2, and and in body water, as represented 
by urine and saliva, was measured by continuous tlow-isotope ratio mass spectrometry 
(CF-ERMS). This technique measures the abundance of the stable isotopes of carbon, 
nitrogen, hydrogen and oxygen in simple gases, CO2, N2, H2 in a stream of carrier gas 
(He). The sample is purified on-line: a water trap removes moisture, and breath CO2 is 
separated from N2 on a GC column in an isothermal oven. The pure gas sample enters the 
ion source of the mass spectrometer, where in a high vacuum it is ionised by bombardment 
with electrons from a hot filament. The ions are separated in a magnetic field on the basis 
of their mass:charge {m/z) ratio. The detector in an isotope ratio mass spectrometer is a 
series of Faraday cups, each of which detects ions of a single mass. For CO2, the 
monitored ion beams are m/z 44, 45 and 46, For H2, the monitored ion beams are m/z 2 
and 3. Specialised instruments are required to measure m/z 2 and 3 in the presence of He 
at m/z 4.
The Department of Child Health took delivery of its first IRMS (Hydra 20-20 IRMS with a 
deuterium spur, PDZ Europa, Crewe, UK) in October 1997, coincident with the start of this 
project. There were no routine laboratory procedures in place at this time and these had to 
be developed as part of this study. To ensure that the isotope ratio mass spectrometer gave 
accurate and precise results, studies involving human subjects were preceded by a series of 
experiments to optimise IRMS operation and the procedures used to prepare samples and 
reference gases. The IRMS source tuning was optimised separately for CO2 and for FI2 
analysis. The laboratoiy CO2 reference gas (5% CO2 in N%) was calibrated against 
references, which were traceable to the international standards and linearity o f CO2 
measurements was checked. The procedure for analysing and ^H in reference waters 
and clinical samples was optimised. H2 ^ ^ 0  and ^H2 0  standard curves were prepared to
■'I
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check the accuracy of *^0 and measurements. The procedure used to fill reference gas 
vials was optimised to give reproducible results, with a coefficient of variation on the 
amount of gas in each vial, of less than 1%.
2,1.2 Measurement of^^C and isotopic abundance
The IRMS was composed o f a 20-20 IRMS interfaced to an automated breath carbon 
analyser (ABCA, PDZ Europa, Crewe, UK) and an autosampler capable of holding 204 x 
10 ml Exetainer breath sampling vials (Labco, High Wycombe, UK).
2.1.2.1 Procedure for filling reference gas vials
Reference gases were prepared on a 20-place vacuum manifold (PDZ Europa, Crewe, UK) 
attached to an Edwards two stage rotary pump, model E2M1.5 with an Edwards active 
pirani gauge and Edwards active gauge controller to monitor the vacuum (all available 
from Northern Scientific, York, UK). The manifold had 20 ports, each with a luer-lock 
stopcock (Sigma-Aldrich, Poole, UK) and a 25 gauge needle (Microlance 3, Beckton 
Dickinson, Cowley, UK). There were isolation taps at either end. Reference gas entered at 
the left-hand side. The flow o f reference gas was controlled by an in-line flow controller, |
and set to 1 0 0  ml min'^ as measured by a bubble flow meter. The outlet to the vacuum 
pump was at the right-hand-side. All reference gas and clinical samples (breath, urine or 
saliva) were prepared in 10 ml Exetainer gas sampling vials (Labco, High Wycombe, UK). 
Evacuated vials are supposed to have a 10 ml draw, but the actual volume of the vial is 12 
ml. The procedure for filling Exetainers was optimised empirically to minimise the 
coefficient of variation (standard deviation o f total beam / mean total beam x 100). The 
manifold was evacuated by closing the gas isolation tap and all the stopcocks, and opening 
the vacuum isolation tap. Exetainers were attached to ports via a needle through the 
septum, leaving the right hand port free. The stopcocks were opened (except for the last 
port) and the tubes evacuated. All the stopcocks were closed and the vacuum pump was 
isolated. The free port was opened and the manifold was flushed with reference gas for 5 
min, after which the Exetainers were filled by opening the stopcocks, one at a time starting 
at the left-hand side, for exactly 10 s. This was timed using a stopwatch to eliminate inter­
individual error between operators.
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2.1.2.2 Measurement of and in breath CO2 and CO2 reference gas
The abundance of and in breath CO2 was measured by monitoring the ion beams at 
m/z 44, 45 and 46. The IRMS source parameters and resistance of the head amplifiers are 
shown in Table 2.1. The source was tuned for maximum sensitivity with a broad flat- 
topped m/z 45/44 ratio trace and maximum width in the plateau of the m/z 46/44 ratio 
traces. This was achieved by small adjustment of the HT, ion repeller and beam focus 
settings. Measurements were made against a reference gas containing 3 % CO2 in N2 (Air 
Products Special Gases, Crewe, UK). This had been calibrated against secondary 
references that were traceable to the international standards (VPDB, Vienna Pee Dee 
Belemnite for and VSMOW, Vienna Standard Mean Ocean Water for ^^O) (Coplen, 
1996) at the Isotope Geosciences Unit, Scottish Universities Environmental Research 
Centre, East Kilbride. The Craig correction (Craig, 1957), which uses the measured 
[12c 16o 18o] 46 to account for the presence of at m/z 45, was applied by
the manufacturers software. Results were expressed as ppm ^^ C or ppm After
maintenance periods, the stability o f the IRMS was checked by trapping CO2 reference gas 
and monitoring the ion beams at m/z 44, 45 and 46 and the ratio traces of 45/44 and 46/44.
Table 2.1 Hydra-IRMS source and detector settings for CO2 and H2 analysis
CO2, a n d " ? ^ W "  "^'H2, [W H ]
Magnet Current (A) 12.5 2.6
HT (V) 2520 2723
Trap Current (pA) 2 0 0  600
Electron Energy (eV) -75 - 7 5
Ion Repeller (V) - 1 1  30
Beam Focus (%) 91 8 6
Head Amplifier Resistance
Beam 1 (MG) 100 100
Beam 2 (MG) 5000 100,000
Beam 3 (MG) 5000 Not applicable
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2.1.2.3 CO2 calibration curve and linearity of abundance
A standard curve was prepared over the expected range of CO2 concentration in exhaled 
breath by preparing tubes o f reference gas containing 0.5-10 % CO2, by injecting pure 
(100 %) CO2 (Air Products Special Gases, Crewe, UK) into evacuated Exetainers using a 
gas-tight syringe (SGE, Burke Analytical, Alva, UK). A measurement is said to be linear, 
if  the isotope ratio (abundance) is constant over the expected concentration range. 
Linearity of measurements was checked by plotting the abundance of (ppm) 
against calculated CO2 concentration. % CO2 was the independent variable, plotted on the 
jc-axis and ppm was the dependent variable plotted on they-axis.
2.1.2.4 Precision of breath CO2 analysis and inter-laboratory check
A bicarbonate breath test (0.5 mg/kg body weight) was performed on a single subject, and 
multiple identical breath samples were obtained using the “bag and mask” technique 
(Weaver et al. 1993). Exhaled air was sampled at intervals by blowing through a one-way 
valve (Ambu, Brondby, Denmark) into a 600 ml gas sampling bag (Laerdal Medical, 
Orpington, UK), which has been fitted with a 3-way Luer tap to facilitate gas transfer. 
Breath samples were transferred to an evacuated Exetainer using a syringe. Five identical 
replicates were prepared at each time point. The abundance of ^^C0 2  was measured as 
described above (Section 2.1.2.2). Four replicates were analysed on the HYDRA-IRMS in 
the Department of Child Health, and one was measured on the 20:20-IRMS (Europa 
Scientific) in the Isotope Biochemistry Laboratory at the Scottish Universities 
Environmental Research Centre, East Kilbride.
2.1.2.5 Preparation of an standard curve
The accuracy of enrichment measurements was checked by preparing a calibration 
curve and plotting the enrichment measured by ERMS against that calculated from the 
weight and the abundance of the stock H2 ^^ 0 . The abundance o f in the stock H2 ^ ^ 0  
was calibrated against the international standard (VSMOW) at the Isotope Geosciences 
Unit, Scottish Universities Environmental Research Centre, East Kilbride. Ideally, the 
gradient of the calibration curve should be 1 .0 .
A series of gravimetric standards containing 0 , 15, 75, 150, 225 and 375 ppm excess 
was prepared from H2 ^ ^ 0  ( 1 0  atom % normalised for deuterium concentration, CK 
Gas Products, Wokingham, UK) diluted with tap-water. Large volumes (1 L) of 0 and 150
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ppm excess were prepared to serve as working standards to be analysed with each 
batch of samples. An aliquot (400 pi) of each sample was pipetted into a 10 ml Exetainer 
gas testing vial (Labco, High Wycombe, UK). Vials were evacuated for one min, filled 
with reference gas (3 % CO2 in nitrogen. Air Products Special Gases, Crewe) as described 
in section 2.2.2.1 and left to equilibrate with the headspace gas for 24 h at ambient 
temperature. During this time the in the water phase equilibrated with the CO2 in the
gas phase. The abundance of in the gas phase was measured by CF-IRMS, monitoring i'm/z 44 and 46. The abundance of in standard waters was calculated with reference to
the known abundance of in the CO2 reference gas, which was traceable to international 
standards. Results were expressed as ppm The enrichment of water samples was 
calculated by subtracting the measured abundance of in the 0  reference (tap water) 
from the measured abundance of in the sample. Results were expressed as ppm excess 
Measured enrichment (ppm excess ^^O) was plotted against enrichment calculated 
from the independent analysis of the stock H2 ^^ 0 , and the weight of H2 ^ ^ 0  and tap water 
used to prepare the reference water. Enrichment calculated from weight was taken as the 
independent variable and plotted on the x-axis.
2.1,2.6 Accuracy and precision of CO2 measurements
Accuracy of measured ^^C0 2  abundance was ensured by calibrating the reference gas 
against the international standard and placing references at intervals during each analytical 
run. The reported isotope ratio was corrected for instrumental drift between references. 
Precision of ^^C0 2  measurements was checked at intervals by analysing batches of 
reference gases and calculating the standard deviation (SD) of three replicates. SD < 0.5 
ppm (<0.05 7oo) was regarded as acceptable (Preston, 1992).
Accuracy of H2 ^ ^ 0  measurements was ensured routinely by including working standard 
waters containing 0 and 150 ppm excess in triplicate at intervals in each batch of 
samples. The gradient of this two-point calibration curve was used to calculate the isotope 
abundance in each sample. The reported isotope ratio was corrected for instrumental drift 
between references as described below (Section 2 .1.3.3). The precision of abundance 
measurements was checked by calculating the standard deviation (n=3) of the standard 
waters, which were included at intervals in each batch of samples. SD < 0,5 ppm was 
regarded as acceptable.
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2,1.3 Measurement of ^H isotopic abundance
2.1.3.2 Preparation of a H standard curve
Accuracy of enrichment measurements was checked by preparing a calibration curve 
and plotting the enrichment measured by IRMS against that calculated from the weight and 
certified abundance of the stock ^H2 0 . Ideally, the gradient of the calibration curve should 
be 1 .0 .
A series of gravimetric standards containing 0 , 15, 30, 75, 1 0 0 , 150, 250, 300, 750, 1100, 
1500 ppm excess was prepared from (99.9 atom % Isotech, CK Gas Products, 
Wokingham, UK) diluted with tap water. Large volumes (1 L) of 0 and 75 ppm excess 
were prepared to seiwe as working standards to be analysed with each batch of samples. 
An aliquot (400 pi) of each sample was pipetted into a 10 ml Exetainer gas testing vial 
(Labco, High Wycombe, UK). Glass inserts (200 pi, Chromacol, Welwyn Garden City, 
UK) containing platinum catalyst (platinum 5 % on alumina powder, -325 mesh, surface 
area > 250 m^.g'\ Sigma Aldrich, Gillingham, UK) were added to each vial, taking great 
care not to wet the catalyst. Exetainer vials were evacuated for one min, filled with 
reference gas (5 % hydrogen in helium. Air Products Special Gases, Crewe, UK) for 10 s 
as described in Section 2.1.2.1, and left to equilibrate at ambient temperature, for 48 h prior 
to analysis. During this time the deuterium in the vapour phase above the sample 
equilibrated with the hydrogen in the reference gas. The abundance of deuterium in the 
gas phase was measured by CF-IRMS (Prosser & Scrimgeour, 1995). The abundance of 
^H in samples was calculated with reference to the known abundance of reference waters, 
placed at inteiwals in each batch of samples, and drift corrected between references.
!
2.1.3.1 Measurement of in reference gas
. -i
Reference gases (5 % hydrogen in helium, Air Products Special Gases, Crewe, UK) were 
prepared as described in Section 2.1.2.1. The IRMS source parameters and resistance of 
the head amplifiers for analysis of deuterium are shown in Table 2.1. The source was 
tuned for minimum m/z 3/2 ratio, with maximum sensitivity. A nominal value for 
abundance o f -42 5 VSMOW was entered in the manufacturer’s software since samples 
are always analysed with reference to gravimetric standard waters. Data were exported to 
a “Reprocessor” programme provided by the IRMS manufacturer, where a non-linear least 
squares regression was applied to determine the contribution of H3 ' to m/z 3.
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Results were expressed as ppm The enrichment of reference waters was calculated by 
subtracting the measured abundance of the tap water ( 0  reference) from that of the 
samples. Results were expressed in units of ppm excess ^H.
2.1.3.2 Calculation of abundance of H and in water samples
A typical batch of samples had the following pattern:
5 reference gas tubes (to condition the system)
3 natural abundance reference waters (0 ppm excess = tap water used to
make enriched reference waters)
3 enriched reference waters (75 ppm excess or 150 ppm excess ^^O)
2  reference gas tubes
18 sample waters (reference waters, urine or saliva)
2  reference gas tubes
3 natural abundance reference waters
3 enriched reference waters (75 ppm excess or 150 ppm excess ^^0)
2  reference gas tubes
18 sample waters (reference waters, urine or saliva) etc....
There were, therefore, 28 samples/standards between the first enriched reference water 
(1 of 3) and the next occurrence of the enriched references in the sample queue. The first 
sample is the 6 ^^  tube in the queue, if the first enriched reference is number 1 (mid-point of 
the standards).
To take account of instrumental drift and fractionation during the equilibration period, the 
output from the ‘Reprocessor’ must be corrected by reference to the gradient of the two- 
point calibration curve and the known natural abundance of the 0  ppm excess reference 
water (150.7 ppm 1986.4 ppm ^^O) to obtain the correct abundance in the sample. This 
was done, using a spreadsheet, by taking a proportion of gradient from the calibration 
curve preceding the samples and a proportion from the gradient from the calibration curve 
following the samples such that the total is 1. The proportion is related to the position of 
the sample relative to the reference waters in the analytical batch.
The gradient (G) of the 2-point calibration curve is the reported abundance of the enriched 
reference water minus the reported abundance of the natural abundance reference water, all 
divided by the actual enrichment of the enriched reference water. The actual enrichment of
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the 75 ppm excess reference water was 73.64 ppm excess. The actual enrichment of the
150 ppm excess reference water was 179.78 ppm excess 18.
Q  __ ^ ^ E R E F  ^ ^ Q R E F
E (2 .1)
where, R A e r e f  
R A o r e f
R E F
2iReported abundance of or in the enriched reference water (ppm) 
Reported abundance of or in the natural abundance reference 
water (ppm)
E r e f  = Actual enrichment of or in the enriched reference water (ppm 
excess)
If N is the number of vials in the repeating pattern (28 in the example above) and n is the 
number of the vial (sample 1 = 6  in the example above), the drift correction takes 
(N-n)/(N+l) times the gradient of the calibration curve preceding the group of samples 
(Gi) and n/(N+l) times the gradient of the calibration curve following the samples (G2). 
The actual abundance ( A A s a m p ,  ppm) of or in each sample is calculated as follows,
AA
f f
vv A  + 1
A fr  
+ n
VvA  + 1 RA0 R B F 2
SAM P
\ \ N  + \ vvA  + 1
A A
a
■ + AAREF (2.2)
where, R A s a m p  ^ Reported abundance of or in the sample (ppm)
R A o r e f i  Reported abundance of the natural abundance reference water preceding 
the samples (ppm)
RA0REF2 = Reported abundance of the natural abundance reference water following 
the samples (ppm)
Gi = Gradient of the 2-point calibration curve preceding the samples
G2 = Gradient of the 2 -point calibration curve following the samples
A A r e f  = Actual abundance o f or *^0 in the natural abundance reference water 
(ppm)
Enrichment of or in the sample (ppm excess) is the actual abundance of or in
the sample minus the actual abundance of or in the baseline sample
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2.1.3.4 Accuracy and precision of measurements
Accuracy of measurements was checked by preparing gravimetric standards containing 
0, 15, 30, 75, 100, 150, 250, 300, 750, 1100, 1500 ppm excess and analysing them with 
reference to the working standards ( 0  and 75 ppm excess ^H) as described above (Section
2.1.3.2) and plotting the calibration curve of measured versus calculated enrichment. 
Enrichment calculated from weight was taken as the independent variable and plotted on 
the x-axis.
Accuracy o f measurements was ensured routinely by including standard waters (tap 
water plus an enriched standard) in triplicate at intervals in each batch of samples. These 
standards were prepared with the samples and treated in exactly the same way as the 
samples, as there is a large fractionation factor associated with preparation o f samples by 
the equilibration method (Scrimgeour et al. 1993). When samples and standards are 
treated in exactly the same manner and held at the same temperature, the fractionation 
factor will be the same for both. The gradient and intercept (natural abundance of the 0 
ppm excess reference water = tap water) of this two-point calibration curve were used to 
calculate the isotope abundance in each sample as described above (Section 2,1.3.3). The 
reported abundance was corrected for instrumental drift between references. Precision of 
measurements was checked by analysing groups of reference gases before each batch of 
samples and by calculating the standard deviation of three replicate analyses of the 
standard waters, which were included at intervals in each batch of samples.
2.2 Measuring CO2 production rate
2.2.1 Study design
The aim of this study was to assess the feasibility of using heart rate monitors to estimate 
CO2 production rate minute-by-minute during breath tests, and to determine the most 
suitable calibration procedure. A pilot study was carried out on two healthy, compliant 
adult volunteers using a [^^Cjbicarbonate breath test. Sources of variation in FCO2 during 
breath tests were investigated. Heart rate and CO2 production rate (FCO2) were 
measured simultaneously while resting and at varying levels of activity above resting. 
Potential methods of calibrating heart rate monitors to predict CO2 production rate were 
investigated. The [^^C]bicarbonate breath test was performed under fasting, fed, resting 
and non-resting conditions. The test was repeated three times each under resting (sitting)
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and non-resting conditions. FCO2 was measured at intervals during each bicarbonate 
breath test using a ventilated hood indirect calorimeter and heart rate monitors were worn 
throughout. PDR was calculated using predicted or measured resting V C O 2 , and also using 
F C O 2  continuously estimated from heart rate using the best individual calibration method. 
Urinary loss of as [^^CJbicarbonate and [^^C]urea was measured during the fasting test.
2,2.2 Predicting and measuring basal/resting metabolic rate
Basal metabolic rate (BMR) is defined as the energy expenditure of a healthy subject lying 
at rest, in a thermally neutral environment, at least 1 2  h postprandially (Harris & Benedict, 
1919). Resting metabolic rate is defined here as measurement of “basal” metabolism, 
where these conditions are not met, usually because the measurement took place 3-4 h after 
the last meal, rather than after an overnight fast.
2.2.2.1 Predicting resting FCO2
Resting PC0 2  can be predicted from basal metabolic rate or from body surface area. The 
latter is most commonly used in breath tests.
Resting FCO2 was assumed to be constant at 300 mmol C0 2 .h'\m'^ body surface area 
(Shreeve et al. 1970), which equals 5 mmol.min"\m^. Body surface area was calculated 
from height and weight using the Haycock et a l  (1978) equation (Equation 2.3).
Surface area (m^)= (weight (kg) x (height (cm) x 0.024265 (2.3)
UCO2 ^  300 X body surface area mmol, h"^  (2.4)
Basal metabolic rate (MJ/d) was predicted from age, gender, height and weight using the 
Schofield (1985) equations. Resting FCO2 was estimated from BMR by assuming a 
respiratory quotient, RQ of 0.85 (IDECG, 1990).
FCO2 (mmol.h'^) = BMR (MJ.d“‘) x 1000 xlOOO (2.5)
24 X EE (kJ.L‘’) x  22.414(E)
where, EE Energy equivalent of CO2 (kJ.U^) = (15.48/0.85) + 5.55 = 23.76 (2.6)
and 22.414 L is the volume occupied by 1 mole of a gas at STP
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1.2.2.2 Measuring resting metabolic rate
Resting metabolic rate was measured after an overnight fast using an open circuit indirect 
calorimeter with a ventilated hood (GEM, Nutren Technologies, Manchester, UK) in a 
thermostatically temperature controlled environment at 2 2  °C. The subjects wore light 
clothing and measurements were made after 15 min acclimatisation lying on a bed. The 
flow rate, O2 and CO2 analysers were calibrated prior to every measurement using 
calibration gases (Zero gas; High Purity N2, 99.999 %. Span gas: gravimetric mix 
composed of 20 % O2, 1 % CO2, balance N2, Air Products Special Gases, Crewe, UK). 
The whole system was calibrated every 3 to 4 months by burning ethanol and adjusting the 
concentration of CO2 entered in the manufacturer’s software for the span gas in to give an 
RQ of 0.667. The repeatability specified by the manufacturer was 0.01 % absolute for O2 
and 0 . 0 2  % absolute for CO2- The GEM ventilated hood indirect calorimeter has a large 
canopy attached to the hood, which enables measurements to be made in sitting and 
standing positions as well as lying on a bed. The flow rate through the hood can be
optimised for each individual so that the fraction of CO2 in expired air (FeC0 2 ) is between
0 . 6  and 0.7 %. This improves the accuracy of the CO2 measurements without causing 
discomfort to the patient.
Oxygen consumption (FO2) and carbon dioxide production rate (FCO2) were calculated as 
follows,
VO2 = (V ix F i0 2 ) - ( V e x F e 0 2 ) (2.7)
VCO2 = (V exFeC 0 2 ) - ( V i x F i C 0 2 ) (2 .8 )
where: Fi~ indicates the fraction of gas in inspired air 
Fe~ indicates the fraction of gas in expired air 
and Vi and Ve are inspired and expired flow rates (L.min'^).
The Haldane transformation assumes that nitrogen is not produced or consumed in the 
lungs and any difference in inspired and expired nitrogen must be due to differences in Ve 
compared to Vi.
Vi = Ve X FeN2 / FiN] (2.9)
and FeNz / FiN2 = (UFe0 2  -  FeC0 2 ) / (l-FiOg -  FiCOa) (2.10)
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The Haldane transformation allows gas exchange calculations to be based on the 
measurement of expired flow only. Thus,
VO  ^ = Ve lzI? £ lE lî£ £ ^ F io \-F e O ,
and
FeCO.
1 -F jO j -FiCO^
RQ = VCO2/FO2
FiO^ \FiCO^
(2.11)
(2 .12)
(2.13)
:
VCO2 (ml.min'^) was converted to mmol.h"^ prior to PDR calculations and mmol.min'Vm^ 
body surface area for comparison with predicted values.
VCO2 (mmol.h"^) = VCO2 (ml .min"x  60 x 1 0 0 0 (2.14)
1000x22.414
where, 22.414 is the volume occupied by 1 mole of a gas at standard temperature and 
pressure (STP).
Resting heart rate (RHR) was measured simultaneously using a Polar Vantage NV heart 
rate monitor (Polar Electro Oy, Kempele, Finland). The time in both instmments was 
synchronised by downloading from the same PC. Data were averaged over one minute 
intervals and downloaded into a proprietary spreadsheet software (Initially, Lotus 1-2-3 
Release 5 for Windows, then Microsoft Excel for Windows 95, version 7a, and finally 
Microsoft Excel 97 SR2).
2.2.3 Calibration of heart rate monitors
The heart rate calibration procedure was performed after breath sampling had ceased. 
Oxygen consumption (VO2), carbon dioxide production rate (FCO2) and heart rate (HR) 
were measured simultaneously, averaged over one minute intervals, with the subject lying 
supine on a bed for 1 0  min, sitting upright on the bed for 6  min and standing at the side of 
the bed for 6  min. Measurements were made with the subject sitting on a bicycle 
ergometer. The hood of the calorimeter was suspended from the ceiling and the cape tied 
around the subject’s waist. The subject then began cycling at approximately 50 cycles per
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min and 0 resistance. Every 5-6 min the resistance was elevated to increase the workload, 
until the subject’s heart rate increased to approximately 150 beats per min. The aim was to 
maintain a constant heart rate for 3 min following an equilibration period at each level of 
work. The subject then lay on the bed and data were collected during the recovery period. 
Data collection ceased when CO2 production rate returned to resting levels.
Data (averaged over one-min periods) were downloaded from the heart rate monitor and the 
indirect calorimeter to a personal computer and read into a proprietary spreadsheet software. 
Resting data collected earlier in the day were also included. Time data were matched to give 
simultaneous readings of both heart rate and VCO2 . VCO2 (mmol.min"\m"^) was plotted 
against heart rate with heart rate the independent variable plotted on the x-axis and FCO2 the 
dependent variable plotted on the j-axis unless otherwise stated. Two linear and four non­
linear calibration methods were explored.
The most accurate calibration method has no bias i.e. the mean difference between 
measured and predicted FCO2 is zero. The standard error of this mean is a measure o f the 
precision of the model. Analysis o f the residuals i.e. the difference between the measured 
FCO2 at any time point and that predicted by the model allows these values to be 
quantified. A paired t-test was performed to assess the statistical significance of the bias 
using a standard statistical software package (Minitab for Windows, Release 11.2).
Effect o f smoothing heart rate
Smoothing HR data can be used to account for the sluggish response of exhaled CO2 to 
changes in heart rate, which may be due to the size and variability of the bicarbonate pool. 
Response time differences may, in addition, be due to difference in detector responses 
between the heart rate monitor and the indirect calorimeter, resulting in an apparent delay 
between HR rise and FCO2 rise, or it could be due to the fact that the output from the 
indirect calorimeter displays time in integer minutes, whereas the output from the heart rate 
monitors displays time to the nearest second. Smoothing brings the exercise and recovery 
data closer to the same line and allows all the calibration data to be included in the model. 
Several smoothing routines were explored, including averaging one or two points either side 
of the point of interest and averaging 2 , 3 and 4 points forward of the point of interest. The 
former has no effect on the relative time of heart rate and FCO2 detection. The most 
appropriate smoothing routine was judged to be the one with coefficient of determination, R ,^ 
closest to unity.
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2.2.3.1 Linear methods
Linear-flex method (after Spurr et a l 1988)
The linear-flex method used resting FCO2 below a critical heart rate and a linear model 
above the critical value. The linear model was the regression line thiough the exercise 
data, but omitting the recovery data. The flex heart-rate was defined as the mean of the 
resting heart rate (lying/sitting) and the first non-resting heart rate (standing) during the 
calibration exercise. The critical value was taken as the flex heart rate plus 10.
Steady state (after Livingstone c? a/. 1992)
This method also used resting FCO2 below a flex point and a linear model above the flex 
point. Resting FCO2 was defined as the mean measured FCO2 for all the resting activities 
(lying, sitting and standing still). An equilibration period was allowed at each work level, 
followed by a 3-min sampling period. The mean of these three data points was plotted on a 
calibration curve of FCO2 versus heart rate. The flex point was defined as the mean of the 
highest heart rate for resting activities and the lowest heart rate on the bicycle ergometer. 
Above the flex point, VCO2 was calculated from the calibration curve.
2.2.3.2 Non-linear methods
Non-linear methods were performed on smoothed heart rate data, including both exercise 
and recovery phases and utilised the “Solver” function o f Microsoft Excel (Walsh & 
Diamond, 1995). This uses the least squares method to determine the line of best fit 
through a data set, such that the root mean square (RMS) of the difference between the 
values predicted by the model and the measured values, is a minimum (Motulsky & 
Ransnas, 1987).
2nd and 3rd order polynomials
A second order polynomial or quadratic fit has the form,
FCO2 = + è*HR (2.15)
A third order polynomial or cubic fit has the form,
FCO2 = + 6 *HR^ + c*HR (2.16)
where, a, b & c are constants determined by the model to minimise the root mean square.
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Logistic model
The logistic model has the form,
a
\ + be -cH R + d (2.17)
where, a, b, c Sc d  are constants determined by the model to minimise the root mean 
square.
Sigmoid Model
The sigmoid model had the form,
VCO. = a + d (2.18)
where, a, b, c Sc d  are constants determined by the model to minimise the root mean square 
and a is the amplitude, b is the centre, c is the width and d  is the offset in Figure 2.1.
CM Width
40 TK
Amplitude
CentreOffset
1509030 1 2 0
Heart Rate (min )
Figure 2.1 Schematic drawing of a sigmoid curve
The Solver options selected for logistic and sigmoid functions are shown in Table 2.2.
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Table 2.2 Solver options for curve fitting using logistic and sigmoid models
Option Value
Maximum time (s) 1 0 0
Iterations 1 0 0
Precision 0 . 0 0 0 0 0 1
Tolerance (%) 0 .0 0 1
Convergence 0 .0 0 1
Use automatic scaling V
Assume non-negative
Estimate Quadratic
Derivative Central
Search Newton
2.2.3.4 Predicting KCO2 from VO2
The response of VCO2 to changes in heart rate may be sluggish due to the size o f the 
bicarbonate pool, and the fact that this is both a source and a sink of CO2 The body has no 
stores of molecular O2 , therefore the response to change in demand is virtually immediate. 
Thus, the calibration curve of FO2 versus heart rate should be more precise, than the 
calibration curve of FCO2 versus heart rate. VCO2 can be predicted from VO2 by assuming 
an RQ of 0.85 (IDECG, 1990). This approach was explored by plotting heart rate versus 
VO2 and fitting a sigmoid model using the method of least squares, as described above.
2.2.4 CJbicarbonate breath tests
Bicarbonate breath tests were used to demonstrate the feasibility of using heart rate 
monitors to continuously measure FCO2 under fasting, fed, resting and non-resting 
conditions. FCO2 was measured at intervals during the test to establish the normal 
variability under fasting, fed, resting and non-resting conditions encountered during 
breath tests. PDR was calculated using a constant value of resting FCO2 predicted from 
body surface area (Section 2.2.2.1 ); a constant value of resting FCO2 predicted from basal 
metabolic rate estimated using the Schofield (1985) equations (Section 2.2.2.1); a constant 
value of measured resting FCO2 (Section 2.2.2.2); and minute-by-minute estimates of 
FCO2 predicted from heart rate (Section 2.2.2.3). Tests were repeated on several occasions
'.I
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at different levels of physical activity. Urinary loss of tracer as [^^CJbicarbonate and 
[^^CJurea were measured.
2.2.4.1 Procedure for [*^ C] bicarbonate breath tests
Studies were undertaken after an overnight fast. Each subject’s body weight was measured 
to the nearest 0.1 kg using Seca scales (model 707, Seca Ltd., Birmingham, UK), which 
were calibrated annually. Body height was measured to 0.1 cm using a Holtain 
stadiometer (Holtain, Crymych, Dyfed, UK). Basal metabolic rate was measured using a 
ventilated hood indirect calorimeter as described in Section 2.2.2.2. The subjects 
consumed a cereal-based test meal, which was standardised for each subject. At the end of 
the test meal sodium [*^C]bicarbonate (0.5 mg.kg'^ body weight, 99 atom % Isotech, 
CK Gas Products, Wokingham, UK) was consumed in -50  ml semi-skimmed milk ( 1 .8  % 
fat).
Alveolar breath was sampled by exhalation into an Exetainer breath-sampling vial (Labco, 
High Wycombe, UK) through a straw until condensation appeared on the side of the vial. 
The cap was replaced immediately. Breath was sampled at baseline and then every min for 
the first 15 min, at 20 min, then every 10 min to 1 h post dose. Breath sampling continued 
every 20 min for 6  h. Breath ^^COz abundance was measured by CF-IRMS as previously 
described. The subjects wore a heart rate monitor throughout the test. The bicarbonate 
breath test was repeated on several occasions as described below (Section 2 .2 .4.3) to 
determine the effect of fasting, sitting and walking during the test. On each occasion the 
subjects avoided food naturally enriched with ^^ C for 3 d prior to the test.
FCO2 was measured using a ventilated hood indirect calorimeter as described in Section 
2.22.2, in the fasting state (before consumption of the test meal), 1 h after the test meal, 
and 3 h after the test meal during each bicarbonate breath test.
2.2.4.2 Thermogenic effect of the meal
On one occasion, FCO2 and FO2 were measured for 2 h following the test meal. The 
thermogenic effect of the meal was taken as the mean FCO2 over the 2  h following the test 
meal divided by the basal rate.
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2 2.4.3 Intra-subject variability of breath CO2 recovery
[^^CJbicarbonate breath tests were performed under three different conditions; fasting, 
resting (R); fed, sitting (S); fed with moderate activity: walking (W). The latter tests were 
repeated three times.
Fasting, resting PDR
On the fasting occasion, basal metabolic rate was measured, the subject remained lying on 
the bed and consumed the dose of sodium [^^Cjbicarbonate dissolved in 50 ml semi­
skimmed (1.8 % fat) milk. Breath was sampled as described above and the subjects 
consumed only water for the remainder of the time. They lay in a supine position, resting, 
but not sleeping for the whole breath sampling period ( 6  h). Urine was sampled before 
measurement of basal metabolic rate and for 36 h following the dose. The volume was 
measured at each void using a IL-measuring cylinder. Samples (1 ml) for [^^Cjbicarbonate 
analysis were pipetted immediately into a labelled Exetainer breath-sampling vial. A 
further sample ( - 2 0  ml) was transferred to a plastic universal bottle for analysis of 
[^^Cjurea (Section 2.2.4.4).
Fed PDR
On the fed occasions, the subjects took the same breakfast each time. This was composed 
of unsweetened breakfast cereal with semi-skimmed ( 1 .8  % fat) milk and a drink of 
unsweetened orange juice. A light lunch composed of low foods was taken after 4 h. 
This meal was the same during each bicarbonate breath test. The subjects sat in an upright 
position during the test and moved around as little as possible.
Walking PDR
During this test, the subjects walked in the vicinity of the hospital for 1 h following 
consumption of the dose, otherwise the test was as described for the fed procedure. On one 
occasion, urine was sampled before measurement of basal metabolic rate and for 36 h 
following the dose as described above.
2.2.4.4 Calculation of percentage dose recovered (PDR) in breath
The enrichment of ^^C0 2  in post-dose breath samples was calculated by subtracting the 
abundance of ^^CÜ2 in the baseline sample from that of the post-dose samples. Percentage 
dose recovered (PDR) in each sample was calculated from CO2 production rate (FCO2) and 
breath CO2 enrichment as follows:
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PDR ^  FCO2 (mmoi.h'^) x breath CO2 enrichment (ppm excess) x 1 0 0  (2.19)
mmol excess in dose x 1 0 *"
where, FCO2 (mmol.h"^) -  VCO2 (ml.min )^ x 60 / 22.414 (2 .2 0 )
22.414 L is the volume occupied by 1 mole of a gas at STP 
and mmol excess in dose ~ tracer dose (mmol) x tracer atom fraction excess 
tracer dose (mmol) = weight substrate (mg) / molecular weight substrate 
atom fraction excess ^  abundance in substrate -  natural abundance
usually = (99-l.ll)/100 = 0.979
The cumulative per cent dose recovered (cPDR) is calculated by summing individual PDR
values averaged over the time interval between samples.
For example, cPDR at time 2  (12) -  cPDRti + ((PDRti + PDRt2 ) /2  x (t2-ti)) (2.21)
cPDRti is cumulative PDR (%) at timel (ti h post dose)
PDRti is PDR h'  ^ at time 1 (ti h post dose)
PDRt2 is PDR h'  ^ at time 2 (t2 h post dose)
The cumulative percentage dose recovered (cPDR) was calculated using a constant value 
of resting FCO2 predicted from body surface area (Section 2.2.2.1); a constant value of 
resting FCO2 predicted from basal metabolic rate estimated using the Schofield equations 
(Section 2 .2 .2 .1); a constant value of measured resting FCO2 (Section 2 .2 .2 .2 ); and minute- 
by-minute estimates of FCO2 predicted from heart rate (Section 2 .2 .2 .3). For the purposes 
of this test, physical activity level (PAL) was defined as cPDR calculated using FCO2 
estimated from heart rate divided by cPDR calculated using FCO2 predicted from surface 
area (Haycock et al. 1978; Shreeve et a i  1970). This definition is mathematically 
equivalent to FCO2 estimated from heart rate divided by resting FCO2 predicted from 
surface area.
2.2.4.5 Urinary loss of C as [^^C]bicarbonate and [^^C]urea following a bicarbonate 
breath test
[^^CJbicarbonate could be excreted in the urine in the form of unchanged tracer and also in 
the form of [^^CJurea, via the urea cycle. The tracer would be expected to appear as 
urinary bicarbonate in the first few hours following the dose, but later it would be in the 
form of [’^ C]urea.
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Urine was sampled at baseline and for 36 h on two occasions: during one of the 
bicarbonate breath tests with moderate activity and during the fasting, resting test. The 
volume was measured at each void using a 1 L-measuring cylinder. Aliquots (1 ml in 
duplicate) for [^^C]bicarbonate analysis were pipetted immediately into labelled 10 ml 
Exetainer breath sampling vials. The volume of these vials is 12 ml, but when evacuated, 
they have a 10 ml draw. A fiirther aliquot (-20 ml) was transferred to a plastic universal 
bottle for subsequent analysis o f [^^CJurea. The remainder of the void was discarded.
PDR^ CO. xExE2 VOL (2 .22)
where, CO2 = mean measured CO2 volume of the sample (11/1000 x % CO2 /100) (L)
E  = mean measured enrichment of the sample (atom % excess)
T v o l  = total urine volume voided at that time point (L)
22.414 = volume of 1 mole of gas at standard temperature and pressure
D  = amount administered (mol)
PvoL ^  volume urine in Exetainer (L)
The cumulative PDR was calculated by summing the PDR of each sample over the 
collection period.
[^^CJurea in urine samples taken before and for 36 h following the test meal was analysed 
as described by Morrison et al. (1999). Urine (50 pi) was pipetted, in triplicate, into 
individual Exetainers. The gas phase in each Exetainer was removed using the vacuum 
manifold described in section 2.1.2.1. The Exetainers were isolated and the manifold 
flushed with pure nitrogen at a flow rate of 100 ml. min'% for 5 min. Each Exetainer was 
opened to the nitrogen stream for 10 s. Type VI jack bean urease (EC 3.5.1.5) (Sigma- 
Aldrich, Poole, UK) was dissolved in 0.05 M phosphate buffer at pH 7 and flushed with 
nitrogen. The activity of the reagent was 1 unit of urease activity per ml buffer. One unit
[^^Cjbicarbonate in urine samples taken before and for 12 h following consumption of the 
dose was quantified by adding 100 pi 3M HCl to the Exetainer immediately prior to 
analysis. Acidification of the sample releases CO2 fi'om urinary bicarbonate into the 
headspace. The ^^C02 abundance and CO2 concentration (%) was analysed by CF-IRMS 
in the same manner as a breath sample (Section 2.1.2). The enrichment above baseline of 
each sample was calculated (ppm excess ^^C). PDR was calculated as the product of the 
mean ^^ C enrichment and the mean amount of carbon in the sample as follows:
:
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should liberate 0.5 pmole CO2 from urea per min at pH 7 and 25 °C. Enzyme solution 
(1 ml) was injected into each Exetainer. The Exetainers were incubated at 37 °C in a 
shaking water bath for 2 h. The reaction was halted and CO2 released into the headspace 
by adding 100 pi 3M HCl (Equation 2.23). CO2 concentration and ^^C02 abundance in the 
gas phase were analysed by CF-IRMS as previously described (Section 2.1.2). The 
amount of carbon, in each sample was calculated from the percentage CO2 produced by 
enzyme hydrolysis.
pH <2
^'C0(NH2)2 + H20  >  ^"C02 + N H / (2.23)
The enrichment above baseline of each sample was calculated (ppm excess ^^C). PDR was 
calculated as the product o f the mean ^^ C enrichment and the mean amount of carbon in the 
sample as above (Equation 2.22). The cumulative PDR was calculated by summing the 
PDR of each sample over the collection period.
2,3 Generic calibration of heart rate monitors
2.3.1 Study design
The aim of this study was to assess potential generic calibration methods to predict FCO2 
from heart rate during ^^C-breath tests. FCO2 was normalised to various body parameters 
including, height", weight" and surface area. Data from both subjects were combined and a 
sigmoid model fitted using the least squares method. PDR during the bicarbonate breath 
tests was calculated using FCO2 predicted from heart rate using the generic calibration 
method for comparison with individual calibration.
2.3.2 Generic calibration methods
Calibration data from both subjects were combined and the effect of scaling FCO2 to 
various body parameters was explored, using the sigmoid model. Normalisation methods 
included scaling to body surface area, weight, weight^ '^ ,^ height, height^, height^ and use of 
relative heart rate. In each case heart rate (HR) was smoothed relative to FCO2 (Section
2.2.3.2). The accuracy and precision of each model were compared as described below to 
determine the best normalisation method.
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Relative heart rate (after Sneddon et al, 1985)
Use of relative heart rate should take account of differences in body size. Small children 
have a greater heart rate than teenagers and adults. Relative heart rate was defined as 
working heart rate (WHR) divided by resting heart rate (RHR), therefore FCO2 was plotted 
against relative heart rate and a linear regression line was drawn through the data with 
RHR>1. Above a relative heart rate flex point of 1.05, the linear regression line was used. 
Below this threshold, resting VCO2 (5 mmol.min"\m"^) was used.
A second form of relative heart rate was explored. This was defined as working heart rate 
minus resting heart rate. FCO2 was plotted against heart rate above the resting value, and a
2.3.2.1 Accuracy and Precision
Accuracy was defined as the difference between the mean measured FCO2 and the mean 
value predicted from heart rate using the model. A negative value indicated that the model 
overestimated the true FCO2 and would therefore overestimate PDR. Accuracy was 
expressed as a percentage of the mean measured FCO2 so that FCO2 normalised to 
different body parameters could be compared. It was necessary to express the results in 
percentage terms as the units of FCO2 normalised to height", weight and surface area are 
different.
Precision was defined as the coefficient of variation (CV) i.e. the standard deviation (SD) 
expressed as a percent of the mean measured FCO2 . Expressing precision as CV, rather 
than SD, allows comparison between methods with results expressed in different units.
linear regression line was plotted through the data with (WHR-RHR)>10. Below this flex 
point, resting FCO2 (5 mmol.min"\m"^) was used, above it the model was used.
I
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2.4 Development of a test meal
2.4.1 Study design
A test meal was designed to carry both hydrophilic (sodium [l-^^C]acetate, sodium 
acetate) and lipophilic ([l-^^C]octanoic acid, pHisjoctanoic acid, [^^C]MTG and 
[^H]MTG) substrates. Deuterium labelled tracers must be given at -10 times the dose of 
^^C-labelled tracers, because of the large pool size of the oxidation product (body water) 
compared with the bicarbonate pool. The palatabihty of the test meal containing the 
expected doses was investigated using unlabelled materials. Experiments were performed 
in vitro to investigate retention o f the labelled compound during preparation and within the 
solid phase of the test meal and to check that distribution of the tracer was homogeneous.
Errors in dosage were controlled by careful weighing to sufficient accuracy, ensuring 
homogeneous distribution within the test meal, taking account of losses during preparation 
and adjusting for incomplete consumption o f the test meal. The natural abundance of 
the test meal was controlled by using low ingredients.
2.4.2 The test meal
The proposed test meal was a biscuit (flapjack) composed of 90 g rolled oats, 40 g butter 
and 40 g honey (weighed to within 1 g). These are all low ingredients (Morrison et al.
2000). The honey and butter were melted over a bain-marie. The tracer (weighed to I 
0.001 g) was stirred into the melted ingredients until dissolved and distributed evenly. The 
oats were added and the mixture and stirred thoroughly until all the liquid was absorbed.
The mixture was spread over the bottom of an aluminium foil-lined tray (160 mm square, 
surface area 0.0256 m  ^or 170 mm diameter, surface area 0.0227 m^), and baked at 130 °C 
for 15 min in a fan-assisted oven. The bowls, spoons, baking tray and foil were weighed 
before and after use, so that the tracer weight could be corrected for losses during 
preparation of the test meal.
The nutritional composition of the test meal was calculated from food composition tables 
(Holland ei al. 1991). This recipe provides 3.13 MJ and is sufficient for two 75 kg adults 
or 3-4 children, depending on their age and size. Subjects were given a portion equivalent 
to 17 to 20 % of their daily energy requirements (Department of Health, 1991) together 
with a drink of unsweetened orange juice or water, as they preferred. The FQ (food
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quotient) of the test meal was calculated from the energy contribution of each nutrient to 
the total metabolizable energy as follows:
FQ -  ((p X  0.81) + (f X  0.71) + (c X  1.00))/100 (2.24)
Where, p, f  and c are the amount of energy from protein, fat and carbohydrate in the test 
meal, expressed as a percentage of total metabolizable energy, and the constants are the 
classical values for the FQ of individual fuels (Lusk, 1928, as cited by Black et al. 1986).
The palatability of the test meal was investigated using unlabelled substrates at the doses 
used for ^^C-breath tests (-13 pmol.kg'^ body weight) and also at the doses required for 
deuterium-labelled tracers (-130 pmol.kg'^ body weight).
Unlabelled sodium acetate, octanoic acid and tripalmitin were purchased (Sigma-Aldrich, 
Poole, UK). Tripalmitin was substituted for MTG as unlabelled MTG was not available. 
Flapjacks were baked containing 150 mg sodium acetate; 300 mg octanoic acid; 300 mg 
sodium octanoate; 1.4 g tripalmitin, the amount required for two adult subjects in a ^^C- 
breath test. Flapjacks were also prepared containing 12 g unlabelled sodium acetate; 3.8 g 
sodium octanoate and 20 g tripalmitin, i.e. the amount required for ^H-validation studies to 
enrich body water by 50 ppm excess ^H. Octanoic acid was converted to sodium octanoate 
to disguise the unpleasant flavour of octanoic acid (Section 2.4.3.1). The amount of butter 
in the flapjack containing 20 g tripalmitin was reduced by this amount. Palatability was 
assessed by the investigators.
2.4.3.1 Conversion of octanoic acid to sodium octanoate
Octanoic acid at the dose required for validation has extremely poor palatability. 
Conversion of octanoic acid to its sodium salt reduces the unpleasant taste and smell, 
Octanoic acid was converted to its sodium salt by adding sodium bicarbonate.
CH3(CH2)6C0 0 H + NaHCOa = CH3(CH2)6COONa + CO2 +H2O (2.25)
The abundance of the test meal was calculated from the abundance o f the 
individual ingredients (Morrison et al. 2000).
2,4.3 Palatability studies
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1 mol octanoic acid requires 1 mol sodium bicarbonate to make 1 mol sodium octanoate. 
MW ^^C-octanoic acid = 144, MW sodium bicarbonate = 84. Therefore, 0.583 g sodium 
bicarbonate is required to neutralise 1 g octanoic acid.
Density of octanoic acid = 0.9 m g.m f\ Therefore, 3.78 g = 4.22 ml.
MW [ l“^^C]octanoic acid = 145 , density = 0.9 mg.mf^
MW [^Hisjoctanoic acid = 169, density = 1 mg.mf^
280 mg [l~^^C]octanoic acid = 310 ql required 0.28 x (84/145) g bicarbonate = 0.162 g 
3.5 g [^Hisjoctanoate = 3.5 ml required 3.3 x (84/169) g bicarbonate = 1.75 g, total 1.912 g
2.4.4 In vitro experiments
Experiments were performed in vitro to check that the hydrophilic tracers ([l-^^C]acetate, 
[l-^^C]octanoate, sodium salts) and the lipophilic tracers ([l-^^C]octanoic acid and 
[^^C]MTG) remained in the biscuit during preparation and to investigate partitioning of the 
tracer between solid and liquid phases in the acid conditions of the stomach.
A flapjack was prepared containing unlabelled sodium acetate and unlabelled sodium 
octanoate at the dose used for ^^C-breath tests (150 mg CHsCOONa = 0.9 mg.g"  ^ flapjack, 
cooked weight and 300 mg CH3(CH2)6COONa = 1 .9  mg.g'^ flapjack). A second flapjack 
was prepared containing unlabelled acetate at the dose used for validation studies 
(12 g CHsCOONa = 70 mg.g'^ flapjack). A flapjack was also prepared with no added 
acetate or octanoate to serve as a control.
Water, 1 ml g" octanoic acid (3.78 ml) was pipetted into a bowl. 4.22 ml octanoic acid 
and 2.20 g sodium bicarbonate were added and mixed together by gently swirling the bowl. 
The reaction to form sodium octanoate was obvious. The honey and butter were added and 
the flapjack made as before.
The molecular weight and density o f [^Hisjoctanoic acid are higher than unlabelled 
octanoic acid therefore the relative amounts of octanoic acid and sodium bicarbonate must 
be adjusted when labelled substrates are used (section 2.7.3).
Clmstine Slater 2004 Chapter 2 , 97
2.4.4.1 Analysis of flapjack acetate and octanoate
A weighed portion of flapjack (-20 g) was broken into small pieces and mixed by vigorous 
swirling with 100 ml 9 g.L'^ NaCl in O.IM HCl, to represent the conditions in the normal 
acid stomach, in a wide-neck screw cap bottle. The bottle was swirled at intervals for the 
first 20 min and allowed to settle before sampling. The pH of the supernatant was checked 
using pH range 1-4 paper. Aliquots (10 ml) were transferred to a plastic universal bottle 
after 20, 60 and 120 min. These were centrifuged at 1000 g  (where g  is the acceleration 
due to gravity) for 5 min. A volume equivalent to 1 jumole acetate at 100 % release into 
the aqueous phase was transferred to a 2 ml glass vial (465 p.1 from the normal dose 
flapjack and 6 jrl from the high dose flapjack). Internal standard (458 nmole 3-methyl 
valerate = 20 pi 22.875 inM solution in 0.3 M NaOH) was added with enough 1 M NaOH 
to make the solution alkaline. Working standards were prepared containing 458 nmole 
3-methyl valerate and 1 pmole sodium acetate and 2 pmole sodium octanoate. The vials 
were dried in an oven at 55 °C overnight. The procedure was repeated four times at acid 
pH (1.5), once using deionised water (pH 6.5) and once using 0.1 M NaOH (pH -13) to 
investigate the yield in non-acid conditions. On the day of analysis, 100 pL 3M HCl and 1 
ml diethyl ether were added to the vial, which was shaken by vortex mixing. The free 
acids were thus extracted into the upper ether layer.
The volatile fatty acids were quantified by capillary gas chromatography (GC) using a ZB 
FFAP megabore column, ID 0.53 mm, length 30 m, film thickness 1 pm (Phenomenex, 
Macclesfield, UIC). The carrier gas was helium set at a flow rate of 7.5 ml.min'^ at ambient 
temperature. The injection volume was 1 pi. The GC temperature program was 80 °C for 
3 min, 80-210 °C at 10 °C min"\ hold for 2 min. The injector and detector temperatures 
were 230 °C.
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2,5 Investigation of [^^C]MTG metabolism
2.5,1 Study design
Once accurate methods had been established to quantify tracer exhalation in breath and 
minor losses via other routes, mass balance could be used to estimate the quantity of tracer 
retained within the body. A series of experiments was undertaken in two compliant 
healthy subjects to investigate the assumptions associated with the [^^CJMTG breath test 
under fasting, fed, resting and non-resting conditions using [^^CjMTG and its metabolites, 
[1-^^Cjoctanoate, [l-^^C]acetate and [^^Cjbicarbonate. Molar equivalent amounts of 
[^^CJMTG, [^^CJoctanoate and [l-^^C]acetate were baked in the test meal described above, 
but [^^Cjbicarbonate was dissolved in a small volume of milk and taken at the end of a 
cereal based test meal, or without the meal to study the effect of fasting during the test. 
[l-^^C]acetate was also taken in a similar manner to study the effect of fasting, feeding and 
composition of the test meal on recovery in breath CO2 . Repeatability of the MTG, 
acetate and bicarbonate tests was measured under ideal conditions i.e. with the subjects 
sitting throughout the test and wearing heart-rate monitors. The feasibility o f performing 
acetate and MTG tests on the same day was also explored.
Doses of [^^CJMTG, [l-^^C]octanoic acid and [l-^^C]acetate were equivalent, when 
expressed in moles of substrate per unit body weight (Table 2.3).
Table 2,3 Molar equivalence of tracer doses for breath tests
Tracer Molecularweight
Dose mg.kg"^ body 
weight
Dose
pmol.kg"^
[^^Cjbicarbonate, Na salt 85 0.5 6
l-[^^C]acetate, Na salt 83 1 13
l-[^^C]octanoic acid 145 2 13
[^^CJMTG 752 10 13
Subjects consumed a diet composed of low foods for three days before each test. 
Baseline vaiiation o f breath abundance was measured under fasting and fed conditions.
Subjects wore heart rate monitors during the tests, so that FCO2 could be predicted 
continuously from the equations determined in Section 2.2. The effect of the test meal on 
PDR in the [l-^^C]acetate breath test was investigated. The effect of fasting and feeding 
during the [l-^^C]acetate breath test, and the effect of physical activity during the
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[^^C]MTG breath test were determined. In all tests PDR was calculated using a constant 
value o f resting FCOg predicted from body surface area; a constant value of resting FCO2 
predicted from basal metabolic rate using the Schofield (1985) equations; a constant value 
of resting VCO2 measured using a ventilated hood indirect calorimeter; and continuously 
measured FCO2 estimated from heart rate using the individual’s own calibration. The 
cPDR values were compared and the physical activity level (PAL) calculated from PDR 
estimated continuously from heart rate divided by PDR estimated using a constant 
measured value of resting FCO2 .
2.5.2 Variation of baseline abundance
Accuracy of breath enrichment measurements depends on constant background 
abundance as well as accurate isotope abundance measurements. A constant and low 
background is more important when cPDR (area under curve) is the calculated end-point, 
rather than for kinetic studies, such as gastric emptying (Maes et al. 1998) where the 
measured end-point is related to rate of appearance. Variation of baseline
abundance was studied on two occasions, one fasting and one fed, after three days on a diet 
low in (Morrison et al. 2000). Breath was collected by blowing into an Exetainer 
breath sampling vial (Labco, High Wycombe, UK) through a straw until condensation 
appeared on the side of the vial. The cap was replaced immediately. Breath was sampled 
every 30 min for 8 h and the abundance was measured by CF-IRMS as previously 
described. The subjects wore a heart rate monitor throughout the test.
On the fasting occasion, subjects stayed in bed for 8 h, drank 50 ml semi-skimmed (1.8 % 
fat) milk instead of breakfast and consumed only water for the remainder of the time. The 
milk was taken to make this test comparable with the fasting acetate (Section 2.5.3) and 
bicarbonate (Section 2.2.4.3) breath tests, where it was used to dissolve the tracer dose. 
Subjects read or listened to the radio for entertainment, but did not sleep.
On the fed occasion, the subjects took breakfast composed of unsweetened breakfast cereal 
with semi-skimmed (1.8 % fat) milk and a drink of unsweetened orange juice. A light 
lunch composed of low foods was taken after 4 li. This meal was the same during each 
^^C-breath test. The subjects remained seated during the test and moved around as little as 
possible.
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2.5.3 Effect of food intake and test meal on cPDR
To study the effect of food intake and composition of the test meal on cPDR, ^^C-acetate 
breath tests (1 mg.kg'^ body weight [l-^^C]acetate (sodium salt), 99 atom %, Cambridge 
Isotope Laboratories, Inc., Andover, MA, USA) were performed under fasting and fed 
conditions. In the fasting test, subjects took the dose in 50 ml semi-skimmed milk (1.8 % 
fat) and lay on a bed for 10 h. They consumed only water for the remainder of the time. 
Subjects listened to the radio for entertainment, but did not sleep. Fed tests compared 
consumption of labelled acetate dissolved in 50 ml semi-skimmed milk, following the 
same standard breakfast as the bicarbonate breath tests, and baked in a flapjack (Section
2.2.2). When the tracer was taken in milk, breath was sampled at baseline and at the same 
intervals as the bicarbonate breath test. When the tracer was taken in a flapjack, breath 
was sampled at baseline, every 10 min for the first hour, followed by every 20 min for 6 h 
and then every 30 min for a further 4 h. Subjects remained seated in an upright position 
during the fed tests and moved around as little as possible. A light lunch composed of low 
foods was taken approximately 4 h after consumption of the test meal. Basal metabolic 
rate was measured as described in Section 2.22.2, and subjects wore a calibrated heart rate 
monitor throughout the test. The cPDR was calculated as described in Section 2.2.4.4.
2.5.4 Effect of physical activity during the [^ ^CJMTG breath test
To investigate the effect of physical activity during the [^^CJMTG breath test, tests were 
performed at rest and under non-resting conditions. The resting test was performed in a 
similar manner to the fed acetate test described above (Section 2.5.3). [^^CjMTG 
(1,3-distearyl, 2[carboxyl-^^C]octanoyl glycerol, 99 atom % Cambridge Isotope 
Laboratories, Inc. Andover, MA, USA), 10 mg.kg'^ body weight (-1.4 g per flapjack) was 
baked in a flapjack (Section 2.2.2). Breath was sampled at baseline, every 20 min for 6 h 
and then every 30 min for a further 4 h, 10 h in total. A light lunch composed of low 
foods was taken 4 h after ingestion of the test meal. Basal metabolic rate was measured as 
described in Section 2.2.2.2. The cPDR was calculated as described in Section 2.2.4.4.
During the non-resting test, the subjects walked, mainly on the flat for a distance of 
approximately 19 km (12 miles) at -3.2 km h"^  (2 miles h"^ ) following ingestion of the test 
meal. A picnic lunch composed of low foods was taken approximately 4 h after 
ingestion of the test meal. cPDR was calculated as above using the measured resting FCO2 
from the resting test.
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2.6 Intra-individual variation in the MTG test
2.6.1 Study design
The aim of this study was to measure intra-individual variation of the cPDR in the 
[^^C]MTG and [1-^^C]acetate breath tests in two healthy adult subjects wearing calibrated 
heart rate monitors. Each test was performed three times with the subjects sitting upright 
during the test. Use of an acetate correction, as a mathematical means of compensating for 
lack of knowledge of CO2 production rate during the [^^CjMTG breath test, was 
investigated. The feasibility of performing simultaneous MTG and acetate breath tests on 
the same day was also investigated.
2.6.2 Intra-individual variation
[^^CjMTG and [l-*^C]acetate breath test were performed three times as described in 
Sections 2.5.4 and 2.5.3. Subjects sat quietly during the tests in an upright position and 
moved around as little as possible. The cPDR was calculated as described in Section 
2.2.4.4.
2.6.3 Use of acetate and bicarbonate correction factors
Acetate and bicarbonate corrections can account for tracer retained in the body during ^^C- 
breath tests (Section 1.4.9). Acetate and bicarbonate connections were applied to the 6 h 
MTG breath PDR (MTG PDReh).
PDR with bicarbonate correction = MTG PDR^h/ Bicarbonate PDR^h x 100 (2.26)
PDR with acetate correction = MTG PDR^h/ Acetate PDR^h x 100 (2.27)
2.6.4 MTG and acetate breath tests on the same day
If acetate correction factors proved to be a useful tool, it would be necessary to perform 
both tests on the same day. The feasibility of doing this was investigated in two healthy 
adult volunteers. Subjects consumed two test meals. The first was a flapjack containing 
10 mg.kg'^ body weight [*^C]MTG (section 2.4.2) and washed down with unsweetened 
orange juice. This was taken instead of breakfast. The second test meal was taken 4 h 
later. This was another flapjack containing 1 mg.kg'’ body weight [ l- ’^ C]acetate, which
Cliristine Slater 2004 Chapter 2 , 102
was also taken with a drink of unsweetened orange juice. Breath was sampled at baseline 
and then every 20 min for 10 h. Water was taken ad libitum during the test. PDR If’ was 
calculated using a constant value of VCO2 predicted from body surface area (Section
2.2.2.1). Fitting two Maes models (Morrison 2000) deconvoluted the curves. Thus, the 
area under the acetate curve (cPDR) and the area under the MTG curve could be 
calculated.
2.7 Deuterium-labelled MTG test
2.7.1 Study design
The aim of this study was to investigate the use of deuterium labelled MTG as a simpler 
alternative to the ’^C-breath test and to validate improvements to the [’^CJMTG breath test. 
Use of deuterium labelled tracers avoids the need to know FCO2 during the test, if an 
accurate estimate of the volume of distribution of the product of oxidation, ^FUO, i.e. total 
body water, is available. Deuterium labelled MTG could offer a simpler alternative to the 
’^ C-breath test and can be used to validate improvements to the [’^CjMTG breath test. Use 
of [^HJMTG was investigated in two healthy adults. [’^ C] and [^HjMTG were taken in the 
same test meal. Breath, saliva and urine were sampled. The volume of distribution of 
(total body water) was measured by ’^0-dilution and basal metabolic rate was measured 
prior to consumption of the test meal. Heart rate monitors were worn, so that FCO2 would 
be estimated continuously during the test from the subjects’ own individual calibration 
curve. On separate occasions, [’^C]/[^H]octanoate and [’^ C]/[^H]acetate tests were 
performed as above. Urinary losses of acetate were also measured during the dual 
tracer acetate test. The cumulative percentage dose recovered (cPDR) in urine or saliva 
was compared with the cPDR from the [’^CJMTG or [ l- ’^C]octanoate test with an acetate 
correction applied. Deuterium labelled MTG is not available commercially, but 20 g 
[^H]MTG was kindly donated by Cambridge Isotope Laboratories, Andover, USA.
2 . 7 . 2  fHJMTG-test
rH]M TG (20 g or 140 mg.kg'' body weight) and ["C]MTG (1.4 g or 10 mg.kg"' body 
weight) were baked in the same flapjack (Section 2.4.3). The amount of butter was 
reduced by 20 g to compensate for the large amount of lipid added as [^HJMTG. The 
[^H]MTG (1,3-distearyl, 2[^Hi5]octanoyl glycerol, 97 atom % ^H) was custom synthesised 
by Cambridge Isotope Laboratories, Inc. Andover, MA, USA.
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Saliva was sampled every 20 min for 6 h and then every 30 min for a further 4 h, starting 
10 min after ingestion of the test meal, so that breath and saliva sampling times were 
offset. Urine was sampled at 2 hourly intervals during the breath test. The dose of 
(0.5 g.kg"’ body weight) was taken after the end of breath sampling and samples o f saliva 
and urine were collected at the same time on the following nine days. Urine and saliva 
samples were stored in plastic universal bottles at -20 °C prior to analysis.
The amount of deuterium entering the body water pool was analysed by CF-IRMS after 
equilibration with 5 % H2 in He, and the PDR in body water was calculated as described in 
section 2.7.2.1. Total body water was measured by ’^0-dilution as described in Section
2.7.2.2.
PDR ^H in body water was compared with cPDRioh [’^C]MTG with acetate and 
bicarbonate correction factors (Sections 2.6.2 and 2.6.3).
2.7.2.1 Measurement of in body fluids
Deuterium-labelled fatty acids and MTG were used in validation studies (Sections 2.7.2, 
2.7.3 and 2.7.4). The deuterium is distributed through the body water pool following 
absorption and oxidation of the fatty acid. Enrichment of ^H in body water can be 
measured by CF-IRMS. Samples and reference waters were prepared according to the 
method of Scrimgeour et al. (1993). Urine and saliva samples were thawed completely, 
shaken, and centrifuged at 1000 g  for 5 min to ensure that any condensate is mixed into the 
sample, as this is fractionated relative to the urine or saliva. The sample (400 p,l) was 
pipetted into 10 ml Exetainer gas testing vials (Labco, High Wycombe, UK). Glass inserts 
(200 j.d, Chromacol, Welwyn Garden City, UK) containing platinum catalyst (platinum 5 
% on alumina powder, -325 mesh, surface area > 250 m^.g'’, Sigma Aldrich, Gillingham, 
UK) were added to each vial, taking great care not to wet the catalyst. Reference waters (0 
and 75 ppm excess ^H) were prepared and analysed with each batch as described in Section
2.1.3.2. Exetainer vials were placed on a twenty-tube manifold and were evacuated for 
1 min. The manifold was brought to atmospheric pressure prior to flushing with reference 
gas for 5 min. Samples and reference waters were filled with reference gas (5 % hydrogen 
in helium, Air Products Special Gases, Crewe, UK) for 10 s. These were left to equilibrate 
with the head-space gas, at ambient temperature, for a minimum of 48 h prior to analysis. 
During this time the deuterium in the vapour phase above the sample equilibrated with the 
hydrogen in the reference gas. The abundance of deuterium in the gas phase was measured
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by CF-IRMS as described in Section 2.1.3. The abundance of in samples was 
calculated with reference to the known abundance of the reference waters. Results were 
expressed as ppm ^H. The enrichment of the post-dose samples was calculated by 
subtracting the abundance of the baseline sample from that of the post-dose samples and 
expressed in units of ppm excess ^H.
Percentage dose recovered in body water was calculated from the enrichment at time 0 
and the TBW (kg) measured by ’^O-dilution (Section 2.7.2.2). enrichment at time 0 is 
the ^’-intercept of the elimination rate curve of the natural logarithm of body water 
enrichment versus time, where time (t) was the independent variable plotted on the %-axis 
and enrichment (ppm excess) was the dependent variable plotted on the^-axis.
PDR = Eto (mmol excess ^H) / D (mmol excess equivalent) x 100 (2.28)
1.1.1.1 Measurement of total body water by dilution in body water
Total body water was measured by dilution in body water (Schoeller et al. 1980) to 
find the volume of distribution of the deuterium labelled tracer, when the test meal 
contained both ’^ C- and ^H-labelled tracer. The weighed dose of (0.5 g.kg“’ body
weight) (Hz’^O, 10 atom % ’^O, normalised for deuterium concentration, CK Gas Products, 
Wokingham, UK) was taken after completion of breath sampling as breath CO2 would 
became enriched with leading to an error in measurement due to the Craig 
correction (Section 2.1.2.2), which could not be cancelled in the software used. An aliquot 
(2 ml) of the stock was retained for analysis as a 1:500 dilution in tap water. A
sample of the tap water was also retained. Baseline samples of saliva and urine were taken 
before consumption of the ’^O-water. Samples were collected at the same time on the
where, Eto = enrichment of body water at time 0, mmol excess
^  TBW (mmol) x enrichment at tO (ppm excess) x 1.04 / 10®
1.04 = ^FI non-aqueous exchange factor (Schoeller & Jones, 1987)
D == dose, mmol excess ^HzO equivalent :
= number atoms in substrate / 2 x mmol excess in dose
mmol excess in dose = tracer dose (mmol) x tracer atom fraction excess 
tracer dose (mmol) = weight substrate (mg) / molecular weight substrate 
tracer atom fraction excess == abundance in sustrate -  natural abundance 
for ^H-compounds this is usually (99.8-0.015) / 100 = 0.998
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following 10 days, noting the time o f each sample and avoiding the early morning urine 
sample. The abundance in body water (saliva or urine) was measured by CF-IRMS 
with reference to gravimetric standards (0 and 150 ppm excess Section 2.1.2.3).
Samples and reference waters were prepared for analysis according to the method of 
Prosser et al. 1991. Urine and saliva samples were thawed completely, shaken, and 
centrifiiged at 1000 g  for 5 min. The sample (400 pi) was pipetted into 10 ml Exetainer gas 
testing vials (Labco, High Wycombe, UK). Vials were evacuated for one min and filled 
with 3 % CO2 in N2 (Air Products Special Gases, Crewe). Reference waters (0 and 150 
ppm excess ’^O) were prepared and analysed with each batch. Samples and reference 
waters were left to equilibrate with the headspace gas for 24 h at ambient temperature. 
During this time the in the water phase equilibrated with the CO2 in the gas phase. The 
abundance of in the gas phase was measured by CF-IRMS, monitoring m/z 44 and 46 
(Section 2.1.2). The abundance of samples was calculated with reference to the known 
abundance of the reference waters and drift corrected between references. Results were 
expressed as ppm ’^O. The enrichment of the post-dose samples was calculated by 
subtracting the abundance of the baseline sample from that of the post-dose samples and 
expressed in units of ppm excess
Total body water was calculated from the y-intercept of the decay curve of the natural 
logarithm of body water enrichment versus time, where time (t) was the independent 
variable plotted on the x-axis and enrichment (ppm excess) was the dependent variable 
plotted on they-axis using the diluted dose method as follows;
TBW (mol) = W TDD(g)/W ’^ODD(g)xD(g)xEDD/E”’Oioxl8.0153 / 1.01 (2.29) 
where,
WTdd = weight (g) tapwater in the dose dilution
W’^Odd = weight (g) ’^O-water in the dose dilution
D = weight (g) ’’’O-water consumed
Edd = enrichment of ”*0 in the dose dilution (ppm excess ’^O)
E ’^Oio = enrichment of ’’’O at time 0 (ppm excess ’^O)
18.0153 = molecular weight water
1.01 non-aqueous exchange factor (Schoeller & Jones, 1987)
TBW (kg) = TBW (mol) x 18.0153 / 1000 (2.30)
Christine Slater 2004 Chapter 1 , 106
2.1.23 Prediction of total body water
In adults, total body water can be estimated from height and weight using the Hume and 
Weyers (1971) equations or height using the Slater and Preston (2002) equation. Hume 
and Weyers (1971) give equations for both genders:
Males:
TBW (kg) = (0.194786 x height, cm) + (0.296785 x weight, kg) -  14.012934 (2.31) 
Females:
TBW (kg) = (0.344547 x height, cm) + (0.183809 x weight, kg) -  35.270121 (2.32)
According to Slater & Preston (2002),
TBW (kg) = 7.4 X (height, m)  ^ (2.33)
The cumulative PDR at the plateau enrichment, calculated using measured TBW, was 
compared with that using TBW estimated using the Hume and Weyers (1971) equations or 
the Slater and Preston (2002) equation.
2.7.3 fHisJoctanoate test
The percentage dose recovered from [^H] and [’^ CjMTG tests were compared with that 
when the tracer is in the form of free octanoic acid, rather than esterified in the form of a 
triacylglycerol.
A flapjack was prepared containing [I- ’^ C]octanoic acid (99 atom % ’^C, Cambridge 
Isotope Laboratories, Inc. Andover, MA, USA), 2 mg.kg'’ body weight (280 mg per 
flapjack) and fHisjoctanoic acid (99.8 atom % ^H, Cambridge Isotope Laboratories, Inc. 
Andover, MA, USA), 25 mg.kg'’ body weight (3.5 g per flapjack), converted to their 
sodium salts by addition o f 1.912 g sodium bicarbonate as described in Section 2.4.3.1.
Baseline breath, saliva and urine samples were obtained. Breath was sampled every 
20 min for 6 h and then every 30 min for a further 4 h, 10 h in total. Saliva was sampled 
every 20 min for 6 h and then every 30 min for a further 4 h, starting 10 min after ingestion 
of the test meal, so that breath and saliva sampling times were offset. Urine was sampled 
at two hourly intervals during the breath test. Total body water was measured by 
”’0-dilution at the end of the breath sampling period as described in Section 2.7.2.2.
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Samples of saliva and urine were collected at the same time on the following nine days. 
Urine and saliva samples were stored in plastic universal bottles at -20 °C prior to 
analysis.
The amount of deuterium entering the body water pool was analysed by CF-IRMS after 
equilibration with 5 % H2 in He, and the PDR in body water was calculated as described in 
Section 2.7.2,1.
The cumulative PDR in breath and body water following the octanoate test was compared 
with that from the mixed triacylglycerol test.
2.7.4 fHsJacetatetest
The cPDR frorii [^H] and [’^CjMTG and octanoate tests were compared with that from the 
[^H]] and [ l - ’^ C]acetate tests.
[ l - ’^C]acetate, sodium salt (1 mg.kg"’ body weight, -140 mg per flapjack) and 
[^H^]acetate, sodium salt (80 mg.kg'’ body weight, 12 g per flapjack, 99.8 atom %, 
Cambridge Isotope Laboratories, Inc., Andover, MA, USA) were baked in the same 
flapjack. Urine and breath samples were collected. Breath was sampled at baseline, then 
every 10 min for the first hour and every 20 min for 5 h and finally every 30 min for a 
further 4 h, 10 h in total. Urine was sampled at baseline and for 24 h following the test 
meal. The volume of urine was measured at each void and three aliquots retained in plastic 
universal bottles. Urine samples were stored at -20 °C until analysis. Breath ’^C02 
abundance was analysed by CF-IRMS as described in section 2.1.1.2. The amount of 
deuterium entering the body water pool was analysed by CF-IRMS as described in section 
2.7.2.1, after equilibration with 5 % H2 in He. The amount of tracer excreted in urine as 
[^Hsjacetate was analysed as its /<2/7.-butyldimethylsilyl (TBDMS) derivative by GC/MS 
(Monison et al. 2003 a) after purification by solid phase extraction (Waldron & Preston,
2001). Recovery of ^ H as ^HOH in body water (at the plateau enrichment) was compared 
with that following the [^HjMTG test using a two-sample t-test. Recovery of ’^ C in breath 
CO2 (cPDR 10 h) was compared with that following the [’^CjMTG test.
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2.7.4,1 Analysis of [^Hs] acetate in urine
Precautions were taken to minimise the blank in this assay. All glassware was add washed 
in 0.1 M HCl and rinsed in deionised, distilled water (DDW) before use. The ultrafiltration 
devices were rinsed with 1 % phosphoric acid. All reagents and solvents were analytical 
grade or better. Volatile fatty acids (VFA) were purchased from Sigma-Aldrich (Poole, 
UK). Solutions (20 mM in aqueous sodium hydroxide) were prepared to serve as internal 
and external standards. Reagent blanks were prepared with each batch of samples. 
Internal standard, 0.4 pmol 3-methylvaleric acid (20 p.1 of a 20 mM solution in NaOH(aq)) 
was added to 10 ml urine. The pH was measured and if <7 adjusted to 7-8 by adding 1 M 
NaOH. NaCl (1.17 g) was dissolved in the sample and this was poured into an 
ultrafiltration unit (Amicon Centriplus centrifugal filter device YM-30, 30 kDa cut-off, 
Millipore (UK) Ltd., Watford, UK) and centrifuged at 3000 g  for 2 h to remove proteins 
and other high molecular weight components. The resulting filtrate was acidified to pH 2 
by adding concentrated phosphoric acid (-20 pi at a time). VF A were concentrated by 
solid phase extraction (SPE), The SPE cartridges (Bakerbond SPE column, 200 mg SDB, 
3 ml capacity, Mallinckrodt Baker UK, Milton Keynes, UK) were conditioned with 2 x 
2 ml methanol, followed by 1 x 2 ml deionised water and 1 x 2 ml dilute phosphoric acid 
(prepared by adding 15 pi concentrated phosphoric acid to 10 ml deionised water, pH 2) 
before loading the samples. The acidified ultrafiltrate was added to the conditioned SPE 
column and the VF A eluted with 3 x 400 pi methanol. Sodium salts of the VF A were 
prepared by adding 100 pi IM  NaOH. The sample was divided between two 2 ml crimp- 
cap vials (2-CV, Chromacol, Welwyn Garden City, UK). The solvent was removed by 
drying in an oven at 55 °C overnight.
VF A were extracted into 500 pi ether upon addition of 100 pL 3M HCl and with vortex 
mixing. The ether phase (200 to 400 pi) was decanted and dried over anhydrous Na2S0 4 . 
An aliquot (100 pi) of the ether phase was added to 100 pi acetonitrile. The TBDMS 
(fôr^.-butyldimethylsilyl) VF A derivatives were formed by addition of 20 pi MTBSTFA 
(Sigma-Aldrich, Poole, UK) and heating at 60 '^ C for 60 min. TBDMS-acetate enrichment 
and concentration were analysed by GC/MS (Hewlett Packard 5890 II GC with an Optic 
temperature programmable injector and Fisons Instruments A200S autosampler + VG 
Trio-1000 quadrupole MS with electron impact ionisation). The GC operated in splitless 
mode with helium (CP grade) as carrier gas. The injector temperature was ramped from 
60 ^C to 300 °C at 16 "^ C s'’ and the transfer line between the GC and the MS was operated
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at 300 °C. The analytical column was a DB5ms (J & W Scientific, Folsom, CA, USA), 
length: 30 m, internal diameter 0,25 mm, film thickness 0.25 pm. The temperature 
program started at 50 ”C and held for 0.2 min then ramped to 200 at 10 °C min"^, then 
from 200 °C to 300 °C at 30 °C m in"\ followed by 2 min at 300 °C. The solvent delay 
was 5 min and the injection volume was 0.5 pi.
The Trio-1000 quadmpole mass spectrometer with electron impact ionisation, was 
operated with a trap current of 150 pA and electron energy of 70 eV. The ion source 
temperature was 200 °C, and the detector multiplier was operated at 500 V. The TBDMS 
derivative has a prominent ion at M-57, i.e. M-(C-(CH3)3). The quantitation masses for 
acetate were m/z 117, 118, 119, 120 (M-57). [^TUjacetate enrichment was determined from 
the ratio (119 + 120)/117, after blank subtraction. The isotopomer at m/z 119, 
corresponding to [^H2]acetate, was included in the enrichment calculation because the 
analysis o f the acetate tracer showed that it contained a significant amount of 
[^H2]acetate. Acetate concentration was determined with reference to the internal standard, 
3-methylvalerate, quantitation ion m/z 173. The response factors of each VF A, relative to 
3-methyl valerate, were determined by analysing a VF A blend of known molar 
composition. The dwell time on each mass was 0.04 s, with a span of ± 0.2 amu.
2.8 [ C]MTG breath test in healthy adults and children
2.8.1 Study design
The aim of this study was to investigate the effect of different levels and patterns of 
activity on the cumulative percentage dose recovered during [’^CjMTG and [’^Cjacetate 
breath tests. [’^C]MTG and [ l - ’^ C]acetate breath tests were performed in a group of 
compliant subjects (healthy adult volunteers), a group of subjects with varying levels of 
activity (healthy child volunteers) and a group of children with cystic fibrosis, all wearing 
individually calibrated heart rate monitors. This study included more healthy control 
subjects than children with cystic fibrosis because previous studies in children (Amarri et 
al. 1997) lacked specificity and had a low positive predictive value, due to low recovery in 
some healthy children. Adults were asked to consume a diet composed of low foods 
for 3 d before the test, and children for 24 h before the test. The cPDR was calculated 
using a constant value of resting UCO2 predicted from body surface area; a constant value 
of resting FCO2 predicted from basal metabolic rate using the Schofield (1985) equations;
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a constant value of resting FCO2 measured using a ventilated hood indirect calorimeter; 
and VCO2 estimated from heart rate on a minute-by-minute basis using the individual’s 
own calibration. The cPDR values were compared and the physical activity level (PAL) 
calculated from PDR estimated continuously from heart rate divided by PDR estimated 
using a constant measured value of resting FCO2 . Use of an acetate correction factor was 
also explored.
2  8.2 Recruitment of subjects
Eight healthy adults, ten healthy children and seven children with cystic fibrosis were 
recruited. [’^C]MTG and [ l - ’^C]acetate breath tests were performed on healthy adults at 
the Department of Child Health, Yorkhill Hospital and on healthy children in their own 
homes. Adults were recruited from amongst the members of staff at the Department of 
Child Health. Eight healthy children were recmited from the families of members o f staff. 
Two additional children were friends or siblings of children with cystic fibrosis, who did 
the test at the same time as their friend or sibling. All subjects gave written informed 
consent to take part in the study.
2.8.3 Calibration of heart rate monitors
Heart rate monitors were calibrated as described in Section 2.2. Calibration procedures 
were compared by analysing the residuals, i.e. the difference between measured FCO2 and 
VCO2 estimated from heart rate using the model. The bias i.e. the mean of the residuals, 
the standard error of this mean and the 95 % confidence interval were calculated using a 
standard statistical software package (Minitab for Windows, Release 11.2). A paired t-test 
was performed on the residuals to determine whether the bias was statistically significant.
2.8.4 Comparison of methods of estimating resting metabolic rate
2.8.4.1 Estimating RMR
PCO2 estimated from height and weight using the Schofield (1985) equations and 
assuming a constant value of 5 mmol.min ’.m'^ (Section 2.2.2.1) were compared with that 
measured at rest using a ventilated hood indirect calorimeter (Section 2.2.2.2). KCO2 
estimated from heart rate during the RMR measurement, using the preferred model, was 
also compared with the measured value. The mean difference between the measured and
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predicted value o f resting FCO2 was calculated for each group of subjects and for the 
whole study group.
2.8.4.2 Effect of position on measured RMR
One of the criteria for measuring basal metabolic rate is that the subject should be lying in 
a supine position (Section 2.2.2.2). Resting metabolic rate is normally measured in this 
position, however it was noted during the heart rate calibration procedure that children 
with cystic fibrosis had an elevated CO2 production rate, when lying compared to sitting. 
This was investigated further by comparing lying FCO2 with sitting FCO2 in healthy 
subjects and in children with cystic fibrosis. The mean difference, standard error of this 
mean and the 95 % confidence interval were calculated using a standard statistical software 
package (Minitab for Windows, Release 11.2). A paired t-test was performed to determine 
whether the difference was statistically significant between healthy control subjects and 
children with cystic fibrosis.
2,8.5 Postprandial or diet-induced thermogenesis
The thermogenic effect of a cereal-based meal was measured in seven adult subjects, 
following measurement of basal metabolic rate. Subjects came to the hospital after an 
overnight fast. They rested on a bed for 20 min preceding measurement of basal metabolic 
rate as previously described (Section 2.2.2.2). The hood of the indirect calorimeter was 
removed, but subjects remained on the bed in a semi-recumbent position. They consumed 
a meal composed of unsweetened wheat- or rice-based breakfast cereal with semi-skimmed 
(1.8 % fat) milk and a glass of unsweetened orange juice and the hood was replaced. 
FCO2 and FO2 measurements continued for 2 h until they had returned to basal levels. The 
subjects watched videos for entertainment during this time. The thermogenic effect of the 
meal was calculated by dividing the mean FCO2 over the 2 h following the meal by the 
basal value and expressing it as a percentage of the basal rate.
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2.8.6 Procedure for [^ ^CJMTG and [1-^ CJacetate breath tests
2.8.6.1 [’^C]MTG breath test in healthy subjects
The test started at 8 am, after an overnight fast. Heart rate monitors were fitted and 
baseline breath samples obtained by the subjects blowing through a straw into an Exetainer 
breath sampling tube until condensation appeared on the side of the tube. The tracer was 
baked in a flapjack as described in Section 2.4. The test meal was taken instead of 
breakfast. Subjects were given a portion in proportion to their body weight such that the 
dose of [’^CjMTG was approximately 10 mg.kg ’ body weight and the energy intake was 
about 17 % of their estimated daily energy needs. A drink of unsweetened orange juice 
was taken with the meal in adults. Some children preferred water or milk. Breath was 
sampled at baseline and then every 20 min for 6 h, followed by every 30 min for 3 h (9 h in 
total). Adult subjects sat in an upright position during the test and moved around as little 
as possible. Children took part in “rainy day” activities of their choice including watching 
television, watching videos, doing homework, playing board games, playing computer 
games and playing quietly in their room. A light lunch of rolls, ham, cheese, potato crisps, 
fruit and unsweetened fruit juice (apple or orange, according to preference) was taken 
approximately 4 h after the test meal. Water was consumed ad libitum during the test. 
Children were given the option of flavouring this with sugar-ft ee cordial.
Heart rate data were downloaded to a PC immediately after the test, but the calibration 
procedure and measurement of RMR took place on a separate occasion. Breath ’^C02 
abundance (ppm ’^C) was measured by CF-IRMS as previously described (Section
2.1.2.2). Enrichment of post-dose samples was calculated by subtracting the abundance of 
the baseline sample from that of the post-dose sample. Enrichment was expressed in units 
of ppm excess ’^C. The PDR h"’ from each sample was calculated using Equation 2.17 
(Section 2.2.4.4). PDR was calculated using the following estimates of FCO2 :
1) Constant value of resting FCO2 predicted from body surface area (Section 2.2.2.1)
2) Constant value of resting FCO2 using the Schofield (1985) equations to predict 
basal metabolic rate, and hence resting FCO2, as described in Section 2.2.2.1
3) Constant value of measured resting FCO2 (Section 2.2.2.2)
4) VCO2 predicted from heart rate around the time of each breath sample using 
individually calibrated heart rate monitors (Section 2.2.3)
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5) FCO2 predicted from heart rate around the time of each breath sample using generic 
calibrations normalised to body surface area and height^ (Section 2.9).
Physical activity level (PAL) during the test was defined as cPDR 6 h calculated using 
method 4 divided by cPDR 6 h calculated using method 3. This is mathematically 
equivalent to non-resting VCO2 divided by resting FCO2, as the breath enrichment and 
dose terms are the same in both calculations and cancel out in the calculation of PAL. 
Non-resting VCO2 divided by resting FCO2 = TEE/REE = PAL.
2.S.6.2 [ C]MTG breath test in children with cystic fibrosis
The consultant paediatrician responsible for the care of children with cystic fibrosis 
identified suitable children from the list of those attending the clinic at the Royal Hospital 
for Sick Children, Glasgow. Families were initially approached by a consultant paediatric 
gastroenterologist, to establish their interest in taking part in the study. If they were 
interested, a researcher contacted them by telephone to confirm the procedure and establish 
a suitable date for the test to take place. Information sheets and consent forms were posted 
to their home with ample time for them to withdraw if they changed their mind.
On the day of the test, the children came to the ambulatory day care unit at the Royal 
Hospital for Sick Children, Glasgow, without having breakfast. Two subjects preferred to 
do the test when they were in hospital for routine intravenous antibiotic treatment and one 
preferred to do the test in her own home. The procedure was explained to the children and 
baseline breath samples were obtained. Heart rate monitors were fitted and the test meal 
consumed without any pancreatic enzyme replacement therapy (PERT). Breath was 
sampled every 20 min for 6 h.
Resting metabolic rate was measured between 3 and 4 h after consumption of the test meal 
as described in Section 2.2.2.2. Separate hoods and air filters for the indirect calorimeter 
were reserved for healthy control subjects, for children with cystic fibrosis who have never 
had antibiotic resistant Pseudomonas aeruginosa isolated from sputum, and for children 
with cystic fibrosis, who have had Pseudomonas aeruginosa colonisation. This 
information was retrieved from the cystic fibrosis clinic database for each subject before 
they came to the hospital. The inside of the hoods were wiped thoroughly with 
chlorhexidine gluconate 0.5 % w/v in industrial methylated spirits BP70 % v/v (Hydrex DS 
Pink, Adams Health Care, Leeds, UK) between subjects.
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A light lunch composed of the same low foods offered to the healthy children was 
taken with the usual PERT after the RMR measurement. Children were entertained by 
playing computer games, watching videos, playing board games with the researcher or 
colouring, depending on their age and interests. At the end of the breath-sampling period, 
the children took part in the heart rate calibration procedure described in Section 2.2.3 
before returning home.
2.8.6.3 [1-^^C]acetate breath test
All of the healthy subjects and three of the children with cystic fibrosis performed a 
[ l- ’^C]acetate breath test (1 mg.kg ’ body weight) within one month of the MTG test. The 
tracer was baked in a flapjack as described in Section 2.4. The dose of [ l- ’^C]acetate was 
of equivalent molarity to that of MTG. The test took place in the same place and in a 
similar manner to the MTG test. Children with cystic fibrosis did not take their usual 
PERT with the test meal, but did take their usual dose with lunch. Breath was sampled at 
baseline, every 10 min for the first hour during the acetate test, followed by every 20 min 
until 6 h after the test meal. Adults and healthy children continued sampling every 30 min 
for a further 3 to 4 h. PDR was calculated using a constant value of resting FCO2 
predicted from body surface area, a constant value of resting FCO2 predicted from basal 
metabolic rate using the Schofield (1985) equations, the measured resting value of VCO2 , 
and continuously measured VCO2 estimated from heart rate using the individual’s own 
calibration.
2.9 [ C]MTG tests using generic heart rate calibration
2,9.1 Study design: search for a generic calibration
Use of a generic calibration, which could be applied to subjects of all ages and size, would 
greatly simplify the breath test procedure by avoiding the need for individual calibration of 
heart rate monitors. Therefore, the aim o f this study was to investigate potential generic 
calibration methods to predict CO2 production rate from heart rate during breath tests 
in subjects with a wide range of age and body habitus and to demonstrate their use in the 
[’^ C]MTG and [ l- ’^ C]acetate breath tests. Heart rate calibration data from all subjects 
were included representing subjects aged from 5 to 47 years, with BMI 21 to 34 kg.m'^ in 
adults and BMI SD score -1.0 to +2.5 in children. Generic calibration methods to predict 
FCO2 from heart rate included normalising FCO2 from the heart rate calibration procedure
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to body surface area, height^, height^ and weight. Data from all subjects were combined 
and a sigmoid model fitted using the least squares method (Section 2.2.3).
Potential generic calibration methods were initially compared by considering the accuracy, 
defined as the mean measured FCO2 minus mean VCO2 predicted from 2-point smoothed 
heart rate, and expressed as a percentage of the mean measured value. This is a measure of 
the overall bias of the method. Precision was defined as the standard deviation of the 
residuals expressed as a percentage of the mean measured KCO2 i.e. the coefficient of 
variation. Accuracy and precision are expressed as percentages to enable comparisons 
between normalisation methods with results expressed in different units.
Univariate analysis o f variance of the relationship between age and each of the constants in 
the sigmoid model for each normalisation method was investigated using the regression 
analysis tool in the data analysis tools of Microsoft Excel 97. In individual subjects, 
normalisation methods were compared by analysing the residuals, i.e. the difference 
between measured VCO2 and FCO2 estimated from heart rate using the generic model. 
The bias, i.e. the mean of the residuals, the standard error of this mean and the 95 % 
confidence interval were calculated using a standard statistical software package (Minitab 
for Windows, Release 11.2). A good model has no bias i.e. the mean of the residuals is 
zero. A paired t-test was performed on the residuals to determine whether the bias was 
statistically significant. The effect of using a generic rather than an individual calibration 
was demonstrated by calculating the PDR in the [’^ CjMTG and [ l- ’^C]acetate breath tests 
using FCO2 predicted from heart rate using each of the generic methods.
2.9,2 Use of a generic calibration or assumed PAL: a pragmatic approach
Individual calibration of heart rate monitors is not practical for a routine test, but heart rate 
could be used to predict FCO2 if a suitable generic calibration was available, or 
alternatively individually calibrated heart rate monitors could be used to determine the 
reference range in healthy subjects and the physical activity level (PAL) under the normal 
conditions of the test. Data were obtained from a previous study (Amarri et al. 1997), in 
which a [’^CJMTG breath test was performed on 45 children with cystic fibrosis, who had 
not taken their usual pancreatic enzyme replacement therapy with the test meal. The tests 
were performed under similar conditions to the current study. The PAL measured in this 
study was applied to the cPDR 6 h data from the previous study and the results compared 
with those obtained in the current study.
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2.10 Empirical compensation for individual FCO2
2,10,1 Introduction
Use of an acetate correction as an empirically derived means of compensating for lack o f 
knowledge of FCO2 during the [’^ C]MTG breath test was investigated by dividing the 
cPDR at 6 h, calculated assuming a constant value of 5 mmol.min’’.m'^, in the MTG test by 
that in the acetate test (Equation 2.27). In this way, the VCO2 terms cancel out, as they are 
assumed to be the same for each test, even if the exact value is unknown. The procedure 
was repeated using cPDR calculated using FCO2 predicted from heart rate using the 
subject’s own individual calibration. The cPDReh acetate was plotted against cPDReh 
MTG for each group of subjects, with MTG PDR^hthe independent variable plotted on the 
x-axis and Acetate PDR^h the dependent vai iable plotted on the>'-axis. The line of unity was 
included.
2.11 Determination of the cut-off point of the [^^C]MTG test
2,11.1 Introduction
To establish whether use o f a minute-by-minute estimate of FCO2 rather than a constant 
resting value of FCO2 improved the discrimination of the MTG breath test, data for 
cumulative percentage dose recovered in 6 h using FCO2 predicted from heart rate in 
healthy children and children with cystic fibrosis were combined. Two graph-receiver 
operator characteristics (TG-ROC) was used to determine the appropriate cut-off for the 
new test with a 6 h sampling time. The positive and negative predictive values of the test 
were calculated. The procedure was repeated for cPDR calculated using a constant resting 
value of FCO2 .
2.11.2Determination of cut-off
The appropriate cut-off for each test above was determined using TG-ROC (Greiner, 1995) 
at the 95% accuracy level. The cut-off point, dO; sensitivity, which equals specificity, 
intermediate range, IR; valid range proportion, VRP were tabulated.
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2,11,3Positive and negative predictive values
The positive and negative predictive values for each MTG test were calculated using the 
equations shown in section 1.4.2.4 and using a prevalence of pancreatic insufficiency in the 
study population of 0.24 (6 out of 25 subjects, who normally took pancreatic enzyme 
replacement therapy). These were compared with the values obtained by Vantrappen et al. 
(1989) in their validation study of the MTG test in adult patients with pancreatic disease.
Christine Slater 2004 Chapter 3, 118
Chapter 3 Results 
Summary of Chapter 3
In this chapter, the results of the experiments and studies outlined in Chapter 2 are 
reported. Accurate quantification of tracer excretion in breath requires accurate 
measurement of breath ’^C0 2  enrichment, accurate measurement of dose ingested and 
accurate measurement of FCO2 If  the aim is to account for all fates of ingested tracer, 
then account must be made for loss o f tracer in stool and urine, and tracer sequestration 
within the body.
Accurate measurement of breath ’^C02 enrichment relies on accurate measurement of 
breath ’^ C0 2  abundance and control of background ’^C0 2  abundance, including the 
composition of the test meal. Accuracy and precision of isotope abundance measurements 
were established (Section 3.1) and variation o f background abundance was quantified 
(Section 3.5). The homogeneity o f labelled substrate distribution within the test meal and 
losses during preparation were checked in vitro (Section 3.4).
The three alternative approaches of addressing the problem of lack of knowledge of true 
FCO2 during breath tests were initially explored in two healthy adult subjects (Sections
3.2 to 3.7). The most promising methods were then applied to a larger group of subjects, 
including eight healthy adults, ten healthy children and seven children with cystic fibrosis 
(Sections 3.8 to 3.11). Methods of predicting and measuring resting FCO2 were compared 
(Sections 3.2.2 and 3.8.3) and the contribution of postprandial thermogenesis to total FCO2 
was measured in adult subjects (Sections 3.2.4 and 3.8.4). Individually calibrated heart 
rate monitors were used to estimate total FCO2 continuously during breath tests 
(Sections 3.2, 3.5, 3.6, 3.8 and 3.9). Use of a generic calibration was explored (Sections
3.3 and 3.9),
Two healthy adults took part in additional studies using [’^C]MTG and its labelled 
metabolites, to study the effect of factors including rest, exercise, fasting and feeding on 
the recovery of ’^ C02 in breath. Simultaneous use of and ^H-labelled tracers (MTG, 
octanoate and acetate) was also investigated (Sections 3.5 to 3.7). ^H-Iabelled tracers are 
potentially advantageous as food intake and physical activity do not affect recovery, and 
relatively little is sequestered into organic compounds.
'■!
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3.1 Validation of laboratory methods
The laboratory methods used to measure isotopic abundance were validated. Thus, 
ensuring that all measurements were accurate (traceable to international standards or 
gravimetrically prepared standard curves), precise (SD of three replicate analyses < 1 ppm) 
and linear (the isotope ratio was constant over the expected concentration range of 0.5-5 % 
CO2). This ensured that measurement of isotopic abundance was not a major source of 
error in the calculation of cumulative excretion.
3.1.1 Measurement of^^C and isosotopic abundance
3 .1.1.1 Reproducibility of filling reference gases
The procedure for filling Exetainers was optimised empirically to minimise the coefficient 
of variation (CV). Using the procedure described in Section 2.1.2.1, it was possible to 
achieve a CV on the total beam (equivalent to peak area) o f -1 %.
3.1.1.2 CO2 calibration curve and linearity of CO2 abundance
The CO2 calibration curve, prepared by injecting known amounts of pure CO2 into an 
evacuated Exetainer, is shown in Figure 3.1, = 1. 0 . Linearity of CO2 abundance
measurements is shown in Figure 3.2. Measured abundance was constant (SD = 1.1 
ppm ’^C) over a ten-fold range of sample size corresponding to the range expected from 
breath samples (0.5 to 5 %).
3.1.1.3 Precision of breath CO2 analysis and inter-laboratory check
The precision of replicate analyses of breath ’^C02 enrichment is shown in Figure 3.3. The 
mean standard deviation o f ’^C0 2  abundance in breath CO2 was 2 ppm excess over the 
range 30 to 620 ppm excess (n = 4 analyses on the instrument used for this work). The 
enrichment of samples analysed in the Isotope Biochemistry Laboratory at the Scottish 
Universities Environmental Research Centre (SUERC) is also shown.
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Initially, the enrichment of the gravimetric standards was calculated based on the weight of 
H2 ^^ 0 , the weight of added tapwater and the abundance of as stated on the 
manufacturer’s Certificate of Analysis. However, independent analysis of the stock Hz^^O
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against the international standard (VSMOW) showed that it contained more than stated 
on the manufacturer’s Certificate of Analysis. Therefore, the enrichment of the standards 
was recalculated and the nominal 150 ppm excess standard was found to contain 179.8 
ppm excess The calibration curve is shown in Figure 3.4. Calibrated ppm excess 
on the x-axis is the enrichment calculated from the independent analysis of the stock 
solution, which is traceable to the international standard. Unlike deuterium, there is not a 
large fractionation factor associated with preparation of samples for analysis by the 
equilibration method. The gradient of the two-point calibration curve, before drift 
correction was typically -1.03. The gradient of the calibration cuiwe after applying the 
drift correction (as described in Section 2.1.3.3) was 1.0, = 1.0.
3.1.1.5 Accuracy and precision of and abundance measurements
Accuracy of and abundance measurements was ensured by calibrating the 
reference gas against the international standards (VPDB for and VSMOW for and 
placing references at intervals in each batch of samples. Reported abundances were drift 
corrected between references. The abundance of in the reference gas was -37.95 ô 
VPDB = 10695.1 ppm The abundance of in the reference gas was +12.57 5 
VSMOW -  2100.7 ppm ^^ O.
Precision of measurements was checked at inteiwals by analysing batches of reference 
gases and calculating the standard deviation of three replicates. SD <0.5 ppm was 
routinely achieved.
Precision of ^^ O measurements was checked by calculating the standard deviation o f the 
three replicate analyses of the reference waters. SD <0.5 ppm ^^ O was routinely achieved 
on both enriched and natural abundance waters.
3.1,2 Measurement of^H isotopic abundance
3.1.2.1 H standard curve
Figure 3.5 shows the standard curve of deuterium enrichment over the whole measured 
range. Figure 3.6 shows the range between 0 and 200 ppm excess, which is the range of 
interest in this study.
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Figure 3.6 Lower region of H standard curve
3.1.2.2 Accuracy and precision of H measurements
Accuracy of measurements was ensured by including working standards (0 and 75 ppm 
excess ^H) at intervals in each analytical run. These standards were prepared with the 
samples and treated in exactly the same way as the samples, as there is a large fractionation 
factor associated with preparation of samples by the equilibration method (Scrimgeour e/ 
aL 1993). The gradient of the two-point calibration curve using the abundance reported
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by the ‘Reprocessor’ was approximately 0.37. The enrichment of the reference waters was 
calculated using this correction factor and the natural abundance of the tap-water sample 
(150.5 ppm ^H) after drift-correction between the standards as described in section 2.1.3.3. 
The gradient of the calibration curve was 1.0053, R^= 0.9999. Precision of 
measurements was checked by calculating the standard deviation of the three replicate 
analyses of the reference waters. SD < 1 ppm was routinely achieved.
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3.2 Measuring CO2 production rate
3,2.1 Subject characteristics
Two healthy adults took part in a series of experiments to test the feasibility of using heart 
rate monitors to measure VCO2 continuously during ^^C-breath tests. The characteristics of 
the subjects are shown in Table 3.1.
Table 3.1 Details of subjects who took part in the pilot study
Subject 1 Subject 2
Gender Female Male
Age 44 46
3,1.3 Predicting and measuring basal/resting metabolic rate
Resting/basal metabolic rate was determined as described in section 2.2.2. The results for 
FCO2 are shown in Table 3.2.
The Shreeve value of 5 mmol C02.m in'\m ‘^  body surface area was close to the measured 
value in Subject 1, but prediction o f VCO2 from BMR estimated using the Schofield 
equations based on height and weight was closer to the measured value in Subject 2.
Table 3.2 Predicted and measured resting VCO2 normalised to body surface area
FCO2 method Subject 1 mmol.min'\m"^
Subject 2 
mmol.min \m'^
Shreeve (1970) predicted 5 5
Schofield (1985) predicted 4.5 4.8
Measured 4.9 4.7
Predicted from HR* 4.9 4.5
Weight (kg) 55 75
Height (m) 1.59 1.83
BMI(kg.m‘^ ) 21.7 22.4
using sigmoid model
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3.2,3 Calibration of heart rate monitors
Figure 3.7 shows time matched heart rate (HR) and VCO2 data from the heart rate 
calibration procedure in a healthy adult subject. Note that at low levels of energy 
expenditure heart rate increases, whilst VCO2 remains relatively unchanged. The two then 
rise in parallel before returning to resting levels when the exercise stopped.
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Figure 3,7 Time matched data from the heart rate calibration procedure
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Figure 3.8 Region of increasing energy expenditure showing equilibration periods
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The best calibration method has no bias i.e. the mean difference between measured and 
predicted FCO2 is zero. This is conveniently displayed using a Bland-Altman plot (Bland 
& Altman, 1986) of the residual (difference between measured and predicted values) 
versus the mean of the measured and predicted values. The standard error of this mean is a 
measure of the precision of the model. Analysis of the residuals i.e. the difference between 
the measured FCO2 at any time point and that predicted by the model allows these values 
to be quantified. A paired t-test was performed to assess the statistical significance of the 
bias. The results o f the analysis of residuals ai e tabulated in Appendix 2 for all subjects 
studied. Subjects 1 and 2 are the ones who took part in the pilot study.
Effect o f smoothing heart rate
Averaging heart rate one or two points either side of the point of interest had no effect on 
the calibration as it has no effect on the relative time o f heart rate and VCO2 detection. 
However, averaging 2, 3 and 4 points forward of the point of interest proved to be useful as 
illustrated in Figure 3.9. The most appropriate smoothing routine was judged to be the one 
with coefficient o f determination, R^, closest to unity. The coefficients of determination for 
the calibration data in Figures 3.9 to 3.11 are tabulated in Table 3.3.
Table 3.3 Coefficient of Determination (R )^ for smoothing routines
Smoothing routine Subject 1 A Subject 1 B Subject 2
Raw HR data 0.84 0.84 0.71
2 points forwai’d 0.89 0.86 0.78
3 points forward 0.91 0.84 0.83
4 points forward 0.92 0.80 0.86
The effect of smoothing was markedly different between individuals on different 
occasions. This may be due to biological variation, but some part of it could be due to the 
fact that the indirect calorimeter has a slower response and its output displays time in 
integer minutes, whereas the output from the heart rate monitors displays time to the 
nearest second. This could result in almost a minute error in matching the output from two 
instruments. Subject 1 performed the heart rate calibration procedure as part of the pilot 
study (Subject lA) and again two years later (Subject IB). On the second occasion, 
smoothing had a much less marked effect than on the first.
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Figure 3.9 Effect of smoothing heart rate by averaging four points forward on 
Subject 2, including both exercise and recovery data
Smoothing heart rate forwards moves heart rate relative to FCO2 and brings data closer to 
a straight line, so that all data (during exercise and recovery) can be included in the model, 
and not just data collected after equilibration at each level of energy expenditure.
3.2.3.1 Linear methods
Linear calibration methods have two components. A resting value of FCO2 is assumed 
below a critical point and a linear model is used above the critical point. Linear calibration 
methods used raw (unsmoothed) heart rate data as in the published methods.
Figure 3.10 shows the calibration curve fitted to the data shown in Figure 3.7 using the 
linear flex method of Spurr ei al. (1988) as described in Section 2.2.3.1. Open symbols are 
the measured data. Filled symbols are the data predicted from heart rate using the linear 
model. Resting heart rate was 69 min"\ the flex point was 76 and therefore the critical 
value, above which the linear model was used, was 86 min~’. Resting LCO2 was 4.54 
mmol.min"\m'^. Figure 3.11 shows the Bland-Altman residual plot of the bias between 
measured VCO2 and LCO2 predicted using the linear model shown in Figure 3.10 applied 
to the whole data set. In this case, the bias was 0 (95 % confidence interval -0.43, 0.44) 
and there was no significant difference between the measured and predicted values of 
VCO2 (P = 0.99, Appendix 2, adult Subject 1).
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Figure 3.10 Liiiear-flex calibration fitted to data from Figure 3.7
Resting HR = 67, flex point = 76, critical value = 86 min . Resting FCO2 = 4.54 
mmol.min'\m'^
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Figure 3.11 Residual plot of data from Figure 3.10
Figure 3.12 shows the calibration curve using the mean steady state values according to the 
method of Livingstone et al. (1992) as described in Section 2.2.3.1. Heart rate at the flex 
point was 73 min  ^ and the mean KCO2 when the subject was lying, sitting and standing.
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was 4.9 mmol.min'\m'^. Figure 3.13 shows the Bland-Altman residual plot of the bias 
between measured FCO2 and FCO2 predicted using the linear model shown in Figure 3.12 
applied to the whole data set. The bias was 0.54 (95 % confidence interval -0.01, 1.07) 
and there was a significant difference between the measured and predicted values of FCO2 
(P = 0.045, Appendix 2, adult Subject 1).
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Figure 3.12 Steady-state calibration curve from data in Figure 3.8
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Figure 3.13 Residual plot of data from Figure 3.12
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3.2.3.2 Non-linear methods
Non-linear methods were performed on smoothed heart rate data, including both exercise 
and recovery phases as described in Section 2.2.3.2. Figures 3.14-3.17 show calibration 
curves using 2^^ and 3'"^* order polynomials, logistic and sigmoid models fitted to the data 
shown in Figure 3.7, as described in Section 2.2.3.2. Open symbols are the measured data. 
Filled symbols are the data predicted from heart rate using the model. Second and third 
order polynomials did not fit the data well at low levels o f activity (lying, sitting and 
standing) and will not be discussed further. The bias was 0 (95 % confidence interval 
-0.34, 0.34) and there was no significant difference between the measured and predicted 
values of FCO2 as the model was established using the method of least squares (see 
Appendix 2, adult Subject 1).
3.2.2.3 Predicting KCO2 from KO2
Figure 3.18 shows the calibration cuiwe for VO2 predicted from heart rate (HR) in Subject
1. Although, the standard error of the bias for VO2 predicted from heart rate was slightly 
less than for VCO2 predicted from heart rate (0.15 compared to 0.17), there was no 
advantage in predicting FCO2 from FO2 . Use of an assumed RQ of 0.85 (IDECG, 1990), 
which was also the FQ of the test meal, introduces a very large error. The mean bias in 
Subject 1 was 0.82 mmol C02.min‘\m"^ (95 % confidence interval 0.44, 1.19, P < 0.001) 
and in Subject 2 was 1.10 mmol C02.min'\m'^ (95 % confidence interval 0.10, 1.92, 
P -0 .0 3 ).
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Figure 3.14 Second order polynomial fitted to the data in Figure 3.7
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Figure 3,15 Third order polynomial fitted to the data in Figure 3.7
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Figure 3.16 Logistic model fitted to the data in Figure 3.7
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Figure 3.17 Sigmoid model fitted to the data in Figure 3.7
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Figure 3.18 Calibration cui've for VO2 predicted from heart rate (sigmoid model)
3.2.4 Qbicarbonate breath tests
3.2.4.1 Variation of measured FCO2 during the bicarbonate breath test
FCO2 (mmol, m i n " b o d y  surface area) was measured in the fasting condition, 1 h after 
the test meal and 3 h after the test meal during each bicarbonate breath test. Tests were 
performed once a week over a six-week period to allow breath abundance to return
to baseline levels between tests. Results are shown in Tables 3.4 and 3.5.
Subjects chose their preferred breakfast of unsweetened breakfast cereal, semi-skimmed 
milk and unsweetened orange juice, which was the same for each test. The meal chosen by 
Subject 1 provided 18 % of her estimated daily energy requirements (Department of 
Health, 1991), whereas the meal chosen by Subject 2 provided only 12 % of his energy 
needs. This may have caused the low VCO2 of Subject 2 at 2 to 3 h following breakfast.
In both subjects the RQ fell during the fasting test, reflecting the switch towards oxidation 
of the body’s lipid reserves, when there was no food intake. There was a difference 
between subjects in the response to sitting or walking during the test. In both subjects, 
FCO2 increased following the meal (by a factor o f -1.2, when the subjects were sitting
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still) and returned towards basal levels (6 % above basal in Subject 1 and 6 % below basal 
in Subject 2) by 2 to 3 h after the meal. However, when subjects were not resting, the 
changes in FCO2 in the female subject (Subject 1) were very similar to when she was 
resting. VCO2 increased by a factor of 1.25 compared to 1.21 and then returned to 1.07 
and 1.06 times basal levels by 3 h after the meal. In Subject 2 (male), the response to 
exercise was different. FCO2 increased to 1.35 times basal at one h after the meal, with a 
gentle walk in the intervening period, and was still 1.22 times basal 3 h after the meal. 
Data are summarized in Table 3.6.
3.2.4.2 Thermogenic effect of the test meal
The thermogenic effect of the cereal based breakfast taken before the [^^CJbicarbonate 
dose was 1.2 x BMR in Subject 1 and 1.3 x BMR in Subject 2 over two hours.
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Table 3.4 Changes in measured FCO2 during bicarbonate breath tests:
VCO2B M R 1 h after breakfast
2-3 h  after 
breakfast
Subject 1
VCO2
VCO2 RQ FCO2 RQ 1 h:BM R FCO2 RQ 3h:B M R
Fasting, resting 5.12 0.83 4.65 0.77 0.91 4.51 0.75 0.88
Fed, sitting 1 4.74 0.82 6.08 0.83 1.28 5.37 0.81 1.13
Fed, sitting 2 5.01 0.83 5.93 0.86 1.18 4.70 0.81 1.02
Fed, sitting 3 4.86 0.79 5.62 0.88 1.16 4.97 0.86 1.02
Fed, walking 1 5.32 0.75 6.49 0.86 1.22 6.29 0.84 1.18
Fed, walking 2 5.15 0.78 6.49 0.84 1.26 5.23 0.75 1.01
Fed, walking 3 4.57 0.88 5.80 0.86 1.27 4.72 0.82 1.03
M ean (ex fasting) 4.94 0.81 6.07 0.86 1.23 5.21 0.82 1.07
C V (% ) 5.6 5.6 5.9 2.1 4.1 11.3 4.6 6.7
VCO2 (m m ofm in  \ body surface area)
Table 3.5 Changes in measured FCO2 during bicarbonate breath tests:
VCO2BM R 1 h after breakfast
2-3 h after 
breakfast
Subject 2
VCO2
VCO2 RQ VCO2 RQ 1 h:BM R VCO2 RQ 3 li BM R
Fasting, resting 4.95 0.90 5.09 0.81 1.03 4.20 0.75 0.84
Fed, sitting 1 5.10 0.88 6.56 0.93 1.29 5.01 0.80 0.98
Fed, sitting 2 5.11 0.92 5.50 0.89 1.08 4.33 0.79 0.85
Fed, sitting 3 4.79 0.84 5.93 0.87 1.24 4.82 0.82 1.00
Fed, walking 1 5.16 0.88 6.83 0.96 1.34 5.49 0.84 1.06
Fed, walking 2 4.99 0.81 7.34 0.94 1.47 6.53 0.82 1.31
Fed, walking 3 4.64 0.81 5.80 0.84 1.25 5.98 0.87 1.29
M ean (ex fasting) 4.97 0.86 6.33 0.91 1.28 5.36 0.82 1.08
C V (% ) 4.2 5.2 11.1 5.1 10.0 15.0 3.5 16.9
VCO 2 (m m ol.m in"\ body surface area)
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Table 3.6 Ratio of non-resting KCO2 to resting KCO2 (mean of 3 different days)
Subject 1 (fem ale) Subject 2 (male)
Time after meal 1 h 3h Ih  3h
Sitting T 2 Ï 1.06 T2Ô ÔÔT
W alking 1.25 1.07 1.35 1.22
3.2.4.3 Intra-subject variability of breath CO2 recovery
Figures 3.19 to  3.24 show the percentage dose recovered (PDR) in 6 h following a
[^^Cjbicarbonate breath test. PD R  w as calculated as described in Section 2.2.4.4 using five
different ways o f  estim ating VCO 2 .
1. Shreeve; a constant value o f  5 m mol.min"\m '^ body surface area
2. MRO: a constant value o f  VCO2 measured under resting, fasting conditions
3. M R l : a constant value o f  VCO2 measured one h after the test meal
4. M R3 : a constant value o f  VCO2 measured three h after the test meal
5. HR: variable VCO2 predicted from heart rate using a sigmoid model
Figures 3.19 and 3.20 show the cum ulative dose excreted in breath w hen the test w as 
perform ed under resting, fasting conditions i.e. w ith the subject lying on a bed and w ith no 
food intake. The 6 h PD R  is approxim ately 60 % in Subject 1 and 80 %  in Subject 2. 
There is no difference betw een using a constant value o f  5 m m o l.m in '\m ‘^  body surface 
area, measured VCO2 in basal conditions and FCO 2 predicted from  heart rate  under these 
conditions.
Figures 3.21 and 3.22 show the cum ulative dose excreted in breath w hen the test is 
perform ed w ith a test meal and the subject sitting in an upright position during the test. A  
second m eal com posed o f  low  foods w as taken 4 h after the test meal.
Figures 3.23 and 3.24 show the cum ulative dose excreted in breath w hen the test is 
perform ed w ith a test meal and the subject w alking during the first hour following the test 
meal. A  second meal com posed o f  low  foods was taken 4 h after the test meal.
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The fed tests were repeated three times on each subject. Data are summarised in Tables 
3.7 and 3.8. These experiments illustrate the problem with ingesting doses of 
[^^Cjbicarbonate by mouth, as it is prone to loss by eructation.
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Figure 3.19 Percentage dose recovered in breath CO2 during a [^ C^] bicarbonate 
breath test (Subject 1) under fasting, resting conditions (R)
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Figure 3.20 Percentage dose recovered in breath CO2 during a [^^CJbicarbonate 
breath test (Subject 2) under fasting, resting conditions (R)
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Figure 3,21 Percentage dose recovered in breath CO2 during a [*^ C] bicarbonate 
breath test (Subject 1) under fed, sitting conditions (S)
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Figure 2.22 Percentage dose recovered in breath CO2 during a [^ C^] bicarbonate 
breath test (Subject 2) under fed, sitting conditions (S)
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Figure 3.23 Percentage dose recovered in breath CO2 during a [^ C^] bicarbonate
breath test (Subject 1) under fed, walking conditions (W)
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Figure 3.24 Percentage dose recovered in breath CO2 during a bicarbonate 
breath test (Subject 2) under fed, walking conditions (W)
Christine Slater 2004 Chapter 3,141
Table 3.7 Summary of 6 h cPDR from [^^C]bicarbonate breath tests on Subject 1
Shreeve MRO MRl MR3 HR PAL
R 1 61.3 61.2 53.8 52.4 63.7 1.0
S 1 65.7 61.7 69.4 61.7 80.9 1.2
S 2 49.2* 46.7* 59.9* 52.8* [60.6]*
S3 44.2* 44.3* 52.4* 41.5* [54.4]*
W 1 19.5* 17.5* 21.2* 18.6* 38.5* 2.0
W 2 42.5 41.8 47.7 43.8 [83.9]
W 3 30.0 28.0 35.2 27.3 [59.2]
HR, VCO2 estimated from heart rate or [ ] during a test with matched diet and activity; 
* Subject reported eructation; PAL = HR cPDR / Shreeve cPDR
Table 3.8 Summary of 6 h cPDR from [^^C]bicarbonate breath tests on Subject 2
Shreeve MRO MRl MR3 HR PAL
R 1 81.5 80.3 82.9 57.6 81.4 1.0
S 1 58.2 54.2 65.8 56.0 64.0 1.1
S 2 32.8* 33.4* 43.0* 32.8* [36.9]*
S3 56.2 57.5 61.9 48.8 64.7 1.2
W 1 29.1 26.4 27.1 28.3 71.5 2.5
W 2 36.4 35.7 40.0 33.7 69.7 2.0
W 3 24.3 22.3 29.3 22.0 61.1 2.5
HR, VCO2 estimated from heart rate or [ ] during a test with matched diet and activity; 
^Subject reported eructation; PAL = HR cPDR / Shreeve cPDR
3.2.4.4 Urinary loss of as [^^C]bicarbonate and [^^Cjurea following a bicarbonate 
breath test
Less than 5 % of ingested tracer was recovered in urine as either as [^^C]bicarbonate or as 
[^^CJurea. The results are shown in Table 3.9 and are in accordance with published values 
(Elia, 1991) following an intravenous infusion of labelled bicarbonate in which 
approximately 2 % of the infused label was recovered in urine, mainly in urea.
Christine Slater 2004 Chapter 3,142
Table 3.9 Urinary loss of as [^^C]bicarbonate and [^^CJurea (Subject 1)
Test [^^CJbicarbonate (%) [^^C]urea(%) Total (%)
~M 7feSing) T8 2^9 4/7 ”
W2 (fed, walking) 0.2 2.0 2.2
3.3 Generic calibration of heart rate monitors
Measured FCO2 was normalised to the body parameters shown in Table 3.10 before 
combining data from both subjects. A sigmoid model was fitted by the method of least 
squares, therefore the mean difference between the measured and predicted values 
(accuracy) is 0. The best generic calibration method was judged to be the one with highest 
precision i.e. the smallest CV. Table 3.10 shows that there was no advantage in using a 
relative heart rate (after Sneddon et al. 1985). Normalisation to height^ or height^ and 
surprisingly, weight had the best precision, but both of these subjects were lean (BMI -22  
kg.m'^).
Table 3.10 Comparison of normalisation methods for a potential generic 
calibration method to predict FCO2 from HR (n = 2 subjects)
Normalisation method Accuracy (%) Precision (%)
Relative HR (WHR/RHR)* 0.00 31.1
Relative HR (WHR-RHR)* 0.00 28.4
Surface area (m^) 0.00 24.0
Weight (kg) 0.00 20.6
Weight"^^ (kg^^ )^ 0.00 23.4
Height (m) 0.00 26.6
Height^ (m^) 0.00 21.9
Height^ (m^) 0.00 20.1
* KCO2 normalised to body surface area
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3.4 Development of a test meal
3.4.1 Nutritional composition and isotopic abundance of the test meal
The abundance of the test meal was calculated from the abundance of in the 
individual ingredients (Morrison et al. 2000) and is shown in Table 3.11 together with the 
energy content of the meal. The nutritional composition of the test meal is shown in Table 
3.12.
Table 3.11 Energy content and abundance of test meal
Ingredients Energy (kJ) Ô^ ^Cvpdb Atom %
90 g Rolled Oats 
40 g Honey 
40 g Butter 
Whole meal
1428
492
1212
3132
-28.07
-25.01
-29.08
-28.08
1.080
1.084
1.079
1.080
Table 3,12 Nutritional composition of the test meal
Per 100 g Wet Weight % Energy
Protein (g) 
Carbohydrate (g) 
Fat (g)
Energy (MI)
6
53
24
1.84
6
45
49
100
The FQ (food quotient) of the test meal was calculated from the energy contribution o f 
each nutrient to the total metabolizable using Equation 2.23.
Thus, FQ = ((5.6 X 0.81) + (49.3 x 0.71) + (45.1 x 1.00))/100 
FQ = 0.85
(3.1)
3.4.2 Palatability studies
The palatability of all the flapjacks containing the amount of substrate required to achieve 
sufficient enrichment o f ^ ^€0% in breath was considered acceptable for subjects of all ages. 
The flapjack containing sodium octanoate was much more palatable than that containing
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octanoic acid, with just a hint of ‘goaty’ flavour. The palatability o f the flapjacks 
containing the high dose of acetate and tripalmitin was acceptable. The flapjack containing 
the high dose of sodium octanoate was tolerable for adults, but not very pleasant and 
probably not palatable for children.
3.4,3 In vitro experiments
3.4.3.1 Analysis of flapjack acetate and octanoate
The control flapjack contained 2 nmol acetate/g flapjack, which is approximately 20 % of 
the normal dose of ^ ^C-acetate. There was no octanoate in the control flapjack.
The results are shown in Tables 3.13 and 3.14. Analysis of acetate from a low pH (pH 1.5) 
has a high coefficient of variation (-23 %), possibly due to the volatility of the protonated 
compounds under these conditions. Acetate is in the form of volatile acetic acid, rather 
than its non-volatile sodium salt under acidic conditions, and is therefore prone to loss to 
the atmosphere. Nearly 80 % of the acetate dose was found in the aqueous phase at acid 
pH, rather than the solid phase. All the dose was in the aqueous phase after 1 h at neutral 
and alkaline pH. At the high dose required for ^H tests, all o f the acetate was in the 
aqueous phase after 1 h at pH 1.5. Octanoate was retained in the solid phase at low pH 
(-8  % release), but was released at high pH (-40 % release). More octanoate was released 
in neutral and alkaline conditions, as this is more water soluble in the form of its sodium 
salt.
Table 3.13 Yield of acetate from flapjack, % normal ^^C-breath test dose (1-4) or 
high dose, after subtraction of the blank
1
Normal dose 
2 3 4 Mean CV (%)
High
dose
Normal
dose
Norm
dose
pH 1.5 1.5 1.5 1.5 2.5 6.5 13
20 min 72 65 75 48 65 19 70 52 46
60 min 68 84 105 91 87 18 106 104 101
120 min 54 95 124 71 86 35 117
Mean 65 81 101 70 79 24 98
CV (%) 15 19 24 30 22 25
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Table 3.14 Yield of octanoate from flapjack, % normal ^^C-breath test dose
Mean CV (%) Normal doseNormal dose 1 2
pH 1.5 1.5 1.5 6.5 13
20 min 9 10 8 9 11 20 24
60 min 8 8 7 8 8 25 36
120 min 7 10 9 9 18 33 50
Mean 8 9 8 8 12 26 37
CV (%) 13 12 13 13
3.5 Investigation of [^^C]MTG metabolism
3.5.1 Variation of baseline abundance
Baseline variation in breath ^^C02 abundance was measured under fasting and fed 
conditions in two healthy adults. The results are shown in Table 3.15. Lower breath ^^ C 
abundance under fasting conditions is a reflection of lipid oxidation under these 
circumstances. There was less variation in background ^^ C abundance under fasting 
conditions than fed conditions.
The maximum enrichment in a ^^C-breath test is usually not more than 100 ppm excess 
^^ C. Even in compliant subjects, under the normal conditions of a test in children i.e. with 
food and sitting, the standard deviation of the background breath ^^C0 2  abundance was 
more than 5 ppm excess. Therefore, it is important to give enough substrate for the peak 
enrichment to be well above the background noise.
Table 3.15 Variation of baseline abundance (ppm) over 8 h in fasting and fed 
conditions after 3 d on a low diet
Subject 1 Subject 2
Mean (ppm ^^C) SD Mean (ppm ^^C) SD
Fasted
Fed
10819
10828
1.3
7.0
10819
10824
1.1
5.2
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3.5.2 Effect of food intake and the test meal on cPDR
The cumulative percentage dose recovered in 6 h, calculated using different estimates of 
KCO2, is shown in Table 3.16. Figure 3.25 shows the recovery of ^^C02 in breath 
following ingestion of 1 mg kg'^ body weight [l~^^C]acetate under fasting and fed 
conditions. PDR was calculated using a variable value of VCO2 estimated from HR 
(smoothed). The bumps in the graphs after approximately 6 h show the tendency to move 
around more later during prolonged breath tests. This would not be obvious if a constant 
value of FCO2 was used to calculate PDR.
appeared in breath CO2 faster when the tracer was taken in milk (both fasting and 
following the breakfast cereal), than when it was baked in a biscuit. This is possibly due to 
the faster rate of gastric emptying of the liquid meal, and thus earlier arrival at the liver.
More was recovered in breath when the tracer was given in milk than when it was 
baked in a flapjack.
3.5.3 Effect of physical activity during the f^CJMTG breath test
The effect of physical activity during the [^^CJMTG breath test was different between 
subjects and different from that observed during the bicarbonate breath test, where 
increasing physical activity tended to increase the cumulative excretion of ^^C0 2  in breath.
This was the case for Subject 2 (Table 3.17), but not for Subject 1. Figure 3.26 shows the 
excretion o f ^^C02 in breath following ingestion of 10 mg [*^C]MTG kg"^  body weight, 
when subjects sat still during the test and when they walked at a fairly slow pace for 7 h.
'■sThe break for lunch, when the subjects stopped walking, 4 h after the test meal, can be 
clearly seen from the data calculated using FCO2 predicted from heart rate. There was a 
small increase in recovery following the second meal, when subjects remained seated.
This is due to the increase in FCO2 following the meal due to diet-induced thermogenesis.
A relatively small error (< 20 %) is observed when a constant value of resting VCO2 is 
used to calculate PDR, if subjects remain seated throughout the test. However, use of 
resting VCO2 when subjects are not resting, results in a gross error, which could amount to 
several hundred percent in extreme cases.
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Table 3.16 Effect of test meal on 6 h cPDR following 1 mg kg^ [1-^^C]acetate
FCO2 prediction Subject 1 Subject 2
Method Fasting Milk Flapjack Fasting Milk Flapjac
Shreeve (constant) 71.7 49.7 44.6 50.2 39.0 29.8
Schofield (constant) 64.1 44.5 39.9 48.6 37.7 28.8
Measured (constant) 61.4 39.9 38.3 46.4 33.9 27.5
HR* (variable) 63.1 46.1 41.5 36.8 34.8 26.1
PAL (HR/Measured) 1.0 1.2 1.1 0.8 1.0 1.0
* HR 2 point smoothed '
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Figure 3.25 Effect of test meal on recovery of in breath CO2 following ingestion
of 1 mg.kg^ [1-^^C] acetate
PDR was calculated using a variable value of FCO2 estimated from smoothed HR.
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Table 3.17 Effect of physical activity on 6 h cPDR following 10 mg kg^ [^^C]MTG
Subject 1 Subject 2FCO2 prediction 
Method Sitting Walking Sitting Walking
6 h 10 h 6 h 8 h 6 h 10 h 6 h 10 h
Shreeve (constant) 43.1 50.4 22.2 22.8 29.2 37.0 18.1 21.8
Schofield (constant) 38.4 44.9 19.8 20.4 28.3 35.8 17.5 21.1
Measured (constant) 31.0 36.3 16.1 16.6 25.5 32.4 15.6 18.8
HR* (variable) 38.6 45.5 36.8 37.7 25.8 33.3 69.7 80.9
PAL (HR/Measured) 1.2 1.2 2.3 2.3 1.0 1.0 4.5 4.3
* HR 2 point smoothed
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Figure 3.26 Recovery of CO2 in breath (FDR h ) following ingestion of 10 mg kg-1
[^^CJMTG under resting (sitting) and non-resting (walking) conditions
PDR was calculated using FCO2 estimated from 2 point smoothed HR using a sigmoid 
model (HR) or using resting FCO2 measured by indirect calorimetry (M).
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3.6 Intra-individual variation in the MTG test
3.6,1 Intra4ndividual variation
Intra-individual variation o f breath ^^C02 recovery was typically <7 % and judged to be 
within the normal limits of biological variation in these two compliant subjects, no matter 
which estimate of VCO2 was used (Tables 3.18 and 3.19). The measured physical activity 
level was 1.0 to 1.2.
Table 3.18 Intra-individual variation of recovery of CO2 in breath 6 h following 
ingestion of 10 mg [^^C]MTG kg"* body weight baked in a flapjack
VCO2 prediction Subject 1 Subject 2
Method 1 2 3 CV (%) 1 2 3 CV(9%
Shreeve (constant) 43.1 40.0 38.5 5.8 29.2 28.7 25.9 6.4
Schofield (constant) 38.4 35.9 34.4 5.6 28.3 27.8 25.1 6.4
Measured* (constant) 31.0 29.4 27.9 5.3 25.5 25.1 22.4 6.9
HR* (variable) 38.6 34.2 34.5 6.9 25.8 25.4 20.5 12.3
PAL (HR/measured) 1.2 1.2 1.2 3.7 1.0 1.0 1.0 5.7
Resting FCO2 measured using a ventilated hood indirect calorimeter. * HR 2 point 
smoothed
Table 3.19 Intra-individual variation of recovery of * CO2 in breath 10 h following 
ingestion of 10 mg [*^C]MTG kg * body weight baked in a flapjack
TCO2 prediction Subject 1 Subject 2
Method 1 2 3 CV (%) 1 2 3 CV (%)
Shreeve (constant) 50.4 48.2 45.4 5.2 37.0 37.6 35.0 3.7
Schofield (constant) 44.9 43.2 40.6 5.0 35.8 36.4 33.8 3.9
Measured* (constant) 36.3 35.4 32.9 5.1 32.4 32.9 30.2 4.5
HR* (variable) 45.5 41.0 40.8 6.3 33.3 33.2 28.5 8.7
PAL (HR/measured) 1.2 1.2 1.2 4.2 1.0 1.0 1.0 4.4
Resting FCO2 measured using a ventilated hood indirect calorimeter. * HR 2 point 
smoothed
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In normal healthy subjects longer sampling time results in a lower CV, as breath ^^C02 
enrichment has almost returned to baseline levels. This will not be the case for patients 
with impaired exocrine pancreatic function, who have not taken their PERT.
Results of [l-^^C]acetate breath tests were very similar to those of [^^CjMTG tests. 
Excretion o f ^^C02 in breath during 6 h following ingestion o f [1-^^CJacetate (1 mg.kg"^ 
body weight) or [^^C]MTG (10 mg.kg'^ body weight) is shown in Tables 3.20 and 3.21.
Table 3.20 Subject 1; Intra-individual variation of cPDR^h following ingestion of
either 1 mg acetate or 10 mg [^^C]MTG per kg body weight
VCO2 prediction 
Method 1
[^^Cjacetate 
2 3 CV (%) 1 2
C]MTG
3 CV C/
Slireeve (constant) 44.6 41.8 49.3 8.4 43.1 40.0 38.5 5.8
Schofield (constant) 39.9 37.5 44.0 8.1 38.4 35.9 34.4 5.6
Measured* (constant) 38.3 40.6 40.3 3.1 31.0 29.4 27.9 5.3
HR* (variable) 41.5 41.4 43.0 2.1 38.6 34.2 34.5 6.9
PAL (HR/measured) 1.1 1.0 1.1 3.1 1.2 1.2 1.2 3.7
Resting VCO2 measured using a ventilated hood indirect calorimeter. * HR 2 point 
smoothed
Table 3.21 Subject 2: Intra-individual variation of cPDR^h following ingestion of 
either 1 mg [^ ^C] acetate or 10 mg ['^C]MTG per kg body weight
FCO2 prediction 
Method 1
[^*C]acetate 
2 3 CV (%) 1 2
CjMTG
3 CV(«/
Shreeve (constant) 29.8 29.3 31.4 3.6 29.2 28.7 25.9 6.4
Schofield (constant) 28.8 28.4 30.3 3.4 28.3 27.8 25.1 6.4
Measured* (constant) 27.5 26.8 28.5 3.1 25.5 25.1 22.4 6.9
HR* (variable) 26.1 23.3 25.0 5.7 25.8 25.4 20.5 12.3
PAlL (HR/measured) 1.0 0.9 0.9 4.9 1.0 1.0 1.0 5.7
Resting VCO2 measured using a ventilated hood indirect calorimeter. * HR 2 point 
smoothed
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3.6.2 Use of acetate and bicarbonate correction factors
The full recovery of from a normal healthy subject undergoing a [^^C]MTG breath
test with the appropriate correction factor should be close to 100 %, assuming losses in 
urine and faeces are small and the same for both tracers. Use of a bicarbonate correction 
factor underestimates oxidation of tracer, because it underestimates fixation o f tracer via 
the TCA cycle. It is an implicit assumption that endogenous CO2 production is the same 
during each test and therefore the actual values will cancel out, so it should not matter 
which estimation of FCO2 is used to calculate PDR. The first two MTG and the first two 
acetate breath tests, performed in a sitting position with the tracer baked in a flapjack, all 
took place within a six-month period. Therefore a ‘Latin Square’ design was used to 
calculate the recovery of tracer at 6 h in each MTG test using each acetate recovery factor 
from the data in Tables 3.20 and 3.21. PDR calculated using a constant value o f FCO2 
(300 mmol.m'^.h"\ after Shreeve, 1970) was used in each case. A bicarbonate recovery 
factor (65.7 % for Subject 1 and 58.2 % for Subject 2, from Tables 3.7 and 3.8) was also 
applied. The results are summarised in Table 3.22, and show that an acetate recovery 
factor and not a bicarbonate recovery factor is appropriate.
Table 3.22 Results of [^^C]MTG breath tests with acetate and bicarbonate 
recovery factors
Subject 1 
MTG
Acetate
1 Mean
Bicarbonate
1
1
2
Mean
96.6
89.7 
93.2
103.1
95.7
99.4
99.9
92.7
96.3
65.6
60.9
63.2
Subject 2 
MTG 1
Acetate
Mean
Bicarbonate
1
1
2
Mean
98.0 
96.3
97.1
99.7 
98.0
98.8
98.8
97.1
98.0
50.2
49.3 
49.7
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3.6.3 MTG and acetate breath tests on the same day
Figure 3.27 shows the measured recovery of ^^C02 in breath, together with the 
deconvoluted curves obtained using the Maes (1998) model, as described by Morrison 
(2000). Peak 1 is the MTG recovery and Peak 2 is the acetate recovery. When the total 
area under the curve was calculated from the model to 16 h, substrate oxidation was 
overestimated in both subjects. This is because recovery of following acetate ingestion 
was less than that following MTG ingestion, implying that there are additional loss routes 
when the label is on acetate, compared to when the label is on octanoate. The recovery of 
in 6 h was similar for both tracers in these two subjects (Table 3.23). However, it is 
not really feasible to perform both tests on the same day in the clinical situation, and the 
assumptions associated with the use o f an acetate correction may not be valid. This will be 
discussed further in Section 4.7.
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Table 3.23 Substrate oxidation (%) calculated from cPDR MTG with an acetate 
correction (data shown in Figure 3.27)
Subject 1 Subject 2
Area under MTG curve (cPDR 0-16 h) 50.9 43.4
Area under Acetate curve (cPDR 0-16 h) 38.8 33.8
MTG with acetate recovery 131.1 128.3
MTG cPDR 6 h 40.7 30.6
Acetate cPDR 6 h 36.3 32.9
MTG (6 h) with acetate recovery (6 h) 112.0 93.1
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Figure 3.27 Measured and modelled MTG (peak 1) and acetate (peak 2) recovery
[^^C]MTG (10 mg.kg’^  body weight) was taken at time 0 and [l-^'^Cjacetate (1 mg.kg 
body weight) was taken 4 h later.
-1
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3.7 Deuterium-labelled MTG test
3,7,1 fH]MTG-test
3.7.1.1 Recovery of tracer in breath and body water following ingestion of [^^C]MTG 
and [^H]MTG in the same test meal
The rate of excretion of tracer in saliva was faster than breath (Figure 3.28) following 
ingestion o f [^^C]MTG and pH]MTG. The appearance of in urine was slower than in 
saliva, as expected.
Recovery of in body water following ingestion of [^HJMTG was compared with 
recovery of in breath CO2 following ingestion of [^^CJMTG with an acetate correction 
and also with a bicarbonate correction. Over 90 % of the tracer was accounted for with the 
acetate correction, but only 40-50 % with the bicarbonate correction. The results are 
summarised in the Table 3.24. Breath recovery with bicarbonate and acetate correction 
factors taken from Tables 3.7 & 3.8 and 3.20 & 3.21 (cPDR calculated using KCO2 
estimated from HR, when subjects were sitting quietly during the test). PDR was 
calculated from the plateau enrichment in saliva and urine. The plateau enrichment was 
the mean enrichment for all samples collected between 6 and 10 h after consumption of the 
test meal.
Table 3.24 Recovery of tracer in breath (6 h) and body water following ingestion of 
[^^C]MTG and [ H]MTG in the same test meal
Test Tracer cPDR Calculation Method Subject 1 Subject
1 ^"C-MTG Measured fasting, resting FCO2 31.0 25.5
2 ^^C-MTG Variable VCO2 estimated from HR 38.6 25.8
3 ^^C-MTG As 2 with bicarbonate correction 47.7 40.1
4 ^^C-MTG As 2 with acetate correction 91.9 104.0
5 ^H-MTG Saliva 95.9 99.2
6 ^H-MTG Urine 92.9 99.8
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Figure 3.28 Recovery of tracer in breath, saliva and urine following ingestion of 
[^ C^] and pHJMTG in the same test meal
3.7.1.2 Measurement of total body water (TBW) by dilution in body water
Total body water measured by dilution was 30.9 kg, 52.3 % body weight in Subject 1 
and 42.9 kg, 53.1% body weight in Subject 2.
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3.7.2 [^HJoctanoate test
3.7.2.1 Recovery of tracer in breath and body water following ingestion of 
[^^C]octanoate and [^H] octanoate in the same test meal
Recovery o f tracer in breath, saliva and urine following ingestion of [^^CJoctanoate and 
[^HJoctanoate in the same test meal was similar to that observed following ingestion o f 
MTG (Table 3.35). The bicarbonate correction factor was 80.9 % for Subject 1 and 64.4 % 
for Subject 2. The acetate correction factor was 42.0 % for Subject 1 and 24.8 % for 
Subject 2.
Table 3.25 Recovery of tracer in breath (6 h) and body water following ingestion of 
[1-^ ^C] octanoate and pHis] octanoate in the same test meal
Test Tracer cPDR Calculation Method Subject 1 Subject 2
r~  ~~^C-MTG Measured fasting, resting FCO2 33.1 32.2
2 ^^C-MTG Variable PCO2 estimated from HR 42.2 30.7
3 ^^C-MTG As 2 with bicarbonate correction 52.2 47.7
4 ^^C-MTG As 2 with acetate correction 100.5 122.8
5 ^H-MTG Saliva 93.1 96.2
6 ^H-MTG Urine 94.2 101.4
3.7.3 fHJacetatetest
3.7.3.1 Recovery of tracer in breath and body water following ingestion of 
[^ C^] acetate and [^H] acetate in the same test meal
Recovery of ^^ C in breath was similar to that previously observed. PDR using FCO2 
estimated from HR was 43 % in Subject 1 and 25 % in Subject 2. PDR ^H in urine was
87.3 % in Subject 1 and 90.8 % in Subject 2. This was lower than observed during the 
[^HisjMTG or [^Hisjoctanoate tests (Table 3.26).
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3.7.3.2 Comparison of MTG, octanoate and acetate recovery
Differences in recovery at the plateau enrichment (6 to 12 h) were compared using a two- 
sample t-test (Table 3.27).
Table 3.26 Comparison of recovery of [^H] in body water following ingestion of 
[^His]MTG, [^His]octanoate and acetate
[ H i5]MTG [ Hisjoctanoate [ Hg]acetate
Subject 1 92.9(0.9) 94.2(1.7) 87.3 (0.6)
Subject 2 99.8(0.2) 101.4(1.0) 90.8(0.2)
Mean (SEM)
Table 3,27 Confidence interval (95%) for the difference in the mean recovery of 
[^HisJMTG versus [^His] octanoate and [^HisJMTG versus [^ Ha] acetate
—— [%i5]MTGv[%i5]octano^ r"''n^ fII^ ^
95% Cl P 95% Cl P
Subject 1 -6.7,4.0 0.52 2.6, 8.6 TÔÔ7
Subject 2 -6.5,2.4 0.19 7.1,10.8 0.002
There was no significant difference in recovery between [^HisJMTG and [^Hisjoctanoate, 
but differences between [^HisJMTG and acetate were significant at the 99 % 
confidence level, with subject 2 showing the greater difference. The same pattern of 
recovery was displayed in the ^^ C breath tests for Subject 2, although not for Subject 1 
(Table 3.28).
Table 3.28 Comparison of recovery of C in breath CO2 10 h after ingestion of 
[‘^C]MTG and [1-^ ^C] acetate
pC ]M T G  [l-% ]acetate  [^^C]MTG v [1-^^C]acetate 
Mean (SEM) Mean (SEM) 95% Cl P
Subject 1 45.6 (0.3) 46.6 (0.2) -2.0, -0.2 0^03
Subject 2 32.5 (0.3) 27.9 (0.2) 3.7, 5.5 <0.001
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3,7.3.3 Prediction of total body water
In the current study, TBW was measured twice by dilution and predicted using the 
Hume and Weyers (1971) or the Slater and Preston (2002) equations. Table 3.29 compares 
the cPDR calculated using measured TBW and predicted TBW in each of the ^H tests.
Table 3.29 Comparison of TBW prediction methods to calculate cPDR in H tests
Measured by O dilution Predicted
Subject 1 (F) 1 Hume & Weyers Slater & Preston
TBW (kg) 
cPDR: MTG 
cPDR: octanoate 
cPDR: acetate
Subject 2 (M)
30.9
90.5
91.8
85.1
32.5
95.2
96.6
89.5
30.2 
88.9 
89.5
83.2
29.7 
87.0
88.2
81.7
Measured by dilution 
1 2
Predicted
Hume & Weyers Slater & Preston
TBW (kg) 
cPDR: MTG 
cPDR; octanoate 
cPDR: acetate
42.9
99.3
100.5
91.0
42.7
98.9
100.0
90.6
46.3
107.1
108.4
98.2
45.4
105.0
106.2
96.2
The prediction equations slightly underestimated TBW in Subject 1 and overestimated 
TBW in Subject 2. The Slater & Preston (2002) equation based on height only was just as 
accurate as the Hume & Weyers (1971) equations based on height and weight. In the 
context o f a non-invasive test of fat digestion, use of predicted TBW with [^HJMTG may 
suffice.
3.7.3.3 Analysis of [^Hs] acetate in urine
<0.5% ingested [^Hg]acetate was excreted as [^Hgjacetate in urine. Therefore loss of tracer 
via this route does not explain the differences observed above.
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3.8 [^^C]MTG breath test in healthy adults and children
3.8.1 Recruitment of subjects
Eight healthy adults, ten healthy children and seven children with cystic fibrosis (CF) took 
part in the study. Their age, gender and anthropometry are shown in Table 3.30. 
Individual data are given in Appendix 2.
Table 3.30 Subject Characteristics
Adult Child CF
N  8 10 7
Age (y) 26 (21 -47) 10(5 - 15) 13 (6 - 15)
Gender (M:F) 6:2 5:5 2:5
Height (cm) 179(159- 187) 135 (108- 178) 146 (116- 176)
Weight (kg) 70 (57 - 108) 38 (20 - 62) 37 (24 - 58)
BMI (kg.m-^) 23.1 (20.7 - 34.3)
BMI SD score 0.89 (-0.96 to +2.54) -0.52 (-0.87 to +1.54)
Median (range)
There was no significant difference in age or height between healthy control children and 
children with cystic fibrosis, but children with cystic fibrosis had a significantly lower BMI 
SD score (P = 0.05), as might be expected.
3.8.1.1 Problems of recruitment of children with cystic fibrosis
Twelve children expressed an interest in taking part in the study when initially contacted 
by the consultant paediatric gastroenterologist. Three withdrew after being contacted by 
the researcher, either because of the time commitment required or because of illness within 
the family. Two (siblings) failed to arrive on the day of the test. A second appointment 
was made, but the family cancelled this when they were contacted on the day before the 
test. Seven children with cystic fibrosis performed MTG breath tests, but a heart rate 
monitor could not be fitted to one child, who was in hospital for routine intravenous 
antibiotic therapy, because of the position of her portacath. There was a problem recording 
the HR data during the breath test in a second child, but he did complete the calibration 
procedure. Therefore heart rate data were only available for five children with cystic
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fibrosis during the breath test, but data from the calibration procedure were obtained from 
six subjects. There were no problems with the calibration procedure in any child with 
cystic fibrosis.
3.8.2 Calibration of heart rate monitors
Results of the residual analysis of heart rate calibration methods for individual subjects are 
shown in Appendix 2. FCO2 was expressed as mmol.min"\m'^ body surface area. 
Accuracy was defined as the difference between measured and modelled FCO2 (i.e. bias) 
expressed as a percentage of mean measured FCO2 for each subject. A negative bias 
indicates an overestimation o f FCO2 by the model. Precision was defined as the standard 
deviation of the residuals expressed as a percentage of mean measured VCO2  i.e. the 
coefficient of variation. Table 3.31 shows the mean and standard error on the mean for all 
24 subjects.
Table 3.31 Comparison of heart rate calibration methods
FCO2 prediction method
Accuracy (%) 
Mean SEM
Precision (%) 
Mean SEM
Linear-flex -1.9 1.6 29.4 2.9
Steady-state -7.8 2.0 35.1 3.4
3rd Order Polynomial (raw HR) 0.1 0.2 28.1 1.4
3rd Order Polynomial (smoothed HR) -0.1 0.3 23.8 1.3
Sigmoid (raw HR) -0.04 0.04 26.7 1.8
Sigmoid (smoothed HR) -0.0002 0.0002 23.2 1.5
From VO2, sigmoid raw HR, RQ=0.85 0.04 0.1 27.6 2.0
There was a significant difference (at the 95 % confidence level) between measured and 
predicted FCO2 using the linear flex method in 4 out of 24 subjects (17 %, 3 adults and 1 
child with cystic fibrosis). The steady-state method consistently overestimated FCO2 , 
giving significantly different estimates in 50 % of subjects (four adults, three control 
children and five children with cystic fibrosis). Non-linear methods, which do not make 
assumptions about resting metabolic rate were more accurate than linear methods. The 
most accurate and precise calibration method was the sigmoid model with smoothed heart 
rate, closely followed by the 3’'*^ order polynomial, but the latter has the disadvantage of
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overestimating FCO2 at low heart rate, therefore the sigmoid model is the preferred model. 
By definition, there was no significant difference between the measured and predicted 
FCO2, when a non-linear model was fitted to individual calibration data using the method 
of least squares. There were problems fitting the model to raw heart rate data in two 
subjects, but a solution was found for all subjects using smoothed heart rate. There was no 
advantage in predicting FCO2 from FO2 by assuming an RQ of 0.85. This method gave 
significantly different estimates of FCO 2 in 50 % of subjects (five adults, five control 
children and two children with cystic fibrosis).
3.8.3 Comparison of methods of estimating resting metabolic rate
3.8.3.1 Estimating RMR
Insufficient resting data were obtained from the heart rate calibration procedure to 
adequately predict resting FCO2 in one healthy control subject (Child 2). Data from this 
child were excluded from the statistical analysis using heart rate calibration, but included 
in the rest. Resting FCO 2 data was available for one child with cystic fibrosis (CF7), who 
could not be fitted with a heart-rate monitor. Therefore seven children with cystic fibrosis 
are included in comparisons which do not require heart rate data. Overall, there was no 
difference between using a constant value of 5 mmol.min"\m"^ and predicting FCO2 from 
height and weight (Table 3.32). Use of smoothed heart rate gave a more accurate estimate 
of resting FCO 2 , than raw heart rate. Resting FCO 2 estimated fi'om raw heart rate was 
significantly different from the measured value at the 95 % confidence level.
Table 3.32 Difference between measured resting FCO2 and predicted resting 
FCO2 (mmol.min^.m^) including all subject groups
Prediction method N Mean SEM 95 % Cl
Shreeve 25 0.22 0.17 -0.13, 0.57 0.21
Schofield 25 -0.21 0.14 -0.49, 0.07 0.14
Raw HR* 23 -0.21 0.06 -0.38, -0.04 0.02
Smoothed HR* 23 -0.09 0.07 -0.22, 0.05 0.19
* Sigmoid model, Control child 2 and CF 7 excluded
When considering only the children, the Schofield equations gave a more accurate estimate 
of resting FCO 2 in children with cystic fibrosis than the Shreeve method (Table 3.33). The
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assumed value of 5 mmol.min'^.m^ was significantly different from resting FCO2 measured 
in the usual supine position. Resting FCO2 estimated from smoothed heart rate using the 
sigmoid model was very close to the measured value in both groups of children. This is a 
very important observation, because it is hoped that FCO2 will be close to resting for the 
majority o f the time during a ^^C-breath test.
Table 3.33 Difference between measured resting FCO2 and predicted resting 
FCO2. Comparison of healthy children and children with cystic fibrosis
Prediction method N Mean difference mmol.min“\m ‘^ SEM 95 % Cl P
Shreeve Control 10 0.30 0.24 -0.25, 0.85 0.25
Shreeve CF lying 7 0.92 0.23 0.35, 1.50 0.01
Shreeve CF sitting 6 0.32 0.29 -0.42, 1.06 0.32
Schofield Control 10 -0.38 0.23 -0.89, 0.14 0.13
Schofield CF lying 7 0.29 0.21 -0.22, 0.80 0.21
Schofield CF sitting 6 -0.26 0.35 -1.15, 0.64 0.50
Raw HR* Control 9 -0.28 0.18 -0.69, 0.12 0.15
Raw HR* CF 6 -0.06 0.11 -0.35, 0.22 0.59
Smoothed HR* Control 9 -0.01 0.13 -0.30, 0.28 0.95
Smoothed HR* CF 6 -0.04 0.10 -0.31, 0.22 0.68
* Sigmoid model. Control child 2 and CF 7 excluded
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3.S.3.2 Effect of position on measured RMR
Resting FCO2 measured in a supine (lying) and sitting position is shown for all subjects in 
Appendix 3 (Table A3.1). There was no significant difference (at the 95 % confidence 
level) between resting FCO2 measured in a supine position and resting VCO2 measured in a 
sitting position in healthy subjects (Table 3.34). However, differences were significant in 
children with cystic fibrosis, who had a lower measured resting FCO2 in the sitting 
position than in the usual supine position.
Table 3.34 Results of paired t-tests on difference between resting FCO2 measured 
in a supine and sitting position
N Mean difference mmol.min"\m"^ SEM 95 % Cl P
All controls 18 -0.12 0.16 -0.46, 0.22 0.46
Adult controls 8 -0.04 0.19 -0.48, 0.40 0.83
Child controls 10 -0.19 0.26 -0.77, 0.40 0.49
Children with CF 6 0.70 0.23 0.11, 1.30 0.03
The mean ± SD resting FCO2 in healthy control children (measured in a supine position) 
was 5.4 ± 0.7 mmol.min'Vm^. That in children with cystic fibrosis was 6.1 ± 0.5 
mmol.min'\m^. This difference was significant at the 95 % confidence level when 
assessed using a two-sample t-test. The 95 % Cl for the difference was -1.34, -0.03. 
P = 0.04. However, when the measurements were made in a sitting position, there was no 
significant difference between FCO2 in healthy control children and KCO2 in children with 
cystic fibrosis. The mean FCO2 in healthy controls, who were sitting, was 5.6 ± 1 . 0  
mmol.min'\m^ and that in children with cystic fibrosis was 5.4 ± 0.8 mmol.min"\m^. The 
95 % Cl for the difference was -0.79, 1.19. P = 0.67.
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3.8,4 Postprandial or diet-induced thermogenesis
CO2 production rate was measured in seven healthy adult subjects for 2 h following a 
cereal based test meal (Table 3.35). The mean FCO2 during this two-hour period (DIT) 
was 116 % of the fasting, resting rate (RMR) measured immediately before the meal.
Table 3,35 Effect of diet-induced thermogenesis on FCO2 following consumption 
of a cereal based test meal
Subject No. Age (y) Gender BM I(kg.m '0 DIT (% RMR)
1 46 F 22.8 22.3
2 47 M 22.2 31.7
3 21 M 23.4 10.3
4 22 F 25.2 15.4
5 32 M 21.7 -0.3
6 26 M 20.7 24.1
7 26 M 34.3 8.4
Mean 31 24.3 16.0
SD 11 4.6 10.9
3.8.5 CJMTG and [1 -^CJacetate breath tests
The cumulative excretion o f in breath CO2 at 6 h following ingestion o f the test meal 
containing [^^C]MTG or [l-^^C]acetate is summarised in Tables 3.36 and 3.37. 
Cumulative PDR was calculated using a constant value o f FCO2 either 5 mmol.min’Vm'  ^
body surface area (Shreeve), predicted from BMR (Schofield) or measured, or a variable 
value estimated from heart rate (HR predicted). Data from individual subjects are shown 
in Appendix 3 (Tables A3.2 and A3.3). Pancreatic sufficient (PS) children include all the 
healthy controls and one child with cystic fibrosis who did not normally take pancreatic 
enzyme replacement therapy. The remainder of the children with cystic fibrosis are 
included in the pancreatic insufficient (PI) group. Children with cystic fibrosis appear to 
have normal acetate metabolism. There was no significant difference between PDR 
calculated using measured resting KCO2 and PDR calculated using a predicted value of 
resting FCO2 .
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Table 3.36 Cumulative PDR at 6 h during the [*^C]MTG breath test
Cumulative 6 h PDR (median, range)
Subject N Shreeve Schofield Measured HR predicted
Adults 
PS Children 
PI Children
8 33.6 (29-43)
11 28.6 (18-40)
5 10.5 (4-20)
33.1 (28-38) 
31.5 (20-40) 
12.1 (5-21)
30.5 (26-33) 
28.2(17-43) 
11.2 (5-20)
41.5 (27-45) 
42.0 (33-62) 
16.8 (6-25)
Table 3.37 Cumulative PDR at 6 h during the [l-'^C]acetate breath test
Subject N
Cumulative 6 h PDR (median, range)
Shreeve Schofield Measured HR predicted
Adults 8
Children 9
Children with CF 3
32.1 (22-45)
27.0 (19-32)
26.1 (20-27)
32.9 (23-40) 
33.2 (22-40) 
30.7(24-31)
29.2(21-38) 
27.8 (20-34) 
24.6 (22-32)
36.2 (27-42) 
44.6 (33-64)
37.2 (33-41)
Table 3.38 Summary of physical activity level (PAL) during the [^^CJMTG test
Healthy adults Healthy children Children with CF
Median
Minimum
Maximum
1.3
1.0
1.6
1.6
1.0
2.2
1.3
1.2
1.5
Table 3.39 Summary of physical activity level (PAL) during the [1-^^C]acetate test
Healthy adults Healthy children Children with CF
Median
Minimum
Maximum
1.2
1.1
1.4
1.7
1.0
2.5
1.4 
1.3
1.5
All o f the healthy control children and one child with cystic fibrosis performed the tests in 
the familiar surroundings o f their own home, where there was a greater choice o f activities 
than at the ambulatory day care unit, Royal Hospital for Sick Children, Glasgow. Two of 
the control children and the remainder of children with cystic fibrosis performed the test at 
the Royal Hospital for Sick Children. The median (range) PAL in children who performed
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the test at home was 1.7 (1.1 to 2.2). The median (range) PAL in children who performed 
the test at the hospital was 1.3 (1.2 to 1.5).
All of the adult subjects, nine o f the healthy control children and three of the children with 
cystic fibrosis performed both [l-^^C]acetate and [^^C]MTG tests. There was little 
difference in the PAL on each occasion (Tables 3.38 and 3.39), but the summary data mask 
individual differences in physical activity (see Tables A3.2 and A3.3). Five of the adults 
and six o f the children had a PAL within 0.1 units on each occasion i.e. they were 
compliant subjects. Three of the adults, the youngest (mean age 21.3), and five of the 
healthy control subjects had a PAL that varied by more than 0.1 units (mean difference 0.3 
units). This was consistent with the observed behaviour in these subjects.
3.9 [^^C]MTG tests using generic heart rate calibration
3,9,1 Search for a generic calibration
Table 3.40 Comparison of normalisation methods for a potential generic 
calibration method to predict FCO2 from HR (« = 24 subjects)
Normalisation method Accuracy (%) Precision (%)
Surface area (m^) 0.00 49.5
Weight (kg) 0.00 46.5
Height^ (m^) 0.00 48.6
Height^ (m^) 0.00 42.7
Surface area (m^) and age 0.00 40.8
Height^ (m^) and age 0.00 40.5
All methods were equally accurate as the model was fitted using the method of least 
squares. Normalisation to height^ was the most precise (Table 3.40). Univariate analysis 
of variance revealed that age was significantly related to amplitude (constant a in equation 
2.16) of the sigmoid curves fitted to data normalised to body surface area (P = 0.01) and 
height^ (P = 0.06), but to no other constant. Therefore age was included in the prediction 
equation to estimate KCO2 from heart rate using the generic calibration for FCO2 
normalised to surface area and height^. Height^ is an unbiased predictor of lean body mass 
(LBM) in all age groups (Slater & Preston, 2002). LBM comprises the major
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metabolically active tissues in the body, therefore it is not surprising that it is also related 
to FCO2 .
The results of applying generic calibrations normalised to surface area, surface area and 
age, height^ and height^ & age to each individual’s heart rate (two point smoothed) during 
the calibration procedure are shown in Appendix 2 and summarised in Table 3.41. The 
ideal generic calibration would have no significant difference between measured FCO2 and 
FCO2 predicted using the generic calibration.
Table 3.41 Accuracy and precision of generic calibration when applied to each 
individuaFs heart rate calibration data: all subjects (« = 24)
FCO2 normalisation method
Accuracy (%) 
Mean (SEM) Range
Precision (%) 
Mean (SEM) Range ■I
Surface area -10.6 (7.2) -104, 35 44.4 (5.0) 17, 116 sÇ
Surface area and age -7.6 (6.7) -100, 37 42.8 (4.5) 19, 115
Height" -8.4 (6.6) -96, 32 41.8(4.5) 19, 106
Height" and age -3.2 (6.2) -84, 38 41.3 (4.1) 22, 96
Apparently reasonable mean accuracy (height^ and age) masks an unacceptably high range, 
which grossly overestimates FCO2 in some subjects. This is shown by a high negative 
value for accuracy. This problem is worse in children than in adults. Tables 3.42 to 3.44 
show accuracy and precision o f the generic calibration in adults, healthy children and 
children with cystic fibrosis. The bias is worse in children with cystic fibrosis than healthy 
children, but there is a wide range in all children, compared to adults.
In adults, normalisation to surface area and age is the most accurate. This level of 
accuracy is acceptable for breath tests, but assumption of resting FCO2 should not 
introduce as large an error in adults as in children, as adults should be more compliant.
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Table 3.42 Accuracy and precision of generic calibration when applied to each 
individual’s heart rate calibration data: adults only in = 8)
Accuracy (%) Precision (%)
FCO2 normalisation method Mean (SEM) Range Mean (SEM) Range
Surface area 
Surface area and age 
Height^
Height^ and age
6.8 (5.7)
1.3 (6.6) 
-3.4 (6.3) 
-4.9 (6.1)
-15, 32 
-20, 36 
-24, 28 
-25, 30
43.8 (9.8)
42.2 (9.6)
41.4 (8.8)
39.6 (8.0)
26,71
23, 72
24, 66 
24, 69
Table 3.43 Accuracy and precision of generic calibration when applied to each 
individual’s heart rate calibration data: healthy children only {n = 10)
Accuracy (%) Precision (%)
VCO2 normalisation method Mean (SEM) Range Mean (SEM) Range
Surface area 
Surface area and age 
Height^
Height^ and age
■14.6(11.7) 
-6.5 (10.9) 
1.6 ( 11.0)
9.5 (10.4)
-96, 35
-78, 37 
-84, 32 
-74, 38
43.4 (7.7)
43.3 (6.1)
40.2 (7.0) 
41.8(6.2)
17, 106 
19, 86 
19, 100 
22, 94
Table 3.44 Accuracy and precision of generic calibration when applied to each 
individual’s heart rate calibration data: healthy children with cystic fibrosis (n = 6)
Accuracy (%) Precision (%)
FCO2 normalisation method Mean (SEM) Range Mean (SEM) Range
Surface area 
Surface area and age 
Height^
Height^ and age
-27.3 (18.4) 
-21.4(18.5) 
-31.7(14.4) 
-22.1 (13.8)
•104, 20 
■100, 25 
-96, -3 
-84, 4
51.8(13.7)
50.5 (13.6) 
50.7(11.8)
46.1 (10.4)
22, 116 
23,115 
24, 106 
23, 96
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3,9.2 Use of generic calibration to estimate VCOzfrom heart rate
Cumulative percentage dose recovered in 6 h from [^^CjMTG and [1-^^C] acetate breath 
tests for individual subjects is shown in Appendix 3 (Figures A3.1-A3.5). Data are 
summarised below in Tables 3.45 and 3.46. Summary data masks the huge errors in some 
individuals, which is introduced by using a generic calibration method. These are more 
obvious in the figures in Appendix 3.
Table 3.45 cPDR (6 h) in breath CO2 following ingestion of [ CjMTG
Subject
Group
HR
individual
calibration
VCO2 estimate
HR generic generic HR generic
hdght"
Adults 41.5 (27-45) 42.6 (29-53) 39.7(28-50) 47.2 (33-54)
PS Children 42.2 (33-62) 47.2(31-68) 43.0 (28-64) 40.7 (26-54) 
PI Children 16.8(6-25) 25.4 (6-34) 21.6 (6-34) 25.4(7-32)
HR generic 
height^ & age
"4 2 jp 4 -5 1 )
37.2 (24-47)
22.1 (6-30)
Adults n = 8, pancreatic sufficient children n = 11 (10 healthy controls and 1 child with 
cystic fibrosis), pancreatic insufficient children with cystic fibrosis n = 5. Median (range)
Table 3,46 cPDR (6 h) in breath CO2 following ingestion of [l-^^C]acetate
Subject
Group
VCO2 estimate
HR HR generic • Tm • Tm. j. . ,  . r  HR generic HR generic HR generic
c d tS l  ( T f  height" height" & age
Adults 36.2 (27-42) 39.9 (27-48) 37.5 (25-46) 40.0 (29-50) 37.7 (28-48)
Children 40.9 (33-64) 49.1 (30-81) 44.5 (27-76) 41.0(25-66) 37.1 (22-63)
Adults n = 8, children w = 11 (9 healthy controls and 2 child with cystic fibrosis). 
Median (range)
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3.9.3 Use of a generic calibration or assumed PAL: a pragmatic approach
Use of individually calibrated heart rate monitors led to complete discrimination between 
children with pancreatic insufficiency and those without. There was no advantage in using 
heart rate monitors with a generic calibration over simply assuming resting FCO2. 
However, if individually calibrated heart rate monitors were used to determine the 
reference range in healthy subjects and to estimate physical activity level during the test 
under realistic conditions i.e. non-resting and with food intake, then this PAL could be 
applied in the calculation of PDR in children with cystic fibrosis. The mean PAL in 
children, who performed the test at the hospital was 1.3 in this study (see Table 3.37). This 
PAL was applied to the cPDR calculated assuming a constant value of 5 mmol.min'\m"^ in 
children with cystic fibrosis and the results compared with using an individual heart rate 
calibration and generic heart rate calibrations (Figure 3.29).
«0 40
X HC M edian 
-H C M in
— HC Max 
♦  CF n o t Pt 
X PI M edian
— PI Min
— PI Max
predicted measured individual Generic sa Generic Shreeve x
resting resting HR & age htS 1.3 for CF;
calibration IHR for
controls
V CO2 prediction method
Figure 3.29 Effect of generic calibration on cPDR 6 h during [‘^C]MTG breath test
Key: HC, healthy control subjects; PI, pancreatic insufficient; IHR, individual heart rate 
calibration.
The mean cPDR (6 h) in pancreatic sufficient subjects, calculated using non-resting FCO2 
estimated from heart rate, was 41.5 %, standard deviation 8.5 %. Therefore, the reference 
range in pancreatic sufficient subjects was 25 to 58 % (mean ± 2SD, n=19). The mean
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cPDR (6 h) in pancreatic insufficient subjects (n=6) was 16,1 %, standard deviation 6.0 %. 
When data from Amarri et al. (1997) were included, assuming a PAL of 1.3, the mean 
cPDR (6 h) in pancreatic sufficient subjects was 39.9 %, standard deviation 8.1 %, and 
therefore the reference range was 24 to 56 % in pancreatic sufficient subjects (n = 26). The 
mean cPDR (6 h) in pancreatic insufficient subjects {n = 44) was 7.7 %, standard deviation
8.7 %.
3.10 Empirical compensation for individual FCO2
When the cumulative percentage dose recovered in 6 h (cPDR 6 h) from the [l-^^Cjacetate 
breath test is plotted against cPDR 6 h from the [^^C]MTG test, the results of subjects with 
normal digestion and absorption should lie either side of the line o f unity. Children with 
exocrine pancreatic insufficiency due to cystic fibrosis have impaired digestion of 
triacyglycerol, but not impaired absorption and metabolism of medium- and short-chain 
fatty acids. Therefore, data from pancreatic insufficient subjects should lie above the unity 
line. This assumes that CO2 production rate is the same during both tests. Figure 3.30 
shows cPDR 6 h calculated using a constant value of resting FCO2 (5 mmol.min"\m'^ body 
surface area). The data are in Appendix 3 (Table A3.4). Figure 3.31 shows cPDR 6 h from 
the same subjects calculated using a variable value of non-resting FCO2 estimated from 
heart rate. This should take into account differences in PAL between the two breath tests 
and improve the discrimination of the test. Data are in Appendix 3 (Table A3.5).
Use of variable non-resting FCO2 estimated fi'om heart rate improved the discrimination of 
the test, but introduced a further level o f complexity over simply using the heart rate 
monitor to estimate physical activity level during the test. Use of FCO2 estimated from 
heart rate introduced a greater spread of data than use of a constant resting value. The 
greater range in healthy children than in healthy adults is a reflection of the more variable 
PAL in this group.
In some healthy subjects use of heart rate monitors brought the recovery closer to the 
expected value of 100 %, but not all. Children 2, 5 and 7 showed low values indicating 
that the recovery o f acetate was higher than MTG. Four healthy subjects (two young 
adults and two children) had much lower recovery of acetate than MTG. These differences 
could be explained by differences in nutritional status on the day of the test causing a 
change in the balance between oxidation and lipogenesis.
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Figure 3.30 cPDR (6 h) calculated using a constant value of resting FCO2
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3.11 Determination of the cnt-off point of the CC]MTG test
3.11.1 Determination of cut-off
The cut-off for a positive test was determined using two graph-receiver operator 
characteristics (TG-ROC) with non-parametric statistics, as data from the pancreatic 
insufficient (PI, test positive) subjects were not normally distributed. Results are shown in 
Tables 3.47 and 3.48.
Table 3.47 Results of TG-ROC analysis (children only, 11 PS, 6PI). PDR 6 h using 
FCO2 values as stated
TG-ROC output Predictedresting
Measured
resting
Predicted from 
HR (IHRC)
Control IHRC, 
CFPAL=1.3
N 17 17 17 17
Cut-off (do, %) 20 20 30 30
Sensitivity/specificity, 6q 0.83 0.83 1.00 1.00
Intermediate range 17, 20 18, 20
Valid range proportion 0.92 0.95 1.0 1.0
Key: IHRC = individual heart rate calibration
Table 3.48 Results of TG-ROC analysis (adults and children, 19 PS, 6PI, except 
where stated otherwise). PDR 6 h using FCO2 values as stated
TG-ROC output Predictedresting
Measured
resting
Predicted from 
HR (IHRC)
Control IHRC, 
CFPAL=1.3*
N 25 25 25 70
Cut-off (do, %) 20 20 25 26
Sensitivity/specificity, 0q 0.86 0.86 1.00 1.00
Intermediate range 18, 20 17, 20
Valid range proportion 0.94 0.93 1.0 1.0
tilthsKey: IHRC = individual heart rate calibration.
* combining data from this study with data from Amarri et al. (1997), total 26 PS, 44 PI.
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3.11.2Positive and negative predictive values
The sensitivity and specificity o f the [^^C]MTG breath test were calculated using the cut­
off points determined by TG-ROC (Table 3.48). The positive predictive value (PPV) and 
negative predictive value (NPV) were calculated using a disease prevalence i.e. prevalence 
of pancreatic insufficiency in the study population of 0.24 (6 out of 25 subjects). Results 
are shown in Tables 3.49 to 3.51 for PDR calculated using a constant value of resting 
FCO2 o f 5 mmol.min'\m"^ (Table 3 .49), constant value of measured resting VCO2 (Table 
3.50) and a variable value o f non-resting VCO2 predicted from heart rate (Table 3.51). 
Vantrappen et a l (1989) had a sensitivity of 0.89, specificity of 0.81, PPV of 0.63 and 
NPV of 0.95 in their MTG validation study in adults with pancreatic disease.
Table 3.49 Sensitivity, specificity, PPV and NPV of the [^^C]MTG test using a cut­
off of 20 % cPDR 6 h, assuming a constant value of resting FCO2 of 5 mmol.min .^m^
Disease + Disease -  Total Sensitivity Specificity PPV NPV 
Test+  5 2 7 " 0.83 Ô89 Ô7Î 0 9 4 ”
T e s t-  1 17 18
Total 6 19 25
Table 3.50 Sensitivity, specificity, PPV and NPV of the [*^C]MTG test using a cut­
off of 20 % cPDR 6 h, assuming a constant value of measured resting FCO2
Disease + D isease- Total Sensitivity Specificity PPV NPV
Test+  5 2 7 0.83 0.89 0.71 0.94
T e s t-  1 17 18
Total 6 19 25
Table 3.51 Sensitivity, specificity, PPV and NPV of the [^^C]MTG test using a cut­
off of 25 % cPDR 6 h, using variable non-resting FCO2 predicted from heart rate
Disease + Disease -  Total Sensitivity Specificity PPV NPV
Test+  6 0 6 1.00 1.00 1.00 1.00
Test -  0 19 19
Total 6 19 25
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Chapter 4 Discussion  
Summary of Results
The experiments described in Chapters 2 and 3 were designed to address the problem 
summarised at the end of Chapter 1 (Section 1.7). The hypothesis governing these studies 
was that the poor positive predictive value o f the [^^C]MTG breath test for intraluminal fat 
digestion was due to lack of knowledge of the true CO2 production rate during the test, 
assuming the accuracy o f tracer dosage and isotope abundance measurements, and there 
were no unaccounted losses in stool or urine.
All measurements of isotope abundance and enrichment were traceable to international 
standards or gravimetrically prepared standard curves. In vitro experiments confirmed that 
the dose of labelled material was homogeneously distributed throughout the test meal, and 
there were no major losses during preparation. Urinary losses of ^^ C as [^^C]bicarbonate, 
[^^Cjurea and [^^Cjacetate amounted to <5 % of the ingested dose. Loss in stool had 
previously been shown to be negligible in lipase sufficient subjects (Slater et al. 2002).
Lack of knowledge of the true CO2 production rate can be addressed either by measuring it 
continuously during the test or by using an empirically derived correction to eliminate the 
need for its measurement. Both of these approaches were investigated. A third approach 
is to use a substrate that is not sequestered into the body’s carbon pools. Use of deuterium 
labelled MTG was also investigated.
[^^CjBicarbonate breath tests were used to demonstrate the feasibility of using calibrated 
heart rate monitors to estimate FCO2 minute-by-minute during breath tests. Calibrated 
heart rate monitors were used to estimate VCO2 during fasting, fed, resting and non-resting 
^^C-breath tests in two healthy adults. The CV was <10 % in three [^^C]MTG breath tests 
and <5 % in three [l-^^C]acetate breath tests performed over an 18-month period with the 
same test meal, plus a second meal four hours later, and subjects sitting still as much as 
possible during the test.
Individually calibrated heart rate monitors were used to estimate FCO2 continually during 
breath tests in eight healthy adults, ten healthy children and six children with cystic 
fibrosis. The most accurate and precise method of estimating FCO2 from heart rate was 
use of a sigmoid model on smoothed heart rate data. Both resting and non-resting FCO2
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can be estim ated using this model. Over all levels o f  energy expenditure, the sigmoid 
model gave an accurate estimate o f  FCO 2 i.e. there was no difference between measured 
KCO2 and FCO 2 predicted using the sigmoid model, and the precision (mean CV ±  SD) 
was acceptable (23.2 ± 7 . 1  %). U se o f  a generic calibration, to avoid the need for 
individual calibration, introduced unacceptably large errors.
Use o f  individually calibrated heart rate m onitors to estimate FCO2 improved the positive 
predictive value o f  the [^^C]MTG test from  0.71 using resting FCO 2 to 1.0 using non­
resting FCO 2 estimated from heart rate, and provided a way o f  determining the reference 
range o f  6 h cumulative ^^C excretion in pancreatic sufficient subjects (24 to 58 %). The 
cut-off point determined using TG -ROC on data from 25 subjects was 25 %, with 
sensitivity, specificity, positive and negative predictive values all =  1.0. For comparison, 
the reference range calculated using a constant value o f  FCO 2 o f  5 mmol.min'Vm'^ w as 
18 to  43 %  and using a constant value o f  m easured resting FCO 2 was 17 to  40 %. In both 
cases the cut-off point was 20 %  with sensitivity and specificity = 0.86, giving an 
equivocal range o f  17 to  20 %. The positive predictive value w as 0.71 and the negative 
predictive value was 0.94, which is sim ilar to  previous studies.
The m ean physical activity level (PAL) in tests that w ere performed under clinical 
conditions was 1.3 tim es resting m etabolic rate. This factor was applied to  the cum ulative 
recovery in six hours during the [^^C]MTG breath test data from  children w ith cystic 
fibrosis (n =  45), who took  part in a previous study. The results were compared with the 
reference range established in this study w ith no loss o f  specificity. This approach could 
be adopted in future [^^C]MTG tests, undertaken under clinical conditions, thus avoiding 
the need for individual heart rate calibration. The mean PA L in children who performed 
the tests in the fam iliar surroundings o f  their own hom e was 1.7, reflecting the greater 
choice o f  activities available to  these children.
Acetate correction factors have been used to  account for sequestered into body pools 
during studies o f  substrate oxidation. Children with cystic fibrosis have normal acetate 
metabolism. The cum ulative 6 h excretion was 20 to  27 % w hen calculated using resting 
FCO2 and 33 to 41 %  when calculated using non-resting KCO2 estimated from  heart rate, 
compared with 19 to  45 % and 27 to  64 % in healthy control subjects. The m edian (range) 
recovery o f  with an acetate conection was 45 (16 to  52) % in children w ith cystic
fibrosis and 98 (71 to  170) % in control subjects, when PD R was calculated using a
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constant value of resting FCO2 . It was 45 (15 to 52) % in children with cystic fibrosis and 
104 (71 to 144) % in control subjects, when PDR was calculated using non-resting KCO2 .
Use of acetate correction factors is not recommended as it requires two breath tests on 
separate occasions, and the assumptions that any deviations from basal FCO2 are the same 
on each occasion and that both tracers are metabolised in an identical manner following 
absorption, may not be valid.
Approximately 95 % ingested was recovered in body water following ingestion of 
pHjMTG by two healthy adults. This was compared with recovery of in body water 
following ingestion o f [^Hi^joctanoate and pHsjacetate by the same subjects to test the 
assumption that MTG, octanoate and acetate are all metabolised in the same manner. Less 
was recovered in body water following ingestion of [^Hs] acetate (87 & 91 %) than 
[^HjMTG (93 & 98 %) or [^Hisjoctanoate (94 & 101 %), suggesting that a greater 
proportion of [^Hs]acetate may be sequestered, most probably during lipogenesis.
4.1 Validation of laboratory methods
Methods were established that were accurate (traceable to international standards or 
gravimetrically prepared standard curves), precise (SD of three replicate analyses < 1 ppm) 
and linear (the isotope ratio was constant over the expected concentration range). Thus, 
measurement of isotopic abundance could be excluded as a source of error in determining 
the percentage dose excreted in breath.
4.2 Measuring CO2 production rate
4.2.1 Predicting and measuring basal/resting metabolic rate
4.2.1.1 Comparison of methods
When considering only the children, the Schofield equations predicting BA4R from height 
and weight gave a more accurate estimate of resting LCO2 in children with cystic fibrosis 
than the Shreeve method (Table 3.33), The Schofield height and weight equations have 
been shown to be superior to the FAO/WHO/UNU and Flarris-Benedict equations (Section 
1.4.3.1) in children with failure to thrive (Kaplan et al. 1995) and in obese children 
(Kaplan et al. 1995; Rodriguez et al. 2002). Resting KCO2 predicted from smoothed heart
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rate using a sigmoid model, was not significantly different from measured resting FCO2 in 
any group, but resting FCO2 predicted from raw heart rate was significantly different 
(Table 3.31). There are no published papers, which smooth heart rate prior to fitting a 
model to predict energy expenditure, and the technique has been criticised because of the 
failure of linear models to adequately predict low levels o f energy expenditure, close to the 
flex point (Livingstone et al. 1992). This is the first study that has attempted to predict 
CO2 production rate from heart rate during breath tests.
4.2.1.2 RQ and FQ
The mean RQ for adult subjects in = 8) was 0.87, which is close to the assumed average 
value of 0.85 used to calculate VCO2 from BMR using the Schofield (1985) equations and 
recommended by IDECG (1990). The food quotient of the test meal, calculated as 
described in Section 2.4.2 from its nutritional composition and the FQ of individual fuels 
(Black et al. 1986), was also 0.85. However, the mean RQ for all subjects {n = 25) was
0.90. Children had a higher RQ than adults. The mean RQ for control children was 0.93 
(n = 10) and that for children with cystic fibrosis was 0.90 (n = 7). A high RQ usually 
implies carbohydrate oxidation. The higher value in children may be a reflection o f the 
fact that measurements were made approximately 3 h after their last meal, whereas adults 
were measured after an overnight fast. Three hours after a meal containing carbohydrate, 
the RQ will be closer to 1.0 because the carbohydrate in a meal is preferentially oxidised 
over the fat (Stubbs, 1998). After a period of starvation, such as overnight, the RQ will 
drop towards 0.7, as lipid replaces carbohydrate as the main energy source (Black, 1986).
Knowledge of RQ during the [^^CJMTG breath test would only be necessary if VCO2 were 
to be predicted from VO2 estimated from heart rate (Section 2.2.3.4), but data shown in 
Section 3.8.2 suggests that this is no more accurate or precise than estimating FCO2 
directly fi'om heart rate.
4.2.1.4 Effect of position on measured FCO2
It has been reported in the literature (Girardet et al. 1994; Amarri et al. 1998; Castro et al. 
2002 and others) that children with cystic fibrosis have elevated resting metabolic rate 
compared with healthy control children. Resting metabolic rate is measured with subjects 
lying in a supine position. Children with cystic fibrosis had a higher CO2 production rate 
when lying than when sitting (Table 3.3, Section 3.8.3.2). Resting FCO2 was significantly
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higher in children with cystic fibrosis than control subjects when measurements were made 
in the supine position, but the difference disappeared when measurements were made in 
the sitting position. Children with cystic fibrosis may have greater difficulty breathing in 
the supine position than when sitting. Therefore, apparently elevated REE in children with 
cystic fibrosis may be due to the fact that REE measurements are made while subjects are 
lying on their back, but children with CF are not truly at rest in this position.
Girardet et a l (1994) found no difference in REE, expressed as kJ per day, between infants 
with cystic fibrosis and controls, but REE was significantly elevated in children with cystic 
fibrosis when expressed per kg body weight or per kg fat-free mass. A similar conclusion 
was reached by Bronstein et al. (1995) with respect to TEE in infants with presymptomatic 
cystic fibrosis. An apparent difference, when EE was expressed per kg body weight, 
disappeared once differences in body composition were taken into account by expressing 
EE per kg fat free mass per day or simply as kJ per day. In this study KCO2 was expressed 
in relation to body surface area, which takes some account of differences in body size and 
composition. The differences observed here cannot be explained by changes in body 
composition, as REE measurements were made continuously over a 30-minute interval. 
The elevated EE observed when children with cystic fibrosis were lying compared to 
sitting deserves further investigation in a larger number of children, as the supine position 
is rarely adopted during daily living activities, even when sleeping.
If FCO2, measured in the supine position, in children with cystic fibrosis is higher than 
FCO2 when these children are sitting quietly during a ^^C-breath test, then use of the 
measured “resting FCO2” to calculate PDR will slightly overestimate the cumulative 
excretion. There may be no advantage in using a measured value of resting FCO2 
compared to a predicted value using the Schofield (1985) equations (Table 3.33). 
However, the magnitude of this error is small compared to other errors associated with 
estimation of FCO2 during the [^^C]MTG test, and will not make a difference to the 
outcome of the test in pancreatic insufficient subjects, who have little capacity for 
triacylglycerol hydrolysis.
4.2,2 Postprandial or diet-induced thermogenesis
The mean FCO2 during the two-hour period following the test meal was 116 % of the 
fasting, resting rate (RMR) measured immediately before the meal. Weststrate (1993) 
found that 86 % of the total observed thermic effect (over 3.5 h) was observed in the first
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2 h of the postprandial period following ingestion of a test meal containing 1.9 MJ in men 
or 1.3 MJ in women. The energy content of the cereal-based test meal consumed in this 
study was approximately 1.5 MJ. In five of the seven adults, FCO2 in the last 10 min o f 
the DIT measurement was within ±7 % of the basal value. In two subjects, FCO2 was still 
-20  % above basal 2 h after the meal. DIT is usually assumed to be -10 % TEE, which is 
14 % REE, assuming PAL =1.4, the Department of Health estimate of energy requirement 
for non-active activities in adults (Department of Health, 1991), and therefore REE is 71 % 
TEE. The thermogenic effect of the test meal is close to what would be expected for an 
average Western Diet, and the test meal alone could account for a PAL of 1.1 to 1.2 during 
the breath-sampling period. However, there is great variability between individuals, 
ranging from 1.0 to 1.3. Ignoring DIT would result in an underestimation of up to 30 % in 
the cumulative PDR during the [^^CjMTG breath test.
4.2.3 Calibration of heart rate monitors
4.2.3.1 Individual calibration of heart rate monitors
In this study, the accuracy o f the linear calibration methods was similar to that reported in 
the original papers by Spurr et al. (1988) and Livingstone ei al. (1992), who measured TEE 
using calibrated heart rate monitors. The mean difference between measured and predicted 
FCO2 using the liner-flex method was -1.9 % ranging from -19 to +9 % in this study, 
compared to an error o f-2.4 % ranging from -15 to +20 % in the original study of Spurr et 
al. (1988). Using the modified linear-flex method of Livingstone et al. (1992), the mean 
difference in this study was <7.8 % ranging from -23.2 to +18.5 %, compared to -3.2 % 
ranging from -16.7 to + 18.8 % in the study of Livingstone et al. (1992). Strath et al. 
(2002), also found that the linear-flex method overestimated energy expenditure in young 
adults, aged 23 to 29 y.
Non-linear methods were more accurate and did not rely on assumptions about resting 
metabolic rate. Dauncey and James (1979) compared a logistic function with several linear 
calibration methods to determine energy expenditure by calibrating heart rate against heat 
production in a calorimeter. Use of the logistic function reduced the error for 24 h heat 
production from >10 % to approximately 5 %. Exponential functions (logistic and 
sigmoid) using smoothed heart rate gave an accurate estimate of resting FCO2 and non­
resting FCO2, using a single function. This was not possible using the flex methods, 
because of the uncertainty at low levels o f energy expenditure around the flex point
Cluistine Slater 2004 Chapter 4, 181
(Dauncey and James, 1979; Spurr et al. 1988; Livingstone et al. 1992). The mean 
difference between measured resting FCO2 and FCO2 predicted from smoothed heart rate 
using a sigmoid model was -  0.09 mmol.min"\m"^ body surface area (n = 23). An accurate 
estimate of FCO2 at low levels of energy expenditure is especially important in the context 
of breath tests.
A third order polynomial has been used in studies of TEE in children (Beghin et al. 2000, 
2001, 2002; Ribeyre et al. 2000b) , but this method overestimates energy expenditure at 
low levels o f activity e.g. sleeping and fasting, and a second function must be used under 
these circumstances to avoid overestimating TEE (Beghin et al, 2000 and Figure 3.15). 
There are no published studies using a sigmoid model to predict energy expenditure from 
heart rate and only two, Dauncey and James (1979) and Li et al. (1993), using a logistic 
model.
All of the curve fitting in this study was done using the Solver add-in to Microsoft Excel, 
which is provided as part of the standard Microsoft Excel package, and is therefore widely 
available. Once the calculations have been set up in the spreadsheet, curve fitting in this 
manner is easy for a novice to learn. The residuals are determined as part of the least 
squares regression analysis and therefore calculation of the accuracy and precision o f the 
model is trivial
4.23.2 Generic calibration of heart rate monitors
There is a loss of precision when a generic calibration is used to estimate energy 
expenditure compared to using individual calibrations. An acceptable generic calibration 
must have a low coefficient of variation (CV). For individual heart rate calibration, the 
mean inter-subject precision of different calibration methods ranged from 23 to 35 %, 
which is similar to the CV on the slope (-22 %) and intercept (-30 %) of the linear 
calibration curves in the Livingstone et a l  (1992) study. Li et a l  (1993) obtained inter- 
individual CV’s of 11 to 20 % using a logistic model to estimate energy expenditure in 
forty female cotton mill workers in Beijing. In the current study, the smallest mean inter­
subject CV was obtained for the sigmoid model using smoothed heart rate (23 %, median, 
22 %, range 13 to 35 % in individual subjects). The broader range of precision here is 
probably explained by the fact that Li et al. (1993) used the average steady state at each 
energy level to establish their model, whereas all data were included in the present study. 
When the generic calibration was applied to each individuals calibration data, the mean
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precision in subjects aged from 5 to 47 y, was 44 % (median, 35 %, range 17 to 116 %), 
when FCO2 was normalised to surface area. When VCO2 was normalised to height^, the 
mean precision was 42 % (median, 38 %, range 19 to 106 %).
Two studies of energy expenditure in farm animals have used a generic calibration to 
predict energy expenditure from heart rate in working cattle and buffalo (Richards & 
Lawrence, 1984; Sneddon e ta/. 1985). Richards and Lawrence (1984) found a correlation 
coefficient for the linear regression of energy expenditure (Watts per kg '^^ )^ versus relative 
heart rate (RHR), i.e. working heart rate/resting heart rate in two cattle and two buffalo of
0.91 with M = 49 data points. Similar results were obtained by Sneddon et al. (1985). In 
this study, the correlation coefficient for the linear regression o f VCO2 (mmol.min"\m-^ 
body surface area) versus relative heart rate was 0.73 in eight adults with n = 593 data 
points. Although the calibration procedure for the cattle covered a fairly wide range of 
heart rate, RHR from 1.0 to 2.2, the live weight of the animals was only 510 kg to 630 kg. 
This may explain the much poorer correlation in this study, where relative heart rate was 
similar (1.0 to 2.4), but there was relatively a much greater range of body size (weight 57 
to 108 kg, B M I21 to 34 kg.m'^).
The only study in humans that has published data attempting to use a generic heart rate 
calibration is that of Li et a l (1993). They used a group calibration obtained by combining 
data (energy expenditure, kj.min"^ and heart rate, beats min* )^ from half o f their subjects 
(n= 20) and applying it to individual heart rate data from the other half. Although the 
mean difference in energy expenditure was fairly small (approximately 2 % of the daytime 
energy expenditure), there was great individual variation ranging from approximately 
-63 % to + 68 %, and the method was deemed to be unsatisfactory. A similar result was 
found in this study (Table 3.41) when the generic calibration was applied to individual 
heart rate data. In subjects aged from 5 to 47 y, normalisation to height^ and age gave the 
most accurate generic calibration. The mean difference between measured and predicted 
FCO2 was -3.2 % (median +2.2 %, range -84 % to + 38 %), but the range was much 
smaller when only adults were considered (-25 % to +30 %). In adults, normalisation to 
surface area and age gave the most accurate generic calibration. The mean difference 
between measured and predicted FCO 2 was 1.3% (median 0.9 %, range -20 % to + 36 %), 
and the mean precision was 42 % (median 32 %, range 23 % to 72%). Therefore, there 
may be some scope for the use of heart rate monitors with a generic calibration as a 
compliance test in adults during ^^C-breath tests that last for extended periods of time, such
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as studies o f oro-caecal transit time and starch fermentation in the colon (Christian et al. 
2002; Morrison et a l 2003b).
An alternative approach is now available, which was not on the market when this study 
commenced. Electronic motion sensors are now available that can apparently monitor low 
levels of activity e.g. the active?AL^^ professional (PAL Technologies, Glasgow, UK). 
These were developed for use in sedentary populations, including joint-replacement and 
stroke patients, and could prove to be a useful tool to estimate PAL during ^^C-breath tests. 
The sensor is strapped to the upper part of the leg and can detect the duration of periods o f 
sitting, standing and moving around. This type of device could be a useful means of 
testing compliance, so that the recovery of in each breath sample could be corrected for 
physical activity level. No calibration is necessary as the output is given in relative MET 
units (Ainsworth et al. 2000).
4.2.4 CJBicarbonate breath tests
4.2.4.1 Recovery of in breath
Bicarbonate breath tests were performed to demonstrate the feasibility of using heart rate 
monitors to continuously measure FCO2 under fasting, fed, resting and non-resting 
conditions. Recovery of labelled CO2 after intravenous infusion of sodium 
[^^Cjbicarbonate is often assumed to be -80  % (Hoerr et al. 1989), but published values 
range from -50  % to 100 %, depending on the length of infusion time, whether the test is 
performed under fasting or fed conditions and under resting or non-resting conditions. 
Leijssen & Elia (1996) reviewed 34 human bicarbonate studies involving 480 subjects. 
Overall, continuous infusions tended to have higher recovery than bolus doses (84 ± 1 1 %  
versus 69 ± 11 %). No significant differences in recovery were found between and 
studies, children and adults or lean and obese subjects. Higher recoveries were found 
during feeding than during fasting (84 ± 8  % versus 74 + 7 %). Barstow et al. (1990) 
studied the influence o f increased metabolic rate on [^^Cjbicarbonate wash-out kinetics. 
Under fasting, resting conditions 6 7 + 5  % of the intravenous bolus dose was recovered in 
breath over a four-hour period. This increased to 80 + 1 1 % in two hours during light 
exercise. Leese et a l (1994) found no difference between recovery following an oral bolus 
dose and an intravenous bolus dose of [^^Cjbicarbonate (63 + 3 %, versus 62 ± 1 %). 
However, Meineke et al. (1993) observed much greater variation in recovery following 
administration of oral doses of [’'^Cjsodium bicarbonate in the fasted state. The mean
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recovery in four hours was 64 %, but ranged from 49 % to 73 %. The authors did not 
attribute this variability to losses due to eructation, but low levels of eructation were 
observed during the present study following oral doses of bicarbonate.
When PDR was calculated using FCO2 predicted from HR (Figures 3.19-3.24 and Tables 
3.7 and 3.8), the results were in line with published studies using an intravenous bolus dose 
of labelled tracer. Therefore individually calibrated heart rate monitors could be used to 
estimate FCO2 during ^^C-breath tests under resting and non-resting conditions. Use of 
resting FCO2 when subjects were not at rest underestimated the true breath excretion rate.
4.2.4.2 Recovei-y of in urine and stool
Excretion of in urine as [^^Cjbicarbonate and [^^C]urea was measured following 
ingestion of [^^Cjbicarbonate. The total urinary loss of was higher in fasting 
conditions (4.7 %) than in fed (2.2 %). This is in accordance with published values (Elia, 
1991) following an intravenous infusion o f labelled bicarbonate in which approximately 
2 % of the infused label was recovered in urine, mainly in urea. Excretion of labelled 
acetate in urine following [^^Cjacetate and [^^Cjoctanoate breath tests was also measured 
(data not included) and found to be < 0.5 % ingested dose.
Any [^^CJMTG or [^^Cjdiacylglycerol (DAG), which escapes digestion or absorption in the 
small intestine will enter the colon, where it may become a substrate for fermentation by 
colonic microflora or it may be excreted in stool. These two fates have been shown by us 
to be negligible in healthy children and children with cystic fibrosis taking their normal 
enzyme supplement (Ling et al. 1998, Slater et al. 2002).
Urinary excretion of^^C is not a major pathway of loss and the sum of urinary and stool 
excretion probably accounts for less than 5 % ingested tracer in the [^^CJMTG test in 
healthy individuals and also children with cystic fibrosis taking their normal enzyme 
supplement,
4.3 Development of a test meal
A test meal was developed that could carry [’^CjMTG, [^ ‘^ Cjoctanoate or [l-'^C]acetate or 
their deuterium labelled analogues. This was a biscuit (flapjack) composed of oats, butter 
and honey, which are all have low natural abundance so that the test meal would not
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perturb the background breath abundance. In vitro experiments confirmed that the 
labelled material was homogeneously distributed throughout the test meal and there were 
no unaccounted losses during preparation.
The recipe given in Section 2.4.2 provides 3.13 MJ or approximately 17 % of the daily 
energy needs of two adults. Children were given a portion amounting to approximately 
20 % of their estimated energy requirements. Subjects of all ages found the test meal 
acceptable. It was also gluten-, lactose- and egg-free, and could therefore be used in tests 
on subjects with special dietary needs and subjects following a vegetarian diet.
In vitro experiments showed that approximately 80 % of the acetate entered the aqueous 
phase under the normal acid conditions found in the stomach and all o f it under neutral and 
alkaline conditions. These findings agree with the results of Braden et al. (1995), where 
85 % of [^^C]acetate and 77 % ^ '^"Tc remained in the liquid phase after incubation of an 
oat-based semi-solid meal with HCl for 30 min, and are in line with the partitioning 
expected between aqueous and other phases. Partitioning of the tracer between solid and 
liquid phases of the test meal, or in the stomach, is more important in the context of gastric 
emptying tests than the current study, where the end point is calculation of area under the 
recovery curve, rather than time to some threshold. The results shown in Tables 3.13 and 
3.14 suggest that the tracer was homogeneously distributed in the flapjack and not lost 
during preparation, implying that errors in dosage are unlikely to be a major source of error 
using this test meal.
4.4 Investigation of [^^C]MTG metabolism
4.4.1 Variation of baseline C abundance
Calculation of cumulative excretion requires knowledge of the enrichment of breath 
^^C02 above background levels. Constant background ^^ C abundance is assumed, which 
requires careful control of diet on the days preceding the test and during the test to avoid 
foods, which are naturally enriched in ‘^ C. Background ^^C02 abundance also depends on 
the nutritional status of the individual. If a person is oxidising glycogen derived glucose as 
their main energy substrate, breath *^ C0 2  abundance will be higher than if they are 
oxidising lipids, assuming these macronutrients were from the same dietary source 
(Schoeller et al. 1977; Schoeller et al. 1984). ^^C-breath tests are usually performed in the 
resting state after an overnight fast. The change from glycogen to lipid as a fuel source is
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sometimes observed as a falling baseline prior to the test. In this study, breath 
abundance was lower under fasting conditions than with food intake and is a reflection of 
lipid oxidation under fasting circumstances. There was less variation in background 
abundance under fasting conditions than fed conditions, but it is impractical to perform 
breath tests in children under fasting conditions.
4.4.2 Effect of food intake and the test meal on PDR in [l-^C]acetate 
breath test
Recovery of in breath CO2 following ingestion of [l-^^C]acetate is higher under fasting 
conditions than fed (Tables 3.16 and 4.1), as acetate is oxidised under fasting conditions, 
whereas it is directed towards Hpogenic pathways under well-nourished conditions (Frayn, 
1996, Mittendorfer et al. 1998). This is contrary to the situation following ingestion o f 
[^^C]bicarbonate, where more is recovered in breath under fed conditions than fasted 
conditions (Leijssen & Elia, 1996).
Table 4.1 cPDR in 6 h following I mg kg^ body weight [1-^^C] acetate under 
fasting and fed conditions
Subject 1 Subject 2
Fasting 63.1 36.8
Liquid meal 46.1 34.8
Solid meal 41.5 26.1
Following a mixed meal, the carbohydrate component of the meal will be preferentially 
oxidised (Stubbs, 1998) and the lipids will be stored either as triacylglycerol in adipose 
tissue, in the case o f dietary long-chain fatty acids, or incorporated into newly formed 
long-chain fatty acids in the case o f acetate. Under normal circumstances the rates of 
glycolysis and of the TCA cycle are integrated, so that only as much glucose is 
metabolised to pyruvate as is needed to supply the TCA cycle with acetyl-CoA. Pyruvate 
and acetyl-CoA are normally maintained at steady-state concentrations (Nelson & Cox, 
2000). But demand for energy is higher following a meal, than under fasting conditions 
and thus, more unlabelled CO2 from glucose metabolism will equilibrate with the labelled 
bicarbonate and flush the latter from the body following a meal. When the ^^ C label is on 
acetate, it is more likely to enter Hpogenic pathways in the fed condition and be
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sequestered in the body, whereas under fasting conditions, when glucose is in short supply, 
acetate is more likely to be oxidised or form ketone bodies. Ketone bodies are an 
important supply of fuel to muscle and brain under fasting conditions, therefore under 
these circumstances the label will be oxidised and appear in breath CO2 .
The form of the test meal affects gastric emptying rate and hence the time it takes for the 
tracer to reach the liver. If the tracer is taken in a liquid, following a solid meal, the liquid 
(aqueous) phase leaves the stomach first (Maes et a i 1996). Therefore, the labelled 
material will reach the liver faster when it is taken in milk (either alone or following 
breakfast cereal), than when it is baked in a biscuit. When the labelled material is 
incorporated into a solid meal, this must be broken down into smaller particles by the 
process of trituration, before it can leave the stomach. The amount of acetate oxidised will 
depend on the nutritional state of the individual and the energy provided by the meal 
relative to their needs.
The breakfast preceding the ingestion of [l-^^C]acetate dissolved in milk (liquid meal), 
which was composed of cereal with semi-skimmed milk and a glass of unsweetened 
orange juice, provided 1600 kJ (-18 % daily energy needs) for Subject 1, but only 1440 kJ 
(-12 % daily energy needs) for Subject 2. When the test meal was flapjack with 
unsweetened orange juice, it provided -17 % of the daily energy needs of both subjects 
(1480 kJ for Subject 1 and 2110 kJ for Subject 2). Therefore, the energy content of the 
meals were similar for Subject 1 (17 versus 18 % estimated daily energy requirements) and 
so was the amount of tracer oxidised. However, the cereal breakfast provided less energy 
than the flapjack to Subject 2 (1 2  versus 17 % estimated daily energy requirements) and 
more acetate was oxidised.
A small increase in recovery was observed following the second meal in both acetate and 
MTG tests, even when subjects remained seated. This is due to the increase in the rate of 
FCO2 following the meal due to diet-induced thermogenesis (DIT), and results in still 
incorporated in TCA cycle intermediates being flushed from the body.
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4.4.3 Effect of physical activity during the [^ ^CJMTG breath test
There was a difference between subjects in the metabolism of [^^CJMTG during gentle 
exercise. Subject 1, female, increased VCO2 during exercise (PAL 2.3 compared to 1.2), 
but not oxidation of [^^C]MTG, (PDReu 38.6 % when resting compared to 36.8 % when 
walking). Subject 2, male, increased FCO2 during exercise (PAL 4.5 compared to 1.0) and 
also substrate oxidation (PDRgh 25.8 % when resting compared to 69.7 % when walking) 
in a similar manner to the bicarbonate breath test (PDRôh in the bicarbonate breath test 
under non-resting conditions -70  %). Thus, in Subject 1 , [l-^^C]acetate produced during 
P“Oxidation o f labelled octanoate must have entered Hpogenic pathways under both 
circumstances, whereas in Subject 2, the labelled acetate was stored under resting 
conditions, but oxidised during exercise. These results probably reflect inter-individual 
variation and depend on the nutritional status (and general fitness) of the individuals, rather 
than gender, as a similar observation was made by Kalivianakis et a l (1997), who 
measured recovery of in breath following ingestion of 4 mg [^^CjMTG kg'^ body 
weight in adults, who cycled at 25 to 35 % VOzmax for 5 h and then rested for 4 h. PDR91, 
ranged from 25.3 % to 85.3 % and was not gender related.
The PAL of 2.3 in Subject 1 is consistent with walking at 2 mile h'  ^ at a slow pace on a 
firm, level surface, which has a MET intensity of 2.5 (Ainsworth et a l 2000). Subject 2 
carried a backpack containing waterproof clothing and a snack for both subjects 
(approximate weight, 7 kg or 15 lb). The average pace over 8  h was approximately 3.2 km 
h"^  (2 mile h'*). Walking, carrying a 15 lb load on level ground has a MET intensity of 3.5 
and increases to 5 going uphill and 7.5 climbing hills with 10-20 pound load. The PAL in 
subject 2 was 4.5. The amount of time spent walking uphill was not noted, but there were 
short stretches of steep ascent. Although the PAL could not be calculated using the 
factorial method (FAO/WHO/UNU, 1985; Ainsworth et a l  2 0 0 0 ), the PAL measured 
using FCO2 estimated from heart rate is close to what might be expected and confirms that 
heart rate monitors can be used to estimate VCO2 during the [^^CJMTG test under non­
resting conditions.
4.4.4 Intra-individual variation in the MTG test
The intra-individual variation of PDRioh in these two subjects was less than 10 %, which is 
better than 22.7 % reported by Kalivianakis et a l  (1997). This is probably due subject 
compliance as repeatability was much better in some individuals than others in the
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Kalivianakis study. Kalivianakis et a l (1999) did not state whether subjects were asked to 
refrain from vigorous exercise on the day before the test, as this could affect RMR (van 
Raaij, 2002), and therefore PDR even if subjects were compliant during the test.
4.5 [^^C]MTG tests using calibrated heart rate monitors
The recovery of calculated using a constant value o f resting FCO2 , during the MTG 
test was in the same range as has been reported previously (Amarri et a l 1997; Wutzke et 
a l  1999; van Dijk-van Aalst et a l  2001; Slater et a l  2002). No matter whether resting 
FCO2 was measured or predicted, there was an overlap between pancreatic sufficient and 
pancreatic insufficient subjects in the cumulative amount of excreted in breath CO2, 
when resting FCO2 was used in the calculation of PDR. The child with cystic fibrosis, 
who was not pancreatic insufficient, had cumulative excretion in the middle of the normal 
range. When a variable non-resting value of FCO2, predicted from heart rate was used, the 
populations of pancreatic sufficient and pancreatic insufficient subjects were completely 
resolved (Table 3.36 and Figure 3.29).
The sensitivity and specificity of the [^^CJMTG test, when PDReh was calculated using a 
constant value of resting FCO2 was 86 %, which is similar to the validation study of 
Vantrappen et a l  (1989), which had a sensitivity of 89 % and specificity of 81 %. Loser et 
a l 1998 performed a validation study of the [^^CJMTG breath test on 27 healthy adults, 26 
patients with chronic pancreatitis (13 of whom had mild and 13 severe exocrine pancreatic 
insufficiency), and 25 patients with non-pancreatic gastrointestinal disease. The results of 
the MTG breath test were compared with the results from other non-invasive tests- faecal 
elastase 1 concentration and faecal chymotrypsin activity. The sensitivity and specificity 
of the [^^CjMTG test for area under the curve at 5 h (PDRsh) was calculated. The report 
does not mention CO2 production rate, but it can probably be assumed that a constant value 
of 300 mmol.h"\m"^ body surface area was assumed in the calculation of PDR. The 
sensitivity of the MTG test in patients with severe exocrine pancreatic insufficiency was 
100 %, but it was only 46 % in patients with mild exocrine pancreatic insufficiency. 
Overall the sensitivity was 73 % and the specificity was 69 %, which is worse than the 
present study and Vantrappen’s (1989) study. The faecal elastase test had a sensitivity of 
92 % and specificity of 90 %, and the faecal chymotrypsin test had a sensitivity of 56 % 
and specificity of 82 %.
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The poor sensitivity and specificity of the Loser et al. (1998) [^^CJMTG test could be due 
to non-compliance of some of the control subjects, with respect to remaining seated 
throughout the test, in which case use o f resting FCO2 in the calculation of PDR is 
inappropriate. The cumulative excretion of in the breath of healthy controls ranged 
from ~5 to 35 %, whereas that from patients with non-pancreatic gastrointestinal disease 
ranged from -15 to 35 %. Amarri et al. (1997) showed that children with non-pancreatic 
gastrointestinal disease have similar breath excretion to healthy controls during the 
[^^CjMTG test (20 to 35 % recovery after 6 h compared with 20 to 42 % in controls).
In the study reported in this thesis, use o f individually calibrated heart rate monitors to 
estimate VCO2 during the [^^C]MTG test improved the positive predictive value of the test 
from 0.71, when resting FCO2 was used, to 1.0 when non-resting FCO2 estimated from 
heart rate was used to calculate PDR.
Individually calibrated heart rate monitors are a useful tool to determine the reference 
range o f cumulative excretion in healthy children during the [^^C]MTG breath test. 
Knowledge of the reference range in healthy children is necessary to assess exocrine 
pancreatic insufficiency in children with cystic fibrosis. Calibrated heart rate monitors can 
also be used to measure physical activity during the test, so that cumulative excretion in 
children with cystic fibrosis can be corrected for non-resting CO2 production rate. There 
was no loss of specificity when this approach was adopted using [^^C]MTG breath test data 
from children with cystic fibrosis (n = 45), who took part in a previous study (Amarri et al. 
1997).
The measured physical activity during the MTG breath test was 1.3 in healthy adults and 
children with cystic fibrosis and 1.7 in healthy children, who performed the test in the 
familiar surroundings of their own home, where there was a greater choice of activities. 
The PAL measured here is closer to what would be calculated from METs (Ainsworth, 
2000), than PARs (Department of Health, 1991) (see Section 1.4.3.5), reflecting the fact 
that the denominator is RMR, rather than BMR. Examples of MET intensities for the 
activities carried out during ^^C-breath tests are shown in Table 4.2.
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Table 4.2 MET intensity (for adults) of activities carried out during *^C-breath 
tests
Code METS Specific activity Example
07010 1.0 Inactivity Lying quietly, watching television
07011 1.0 Inactivity Lying quietly, in bed, listening to music, not talking or reading
07020 1.0 Inactivity Sitting quietly, watching television
07030 0.9 Inactivity Sleeping
07070 1.0 Inactivity Reclining - reading
09010 1.5 Miscellaneous Sitting - playing cards, playing board games
09020 1.3 Miscellaneous Sitting -  reading book, newspaper etc.
09040 1.8 Miscellaneous Sitting -  writing, desk work, typing
09050 1.8 Miscellaneous Standing -  talking or talking on the phone
09060 1.8 Miscellaneous Sitting -  studying including reading or writing
09071 2.0 Miscellaneous Standing
09075 1.5 Miscellaneous Sitting-arts and crafts, light effort
09085 1.8 Miscellaneous Standing-arts and crafts, light effort
09100 1.5 Miscellaneous Sitting, relaxing, talking, eating
17070 3.0 Walking Downstairs
17130 8.0 Walking Upstairs
17150 2.0 Walking Household
17152 2.5 Walking Walking, 2 mph, slow pace, firm surface
05170 2.5 Home activities Sitting, playing with children, light, only active periods
05175 4.0 Home activities Walk/run, playing with children, light, only active periods
From Ainsworth et al. (2000)
The measured physical activity level in individual breath tests was in accordance with the 
observed behaviour, although activity diaries were not kept. The MET intensities shown 
above indicate that even short bursts of activity can lead to an underestimation o f the 
percentage dose recovered in breath at that time if a resting value is erroneously assumed.
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4.6 [^^C]MTG tests using generic heart rate calibration
Use of generic calibration methods appears to have more potential in adults than in 
children (Appendix 3, Figures A3.1 to A3.5). The generic calibration using height^ and 
age proved to be useful in the healthy control child with a poor heart rate calibration that 
overestimated resting FCO2 (Section 3.8.3.1), but overestimated FCO2 in one healthy child 
and two children with cystic fibrosis. It also underestimated FCO2 in one healthy child. 
Normalisation to surface area was no better than height^ in the children with cystic fibrosis 
and grossly overestimated FCO2 in two healthy control children for whom normalisation to 
height^ gave a more accurate estimate of FCO2 . There was no advantage in using a generic 
calibration to estimate FCO2 from heart rate over using a constant PAL (Section 3.9.2).
4.7 Sequestration of within the body
4.7.1 Empirical compensation for individual VCO2
Once accurate methods had been established to quantify tracer exhalation in breath and 
other minor losses, mass balance could be used to estimate the quantity of tracer retained 
within the body. If  oral doses of acetate are assimilated in the same manner as other fatty 
acids, then all the processes that occur after P-oxidation of octanoic acid are common to 
both labelled substrates and recovery of in breath CO2 from the [1-^^C]acetate breath 
test can be used to correct the recovery from the [^^C]MTG test for label that is retained in 
the body.
The acetate correction factor accounts for label fixation that might occur at any step 
between the entrance o f acetyl-CoA into the TCA cycle until recovery of label in breath 
CO2 [1-^^C]acetate is the appropriate form for use with fatty acids labelled at C l. An 
assumption in its use is that there are no other major routes of sequestration of label and 
that oxidation of acetate and octanoate take place at the same rate. Less than 5 % of 
ingested ^^ C is excreted in stool and urine in healthy subjects and children with cystic 
fibrosis taking their normal pancreatic enzyme replacement therapy (Sections 3.2.4.4,
3.7.3.3 and Slater et al. 2002), assuming that excretion of label as [^^Cjbicarbonate and 
[*^C]urea is similar during the [1-‘^ C]acetate and [’'^CjMTG breath tests as during a 
bicarbonate breath test (Leijssen & Elia, 1996). If these assumptions are true, then 
recovery in breath corrected for label sequestered in the body should be 95 to 100 % and 
should be similar to the recovery of in body water following ingestion of [^FljMTG.
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There was a wide range of recovery of when the acetate correction factor was applied 
to the recovery of from the MTG test. Recovery ranged from 71 to 170 % of the 
ingested dose, with a median of 98 %, when PDR was calculated using a constant value o f 
resting FCO2 (i.e. the same value for each breath sample in both tests). It was 71 to 144 % 
with a median of 104 %, when PDR was calculated using non-resting FCO2 estimated 
from heart rate, suggesting that PAL and therefore FCO2 was not identical during both 
tests. In some healthy subjects use of heart-rate monitors brought the recovery closer to 
the expected value of almost 100 %, but not all. Four healthy subjects (two young adults 
and two children) had very high recovery after applying the acetate correction. This occurs 
when there is much lower recovery of following ingestion of [l-^^C]acetate than 
[^^CjMTG. Three healthy children showed low values after applying the acetate 
correction, indicating that the recovery during the acetate breath test was higher than the 
MTG test. These differences could be explained by differences in nutritional status on the 
day of the test causing a change in the balance between oxidation and lipogenesis. De 
novo lipogenesis can be fairly important on a high carbohydrate diet and might vary fiom 
one individual to another, depending on their dietary profile.
In hpogenic states, some acetate may be incorporated into newly synthesised fatty acids 
(Hellerstein et al. 1991). Thus, some label may be lost before the possible exchange with 
TCA cycle intermediates and/or bicarbonate. Under these circumstances the acetate 
correction factor overestimates substrate oxidation, because de novo lipogenesis occurs in 
the cytosol of the hepatocyte and oxidation of exogenous acetate occurs in tissues other 
than the liver (Gurr et al. 2002). The extent of overestimation depends on the rate of de 
novo fatty acid synthesis (Mittendorfer et al. 1998). In addition, under conditions of 
negative energy balance, the opposite may be true. Acetate is released from the test meal 
under the acid conditions of the stomach (Section 3.4.3), and is rapidly absorbed and 
available for oxidation in tissues other than the liver. MTG has to reach the small intestine 
for digestion by pancreatic lipase before the labelled octanoate can be absorbed. The 
labelled molecule has to enter the mitochondrion for (3-oxidation prior to release of the 
label during the TCA cycle. Therefore, the acetate correction, in the context of ‘^ C-breath 
tests, depends on the nutritional status of the individual, as well as physical activity during 
the test, being the same on each test day. This is hard to control in free-living subjects.
Use o f acetate correction factors is not recommended, as it requires two breath tests on 
separate occasions and the assumptions that FCO2 is the same on each occasion, and that 
both tracers are metabolised in an identical manner may not valid. Ideally, the tracer used
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to correct for sequestration within the body, should be administered simultaneously with 
[^^C]MTG and be subject to the same metabolic processes following absorption. Use of 
[l-^'^Cjoctanoate, sodium salt, with [^^C]MTG would be better than [l-^^C]acetate, but this 
option is not available in children for ethical reasons, because of the radiation hazard 
involved with the use of and the taste of octanoate would be unacceptable to children. 
From the point of view of minimising radiation dose, it would be better to use 
[1-^^Cjoctanoate and [^"^CJMTG, as less radioactivity would be absorbed in the target 
population with pancreatic disease and most of the tracer would be excreted in stool, but 
this would also introduce palatability problems.
The radioactivity in breath-C02 resulting from the oxidation of ^"^C-labelled tracers can be 
measured by liquid scintillation counting after trapping in hyamine hydroxide containing 
an indicator (Ozker et al. 1977). Maes et al. (1996) used simultaneous doses of 
[l-^^C]octanoate and [^"^CjMTGto correct the rate of intraluminal lipolysis for differences 
in gastric emptying rate in adults, but they did not calculate percentage dose recovered for 
either tracer. This approach might be acceptable in adult pancreatitis patients, but not in 
children with cystic fibrosis.
4.7,2 Comparison of MTG, octanoate and acetate metabolism
Deuterium labelled tracers showed that recovery of label following ingestion of 
[^Hsjacetate was lower than [^HisjMTG, which was similar to [^Hisjoctanoate. This 
suggests that MTG is handled in the same way as octanoate once the long chain fatty acids 
at the sn-\ and sn3 positions o f MTG have been hydrolysed by pancreatic enzymes, but the 
assumption that octanoic acid is metabolised in an identical manner to exogenous acetate 
may be false.
In the discussion that follows, it is necessary to distinguish between exogenous acetate, 
which is acetate derived from the diet or from fermentation of carbohydrates in the colon, 
and endogenous acetate, which is acetate derived intracellularly from intermediary 
metabolism.
Neither exogenous acetate nor octanoate are esterified into triacylglycerol within 
enterocytes during absorption, because the specific acyl-CoA synthetases required for their 
activation are not present (Frayn, 1996). Activation is necessary before any further 
metabolism can take place. Therefore exogenous acetate is carried to the liver, where
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acetyl-CoA synthetase (EC 6.2.1.1) is present in the cytosol. Pouteau et al. (1996) found 
that 60 % (range 42 to 79 %) of an intragastric infusion (lasting three hours) of 
[1-^^C]acetate was removed from the circulation during first-pass metabolism in the 
splanchnic bed of healthy human volunteers in the post absorptive state. Approximately 
70 % of the tracer dose was oxidised. Recovery was less in the current study; the median 
(range) recovery of in breath CO2 in six hours was 36 % (15 to 42 %) in adults and 
41 % (33 to 64 %) in children. This is probably because the tests were performed in the 
fed state and therefore more tracer would be directed towards lipogenesis than oxidation.
Acetate is activated by acetyl-CoA synthetase (EC 6.2.1.1). A cytosolic acetyl-CoA 
synthetase is present in the cytosol of some tissues, including the liver, where it functions 
by activating acetate for fatty acid synthesis (Section 1.3.6.1). Carnitine acetyl-transferase 
(CAT) catalyses the interconversion between acetyl-CoA and acetylcarnitine. In rat liver, 
CAT is found in the lumen of mitochondria and peroxisomes, but is absent from the 
cytosol or cytosol-facing membranes and is therefore not available to cytosolic acetyl-CoA 
(Zammit, 1999a). The absence of a cytosolic (or cytosol-facing) CAT in the liver and 
acetyl-CoA synthetase in liver mitochondria, allows acetate to be transported fiom this 
tissue and to be activated and oxidised in the mitochondria o f other tissues (Gurr et al. 
2002). Therefore the main site of exogenous acetate oxidation is not the liver. Breath 
^^ C0 2  following ingestion of [1-^^C]acetate arises from oxidation of the substrate in tissues 
other than the liver, such as skeletal muscle. In the liver, the likely fate of exogenous 
acetate is incorporation into long-chain fatty acids by de novo lipogenesis, but chain 
elongation in the smooth endoplasmic reticulum is also possible.
In contrast, octanoic acid is activated in the mitochondrial matrix (Zammit, 1984) prior to 
p-oxidation, therefore octanoic acid cannot take part in Hpogenic reactions in the cytosol. 
Oral doses of [l-^^C]octanoate are rapidly oxidised to [l-^^C]acetyl-CoA at the first pass 
through the mitochondrial p-oxidation pathway (Section 1.3.5.4), mainly in the hepatocyte. 
[l-^^C]acetyl-CoA reacts with oxaloacetate to form citrate in the TCA cycle (Section 
1.3.5.5). The label may eventually appear in breath CO2, or be sequestered into organic 
compounds by the biosynthetic pathways and anaplerotic reactions shown in Figure 1.11. 
Under conditions of high rates of fatty acid oxidation, the production of [l-^^C]acetyl~CoA 
can exceed the capacity of the TCA cycle and the excess is converted by CAT to 
[1-^^C]acetylcarnitine, which must be exported from the hepatocyte or cross the 
endoplasmic reticular or peroxisomal membranes, for activation to [ l- ’^C]acetyl-CoA prior 
to further metabolism (Section 1.3.5.5). The fact that elevated acetylcarnitine
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concentrations are observed in plasma under these conditions, whereas cytosolic CoA 
content remains sufficiently high to enable continued activation of fatty acids, suggests that 
very little metabolism of the acetyl units exported from the mitochondria occurs prior to its 
release from the cell (Zammit, 1999a). Under these conditions endogenous acetate can be 
metabolised in tissues other than the liver, such as skeletal muscle.
Pakula et al. (1997) studied the incorporation of [l-^"^C]acetate and [l-^"^C]octanoate into 
cellular lipids by HepG-2 cells. They found that the radioactivity was recovered mainly in 
phospholipids, rather than triacylglycerol, and was recovered exclusively in long-chain 
fatty acids. There would be additional fates in vivo. Indeed, Carnielli et al. (1994) found 
12 % dietary octanoate in plasma triacylglycerol in premature infants fed a formula 
containing medium-chain triacylglycerol, suggesting that most of the octanoic acid was 
absorbed via the hepatic route. Label was also recovered in long-chain fatty acids (C14:0, 
C16:0, C18:0 and C18:l) from plasma triacylglycerol, although only C14:0 (5.3 ± 2.8 %) 
and C16:0 (9.1 ± 4,8 %) could be quantified due to incomplete chromatographic separation 
of Cl 8:0 and C l8:1. It is not possible to determine the location of the label within the 
molecule, when enrichment is measured by GC-combustion-IRMS.
Under the conditions o f a [^^C]MTG breath test i.e. mainly resting and with food intake, 
label from both [l-^^C]acetate and [l~^^C]octanoate can be incorporated into long-chain 
fatty acids, but the rate will not be the same. De novo lipogenesis using exogenous sources 
of [l-^^C]acetate occurs in the cytosol of hepatocytes, whereas octanoate must undergo 
P-oxidation in the mitochondria (Figure 1.9). For the label to be incorporated into long- 
chain fatty acids, acetyl-CoA must be transferred from the mitochondria to the cytosol, but 
the mitochondrial membrane is not permeable to acetyl CoA, therefore acetyl groups cross 
the mitochondrial membrane in the form of citrate (Figure 1.12) or acetylcarnitine. Citrate 
is formed in the mitochondrial matrix by the condensation of acetyl-CoA with 
oxaloacetate. It can continue in the TCA cycle, but when present at high levels, citrate is 
transported to the cytosol, where it is cleaved by citrate lyase (EC 4.1.3.6) activity to 
regenerate acetyl-CoA and oxaloacetate (Stryer, 1988). The cytosolic acetyl-CoA can 
enter hpogenic pathways in the same way as exogenous acetate. Oxaloacetate is recycled 
via pymvate.
Label from [l-^^C]octanoate can be incorporated into monounsaturated long-chain fatty 
acids after mitochondrial P-oxidation of the label from octanoic acid. There is a fatty acid 
chain elongation system in the mitochondria of mammalian liver, which occurs by the
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addition of 2C units from acetyl-CoA to monoenoic acyl-CoAs (Gurr et al. 2002), but this 
is a minor route of endogenous fatty acid synthesis, as the products are 20;l(n~9), 22:l(n-9) 
and 24:l(n-9), which are not major components of body tissues (Montgomery et al. 2003). 
The more likely metabolic fate of the tracer is incorporation into amino acids via the TCA 
cycle or export from the mitochondrion and incorporation into long chain fatty acids via de 
novo lipogenesis in the cytosol followed by chain elongation in the endoplasmic reticulum.
4.8 The deuterium-labelled MTG test
The deuterium labelled MTG test could be a useful test of exocrine pancreatic 
insufficiency in its own right. Sequestration of deuterium into organic compounds is low 
compared to ^^ C (Figures 4.1 and 4.2) and the test is not affected by physical activity and 
food intake, both of which give rise to uncertainty about the volume of distribution of the 
tracer in ^^ C breath tests.
The protocol adopted here was more complex than necessary for a routine test. Firstly, as 
[^^C]MTG and [^H]MTG were being used simultaneously and it was also desirable to 
measure TBW, the H2^^0 dose was given after the breath test was completed in order 
to avoid interference during ^^C02 analysis. Far more saliva samples were taken than 
strictly necessary so that the absorption kinetics could be compared with those of free 
octanoic acid and acetic acid. TBW was deliberately measured over a much longer period 
than necessary. The plateau formed in saliva after 4-8 h and in urine after 6-10 h would be 
sufficient.
The rate of excretion of tracer in saliva was faster than breath following ingestion of 
[^H]MTG and [^^C]MTG (Figure 3.28). The same was observed following ingestion of 
[l-^^C]octanoate and [^Hi^joctanoate. The appearance of in urine was slower than in 
saliva, as expected. If [^H]MTG were to be used as a routine test, an 8 h urine or saliva 
collection period would suffice, as the enrichment of both had reached a plateau by this 
time, and in children the equilibration time is faster than in adults due to their smaller body 
size and faster water turnover. Hourly saliva collections would be sufficient or aliquots of 
each urine sample passed for 6 to 8 h. It is only necessary to save 10 to 20 ml for analysis. 
Urine collections have the advantage that there is a large excess of sample over that 
required for analysis, allowing repeat analysis as necessary. They are also less prone to 
evaporative loss, which will cause isotope fractionation. It is difficult to collect more than 
1 ml saliva at any time point, and subjects must not drink within half an hour of sampling,
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therefore any food or fluid intake must be taken immediately after sampling saliva, which 
is particularly difficult to achieve in children. For these reasons, urine sampling is 
preferred over saliva sampling of the body water pool. The minimum number of samples 
required is one baseline sample and one post-dose sample 6 to l2  h later.
The calculated PDR for both and labelled tracers depends on the accuracy of the 
measured, or predicted, volume of distribution of the tracer. The volume of distribution of 
is total body water (TBW) and o f is endogenous production of CO2 from metabolic 
processes. Measuring TBW during tests by dilution routinely would be impractical 
because of the scarcity and expense o f H2 ^ ^ 0  (~£6,000 per litre for 10% enriched H2 ^^ 0 , 
which is -£200 per measurement for an adult subject, less for a child, but availability is 
unpredictable at the current time), although no additional samples would be required. 
Total body water could be assumed to be a fixed percentage of body weight (ICRP, 1975), 
but this would introduce large errors in lean or overweight adults, and in children. 
Prediction from height and weight (Hume & Weyers, 1971) is a possibility in adults. 
Alternatively, TBW can be estimated from bioelectrical impedance measurements (Hannan 
et al, 1994), but equations to calculate TBW from impedance need to be established for 
each group of subjects. They have not been properly validated in children (Reilly et a l 
1996; Parker et al. 2003).
Slater & Preston (2002) found that TBW could be estimated from height^ with reasonable 
accuracy in a wide variety of subjects (135 males and 126 females), aged from 3 to 87 y. 
Subjects included healthy adults, wasted cancer patients, obese adults, children with HIV 
and healthy children. The mean bias compared to TBW measured by isotope dilution was
0.5 kg (95 % Cl 0.1 to 1.0 kg) and was less than other methods applied in this wide range 
of subjects as shown in Table 4.3.
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Figure 4.1 Summary of loss processes of H during the [^H]MTG test
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Figure 4.2 Summary of loss processes of during the [^^CJMTG breath test
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Table 4.3 Comparison of TBW prediction methods
TBW prediction method Mean difference (kg)* SEM 95% Cl
"T B W ^Y ixH t^  —  - ~0.22 0.11, 0^99
TBW = 0.55 X body weight -1.95 0.28 -2.51,-1.40
Hume & Weyers -1.20 0.26 -1.70,-0.69
BIA(n=108) -2.12 0.22 -2.55,-1.69
^Measured TBW minus predicted TBW for all 261 subjects, unless stated otherwise.
from Slater & Preston (2002)
Table 3,28 shows that the error introduced by using a predicted value of TBW is relatively 
small and therefore use of a predicted value of TBW might be good enough in the context 
of a non-invasive test of fat digestion (~5 % error), but the problem remains that [^H]MTG 
is not yet commercially available and ~10 times as much [^HJMTG is required to label 
body water, as [^^CjMTG to label the bicarbonate pool. However, only one baseline and a 
minimum of one, but preferably two or three post dose urine samples are required over a 
period of 8 tolO h in adults and 6 to 8 h in children. Therefore the test could be performed 
as part o f the routine annual assessment of children with cystic fibrosis to either assess the 
need for PERT or check that the current dose is adequate. The test could be performed 
overnight, if this was more practical. In this case, the test meal would be consumed in the 
evening and urine samples would be obtained at baseline and the following morning, as the 
plateau enrichment of body water is maintained for approximately 16 h.
The abundance of ^H in body water spaces has been measured using Fourier transform 
infrared spectrophotometry (Jennings et a l  1999), which is less expensive instrumentation 
than IRMS, but studies measuring deuterium dilution by this technique have used ten times 
the normal dose of ^ HgO to achieve sufficient analytical precision (Wells et a l  1999, Cisse 
et a l  2002). It would be prohibitively expensive to use doses o f [^HjMTG at this level, 
which would amount to approximately 50 g for a child weighing 30 kg.
The advantages and disadvantages o f the [^HJMTG test and [^^C]MTG test are compared 
in Figure 4.3, but the [^HjMTG test could be a simpler, more robust non-invasive test of fat 
digestion, if  the tracer were available at a reasonable cost. Both tests avoid the need for 
stool sampling, which is greatly disliked by patients and their parents.
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Advantages o f the [^^CJMTG breath test
1. Requires 10-15 times less tracer than the [^HJMTG test
2. No sample preparation prior to analysis
3. Continuous flow IRMS gives fast, accurate analysis in breath CO2
4. Relatively inexpensive in terms of tracer and analytical costs
Disadvantages o f the [^^C]MTG breath tests
1. The volume o f distribution of the tracer is subject to fluctuation due to physical 
activity and postprandial thermogenesis
Advantages o f the [^H]MTG test
1. Only one pre-dose and one post-dose sample of urine taken between 6 and 16 h 
post-dose are necessary to calculate PDR
2. Total body water can be estimated from height
Disadvantages o f the [^HJMTG test
1, Tracer cost is very high, although ^H20 is relatively inexpensive, therefore the 
cost of [^HjMTG per gram could be cheaper than [^^CjMTG. Lower tracer 
dosage would be possible but may result in greater analytical cost.
Figure 4.3 Comparison of [*^ C] and f^HJMTG tests
An ideal pancreatic function test would be inexpensive, easily performed, repeatable and 
reliable (Couper et a l  2002). It should be specific for pancreatic disease and able to define 
the exact level of pancreatic function in subjects with pancreatic insufficiency in whom 
partial impairment of exocrine ftmction is present, but nutrient assimilation is unaffected. 
There should be no interference from pancreatic enzyme supplements. Unfortunately, the 
ideal test does not exist, but the [^HjMTG test may come close.
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Chapter 5 Conclusions
• Use of individually calibrated heart rate monitors to estimate VCO2 during the 
[^^C]MTG test increased the positive predictive value of the test from 0.71 using 
resting VCO2 to 1.0 using non-resting FCO2 estimated from heart rate.
9  Individually calibrated heart rate monitors can be used to estimate the physical activity
level during tests that are performed under realistic conditions, which did not require 
children to sit absolutely still for six hours and include a second meal during the test.
• Individually calibrated heart rate monitors are a useful tool to determine the reference 
range of cumulative excretion in healthy children during the [^^C]MTG breath test.
• The cumulative excretion of in the breath o f children with cystic fibrosis can be 
corrected for non-resting CO2 production rate once the physical activity level during 
the test has been determined. There was no loss of specificity when this approach was 
adopted using [^^C]MTG breath test data from children with cystic fibrosis (n = 45), 
who took part in a previous study in the same clinical setting.
» Use of an acetate correction factor to account for tracer sequestered in the body during
[^^CJMTG breath tests is not recommended as it requires two breath tests on separate 
occasions, and the assumptions that VCO2 is the same on each occasion and both 
tracers are metabolised in an identical manner following absorption may not be valid.
« The [^H]MTG test may provide a simpler, more robust non-invasive test of fat
digestion, if supplies of this novel stable isotope labelled tracer are secured. The test 
could be performed during the annual assessment of children with cystic fibrosis, as the 
results are not affected by physical activity or food intake during the test.
® A major advantage of both MTG tests of fat digestion, and therefore indirectly of
exocrine pancreatic function, is the avoidance of stool sampling, which is necessary for 
the other commonly used tests i.e. faecal elastase test and fat balance measurements.
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Chapter 6 Recommendations for further work
6.1 Clinical validation studies
A clinical validation study comparing simultaneous [^^CjMTG and [^H]MTG tests with the 
best currently available non-invasive test of exocrine pancreatic function in children with 
cystic fibrosis, i.e. the faecal elastase-1 test (Loser et a l 1998; Nousia-Arvanitakis, 2003) 
is recommended.
Use of recently introduced “intelligent” electronic motion sensors that can monitor low 
levels of activity, but do not require calibration should be investigated. These could be 
used to estimate the physical activity level around the time of each breath sample, so that 
the recovery in the [^^C] test can be adjusted for non-resting conditions as necessary.
The sensitivity and specificity of the faecal elastase test should be compared with the new 
[^^C]MTG test that includes a compliance test for physical activity during the MTG test 
and a second meal to avoid problems associated with falling background abundance 
in fasted subjects.
The sensitivity and specificity of the faecal elastase test should be compared with that of 
the pHJMTGtest.
A clinical validation study of the improved [’^C]MTG test versus the [^HJMTG test and 
faecal elastase test should be carried out in adults with pancreatic disease, who display a 
wider range of pancreatic insufficiency than children with cystic fibrosis.
6.2 Macronutrient metabolism
6.2.1 Lipid metabolism
[l-^^C]acetate has been used in an analogous way to that described in this thesis to provide 
acetate correction factors in studies of lipid metabolism (Sidossis, 1995a). Mass 
isotopomer distribution analysis (MIDA) is a technique for studying the biosynthesis and 
turnover of macronutrients in vivo (Hellerstein & Neese, 1992; 1999). The method has 
potential for measuring fatty acid and cholesterol metabolism (Hellerstein, 1995) and has 
been used to measure de novo lipogenesis and re-esterification of fatty acids (Hellerstein et
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a l  1993), but large quantities o f very expensive tracers are required. Recently, a method 
was introduced using a very inexpensive tracer (^HzO) to measure triglyceride synthesis 
and turnover in vivo (Turner et al. 2003). Methods utilising [l,2-^^C]acetate or 
acetate and MIDA may have potential for studying the effect of exogenous acetate 
production on lipid metabolism in vivo, and hence investigation of mechanisms of 
prevention o f coronary heart disease.
6.2.2 Protein metabolism
Some of the current problems o f protein metabolism concern the quantitation of the 
breakdown rate of key proteins, particularly in inflammatory disease (Preston et al, 1998). 
[l-^^C]acetate can be used as an intrinsic tracer delivering labelled carbon atoms to 
aspartate and glutamate through TCA cycle intermediates. Because these labels are either 
rapidly exchanged or incorporated into protein, they can potentially be used to measure 
protein degradation (Millward, 1970).
6.2.3 Carbohydrate metabolism
Acetate is as important an intermediate in carbohydrate metabolism as it is in lipid 
metabolism. Oral doses of [^^CJacetate can be used to measure total acetate production in 
studies of colonic fermentation of carbohydrate. Carbohydrates that are not digested by 
small intestinal enzymes reach the colon, where they are substrates for fermentation by the 
colonic microflora. The products of carbohydrate fermentation are short-chain fatty acids, 
principally acetate, propionate and butyrate. Intravenous administration of labelled acetate 
will underestimate total acetate production, because no account is taken of endogenous 
acetate removed during first pass metabolism in the splanchnic bed. For instance, Wolever 
et al. (1995) found significantly more ^^ C in seium lipids after rectal than intravenous 
adminstration of [l,2-^^C]acetate.
The potential health benefits of foods containing slowly digestible and resistant starch, and 
the effect of food processing on the digestion and metabolism of starchy foods is an area of 
active research interest e.g. the EU Eurostarch project (www.eurostarch.org), “Stable 
isotope applications to monitor starch digestion and fermentation for the development of 
functional foods”. Consumption o f plant-based cereal foods containing slowly digestible 
and resistant starch could be beneficial in the prevention of colon cancer and the 
prevention and treatment of obesity and type 2 diabetes, which are major issues of public
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health concern. Chronic diseases such as the metabolic syndrome and cancer have been 
attributed to the “Western Lifestyle” with lack of physical activity and a diet containing too 
much fat and refined carbohydrates.
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Validatiou study of the mixed triglyceride breath test for assessing fat digestion 
Information sheet for parents and volunteers
Children get most o f their energy from fat and sugar in their diet. However, we know very little about 
how they digest these nutrients and what happens after they have been absorbed. One way of finding 
out is to label the fat and then measure how well it is digested and absorbed, by collecting samples of 
children’s breath before and after a meal.
We are therefore inviting your child to take part in a research project which will give us information 
about children’s digestion, 1If your child decides to take part, wc will ask you to bring your him or her to the hospital on two >
occasions, in the morning having missed breakfast. I f  you prefer we can do (he test in your own home;
whichever is the most convenient to you. We will put a heart rate monitor on your child. This consists
of a strap, which is worn around the chest and a wrist watch which collects the data. We will ask your
child to blow through a straw into a glass tube to give us a sample of their breath. Your child will tlren
be asked to eat a biscuit made from oats, butter and honey and containing a small amount of fat j
labelled with carbon-13. This is a non-radioactive, natnially occuring element. The fat is a normal part
of our everyday food. There are therefore no side effects associated with eating this biscuit. ;
The carbon-13 will gradually appear in your child’s breath over the next few hours and we will collect 
breath samples by asking him or her to blow through a straw into a tube at inteivals. After the first 3
hours, we will measure how much carbon dioxide your child is breathing out using a special hood .
connected to a 'calorimeter'. This takes about 15 minutes. Your child will then be able to have a meal '
made of his or her usual foods, but avoiding sweets, sugary drinks and foods containing com. We will 
continue to collect breath samples for 6 hours on the first occasion and 10 hours on the second
occasion. You will be free to go home after 6 hours, but we would ask you to collect breath samples in I
the tubes provided until bed time.
ÎOn the first occasion, we will measure the carbon dioxide produced in your child’s breath when he or
she is lying on a bed or sofa, when they arc sitting up and while they are dancing to some music. This j
will not take longer than 30 minutes. We do this because heart rate is related to oxygen consumption 
and carbon dioxide production, and we hope that in the future we will be able to use the heart rate 
monitors alone to estimate carbon dioxide production.
tft is up to you and your cliild to decide whether or not to take prut. If  yotrr child decides to take part, 
you will both be asked to sign a consent form and will be given copies o f the consent form and this 
sheet to keep. If  your child decides to lake pari he or she is free to withdraw at any time and without 
giving a reason. This will not affect the standard o f care your child receives. We have done hundreds 
o f breath tests on children. Breath tests are used to diagnose a number o f  childhood diseases, and they j-
iue absolutely safe and painless. All infonnation obtained during the study will be treated as 
confidential.
i:
If you have any questions about the project please do not hesitate to contact Christine Slater on 
0141-201-0502.
Thank you for reading this.
Christine Slater Dr Tom Preston Prof Lawrence Weaver
Senior Research Assistant Senior Lecturer Consultant Paediatrician
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V a lid a tio n  s tu d y  o f  t h e  m ix e d  t r ig ly c e r id e  b r e a th  t e s t  f o r  a s s e s s i n g  f a t  d ig e s t io n  
In fo rm a tio n  s h e e t  f o r  c h i ld r e n
W e  w ou ld  like y o u  to  h e lp  u s  to find o u t m ore  a b o u t h o w  you r fo o d  is  d ig e s te d  a fter  you  
h a v e  s w a llo w e d  it. W e  n e e d  to  k n ow  w h a t h a p p e n s  in h ea lth y  ch ild ren , s o  th a t w e  ca n  
h e lp  ch ild ren  w h o  a r e  ill.
Y ou  c a n  h e lp  u s  b y  c o m in g  to  th e  hosp ita l for  a  d a y , or  w e  c a n  c o m e  to  y o u r  h o u s e .
W e  will a s k  you  to  e a t  a  b iscu it m a d e  o f  o a ts ,  bu tter an d  h o n e y  a n d  th en  b lo w  into a  tu b e  
w h e n  w e  a sk . B low in g  into a  tu b e  is a  w a y  o f  co lle ct in g  th e  air th a t y o u  breath  out.
W e  will a ls o  a s k  y o u  to  w e a r  a  h eart-ra te  m onitor. T h is  is  a  b e lt th a t y o u  w e a r  round you r  
c h e s t ,  w h ich  c a n  h e a r  you r  h ea rt b e a tin g . W e  w ou ld  a ls o  like y o u  to w e a r  a  w a tc h  w h ich  
c o u n ts  you r  h e a r t-b e a ts . T h is d o e s  n o t hurt in a n y  w a y  an d  you  will b e  a s k e d  to  k e e p  it on  
all day .
Y ou  will n o t b e  a llo w e d  to  run a rou n d , but y o u  c a n  w a tch  TV, p lay  c o m p u te r  g a m e s ,  read  
b o o k s  o r  p lay  b oard  g a m e s .  W e  will s tu d y  2  ch ild ren  e a c h  tim e, s o  y o u  will h a v e  a  friend  
to  p la y  with.
A fter a  fe w  h o u rs  w e  will a s k  y o u  to  lie  o n  a  b ed  an d  b rea th  into a  s p e c ia l  m a c h in e . Y ou  
h a v e  to  lie  still for a b o u t 1 0  m in u te s , if y o u  c a n  k e e p  still for th a t lo n g . It d o e s  n o t m atter  if 
y ou  m o v e  a b o u t a  little bit. W e  will a ls o  a sk  y o u  to  sta n d  up  an d  th en  ju m p  up an d  d o w n  
w h ile  w e  m e a s u r e  y o u  b rea th in g , i h a v e  s o m e  p h o to g r a p h s  o f  m e  lying o n  a  b ed  an d  
riding a n  e x e r c is e  b ik e. If y o u  w a n t, w e  cou ld  ta k e  a  p h o to  for y o u  to  s h o w  y o u r  fr iends.
N o n e  o f  th is  hurts in a n y  w a y , but if you  a re  u n h a p p y  w e  c a n  s to p  a t  a n y  tim e.
T h an k  y o u  for rea d in g  th is.
C h ristin e S la ter  Dr P r e sto n  P r o fe s s o r  W e a v e r
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UNIVERSITY
C o n s e n t  fo rm  of
GLASGOW
V a lid a tio n  s tu d y  o f  th e  m ix e d  t r ig iy c e r id e  b r e a th  t e s t  f o r  a s s e s s i n g  f a t  d ig e s t io n
I h a v e  read  an d  u n d e rs ta n d  th e  Inform ation s h e e t  c o n c er n in g  th e  a b o v e  s tu d y . I g iv e  
p e r m iss io n  for m y child n a m e d  b e lo w  to  ta k e  part in th is  stu d y .
I u n d ersta n d  th at ou r  participation  is vo lun tary  an d  th at w e  are  fr e e  to  w ith draw  a t a n y  
tim e, w ith ou t g iv in g  a n y  r e a s o n , w ith ou t m y ch ild ’s  m ed ica l c a r e  or  le g a l rights b e in g  
a ffe c te d .
N a m e  o f  Child  .................................................................................................................................
D a te  o f  B ir th ..........................................................
S ig n a tu re  o f  C h i ld ..............................................................................................................D a te
N a m e  o f  P aren t/G u ard ian  
A d d r e s s ......................................
T e le p h o n e  n u m b e r .....................................................................................................................
S ig n a tu r e  o f  P a r e n t /G u a r d ia n ................................................................................ D a te
N a m e  o f  R e s e a r c h e r ...............................................................................................................
S ig n a tu r e  o f  R e s e a r c h e r .............................................................................................D a te
N a m e  o f  W i t n e s s ........................................................................................................................
S ig n a tu re  o f  W i t n e s s ....................................................................................................D a te
DEIWRTMKNT OF CHILD HEALTH 
Royal Hospital fni Sit;k Children, Yorkhill, Glasgow G3 8Sf 
Samson Gemviell Chair of Child Hmlik: Professor L T Weaver 
Leonard Goiv Lecturer.-Dr T f , Turner 
.S>N(Vii /.rcturrrj. Dr ;V1 D C Donaldson, Dr M U Drummond, Di ] V Palon, Dr D H Slone. Dr D M Tappiii 
-Jèhphone:i)W-'H)\ 0(100 (Hospital) 0141-201 0337
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Appendix 2 HR calibration summary tables
Comparison of measured KCO2 normalised to body surface area (mmol.min '.m ’^ ) with 
FCO2 predicted from heart rate (HR) using the model stated. The first eight rows are 
individual calibrations for that subject. Generic relates to the effect of predicting FCO2 
from HR by applying a generic calibration, which was obtained by combining data from all 
24 subjects and fitting a sigmoid model. The Tables also show data normalised to height^ 
(mmol.min'^m"^) using individual and generic calibrations. The mean, standard error and 
95% confidence interval for data normalised to height^ cannot be directly compared with 
data normalised to body surface area as the units are different, but they can be compared 
between subjects.
N = number of data points in calibration curve
Mean = mean difference between measured and predicted VCO2 i.e. bias of the model
Best model has mean = 0
SEM = standard error on the mean
95 % Cl = 95 % confidence interval for mean difference
P probability that there is no difference between measured and predicted FCO2 using a 1- 
sample T-Test
BMI = Body mass index (weight (kg)/ height (m)^)
BMI SDS = BMI Standard deviation score from British Growth Reference Charts (Child 
Growth Foundation 96)
FCO2 was predicted from FO2 assuming a RQ of 0.85. VO2 was normalised to body 
surface area and predicted from HR using a sigmoid model.
All generic predictions used a sigmoid model.
Surface area (m^) = weight (kg)"'^^^  ^x height (cm)®'^ ^^ '^  x 0.024265 (Haycock, 1978)
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Subject: Adult 1, female, age 46 y, height 158.8 cm, weight 57.6 kg, BMI 22.8
Model N Mean SEM 95 % Cl P
Linear-Hex (sa) 75 0.00 0.22 -0.43, 0.44 0.99
Steady state (sa) 75 0.54 0.27 0.01, 1.07 0.05
3*^  ^order polynomial, raw HR (sa) 75 -0.00 0.17 -0.34, 0.34 1.00
3"^  ^order polynomial, sm HR* (sa) 75 0.00 0.17 -0.34, 0.34 1.00
Logistic, sm HR* (sa) 75 0.00 0.17 -0.34, 0.34 1.00
Sigmoid, raw HR (sa) 75 -0.00 0.17 -0.33, 0.33 1.00
Sigmoid, sm HR* (sa) 75 -0.00 0.17 -0.34, 0.34 1.00
FCO2 predicted from FO2 (sa) 75 0.82 0.19 0.44, 1.19 <0.001
Generic surface area 75 -0.05 0.22 -0.49, 0.40 0.83
Generic surface area and age 75 -1.53 0.31 -2.15, -0.92 <0.001
Sigmoid, sm HR* (height^) 75 0.00 0.07 -0.13, 0.14 1.00
Generic height^ 75 0.03 0.08 -0.14, 0.19 0.76
Generic height^ and age 75 -0.26 0.08 -0.43, -0.10 0.002
(sa) = FCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: Adult 2, male, age 47 y, height 182.9 cm, weight 74.2 kg, BMI 22.2
Model N Mean SEM 95 % Cl F
Linear-Hex (sa) 68 -1.31 0.53 -2.34, -0.25 0.02
Steady state (sa) 68 -0.66 0.68 -2.02, 0.71 0.34
3^^^  order polynomial, raw HR (sa) 68 -0.00 0.43 -0.85, 0.85 1.00
3*^^^ order polynomial, sm HR* (sa) 68 -0.00 0.37 -0.74, 0.74 1.00
Logistic, sm HR* (sa) 68 -0.00 0.36 -0.72, 0.72 1.00
Sigmoid, raw HR (sa) 68 -0.00 0.42 -0.84, 0.84 1.00
Sigmoid, sm HR* (sa) 68 -0.00 0.36 -0.72, 0.72 1.00
FCO2 predicted from FO2 (sa) 68 1.01 0.46 0.10, 1.92 0.03
Generic surface area 68 2.86 0.64 1.56, 4.14 <0.001
Generic surface area and age 68 1.74 0.48 0.78, 2.71 <0.001
Sigmoid, sm HR* (height^) 68 0.00 0.12 -0.23, 0.23 1.00
Generic height^ 68 0.41 0.17 0.06, 0.76 0.02
Generic height^ and age 68 0.18 0.18 -1.18, 0.54 0.31
(sa) = FCO2 normalised to body surface area, predicted from height and weight
* sm HR = heart rate smoothed 2 points forward
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Subject: Adult 3, male, age 21 y, height 187.0 cm, weight 81.7 kg, BMI 23.4
Model Mean SEM 95 % Cl P
Linear-Hex (sa) 77 0.61 0.25 0.11, 1.15 0.02
Steady state (sa) 77 0.59 0.58 -0.56, 1.73 0.31
order polynomial, raw HR (sa) 77 -0.00 0.24 -0.49, 0.49 1.00
3^  ^order polynomial, sm HR* (sa) 77 -0.00 0.26 -0.52, 0.52 1.00
Logistic, sm HR* (sa) 77 0.00 0.25 -0.50, 0,50 1.00
Sigmoid, raw HR (sa) 77 0.00 0.24 -0.48, 0.48 1.00
Sigmoid, sm HR* (sa) 77 -0.00 0.25 -0.50, 0.50 1.00
KCO2 predicted from VO2 (sa) 77 0.96 0.26 0.43, 1.48 <0.001
Generic surface area 77 0.13 0.31 -0.48, 0.74 0.67
Generic surface area and age 77 0.20 0.26 -0.32, 0.73 0.44
Sigmoid, sm HR* (height^) 77 -0.00 0.08 -0.16, 0.16 1.00
Generic height^ 77 -0.59 0.08 -0.75, -0.42 <0.001
Generic height^ and age 77 -0.48 0.08 -0.64, 0.31 <0.001
(sa) = KCO2 normalised to body surface area. predicted from height and weight
* sm HR = heart rate smoothed 2 points forward
Subject: Adult 4, female, age 22 y, height 162.9 cm, weight 67.0 kg, BMI 25.2 
Model N Mean SEM 95 % Cl
Linear-Hex (sa) 65 -0.30 0.24 -0.77, 0.17 0.21
Steady state (sa) 65 -0.49 0.25 -1.00, 0.02 0.06
3"^  order polynomial, raw HR (sa) 65 -0.00 0.21 -0.42, 0.42 1.00
3'^ order polynomial, sm HR* (sa) 65 -0.00 0.21 -0.42, 0.42 1.00
Logistic, sm HR* (sa) 65 0.00 0.20 -0.40, 0.40 1.00
Sigmoid, raw HR (sa) 65 0.00 0.21 -0.41, 0.41 1.00
Sigmoid, sm HR* (sa) 65 0.00 0.20 -0.40, 0.40 1.00
VCO2 predicted from VO2 (sa) 65 0.92 0.24 0.43, 1.41 <0.001
Generic surface area 65 -1.15 0.23 -1.62, -0.69 <0.001
Generic surface area and age 65 -1.42 0.23 -1.87, -0.97 <0.001
Sigmoid, sm HR* (height^) 65 0.00 0.08 -0.16, 0.16 1.00
Generic height^ 65 -0.37 0.09 -0.56, -0.19 <0.001
Generic height^ and age 65 -0.33 0.08 -0.49, -0.16 <0.001
(sa) = VCO2 normalised to body surface area. predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Adult 5, male, age 32 y, height 180.4 cm, weight 70.7 kg, BMI 21.7
Model N Mean SEM 95 % C l P
Linear-Hex (sa) 74 -1.27 0.24 -1.75, -0.79 <0.001
Steady state (sa) 74 -1.85 0.26 -2.37, -1.34 <0.001
3^  ^order polynomial, raw HR (sa) 74 0.00 0.22 -0.44, 0.44 1.00
3*^*^ order polynomial, sm HR* (sa) 74 -0.00 0.19 -0.38, 0.38 1.00
Logistic, sm HR* (sa) 74 -0.00 0.19 -0.38, 0.38 1.00
Sigmoid, raw HR (sa) 74 0.00 0.22 -0.44, 0.44 1.00
Sigmoid, sm HR* (sa) 74 -0.00 0.19 -0.38, 0.38 1.00
FCO2 predicted from VO2 (sa) 74 1.42 0.25 0.93, 1.91 <0.001
Generic surface area 74 0.75 0.30 0.15, 1.36 0.02
Generic surface area and age 74 0.21 0.23 -0.25, 0.67 0.37
Sigmoid, sm HR* (height^) 74 -0.00 0.06 -0.12, 0.12 0.99
Generic height^ 74 -0.33 0.07 -0.47, -0.19 <0.001
Generic height^ and age 74 -0.37 0.07 -0.51, -0.23 <0.001
(sa) = FCO2 normalised to body surface area. predicted from height and weight
sm HR = heart rate smoothed 2 points forward
Subject: Adult 6, male, age 26 y, height 182.2 cm, weight 68.7 kg, BMI 20.7 
Model N Mean SEM 95 % Cl
Linear-Hex (sa) 60 0.31 0.39 -0.47, 1.10 0.43
Steady state (sa) 60 -0.31 0.49 -1.28, 0.66 0.53
3"^  ^order polynomial, raw HR (sa) 60 -0.00 0.38 -0.77, 0.77 1.00
3'*'* order polynomial, sm HR* (sa) 60 -0.00 0.29 -0.58, 0.58 1.00
Logistic, sm HR* (sa) 60 0.00 0.29 -0.58, 0.58 1.00
Sigmoid, raw HR (sa) 60 0.00 0.38 -0.77, 0.77 1.00
Sigmoid, sm HR* (sa) 60 0.00 0.29 -0.58, 0.58 1.00
FCO2 predicted from FO2 (sa) 60 0.57 0.39 -0.21, 1.35 0.15
Generic surface area 60 0.17 0.34 -0.51, 0.85 0.61
Generic surface area and age 60 -0.04 0.30 -0.63, 0.55 0.90
Sigmoid, sm HR* (height^) 60 -0.00 0.09 -0.18, 0.18 1.00
Generic height^ 60 -0.51 0.09 -0.69, -0.33 <0.001
Generic height^ and age 60 -0.54 0.10 -0.74, -0.35 <0.001
(sa) = FCO2 normalised to body surface area, predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Adult 7, male, age 26 y, height 177.6 cm, weight 108.2 kg, BMI 34.3
Model N Mean SEM 95 % Cl P
Linear-flex (sa) 74 -0.81 0.30 -0.78, 0.41 0.55
Steady state (sa) 74 -0.98 0.27 -0.51,-0.44 <0.001
3*^  ^order polynomial, raw HR (sa) 74 -0.00 0.24 -0.48, 0.48 1.00
3"^"^ order polynomial, sm HR* (sa) 74 -0.00 0.23 -0.46, 0.46 1.00
Logistic, sm HR* (sa) 74 0.00 0.22 -0.44, 0.44 1.00
Sigmoid, raw HR (sa) 74 0.00 0.23 -0.47, 0.47 1.00
Sigmoid, sm HR* (sa) 74 -0.00 0.22 -0.44, 0.44 1.00
VCO2 predicted from FO2 (sa) 74 0.45 0.23 -0.02, 0.91 0.06
Generic surface area 74 -0.41 0.26 -0.93, 0.12 0.13
Generic surface area and age 74 -0.86 0.25 -1.36, -0.37 <0.001
Sigmoid, sm HR* (height^) 74 -0.00 0.10 -0.19, 0.19 1.00
Generic height^ 74 0.02 0.10 -0.19, 0.24 0.83
Generic height^ and age 74 0.04 0.10 -0.15, 0.24 0.66
(sa) = FCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: Adult 8, male, age 21 y, height 171.0 cm, weight 68.4 kg, BMI 23.4
Model N Mean SEM 95 % Cl
Linear-flex (sa) 66 -0.75 0.49 -1.73, 0.22 0.13
Steady state (sa) 66 1.32 0.82 -0.33, 2.96 0.11
3^  ^order polynomial, raw HR (sa) 66 -0.00 0.42 -0.84, 0.84 1.00
3^ "^  order polynomial, sm HR* (sa) 66 -0.00 0.37 -0.73, 0.73 1.00
Logistic, sm HR* (sa) 66 0.00 0.36 -0.72, 0.72 1.00
Sigmoid, raw HR (sa) 66 -0.00 0.42 -0.83, 0.83 1.00
Sigmoid, sm HR* (sa) 66 -0.00 0.36 -0.72, 0.72 1.00
FCO2 predicted from VO2 (sa) 66 0.34 0.43 -0.53, 1.20 0.44
Generic surface area 66 2.75 0.64 1.47, 4.04 <0.001
Generic surface area and age 66 3.05 0.64 1.79, 4.43 <0.001
Sigmoid, sm HR* (height^) 66 -0.00 0.13 -0.26, 0.26 1.00
Generic height^ 66 0.87 0.22 0.43, 1.31 <0.001
Generic height^ and age 66 0.94 0.23 0.48, 1.40 <0.001
(sa) FCO2 normalised to body surface
* sm HR = heart rate smoothed 2 points
area, predicted from height and weight 
forward
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Subject; Child 1, male, age 13.6 y, height 145.5 cm, weight 57.2 kg, BMI SDS 2.28
Model N Mean SEM 95 % Cl P
Linear-flex (sa) 30 0.48 0.62 -0.79, 1.749 0.45
Steady state (sa) 30 -0.50 0.78 -2.10, 1.09 0.52
order polynomial, raw HR (sa) 30 -0.00 0.46 -0.94, 0.94 1.00
3'^ order polynomial, sm HR* (sa) 30 0.00 0.39 -0.80, 0.80 1.00
Sigmoid, raw HR (sa) 30 0.00 0.49 -1.00, 1.00 1.00
Sigmoid, sm HR* (sa) 30 0.00 0.34 -0.69, 0.69 1.00
FCO2 predicted from VO2 (sa) 30 0.34 0.75 -1.20, 1.88 0.65
Generic surface area 30 0.53 0.46 -0.41, 1.47 0.26
Generic surface area and age 30 1.06 0.46 0.11, 2.01 0.03
Sigmoid, sm HR* (height^) 30 0.00 0.17 -0.34, 0.34 1.00
Generic height^ 30 1.04 0.20 0.63, 1.46 <0.001
Generic height^ and age 30 1.26 0.21 0.84, 1.69 <0.001
(sa) = VCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: Child 2, female, age 11.1 y, height 137.3 cm, weight 43.6 kg, BMI SDS 1.81
Model N Mean SEM 95 % Cl p
Linear-flex (sa) 27 -0.56 0.71 -2.03, 0.90 0.44
Steady state (sa) 27 -0.40 0.43 -1.29, 0.49 0.36
3"^  ^order polynomial, raw HR (sa) 27 0.00 0.29 -0.60, 0.60 1.00
3"^  ^order polynomial, sm HR* (sa) 27 -0.00 0.24 -0.48, 0.48 1.00
Sigmoid, raw HR (sa) 27 -0.00 0.32 -0.65, 0.65 1.00
Sigmoid, sm HR* (sa) 27 0.00 0.24 -0.49, 0.49 1.00
FCO2 predicted from VO2 (sa) 27 0.28 0.32 -0,38, 0.94 0.39
Generic surface area 27 -1.10 0.27 -1.65, -0.55 <0.001
Generic surface area and age 27 -0.52 0.33 -1.20, 0.16 0.13
Sigmoid, sm HR* (height^) 27 0.00 0.08 -0.16, 0.16 1.00
Generic height^ 27 0.22 0.13 -0.05, 0.48 0.11
Generic height^ and age 27 0.42 0.14 0.12, 0.72 0.007
(sa) = VCO2 normalised to body surface area, predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Child 3, male, age 9.0 y, height 123.4 cm, weight 35.1 kg, BMI SDS 2.54 
Model N Mean SEM 95%  C l
Linear-flex (sa) 29 -0.56 0.40 -1.39, 0.26 0.17
Steady state (sa) 29 -0.80 0.44 -1.69, 0.10 0.08
3"^*^ order polynomial, raw HR (sa) 29 -0.00 0.37 -0.75, 0.75 1.00
3^  ^order polynomial, sm HR* (sa) 29 -0.00 0.23 -0.47, 0.47 1.00
Sigmoid, raw HR (sa) 29 -0.00 0.37 -0.75, 0.75 1.00
Sigmoid, sm HR* (sa) 29 -0.00 0.23 -0.47, 0.47 1.00
FCO2 predicted from FO2 (sa) 29 0.35 0.42 -0.51, 1.21 0.41
Generic surface area 29 -3.21 0.23 -3.68, -2.74 <0.001
Generic surface area and age 29 -2.57 0.27 -3.12, -2.02 <0.001
Sigmoid, sm HR* (height^) 29 0.00 0.12 -0.26, 0.26 1.00
Generic height^ 29 0.16 0.16 -0.17, 0.49 0.31
Generic height^ and age 29 0.58 0.14 0.29, 0.87 <0.001
(sa) = FCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: Child 4, female, age 14.3 y, height 152.9 cm, weight 40.8 kg, BMI SDS -0.96
Model N Mean SEM 95 % Cl P
Linear-flex (sa) 33 -2.44 1.33 -5.15, 0.27 0.08
Steady state (sa) 33 -1.32 1.09 -3.54, 0.90 0.24
3*^^^ order polynomial, raw HR (sa) 33 0.00 0.73 -1.48, 1.48 1.00
3^  ^order polynomial, sm HR* (sa) 33 0.00 0.59 -1.21, 1.21 1.00
Sigmoid, raw HR (sa) 33 0.00 0.73 -1.49, 1.49 1.00
Sigmoid, sm HR* (sa) 33 0.00 0.61 -1.24, 1.24 1.00
FCO2 predicted from FO2 (sa) 33 2.48 0.82 0.81, 4.14 0.005
Generic surface area 33 4.47 0.80 2.85, 6.09 <0.001
Generic surface area and age 33 4.84 0.74 3.34, 6.36 <0.001
Sigmoid, sm HR* (height^) 33 0.00 0.22 -0.45, 0.45 1.00
Generic height^ 33 1.43 0.27 0.89, 1.98 <0.001
Generic height^ and age 33 1.59 0.27 1.04, 2.13 <0.001
(sa) = FCO2 noimalised to body surface area, predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Child 5, male, age 9.5 y, height 130.4 cm, weight 31.5 kg, BMI SDS 1.11
Model N Mean SEM 95 % Cl
Linear-flex (sa) 23 0.09 0.26 -0.44, 0.62 0.73
Steady state (sa) 23 -0.78 0.28 -1.36, -0.191 0.01
3*^  ^order polynomial, raw HR (sa) 23 0.00 0.24 -0.49, 0.49 1.00
3”^*^ order polynomial, sm HR* (sa) 23 0.00 0.26 -0.54, 0.54 1.00
Sigmoid, raw HR (sa) 23 0.00 0.24 -0.49, 0.49 1.00
Sigmoid, sm HR* (sa) 23 0.00 0.26 -0.54, 0.54 1.00
FCO2 predicted from FO2 (sa) 23 0.93 0.24 0.43, 1.42 <0.001
Generic surface area 23 -0.28 0.27 -0.84, 0.27 0.31
Generic surface area and age 23 0.51 0.28 -0.07, 1.10 0.08
Sigmoid, sm HR* (height^) 23 0.00 0.12 -0.26, 0.26 1.00
Generic height^ 23 0.62 0.13 0.29, 0.83 <0.001
Generic height^ and age 23 0.60 0.13 0.65, 1.17 <0.001
(sa) = FCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: Child 6, female, age 8.5 y, height 120.6 cm, weight 25.9 kg, BMI SDS 0.76
Model N Mean SEM 95 % C l p
Linear-flex (sa) 22 0.77 0.46 -0.19, 1.73 0.11
Steady state (sa) 22 -0.34 0.36 -1.09, 0.42 0.36
3^  ^order polynomial, raw HR (sa) 22 -0.00 0.33 -0.68, 0.68 1.00
3^^^  order polynomial, sm HR* (sa) 22 0.00 0.30 -0.61, 0.62 1.00
Sigmoid, raw HR (sa) 22 -0.00 0.33 -0.68, 0.68 1.00
Sigmoid, sm HR* (sa) 22 0.00 0.30 -0.62, 0.62 1.00
FCO2 predicted from FO2 (sa) 22 0.59 1.01 -1.51, 2.69 0.56
Generic surface area 22 1.02 0.38 0.24, 1.80 0.01
Generic surface area and age 22 1.59 0.35 0.87, 2.31 <0.001
Sigmoid, sm HR* (height^) 22 0.00 0.16 -0.33, 0.33 1.00
Generic height^ 22 1.75 0.26 1.21, 2.87 <0.001
Generic height^ and age 22 2.04 0.26 1.51, 2.58 <0.001
(sa) = FCO2 normalised to body surface area. predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Child 7, female, age 5.5 y, height 108.4 cm, weight 20.2 kg, BMI SDS 1.03
Model N Mean SEM 95 % Cl
Linear-flex (sa) 29 0.59 0.31 -0.04, 1.22 0.07
Steady state (sa) 29 -0.47 0.37 -1.22, 0.28 0.21
3^  ^order polynomial, raw HR (sa) 29 0.00 0.23 -0.48, 0.48 1.00
3*'^  order polynomial, sm HR* (sa) 29 -0.00 0.16 -0.32, 0.32 1.00
Sigmoid, raw HR (sa) 29 -0.00 0.24 -0.50, 0.50 1.00
Sigmoid, sm HR* (sa) 29 0.00 0.16 -0.32, 0.32 1.00
VCO2 predicted from VO2 (sa) 29 1.02 0.17 0.68, 1.37 <0.001
Generic surface area 29 -6.55 0.28 -7.13, -5.97 <0.001
Generic surface area and age 29 -5.30 0.26 -5.82, -4.77 <0.001
Sigmoid, sm HR* (height^) 29 0.00 0.09 -0.20, 0.19 0.99
Generic height^ 29 -1.27 0.10 -1.48, -1.07 <0.001
Generic height^ and age 29 -0.69 0.13 -0.96, -0.42 <0.001
(sa) = VCO2 normalised to body surface area. predicted from height and weight .
sm HR = heart rate smoothed 2 points forward
Subject: Child 8, male, age 14.7 y, height 178.2 cm, weight 62.3 kg, BMI SDS 0.21
Model N Mean SEM 95 % C l
Linear-Hex (sa) 56 0.28 0.30 -0.32, 0.88 0.35
Steady state (sa) 56 0.32 0.31 -0.30, 0.93 0.30
3“  ^order polynomial, raw HR (sa) 56 0.01 0.29 -0.57, 0.59 0.97
3“^*^ order polynomial, sm HR* (sa) 56 0.00 0.28 -0.57, 0.57 1.00
Sigmoid, raw HR (sa) 56 0.01 0.29 -0.57, 0.57 1.00
Sigmoid, sm HR* (sa) 56 0.00 0.28 -0.56, 0.56 1.00
VCO2 predicted from VO2 (sa) 56 0.73 0.29 0.14, 1.32 0.02
Generic surface area 56 -3.48 0.38 -4.24, -2.72 <0.001
Generic surface area and age 56 -3.29 0.48 -4.25, -2.33 <0.001
Sigmoid, sm HR* (height^) 56 0.00 0.09 -0.17, 0.17 1.00
Generic height^ 56 -2.14 0.17 -2.47, -1.81 <0.001
Generic height^ and age 56 -1.89 0.18 -2.26, -1.52 <0.001
(sa) = VCO2 normalised to body surface area, predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: Child 9, male, age 8.8 y, height 132.0 cm, weight 25.8 kg, BMI SDS -0.79 
Model N Mean SEM 95 % Cl
Linear-flex (sa) 42 -0.22 0.42 -1.07, 0.63 0.61
Steady state (sa) 42 -1.84 0.72 -3.30, -0.38 0.02
3'^ ‘* order polynomial, raw HR (sa) 42 0.01 0.48 -0.97, 0.98 0.99
3^^^ order polynomial, sm HR* (sa) 42 -0.00 0.34 -0.69, 0.69 1.00
Sigmoid, raw HR (sa) 42 -0.00 0.48 -0.97, 0.97 1.00
Sigmoid, sm HR* (sa) 42 -0.00 0.35 -0.71, 0.71 1.00
FCO2 predicted from FO2 (sa) 42 0.83 0.57 -0.32, 1.99 0.15
Generic surface area 42 0.48 0.40 -0.33, 1.28 0.24
Generic surface area and age 42 1.46 0.37 0.72, 2.21 <0.001
Sigmoid, sm HR* (height^) 42 0.04 0.14 -0.25, 0.34 0.76
Generic height^ 42 0.36 0.16 0.03, 0.69 0.03
Generic height^ and age 42 0.76 0.16 0.45, 1.08 <0.001
(sa) = FCO2 normalised to body surface area. predicted flom height and weight
sm HR = heart rate smoothed 2 points forward
Subject: Child 10, female, age 15.2 y, height 151.8 cm, weight 49.3 kg, BMI SDS 0.48
Model N Mean SEM 95 % Cl _ _
Linear-flex (sa) 40 -0.34 0.27 -0.88, 0.19 0.20
Steady state (sa) 40 -0.91 0.30 -1.51, -0.32 0.004
3^^^ order polynomial, raw HR (sa) 40 -0.17 0.34 -0.87, 0.53 0.62
3*^^^ order polynomial, sm HR* (sa) 40 0.00 0.37 -0.74, 0.74 1.00
Sigmoid, raw HR (sa) 40 0.05 0.28 -0.52, 0.62 0.87
Sigmoid, sm HR* (sa) 40 0.00 0.37 -0.75, 0.75 1.00
FCO2 predicted from FO2 (sa) 40 1.08 0.42 0.23, 1.92 0.01
Generic surface area 40 0.05 0.44 -0.85, 0.95 0.91
Generic surface area and age 40 0.55 0.44 -0.33, 1.44 0.22
Sigmoid, sm HR* (height^) 40 -0.00 0.15 -0.31, 0.31 1.00
Generic height^ 40 0.14 0.19 -0.23, 0.52 0.45
Generic height^ and age 40 0.31 0.18 -0.06, 0.68 0.10
(sa) = FCO2 normalised to body surface area, predicted from height and weight
* sm HR = heart rate smoothed 2 points forward
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Subject: CFl, male, age 13.8 y, height 146.3 cm, weight 37.1 kg, BMI SDS -0.61
Model N Mean SEM 95 % Cl P
Linear-flex (sa) 39 0.16 0.33 -0.52, 0.84 0.64
Steady state (sa) 39 -2.11 0.37 -2.86, -1.36 <0.001
3*^‘^ order polynomial, raw HR (sa) 39 0.00 0.32 -0.64, 0.64 1.00
3*^  ^order polynomial, sm HR* (sa) 39 -0.00 0.28 -0.56, 0.56 1.00
Sigmoid, raw HR (sa) 39 0.00 0.32 -0.64, 0.64 1.00
Sigmoid, sm HR* (sa) 39 0.00 0.29 -0.58, 0.58 1.00
FCO2 predicted from FO2 (sa) 39 -1.30 0.67 -2.66, 0.05 0.06
Generic surface area 39 -0.39 0.30 -1.00, 0.22 0.21
Generic surface area and age 39 0.29 0.32 -0.36, 0.94 0.38
Sigmoid, sm HR* (height^) 39 -0.00 0.11 -0.22, 0.22 1.00
Generic height^ 39 -0.24 0.12 -0.49, 0.01 0.06
Generic height^ and age 39 0.10 0.12 -0.14, 0.35 0.40
(sa) = FCO2 normalised to body suiFace area. predicted from height and weight
sm HR = heart rate smoothed 2 points forward
Subject: CF3, male, age 14.4 y, height 176.2 cm, weight 57.8 kg, BMI SDS -0.42
Model N Mean SEM 95 %  C l P
Linear-flex (sa) 35 -1.20 0.73 -2.69, 0.28 0.11
Steady state (sa) 35 -1.79 0.69 -3.19, -0.38 0.01
3"^"^ order polynomial, raw HR (sa) 35 -0.00 0.52 -1.06, 1.06 1.00
3”  ^order polynomial, sm HR* (sa) 35 -0.00 0.51 -1 03, 1.03 1.00
Sigmoid, raw HR (sa) 35 -0.09 0.63 -1.37, 1.19 0.89
Sigmoid, sm HR* (sa) 35 -0.00 0.51 -1.03, 1.03 1.00
FCO2 predicted from FO2 (sa) 35 0.32 0.50 -0.70, 1.35 0.53
Generic surface area 35 1.83 0.52 0.78, 2.88 0.001
Generic surface area and age 35 2.28 0.52 1.22, 3.33 0.001
Sigmoid, sm HR* (height^) 35 -0.00 0.15 -0.32, 0.32 1.00
Generic height^ 35 -0.09 0.16 -0.42, 0.24 0.60
Generic height^ and age 35 -0.09 0.16 -0.42, 0.24 0.60
(sa) = FCO2 normalised to body surface area, predicted from height and weight
* sm HR = heart rate smoothed 2 points forward
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Subject: CF5, female, age 14.9 y, height 158.3 cm, weight 44.9 kg, BMI SDS -0.87
Model N Mean SEM 95 % Cl
Linear-flex (sa) 44 -0.16 0.36 -0.88, 0.55 0.65
Steady state (sa) 44 -1.62 0.45 -2.53, -0.71 <0.001
3"^  ^order polynomial, raw HR (sa) 44 0.05 0.35 -0.66, 0.76 0.88
3"^^^ order polynomial, sm HR* (sa) 44 0.30 0.31 -0.34, 0.93 0.35
Sigmoid, raw HR (sa) 44 0.00 0.34 -0.69, 0.69 1.00
Sigmoid, sm HR* (sa) 44 0.00 0.24 -0.49, 0.49 1.00
FCO2 predicted from FO2 (sa) 44 1.27 0.33 0.61, 1.94 <0.001
Generic surface area 44 0.21 0.49 -0.79, 1.19 0.68
Generic surface area and age 44 0.57 0.49 -0.42, 1.56 0.25
Sigmoid, sm HR* (height^) 44 -0.00 0.09 -0.17, 0.17 1.00
Generic height^ 44 -0.30 0.18 -0.66, 0.06 0.10
Generic height^ and age 44 -0.11 0.18 -0.47, 0.25 0.55
(sa) = FCO2 normalised to body surface area, predicted from height and weight
* sm HR = heart rate smoothed 2 points forward
Subject: CF6, female, age 12.5 y, height 156.1 cm, weight 40.8 kg, BMI SDS -0.52
Model Mean ' SEM 95 % C l P
Linear-flex (sa) 51 -0.07 0.26 -0.61, 0.46 0.78
Steady state (sa) 51 -1.05 0.28 -1.62,-0.49 <0.001
3"^  ^order polynomial, raw HR (sa) 51 -0.00 0.24 -0.48, 0.48 1.00
3^"^  order polynomial, sm HR* (sa) 51 -0.00 0.18 -0.36, 0.36 1.00
Sigmoid, raw HR (sa) 51 0.00 0.21 -0.42, 0.42 1.00
Sigmoid, sm HR* (sa) 51 -0.00 0.17 -0.33, 0.33 1.00
FCO2 predicted from KO2 (sa) 51 0.68 0.28 0.11, 1.25 0.02
Generic surface area 51 -1.99 0.23 -2.46, -1.52 <0.001
Generic surface area and age 51 -1.48 0.23 -1.94,-1.03 <0.001
Sigmoid, sm HR* (height^) 51 0.00 0.06 -0.11, 0.11 1.00
Generic height^ 51 -1.24 0.08 -0.41, -1.07 <0.001
Generic height^ and age 51 -0.91 0.08 -1.08, -0.74 <0.001
(sa) = FCO2 normalised to body surface area. predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Subject: CF8, female, age 8.9 y, height 130.8
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cm, weight 26.0 kg, BMI SDS -0.54
Model N Mean SEM 95 % Cl P
Linear-flex (sa) 38 0.07 0.15 -0.24, 0.38 0.65
Steady state (sa) 38 -0.61 0.15 -0.91,-0.31 <0.001
3*^  ^order polynomial, raw HR (sa) 38 0.00 0.14 -0.29, 0.29 1.00
3'^ ‘* order polynomial, sm HR* (sa) 38 -0.00 0.15 -0.31, 0.31 1.00
Sigmoid, raw HR (sa) 38 0.00 0.13 -0.26, 0.26 1.00
Sigmoid, sm HR* (sa) 38 -0.00 0.15 -0.31, 0.31 1.00
VCO2 predicted from FO2 (sa) 38 0.06 0.32 -0.58, 0.71 0.84
Generic surface area 38 -6.58 0.34 -7.28, -5.89 <0.001
Generic surface area and age 38 -6.34 0.43 -7.22, -5.46 <0.001
Sigmoid, sm HR* (height^) 38 -0.00 0.06 -0.13, 0.13 1.00
Generic height^ 38 -2.60 0.13 -2.87, -2.32 <0.001
Generic height^ and age 38 -2.29 0.15 -2.60, -1.98 <0.001
(sa) = FCO2 normalised to body surface area, predicted from height and weight 
* sm HR = heart rate smoothed 2 points forward
Subject: CF9, female, age 8.4 y, height 124.3 cm, weight 25.0 kg, BMI SDS 0.02
Model N Mean SEM" 95%  C l
Linear-flex (sa) 41 0.60 0.26 0.07, 1.14 0.03
Steady state (sa) 41 -0.20 0.28 -0.78, 0.38 0.49
3^  ^order polynomial, raw HR (sa) 41 -0.00 0.27 -0.54, 0.54 0.99
3'^ order polynomial, sm HR* (sa) 41 -0.00 0.16 -0.34, 0.33 0.97
Sigmoid, raw HR (sa) 41 0.00 0.24 -0.49, 0.49 1.00
Sigmoid, sm HR* (sa) 41 0.00 0.16 -0.33, 0.33 1.00
KCO2 predicted from FO2 (sa) 41 0.13 0.27 -0.42, 0.69 0.63
Generic surface area 41 -4.22 0.32 -4.86, -3.58 <0.001
Generic surface area and age 41 -3.51 0.35 -4.21, -2.81 <0.001
Sigmoid, sm HR* (height^) 41 -0.00 0.08 -0.16, 0.16 1.00
Generic height^ 41 -1.14 0.19 -1.53,-0.74 <0.001
Generic height^ and age 41 -0.69 0.20 -1.10, -0.28 0.001
(sa) = FCO2 normalised to body surface area, predicted from height and weight
sm HR = heart rate smoothed 2 points forward
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Appendix 3 Individual results from ^^C-breath tests
Table A3.1 Effect of position on measured resting FCO2
Subject
Measured FCO2 (mmol.min .m' ) 
Lying Sitting Difference
Adult 1 4.81 5.56 -0.76
Adult 2 4.71 4.39 0.32
Adult 3 4.46 4.22 0.24
Adult 4 4.55 4.51 0.04
Adult 5 6.78 6.68 0.10
Adult 6 4.34 3.59 0.75
Adult 7 4.76 5.49 -0.73
Adult 8 4.61 4.90 -0.29
Child 1 5.13 5.13 0.00
Child 2 4.48 4.09 0.38
Child 3 5.10 5.36 -0.26
Child 4 6.52 6.92 -0.40
Child 5 5.80 6.32 -0.52
Child 6 4.73 6.98 -2.25
Child 7 5.72 5.85 -0.13
Child 8 5.53 5.19 0.34
Child 9 6.58 6.26 0.32
Child 10 4.58 3.94 0.64
CFl 6.82 6.56 0.26
CF3 6.35 5.88 0.46
CF5 5.48 5.36 0.12
CF6 5.80 4.54 1.26
CF8 6.15 4.62 1.53
CF9 6.03 5.46 0.57
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Table A3.2 Cumulative PDR at 6 h during the [*^C]MTG breath test
CunmkühæITMl(6h)
Subject Shreeve Schofield Measured
resting
HR predicted PAL*
Adult 1 43.1 38.4 31.1 38.6 1.2
Adult 2 29.2 28.2 25.5 25.8 1.0
Adult 3 32.7 33.2 30.6 35.0 1.1
Adult 4 33.6 30.8. 25.8 39.7 1.5
Adult 5 37.3 37.7 30.7 38.6 1.3
Adult 6 35.2 37.9 30.4 42.2 1.4
Adult 7 33.5 32.9 33.3 44.1 1.3
Adult 8 31.7 32.9 26.8 41.9 1.6
Child 1 17.2 20.0 17.9 36.3 2.1
Child 2 27.3 27.7 21.0 44.3 2.1
Child 3 32.3 40.2 33.6 46.8 1.4
Child 4 21.4 22.4 28.2 51.8 1.7
Child 5 19.2 23.6 22.9 34.9 1.5
Child 6 28.6 33.9 27.8 61.6 2.2
Child 7 25.4 31.5 19.4 32.7 1.7
Child 8 29.0 32.1 31.3 31.9 1.0
Child 9 33.5 41.3 43.2 57.6 1.4
Child 10 39.8 39.6 32.7 40.2 1.3
CFl 4.1 4.9 5.1 6.1 1.2
CF3 10.3 11.4 11.3 14.7 1.3®
CF4 10.7 12.8 11.4 - -
CF5 20.2 20.7 19.9 16.8 1.2
CF6 28.8 30.2 32.0 41.0 1.3
CF8 12.0 13.9 11.0 16.8 1.5
CF9 9.3 10.9 11.0 13.8 1.3
*PAL = cPDR calculated using VCO2 estimated from heart rate/measured resting FCO2 
= non-resting FCOs/resting FCO2 or TEE/REE 
* assumed PAL due to problem recording heart rate during the test
Please refer to the note following Table A3.3.
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Table A3.3 Cumulative PDR at 6 h during the [1-^^C]acetate breath test
Subject Shreeve
Cumulative PDR (6 h)
Schofield Measured HR predicted PAL* 
______  resting______________________
Adult 1 44.6 39.9 38.3 41.5 1.1
Adult 2 29.8 28.8 27.5 26.1 1.0
Adult 3 22.4 22.8 21.0 26.9 1.3
Adult 4 38.7 35.4 29.6 35.0 1.2
Adult 5 37.4 37.8 30.7 37.4 1.2
Adult 6 33.4 35.9 28.8 39.5 1.4
Adult 7 30.9 30.3 30.6 40.0 1.3
Adult 8 25.8 26.8 21.8 31.6 1.4
Child 1 18.7 21.8 19.5 33.6 1.7
Child 2 36.1 36.6 27.8 63.7 2.3
Child 3 29.2 36.4 30.4 35.0 1.1
Child 4 25.0 26.2 32.9 54.2 1.6
Child 5 27.0 33.2 32.3 46.6 1.4
Child 6 25.5 30.2 24.8 63.1 2.5
Child 7 31.8 39.4 24.3 40.3 1.7
Child 8 31.1 34.5 33.6 33.0 1.0
Child 9 19.7 24.3 25.4 44.6 1.8
CFl 26.1 30.7 32.1 40.9 1.3
CF4 20.4 24.4 21.8 - -
CF8 26.7 30.9 24.6 37.2 1.5
*PAL = cPDR calculated using FCO2 estimated from heart rate/measured resting FCO2 
= non-resting FCOz/resting FCO2 or TEE/REE
Please refer to the note on the following page.
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Notes for Tables A3.2 and A3.3:
1. Control child 6 had a poor heart rate calibration due to insufficient measurements at 
near resting conditions and therefore may have overestimated FCO2 at low levels of 
energy expenditure, resulting in high PDR and high PAL. This subject performed 
the test at the same time as subjects 4, 5 and 7 and had a similar pattern of activity 
during the test. Her PAL should have been between 1.5 and 1.7. The high PAL in 
control children 1 and 2 is consistent with the observed behaviour of these children, 
although a detailed activity diary was not kept during the test.
2. Healthy control children 1-8 and CF9 performed the tests in the familiar 
sunoundings of their own home, where there was a greater choice of activities than 
at the ambulatory day care unit. Royal Hospital for Sick Children, Glasgow. 
Control children 9 and 10 and the remainder of children with cystic fibrosis 
performed the test at the Royal Hospital for Sick Children.
3. Subject CFl was normally on high dose pancreatic enzyme replacement therapy 
(PERT). Subject CF6 did not normally take PERT. Subject CF 4 could not be 
fitted with a heart rate monitor. This problem was not identified until the day of the 
test.
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Subject Shreeve Measured
resting
VCO2 estimate
HR HR 
individual generic 
calibration surface 
area 
(sa)
HR
generic 
sa & 
age
HR
generic
height^
HR
generic 
height^ 
& age
1 43.1 31.1 38.6 43.2 42.2 40.1 41.2
2 29.2 25.5 25.8 29.3 28.9 33.2 34.3
3 32.7 30.6 35.0 39.6 33.3 48.2 42.7
4 33 6 25.8 39.7 52.6 49.5 52.1 47.4
5 37.3 30.7 38.6 41.9 38 3 51.8 49.2
6 35.2 30.4 42.2 49.6 45.5 46.3 42.0
7 33.5 33.3 44.1 43.4 41.2 54.1 51.2
8 31.7 26.8 41.9 35.7 32.0 37.4 35.1
100 
90 
80 
70 
«  60
I  50 
% 40
30 
20
S h r e e v e  M e a s u r e d  H R  ind iv id  G e n e r ic  s a  G e n e r ic  s a  G e n e r ic  G e n e r ic  
r e s t in g  c a lb  & a g e  h t3  h t3  & a g e
1/C02 estimate
Measured resting = resting VCO2 measured using a ventilated hood indirect calorimeter
Figure A3.1 Cumulative excretion (6 h) o f i n  breath CO2 following ingestion of
['^CJMTG in eight healthy adults
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Subject Shreeve Measured
resting
FCO2 estimate
HR HR 
individual generic 
calibration surface 
area 
(sa)
HR
generic 
sa & 
age
HR
generic
height^
HR
generic 
height  ^
& age
1 17.2 17.9 36.3 31.1 29.8 26.1 24.1
2 27.3 21.0 44.3 49.3 44.8 39.1 34.7
3 32.3 33.6 46.8 67.7 63 6 46.8 42.3
4 21.4 28.2 51.8 30.5 27.6 32.7 29.7
5 19.2 22.9 34.9 37.1 33.8 31.1 27.7
6 28.6 27.8 61.6 53.1 47.4 39.7 34.8
7 25.4 19.4 32.7 64.8 60.9 44.6 40.7
8 29.0 31.3 31.9 40.0 35 9 50.6 45.8
9 33.5 43.2 57.6 57.0 49.5 54.4 46.8
10 39.8 32.7 40.2 45.2 41.2 41.7 39.6
100 
90 
80 
70 
5  60
OC 50 Q% 40
30 
20
Shreeve Measured HR individ Generic Generic Generic Generic
resting calb sa sa & age
V CO2 estimate
ht3 ht3 & age
Measured resting = resting VCO2 measured using a ventilated hood indirect calorimeter
Figure A3.2 Cumulative excretion (6 h) of in breath CO2 following ingestion of
i C]MTG in ten healthy children
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HR
individual
Subject Shreeve Measured calibration 
resting
FCO2 estimate 
HR HR
generic generic 
surface sa &
HR
generic
height^
area
(sa)
age
HR
generic 
height  ^
& age
CFl 4.1 5.1 6.1 6.5 5.9 6.6 5.9
CF5 20.2 19.9 16.8 29.0 25.1 32.3 28.5
CF6 28.8 32.0 41.0 53.6 50.1 62.5 56.4
CF8 12.0 11.0 16.8 33 8 33.9 32.4 30.4
CF9 9.3 11.0 13.8 21.7 18.2 18.5 15.7
CF6 was not normally taking pancreatic enzyme replacement therapy
<00^Q
CLO
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Shreeve Measured HR indivd Generic Generic Generic Generic
resting calb sa sa & age
V CO2 estimate
hl3 ht3 & age
Measured resting = resting I/CO2 measured using a ventilated hood indirect calorimeter
Figure A3.3 Cumulative excretion (6 h) of * C in breath CO2 following ingestion of
[^^CJMTG in five children with cystic fibrosis
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Subject Shreeve Measured
resting
FCO2 estimate
HR HR 
individual generic 
calibration surface 
area (sa)
HR
generic 
sa & 
age
HR
generic
height^
HR
generic 
height  ^
& age
1 44.6 38.3 41.5 47.9 46.5 45.3 45.4
2 29.8 27.5 26.1 29.6 29.4 34.0 35.2
3 22.4 21.0 26.9 27.4 25.5 32.5 36.7
4 38.7 29.6 35.0 42.4 40.0 37.3 36.5
5 37.4 30.7 37.4 40.7 37.6 50.0 48.3
6 33.4 28.8 39 5 46.5 42.5 42.7 38.7
7 30.9 30.6 40.0 39.2 37.3 48.1 45.7
8 25.8 21.8 31.6 27.7 25.3 28.9 27.9
100
£<s>
0^OÛ.o
Shreeve Measured HR individ Generic Generic Generic Generic 
resting calb sa sa & age ht3 ht3 & age
V  CO2 estimate
Measured resting = resting VCO2 measured using a ventilated hood indirect calorimeter
Figure A3.4 Cumulative excretion (6 h) of in breath CO2 following ingestion of
[1-^^CJacetate in eight healthy adults
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VCO2 estimate
HR HR HR
Subject Shreeve Measured individual generic generic
resting calibration surface sa & age
_________________________________________area (sa)__________
HR
generic
height^
HR 
generic 
height  ^
& age
1 18.7 19.5 33.6 81.0 76.4 52.1 40.7
2 36.1 27.8 63.7 54.3 50.7 41.0 37.1
3 29.2 30.4 35.0 53.2 47.0 36.2 31.4
4 25.0 32 9 54.2 49.1 44.5 36.6 32.3
5 27.0 32.3 46.6 72.8 69.1 58.4 53.2
6 25.5 24.8 63.1 30.0 27.1 25.2 22.4
7 31.8 24.3 40.3 34.1 30.5 36.9 30.0
8 31.1 33 6 33.0 39 5 34.6 49.3 44.5
9 19.7 25.4 44.6 40.9 38.1 40.0 36.1
CFl 26.1 32.1 40.9 43.9 40.0 45.0 40.1
CF8 26.7 24.6 37.2 68.8 68.7 65.6 62.7
100
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CL 40 o 30
20
Shreeve Measured HR individ Generic Generic Generic Generic 
resting calb sa sa & age ht3 ht3 & age
V CO2 estimate
Measured resting = resting VCO2 measured using a ventilated hood indirect calorimeter
Figure A3.5 Cumulative excretion (6 h) of C in breath CO2 following ingestion of 
[1-*^CJacetate in nine healthy children and two children with cystic fibrosis
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Table A3.4 Cumulative PDR 6 h (Shreeve VCO2) with acetate recovery
Subject MTG
Cumulative PDR (6 h)
Acetate MTG with acetate recovery
Adult 1 43.1 44.6 96.8
Adult 2 29.2 29.8 98.0
Adult 3 32.7 22.4 145.9*
Adult 4 33.6 38.7 86.9*
Adult 5 37.3 37.4 108.1
Adult 6 35.2 33.4 101.7
Adult 7 33.5 30.9 108.5
Adult 8 31.7 25.8 122.9*
Child 1 17.2 18.7 91.7*
Child 2 27.3 36.1 75.7*
Child 3 32.3 29.2 110.4*
Child 4 21.4 25.0 85.6
Child 5 19.2 27.0 71.0
Child 6 28.6 25.5 112.1*
Child 7 25.4 31.8 79.9
Child 8 29.0 31.1 93.2
Child 9 33.5 19.7 170.2*
CFl 4.2 26.1 16.0
CF4 10.7 20.4 52.3
CF8 12.0 26.7 44.8
*PAL more than 0.1 units different between tests (Tables A3.2 & A3.3)
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Table A3,5 Cumulative PDR 6 h (FCO2 estimated from HR) with acetate recovery
Subject MTG
Cumulative PDR (6 h)
Acetate MTG with acetate recovery >1
Adult 1 38.6 41.5 92.9
■ J
Adult 2 25.8 26.1 98.1 ?
Adult 3 35.0 26.9 130.5 î i
Adult 4 39.7 35.0 113.4
Adult 5 38.6 37.4 111.4 Î
Adult 6 42.2 39.5 106.9 Î■Î
Adult 7 44.1 40.0 110.2
Adult 8 41.9 31.6 132.5
Child 1 36.3 33.6 103.9
Child 2 44.3 63.7 71.2
Child 3 46.8 35.0 133.7 ■|
Child 4 51.8 54.2 95.6
Child 5 34.9 46.6 75.0 ■ ' . s„:f'
Child 6 61.6 63.1 97.5 1.V
Child 7 32.7 40.3 81.0
Child 8 31.9 33.0 96.6
Child 9 57.6 44.6 129.1
CFl 6.1 40.9 15.1
CF4 16.0* 30.6 523
CF8 16.8 37.2 44.8
* Assuming PAL 1.5 same as subject CF8, who did test at same time '1
